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Preface
In this thesis, the characteristics of a variety of inherited retinal dystrophies are described, 
which could cause significant visual disability. Each time a patient visited our outpatient clinic, 
sometimes after hours of travelling, the impact of being visually impaired became obvious 
to me. This does not only include the inability of doing your hobbies, but also includes the 
daily matters in life that are often done without thought by seeing individuals. I was pleasantly 
surprised to hear that one patient told me he ran under the guidance of a ‘buddy’ and that 
blind individuals even can ski like this. This is in contrast to inability to perform their profession 
that patients may face.
Inherited retinal dystrophies are not apparently visible from the outside. This sometimes 
leads to reactions of incomprehension among the patient’s peers, for example when they are 
not recognized or noticed. On the other hand, the blind often have to put their – both literally 
and figuratively – blind trust in their peers or guide dog to maneuver in public. Despite the 
bad visual prognosis, many patients have shown an adaptability and positive mood that 
earns respect for both patients and their parents/family. I sincerely hope that the research 
described in this thesis will add to a future with improved counseling and prognosis with 
regard to these severe eye disorders.
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Voorwoord
In dit proefschrift worden de kenmerken beschreven van enkele erfelijke netvliesaandoeningen 
die tot een ernstige visuele handicap kunnen leiden. Iedere keer wanneer er een patiënt, 
soms na uren reizen, bij ons op de polikliniek kwam voor onderzoeken, werd mij weer 
duidelijk welke impact slecht zien op je leven heeft. Hierbij speelt het niet het niet meer 
kunnen uitvoeren van hobby’s, maar juist ook om de dagelijkse zaken in het leven, de dingen 
waar je als ziende vaak niet eens bij nadenkt. Ik was dan ook enigszins verbaasd toen 
een blinde patiënt mij uitlegde dat hij hard liep onder begeleiding van een zogenoemde 
‘buddy’ en dat zelfs skiën tot de mogelijkheden behoorde. Daarentegen zijn het uitvoeren 
van beroepsmatige werkzaamheden dikwijls onmogelijk.
Erfelijke netvliesaandoeningen zijn niet zichtbaar aan de buitenkant en vraagt daarmee 
veel begrip van zowel patiënt als omgeving. Reacties van onbegrip vanuit de omgeving 
van de slechtziende komen geregeld voor, bijvoorbeeld wanneer iemand niet herkent of 
opgemerkt wordt. Hier staat lijnrecht tegenover dat de patiënt meestal – zowel letterlijk als 
figuurlijk – blind vertrouwen moet hebben in zijn medemens of een geleidehond om zich thuis 
of in het openbaar te manoeuvreren. Ondanks de vaak slechte visuele prognose tonen de 
meeste patiënten toch een aanpassingsvermogen en positiviteit die bewondering afdwingt 
voor zowel patiënten als ouders/familie. Ik hoop oprecht dat het onderzoek beschreven in dit 
proefschrift bij mag dragen aan een toekomst met een betere counseling en prognose ten 
aanzien van deze ernstige oogaandoeningen.
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List of abbreviations
A2E N-retinylidene-N-retinylethanolamine 
ABCR ATP-binding cassette transporter
AMD Age-related macular degeneration
AON Antisense oligonucleotidess
APEX Arrayed-primer extension 
arRP autosomal recessive retinitis pigmentosa
ATP Adenosine triphosphate
BBS Bardet-Biedl syndrome
BCAMD Benign concentric annular macular dystrophy 
BCVA Best corrected visual acuity
BDNF Brain-derived neurotrophic factor 
BEM Bull’s eye maculopathy
CAI Carbonic anhydrase inhibitor
CD Cone Dystrophy
cDNA Complementary deoxynucleic acid
CFC Cystoid fluid collection
CFT Central foveal thickness
cGMP Cyclic guanosine monophosphate
CI Confidence interval
CL Contact lens (electrodes)
CME Cystoid macular edema
CNTF Ciliary neurotrophic factor 
CRALBP Cellular retinaldehyde binding protein 
CRBP Cellular retinoid-binding protein
CRD Cone-rod dystrophy
cSLO Confocal scanning laser ophthalmoscopy 
CSNB Congenital stationary night blindness
DCMD Dominant cystoid macular dystrophy
DNA Deoxyribonucleic acid
DTL Dawson-Trick-Litzkow (electrodes)
ELM External limiting membrane
EOG Electrooculography
ERG Electroretinography
ERM Epiretinal membrane
EVS Exome variant server
FA Fluorescein angiography
FAF Fundus autofluorescence
ffERG Full-field electroretinography
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FP Fundus photography
GAT Gene augmentation therapy
GCL Ganglion cell layer
GDNF Glial-cell derived neurotrophic factor 
GTP Guanosine-5’-triphosphate
HGVS Human genome variation society
HRM High resolution melting
IFT Intraflagellar transport
ILM Internal limiting membrane
IMPG2 Interphotoreceptor matrix proteoglycan-2 
INL Inner nuclear layer
IPL Inner plexiform layer
IPM Interphotoreceptor matrix
iPSC Induced pluripotent stem cells
IRBP Interphotoreceptor retinoid-binding protein
IRD Inherited retinal dystrophies
ISCEV International Society for Clinical Electrophysiology of Vision
LCA Leber congenital amaurosis
LogMAR Logarithm of the minmal angle of resolution
LRAT Lecithin:retinol acetyltransferase 
MD Macular dystrophy
mfERG Multifocal electroretinography
MLPA Multiplex ligation-dependent probe amplification 
mRNA Messenger ribonucleic acid 
NGS Next-generation sequencing
NMD Nonsense-mediated decay
OCT Optical coherence tomography
ONL Outer nuclear layer
OPL Outer plexiform layer
PCR Polymerase chain reaction
PHARC (Acronym) polyneuropathy, hearing loss, ataxia, retinitis pigmentosa and cataract
PR+RPE Photoreceptor-Retinal pigment epithelium complex
PSC Posterior subcapsular cataract
PTA Pure tone average
RD Retinal dystrophies
RdCVF Rod-derived cone viability factor 
RDH All-trans-retinal dehydrogenase
RDH5 11-cis-retinol dehydrogenase 
RNA Ribonucleic acid 
RP Retinitis pigmentosa
RPE Retinal pigment epithelium
RPE65 RPE specific protein 65 kDa 
RT Retinal thickness
List of abbreviations  |  15
SD-OCT Spectral domain optical coherence tomography
STGD1 Stargardt disease
TD-OCT Time domain optical coherence tomography
tRNA Transport ribonucleic acid 
UPSIT University of Pennsylvania Smell Identification Test
VA Visual acuity
VEGF Vascular endothelial growth factor
VMD Vitelliform macular dystrophy
VPA Valproic acid
WES Whole exome sequencing
XIAP X-linked inhibitor of apoptosis 
Gene names are not generally included in this list. The Retinal Network (RetNet), available 
at www. https://sph.uth.edu/retnet/, can used for reference of gene names.
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Historical background
The field of inherited retinal disease rapidly expanded after the invention of the ophthalmo-
scope by Hermann Helmholtz in 1851. This device enabled examination of the retina and 
optic disc and caused a true revolution in ophthalmology.1 Few years later in 1853, Van Trigt 
published a colored atlas depicting the normal retina as well as a variety of pathological 
disorders, including retinitis pigmentosa.2 The first description of retinitis pigmentosa as 
a distinct clinical entity is generally ascribed to the Dutch ophthalmologist Franciscus C. 
Donders in 1855.3 More than a century earlier, however, Rüdiger F. Ovelgün described a form 
of familial night blindness that closely resembled the disorder that would later become known 
as retinitis pigmentosa.4 Even though the term ‘retinitis’ was an obvious misnomer, the name 
endured till present time.
In 1909, the German ophthalmologist Karl Stargardt described seven patients from two 
families who experienced vision loss starting in the first two decades of life.5 Although the 
patients initially revealed a normal fundus, in time Stargardt observed the development of 
macular atrophy and yellowish retinal flecks. This disorder was soon referred to as Stargardt’s 
macular dystrophy. Years later, in 1965, Franceschetti described a similar disease, which 
he named ‘fundus flavimaculatus’, characterized by retinal flecks that reached into the 
peripheral retina and a supposedly milder clinical course with a later age at onset.6 In fact, 
fundus flavimaculatus was similar to the phenotypic characteristics of a second patient from 
Stargardt’s original families published by Rosehr in 1954.7,8 These days, especially after 
the identification of the molecular genetic cause, Stargardt disease (STGD1) and fundus 
flavimaculatus are considered subtypes of the same clinical entity.
Retinal disorders are prominently featured in the milestones in human genetics. One 
of the earliest and most extensive documented pedigree showing an autosomal dominant 
mode of inheritance involves the family of Jean Nougaret (1637-1719), who suffered from 
congenital stationary night blindness (CSNB).9,10 In 1911, Wilson localized the locus of color 
blindness to the human X-chromosome, which was the first disease gene ever mapped.11 
The era of molecular genetics in retinal disease commenced with the discovery of a locus 
on the X chromosome in patients with X-linked retinitis pigmentosa by Bhattacharya and 
colleagues in 1984.12 In 1990, Dryja and co-workers identified Rhodopsin as the first gene 
to be associated with autosomal dominant retinitis pigmentosa, and the same year Cremers 
et al found mutations in the REP-1 gene responsible for choroideremia.13,14 In 1991, the 
peripherin-2 (PRPH2, formerly known as RDS/peripherin) gene was identified as a cause of 
autosomal dominant retinitis pigmentosa.15,16 Its involvement in various macular dystrophies 
was discovered in the following years.17,18 Up to date, over 200 genes have been identifiedthat 
have been associated with a wide variety of inherited retinal dystrophies (RetNet, available 
at https://sph.uth.edu/retnet/).
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1
Figure 1.1. Anatomy of the human eye.
Anatomy and physiology of the eye
The eye is a highly specialized organ that enables us to perceive light and thereby our 
surroundings. The light that is emitted or reflected by the objects around us enters the eye 
through the cornea. The lens focuses the light beams on the retina, which lines the inner 
surface of the posterior segment of the orbital globe (Figure 1.1). The anatomy of the posterior 
part of the globe consists of three major tissue layers: the sclera, the choroid and the retina. 
The sclera is the outer shell of the orbital globe and is build of collagen fibrils and a few 
elastic fibers embedded in a matrix of proteoglycans. The choroid is a vascular layer that 
nourishes the retina; these layers are separated by Bruch membrane. The choroid and retina 
will be reviewed in detail in the following paragraphs.
The retina
The retina is part of the central nervous system. It originates from an evagination from the 
future diencephalon of the prosencephalon (forebrain) called the optic vesicle, as early as day 
24 of embryologic development. The optic vesicle folds into the optic cup, which includes the 
tissue that will develop into the pigmented retina, which will develop into the retinal pigment 
epithelium (RPE), and the neural retina.19,20 These two layers form a functional unit.
The neuroretina
The neuroretina is the transparent multilayered tissue adjacent to the RPE layer. Its layered 
architecture includes three nuclear layers containing the neurons, and two plexiform layers 
of synapses (Figure 1.2). The outer nuclear layer (ONL) contains the cell bodies of the 
photoreceptors. The inner nuclear layer (INL) contains the cell bodies of the bipolar, amacrine, 
horizontal and Müller cells, and the ganglion cell layer (GCL) contains the cell bodies of the 
ganglion cells. These cell layers interconnect via synapses that are present in the outer and 
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inner plexiform layer (OPL and IPL, respectively). Histologists as well as ophthalmologists 
recognize an additional intraretinal ‘membrane’: the external limiting membrane (ELM), 
which actually reflexes a linear confluence of junctional complexes between Müller cells and 
photoreceptors. The innermost layer of the retina that borders on the vitreous cavity is named 
the internal limiting membrane (ILM).
The neuroretina is responsible for the transition of photonic stimuli to electrical neuronal 
signals, structuring of these signals and the first step of the transport to the central visual 
pathway. The fundamental synaptic chain that facilitates vision is photoreceptor à bipolar 
cell à ganglion cell.21 Horizontal cells in the OPL provide lateral interactions in this chain.22 
Amacrine cells help in signal processing by responding to specific alterations in retinal 
stimuli, for example sudden changes in light intensity. Müller glial cells span all layers of the 
neuroretina, and thereby provide a soft embedding for the neurons.23 Additionally, Müller 
cells are responsible for the homeostatic and metabolic support of the neuroretina, including 
regulation of vasoconstriction and vasodilatation of retinal vessels.24
Figure 1.2. Histologic and schematic appearance of the healthy human retina.
(Adapted from: Hartong DT et al, 2006.25)
The central retina, called macula (or macula lutea, yellow spot), is located at the posterior 
pole of the ocular orbit between the optic disc and the vascular arcades and measures 
5.5 mm in diameter (Figure 1.3A). This area contains accumulated oxygenated carotenoids, 
especially lutein and zeaxanthin, which contribute to its yellow color. The macula contains 
two or more ganglion cell layers, totaling half of all the ganglion cells in the retina.
The fovea (or fovea centralis) covers the central 1.5 mm of the macula and contains high 
numbers of cone photoreceptor cells that provide high spatial acuity. Its 0.35-mm-diameter 
center, called foveola, is densely packed with slender, elongated cone photoreceptors, and 
has a laterally displaced inner nuclear layer and ganglion cell layer. This configuration leads 
to a central depression: the foveal pit (Figure 1.3B).
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1Figure 1.3. The topography of the posterior retina. A, Color fundus photograph with 
overlaying ETDRS grid chart to define the 
subfields of the macula. B, Cross-sectional 
presentation of the macular retina that 
highlights the anatomical differences between 
the macular subfields.
Photoreceptors. After light has travelled 
through the entire neuroretina it meets 
the photoreceptors where the photonic 
energy is converted into an electrical 
neuronal current. Photoreceptors are highly 
specialized neurons that can be segmented 
in a synaptic end facing the bipolar cells 
in the OPL, the cell body containing the 
nucleus, and inner and outer segments 
that are linked by the connecting cilium 
(Figure 1.4).
The connecting cilium is a primary 
immotile cilium that contains a 9+0 
axoneme, consisting of 9 doublets of micro-
tubules without a central microtubule, 
which is connected to the basal body in 
the distal tip of the inner segment.26 Along 
this axoneme, bidirectional intraflagellar 
transport takes place, carried out by two distinct multiprotein complexes, IFT-A and IFT-B, 
and microtubule based motor assemblies kinesin-2 (anterograde transport) and cytoplasmic 
dynein (retrograde transport).27 This mechnanism allows for efficient transportation of vital 
components used in the visual (retinoid) cycle, the phototransduction cascade and disc 
formation from the cell body to the outer segment.
The axoneme extends into the photoreceptor’s outer segment, where cytoplasmic 
membranous discs are stacked. Within these discs, the phototransduction takes place 
that starts with the the capture of photons by visual pigments, which initiate the electrical 
neuronal signal (see below).28,29 New discs evaginate from the plasma membrane around the 
connecting cilium, old discs are shed at the tip of the outer segment and phagocytized and 
further processed by the RPE.30,31
The inner segment can be divided into the myoid and ellipsoid sections. The ellipsoid 
is adjacent to the connecting cilium and contains the metabolic machinery including 
large numbers of mitochondria. The myoid is closer to the photoreceptor nucleus and has 
ribosomes, some endoplasmic reticulum, Golgi bodies and small numbers of mitochondria.32
Based on morphology and visual pigment, two types of photoreceptors are recognized: 
rods and cones. Cone photoreceptor cells function best in bright light, due to a relatively 
low sensitivity to light in combination with a high level of visual pigment regeneration, and 
facilitate high spatial resolution.
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Figure 1.4. Schematic representation of a rod (left) and cone (right) photoreceptor. The outer segments 
of rods contain discs, whereas cones contain lamellae that are continuous with the plasma membrane.
There are three subtypes of cones: the S (‘blue’) cones, the M (‘green’) cones and the L 
(‘red’) cones that allow for color vision. The S cones contain iodopsin that is most sensitive 
to short wavelength light, whereas the iodopsin in M and L cones are sensitive to medium 
and long wavelength light, respectively.33,34 Rod photoreceptors cells contain rhodopsin and 
are far more sensitive to light compared to cones. Therefore, rods provide vision in dim light 
conditions and sense brightness, contrast and motion.
The distribution of rods and cones varies with the topographical location in the retina. 
On average, the retina contains 4.6 million cones, and approximately 92 million rods that are 
mainly distributed in the (mid)peripheral retina.35 The foveola contains the highest density of 
M- and L-cones, on average at 199,000 cones/mm2 and is highly variable between individuals 
(100,000-324,000 cones/mm2), but cone density falls steeply with increasing eccentricity 
(Figure 1.5); S-cones however are virtually absent in the foveola.35,36 Over the (mid)peripheral 
retina, the cone subtypes are equally distributed.37 Rod photoreceptors are also absent in 
the foveola, but rapidly grow in number with increasing eccentricity with a maximal density of 
~160,000/mm2 at ~20° eccentricity, which decreases towards the periphery (Figure 1.5).35,38 
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1Although the peak rod density is high, visual acuity is limited in this region. This is the result of summation of multiple rod responses to a single ganglion cell in each receptive field, which 
increases sensitivity at the cost of image resolution. This is in contrast with the one to one 
ratio between cones and ganglion cells at the fovea.
Figure 1.5. The distribution of rod and cone photoreceptors throughout the retina. (Source: Lindsay P 
et al, 197739)
The retinal pigment epithelium
The RPE consists of a monolayer of hexagonal cuboidal cells that are located between the 
Bruch membrane and the neuroretina (Figure 1.6). The apical side of RPE cells has villous 
processes that extend in the extracellular matrix between the photoreceptors and envelope 
the photoreceptor outer segments.40,41 Every 24 hours, RPE cells phagocytize the outer 10% 
of the rod and cone outer segments, which contains the ‘oldest’ discs with the highest load of 
(toxic) by-products of the visual cycle (see below). Each RPE cell generally contacts multiple 
photoreceptor outer segments and therefore is the most phagocytic cell in the human body.42 
The phagosome with the shed outer segment subsequently fuses with organelles filled with 
lytic enzymes called lysosomes, and the phagosome’s content is digested. During lifetime, 
a single RPE cell phagocytoses ~3 billion photoreceptor outer segments.43
The lateral surfaces of RPE cells contain tight junctions (zonulae occludentes) that closely 
connect the adjacent RPE cells. These bonds prevent the free movement of water-soluble 
molecules through the RPE layer, forming the outer blood-retina barrier. RPE cells closely 
regulate transport by a wide variety of active channels and pumps to actively transport ions 
and metabolites from the neuroretina to the choriocapillaris and vice versa.44 Additionally, the 
RPE keeps the neuroretina attached by draining the subretinal space from water, a process 
for which the RPE has a large reserve capacity (up to 2 mL per 24 hours).45-47
The pigmentation of RPE cells is caused by melanin-containing spheroidal cytoplasmic 
organelles called melanosomes, which provide the ability to absorb light. By this, the RPE 
absorbs scattered light and minimizes phototoxic effects. Furthermore, melanin has anti-
oxidative abilities.48 However, during life, an increasing portion of the available melanin 
becomes oxidized and accordingly the number of melanosomes decreases with age.49,50
In addition to these functions, the RPE plays an important role in the maintenance of the 
interphotoreceptor matrix, Bruch membrane and the choriocapillaris by the secretion of a 
variety of factors, including hyaluronan, VEGF and tissue inhibitor of metalloproteinases-3 
(TIMP-3),51-55 Its role in the visual (retinoid) cycle is discussed separately below.
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Figure 1.6. Schematic representation of  the 
retinal pigment epithelium and its close 
relationship to the photoreceptors and chorio-
capillaris. (Source: de Jong et al, 2006.56)
Like in the neuroretina, there are topo-
graphical differences in the RPE layer. 
For instance, the density of RPE cells 
is highest in the fovea and decreases 
eccentrically.49,57,58 Additionally, macular 
RPE cells contain a larger number of 
melanosomes compared to peripheral 
RPE cells.49 Macular RPE cells also are 
taller and have a smaller diameter,49,57-59 
which consequently leads to a lower 
number of photoreceptors per RPE cell.60
The choroid
The choroid consists of arterioles and 
venules that are connected by a meshwork 
of fenestrated capillaries. Blood enters 
the choroid through the posterior ciliary 
arteries. The large-caliber choroidal 
vessels are located in the outer layer, 
also known as the Haller layer.61 The 
capillary meshwork, the choriocapillaris, is 
the most inner layer of the choroid located just outside Bruch membrane (Figure 1.6). The 
fenestrated capillaries of the choriocapillaris permit the extravasation of small molecules (e.g. 
fluorescein), while larger molecules (e.g. albumin) remain intravascular.62,63 Blood from the 
choriocapillaris leaves the eye through four or five vortex veins that drain into the superior 
and inferior ophthalmic veins.
The blood flow rate in the choroid is highest of any tissue in the human body.61,64 This is 
necessary to nourish the retina and remove lactic acid, since the retina has one of the highest 
metabolic rates per gram of tissue in the body.65 The high choroidal blood flow rate also plays 
an important role in the drainage of thermal energy from light absorption.61,66-68
The choriocapillaris provides oxygen and nourishment to the retinal pigment epithelium 
(RPE) and the outer one-third of the retina, but 90% of the oxygen delivered to the retina by the 
choroid is consumed by photoreceptors.61,64,69 The choriocapillaris depends on trophic factors 
produced by the RPE, among which factors that induce endothelial fenestration and vascular 
endothelial growth factors (VEGFs) necessary for the integrity of the choriocapillaris.53,70-72 
Atrophy of the choriocapillaris after degeneration of the RPE has been observed in animal 
studies,73,74 as well as in patients with retinal dystrophies that primarily affect the RPE.
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1Physiology of visionVision is mediated by the phototransduction cascade, which takes place in the outer segment 
discs in both rod and cone photoreceptors. In this process, a light photon is captured by 
visual pigment and transduced into an electrical neuronal current. The visual (retinoid) cycle, 
the other vital cycle that partly takes place in the photoreceptor outer segments as well, 
recycles the vitamine A (retinoid) derivate 11-cis-retinal that converts into all-trans-retinal on 
photoactivation. Both the phototransduction cascade and the visual cycle are essential for 
vision and many of the underlying causes for inherited blindness can be found in defects in 
these complex systems.
The phototransduction cascade
The phototransduction system consists of a cascade of successive reactions following the 
excitation of rhodopsin with a photon (Figure 1.7). Rhodopsin is composed of the protein 
opsin and the chromophore 11-cis-retinal. Upon capture of a photon, 11-cis-retinal converts 
to its isomer all-trans-retinal, which subsequently transforms rhodopsin to the photoactive 
metarhodopsin II.75 Metarhodopsin II degenerates through several intermediates, one 
of which activates the G-protein transducin, which on its turn activates a cyclic GMP 
(cGMP) phosphodiesterase that hydrolyses cGMP to 5’-GMP.76 This leads to a decrease 
of the concentration of cGMP in the photoreceptor cytoplasm, which results in closure of 
the photoreceptor plasma membrane cGMP-gated cation channels. This in turn leads to a 
hyperpolarized plasma membrane caused by a significant drop in intracellular calcium levels. 
Hyperpolarization of the plasma membrane results in a decreased glutamate excretion at the 
photoreceptor’s synapse.
After phototransduction, the recovery phase starts. In this phase, recovery of the pre-
photoactivation situation occurs: (1) phosphorylation of metarhodopsin II by rhodopsin 
kinase and subsequent binding of arrestin, which stops the activation of transducin,77,78 
(2)  dissociation of all-trans-retinal from the visual pigment, which is recycled to 11-cis-
retinal via the visual (retinoid) cycle (see below), (3) inactivation of transducin by GTPase 
accelerating protein and thereby silencing the phosphodiesterase,79,80 and (4) restoration of 
the intracellular cGMP levels by guanylate cyclase.81 After all-trans-retinal has dissociated 
from the opsin, arrestin dissociates and the phosphates are removed. Regeneration of 
rhodopsin occurs when regenerated 11-cis-retinal binds to opsin.
The visual cycle
The vitamin A derivate 11-cis-retinal is crucial for the phototransduction cascade. Dietary 
vitamin A (all-trans-retinol) is absorbed from the blood and converted to 11-cis-retinal in the 
RPE. The visual cycle is a complex process that is focused on the regeneration of 11-cis-
retinal from all-trans-retinal that is produced in the phototransduction cascade (Figure 1.7), 
and takes place simultaneously with the phototransduction process.
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Figure 1.7. Schematic representation of the visual (retinoid) cycle (upper panel) and the 
phototransduction cascade (lower panel). Upper panel: The retinoid cycle regenerates 11-cis-retinal 
from all-trans-retinal. The process takes place in the outer segment discs, photoreceptor cytoplasma, 
interphotoreceptor matrix and cytoplasma of the RPE. Lower panel: The phototransduction cascade 
results in hyperpolarization of the photoreceptor’s plasma membrane after activation of rhodopsin 
by a photon in the outer segment discs. ABCA4, ATP-binding cassette transporter type 4 (the gene 
underlying the ATP-binding cassette transporter ABCR); cGMP, cyclic guanosine monophosphate; 
CNGA1, cyclic nucleotide gated channel alpha 1; CNGB1, cyclic nucleotide gated channel beta 1; 
CRALBP, cellular retinaldehyde binding protein; GUCY2D, guanylate cyclase 2D; GCAP, guanylate 
cyclase activating protein 1A (official gene symbol: GUCA1A); GDP, Guanosine-5’-diphosphate; GTP, 
Guanosine-5’-triphosphate; IRBP, interphotoreceptor matrix retinal binding protein; LRAT, lecithin:retinol 
transferase; PDE6A, phosphodiesterase 6A; PDE6B, phosphodiesterase 6B; RAL, retinal; RDH5, 
11-cis-retinol dehydrogenase; RE, retinyl esters; RGR, RPE-retinal G protein-coupled receptor; RHO, 
rhodopsin; RHOa, photoactivated rhodopsin; ROL, retinol; RPE65, RPE specific protein 65 kDa; SAG, 
S-antigen (or Arrestin). (Adapted from: den Hollander AI et al, 2010.92)
After photoactivation, all-trans-retinal is released from the activated visual pigment into 
the lumen of the outer segment discs. Here, it reacts with phosphatidylethanolamine and 
forms N-retinylidene-phosphatidylethanolamine (N-retinylidene-PE).82 Through the flippase 
activity of the ABCR (ATP-binding cassette) transporter, the all-trans-retinal is released into 
the cytosol of the photoreceptor, where all-trans-retinal dehydrogenase (RDH) reduces 
all-trans-retinal to all-trans-retinol.83,84 Subsequently, all-trans-retinol is transported into 
the interphotoreceptor space where it binds the interphotoreceptor matrix retinal binding 
protein (IRBP) that transports it into the RPE.85 Once in the RPE’s cytoplasm, all-trans-retinol 
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1binds to cellular retinol binding protein (CRBP), after which all-trans-retinol is re-isomerized by a cascade involving lecithin:retinol acetyltransferase (LRAT), RPE specific protein 65 
kDa (RPE65) and 11-cis-retinol dehydrogenase (RDH5).86-90 The resulting 11-cis-retinal 
is transported into the interphotoreceptor matrix by cellular retinaldehyde binding protein 
(CRALBP) and subsequently transported back into the photoreceptor’s cytosol by IRBP. 
Once in the photoreceptor, 11-cis-retinal binds opsin to form a new unexcited rhodopsin 
molecule. This pathway accounts for the re-isomerization of retinal in rods. Cones have a 
secondary visual cycle located in cone outer segments and Müller cells, which enables 
regeneration of 11-cis-retinal at a 20-fold faster rate.91
Clinical and functional assessment
Inherited retinal dystrophies (IRDs) display a wide spectrum of phenotypes. A diagnosis 
can often be made with a thorough history and ophthalmologic examination, including the 
age at onset, the severity and type of complaints, family history, retinal appearance and 
the progression over time. However, further clinical assessment may be necessary in the 
differential diagnostic track, evaluation of progression, and, in academic settings, for discovery 
of the molecular defect underlying the disorder. Additional functional evaluation of the retina 
includes visual acuity and visual field measurements, electrophysiological examinations, 
color vision tests and retinal imaging techniques, such as fundus autofluorescence (FAF) 
imaging, optical coherence tomography (OCT) and fluorescence angiography (FA). 
Nevertheless, identification of the correct diagnosis in patients with IRDs is often difficult due 
to the significant clinical overlap, and molecular genetic analyses are necessary.
Clinical ophthalmic examination
Visual acuity
Psychophysical testing measures the behavioral response to a stimulus, and includes 
visual acuity (VA) assessment, visual field measurements and color vision tests. VA is a 
measure for the keenness of sight, and was already performed by Egyptians 5000 years 
ago.93 In the past few centuries, visual acuity has been well studied. Nowadays, we assess 
VA under standardized conditions with letters, numbers or figures of known visual angle at 
standard distances under standard illumination. The outcome is the quotient d/D, in which 
‘d’ represents the distance at which the letter was read by the patient, and ‘D’ represents the 
distance from which a ‘normal sighted’ eye would be able to read that specific letter. Many 
different tests and notations are used, although the results often are interchangeable. In case 
other types of testing are required, e.g. in preverbal children, numerous age-adapted tests 
are available. In newborns, VA is not measurable, although fixation or fixing and following 
behavior can indicate the presence of vision.
Ophthalmoscopy
The easiest technique to visualize the posterior segment of the eye is direct ophthalmoscopy. 
The ophthalmoscope provides a monocular image of the retina at a high magnification (15x). 
More often used by ophthalmologists is indirect ophthalmoscopy, which includes the use of 
an additional lens between the observer and the patient. This provides a stereoptic view on 
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the retina with lower magnification (2-3x when 20, 28 or 30 diopter noncontact lenses are 
used). Indirect ophthalmoscopy using the slit-lamp microscope is preferred to evaluate the 
retina in more detail since the slit-lamp provides an additional magnification. For longitudinal 
follow-up of retinal abnormalities, color fundus photographs can be taken on regular intervals.
Perimetry
The assessment of the visual field, or perimetry, can be performed in a kinetic or static 
manner. The kinetic perimetry uses moving test light of standardized size and intensity. The 
lights are being moved within a ganzfeld dome to map the outer border of the area in which 
the spot of that specific size and intensity is seen by the patient (Figure 1.8A). Static perimetry 
uses test lights that have a fixed location in the visual field. During the test, lights appear and 
increase in strength. As soon as the patient observes the light, the sensitivity of that specific 
location in the visual field is known (Figure 1.8B). A proper fixation to a central spot is crucial 
in order to get reliable measurements.
Figure 1.8. Schematic illustration of the kinetic and static approach to perform a perimetry. A, In a 
kinetic perimetry, the outer borders of stardardized sensitivities (called isopters) are determined. B, In 
static perimetry, the sensitivity of specific locations in the visual field are determined. DLS, differencial 
luminance sensitivity. (Source: Schiefer, Wilhelm, Hart (eds.). Clinical neuro-ophthalmology – A practical 
guide, Springer, Berlin/Heidelberg/New York, 2007.94)
Color vision
Color vision tests have been used for many years to demonstrate abnormalities in retinal 
disorders with specific cone photoreceptor involvement. In the evaluation of IRDs, 
protanomaly, deutanomaly and tritanomaly correspond to abnormalities of the L (‘red’), 
M (‘green’) and S (‘blue’) cones, respectively. Protanomaly and deutanomaly are more 
prominent in diseases involving the foveal cones, like for example achromatopsia and cone 
dystrophy, whereas tritanomalies are usually more prominent in generalized photoreceptor 
dystrophies. However, interpretation of the many different color vision tests that are available 
nowadays is difficult since color vision is not yet fully understood.
General introduction   |  29
1Dark adaptationThe dark adaptation test is performed to measure the thresholds of cone and rod sensitivity 
after exposure to light. The sensitivity to light recovers faster in cones than in rods. However, 
the absolute level of sensitivity to light is much higher in rod photoreceptors. During 
dark adaptation testing, the patient is initially exposed to light of standardized intensity. 
Subsequently, the light is turned off, and each one to two minutes a light of increasing 
intensity tests the patient’s light sensitivity. The sensitivity measurements are plotted against 
time. In clinical practice, this examination can be used to objectify night blindness, especially 
in patients with scotopic full-field ERG responses within the normal limits, or minimal to no 
peripheral pathology on perimetry.
Electrophysiology
Electrophysiology provides objective data on retinal function. Most commonly used 
examinations include the full-field electroretinography (ERG) and multifocal ERG (mfERG). The 
ERG measures the mass response of the action potential produced by the photoreceptors in 
the retina after light flash stimulation. The examination is divided in a scotopic (dark-adapted) 
phase, and a photopic (light-adapted) phase. The scotopic responses are measured 
after a period of dark adaptation sufficient to reach maximal rod sensitivity to light. The 
photopic responses are measured after several minutes of light adaption to bleach out rod 
photoreceptors, which enables isolated measurement of cone photoreceptors.
During the scotopic phase isolated rod responses are measured with a light stimulus 
below the sensitivity threshold of cones. In addition, two more dark-adapted measurements 
are performed: the maximal (mixed) response, which includes the combined responses of 
rod and cones, and the oscillatory responses, which originates from photoreceptors, bipolar, 
amacrine and ganglion cells.95-99 In the light-adapted phase, two measurements of the 
cone photoreceptors are performed, including isolated cone response and the 30Hz flicker 
response. Normal graphs of these five basic measurements are provided in Figure 1.9.
The mfERG provides a topographic measurement of retinal electrophysiological activity. 
Local ERG responses are calculated after pseudorandom stimulation of 61 or 103 hexagonal 
areas under light-adapted conditions. Local electrical responses are visualized in a graph 
pattern, and amplitudes can be plotted in a 3D map. In this manner, localized retinal damage 
that often is not visible in the panretinal responses of the full-field ERG can be objectified 
and quantified.
The electro-oculogram (EOG) measures the difference in electrical potential between 
the front and back of the eye (corneo-fundal potential). This potential is mainly derived from 
the RPE, and changes in response to retinal illumination. Like in full-field ERG testing, an 
EOG is tested in both a scotopic and photopic setting. The amplitude of the corneo-fundal 
potential is expressed as a ratio of the maximum (peak) amplitude in the photopic phase 
and the minimal (trough) amplitude during the scotopic phase, and is referred to as the light/
dark ratio, or Arden ratio. To enhance comparison of electrophysiological examinations of 
studies, standard conditions have been published by the International Society for Clinical 
Electrophysiology of Vision (ISCEV).100-102
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Retinal imaging
Confocal scanning laser ophthalmoscopy
In confocal scanning laser ophthalmoscopy (cSLO), a diode laser beam scans the retina 
rapidly in a raster fashion. A confocal photodiode that is conjugated to the retinal plane 
detects the backscattered light. The confocal filter provides a high resolution, since only light 
reflected from the narrow spot illuminated by the laser is recorded, and the out-of-focus light 
is suppressed. Different laser wavelengths provide evaluation of different tissues of the retina. 
For example, 488 nm wavelength cSLO is used for (blue-light) fundus autofluorescence 
imaging and fluorescein angiography, whereas 700-1400 nm wavelengths are used for 
infrared reflectance imaging. This technique provides en face imaging of the retina at a high 
magnification.
Figure 1.9. Diagram of the five basic ERG responses defined by the Standard. These waveforms are 
exemplary only, and are not intended to indicate minimum, maximum or even average values. Large 
arrowheads indicate the stimulus flash. Dotted arrows exemplify how to measure time-to-peak (t, implicit 
time), a-wave amplitude and b-wave amplitude. (Source: Marmor MF et al, 2008.100)
Optical coherence tomography
Optical coherence tomography (OCT) is a noninvasive, noncontact imaging modality that 
provides a cross-sectional image of the retina, comparable to a histological section, with 
axial resolution that can be as high as 3 μm when Spectral-domain (SD) technology is 
used.103 The image is based on the backscattered light from the different layers of the retina, 
comparable to ultrasound and radar imaging. Spectral-domain OCT provides A-scans (one-
dimensional depth scans) of 2,048 pixels with a scan velocity of 18,000-55,000 A-scans 
per second.103 This results in a two-dimensional image of the retina. Multiple OCT scans that 
are topographically orientated on cSLO en face infra-red images, allow three-dimensional 
reconstruction of the retina. SD-OCT imaging can be used to highlight subtle abnormalities 
in retinal structure.104 On SD-OCT images 11 retinal layers can be recognized, in addition to 
the vitreous, Bruch membrane, choroid and the sclera (Figure 1.10).
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Figure 1.10. Optical coherence tomogram showing a cross-sectional scan of the normal retina and 
choroid at the level of the foveal depression.
Fundus autofluorescence imaging
Fundus autofluorescence (FAF) enables evaluation of the RPE function, and can be acquired 
in a rapid, noncontact, noninvasive manner. This technique uses the intrinsic autofluorescence 
that is emitted by a substance after being stimulated by excitation energy. Ocular tissues 
that autofluorescence include corneal epithelium and endothelium, lens tissue, macular and 
RPE pigments. In clinical practice, the autofluorescent characteristics of RPE pigments are 
most commonly used. FAF images can be acquired with a cSLO with a blue laser (488 
nm) for excitation. Since the autofluorescence signal is much lower compared to fluorescein 
angiography and IR fundus reflectance, series of single FAF images are recorded that are 
subsequently averaged and normalized into a mean image.43
The autofluorescent compound in the RPE cells is lipofuscin.105-107 When RPE cells 
phagocytize photoreceptor outer segments, and subsequently process the content 
of these outer segments, lipofuscin is formed as a by-product. N-retinylidene-N-
retinylethanolamine (A2E) is the primary fluorophore of lipofuscin. High levels of lipofuscin, 
appear hyperautofluorescent on FAF images as observed in increased outer segment 
phagocytosis in photoreceptor degeneration, whereas a decrease in lipofuscin levels appear 
as hypoautofluorescence. Absence of autofluorescence can either be caused by the lack of 
lipofuscin, for example in case of RPE atrophy, or by blockage of the autofluorescence signal, 
as is observed at the blood vessels (Figure 1.11) and in case of preretinal hemorrhage.106
Fluorescein angiography
Fluorescein angiography (FA) allows examination of the retinal and choroidal circulation after 
intravenous injection or oral intake of sodium fluorescein, a molecule that fluoresces with 
green light (520-530 nm) when excited with blue light (465-490 nm). When the reflected blue 
and emitted green light exit the eye, the blue light is filtered out by a yellow-green barrier 
filter. This results in black and white images, where white represents high fluorescence, 
and black represents no fluorescence. Fluorescein normally does not pass the endothelium 
of the retinal vessels (the inner blood-retina barrier) or the RPE into the subretinal space 
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(outer blood-retinal barrier). In the choroid, due to the fenestrated vessels that leak the dye, 
fluorescein is diffusely present in the extravascular matrix, which causes diffuse background 
fluorescence on FA images.
Figure 1.11. Fundus autofluorescence of 
a normal central retina. The retinal blood 
vessels appear black due to blockage of the 
autofluorescent signal. The fovea is darker 
because of the presence of macular pigment.
When pathology is present, leakage 
appears as local hyperfluorescence, just as 
local defects in the RPE layer that permit a 
direct view on the fluorescein present in the 
choroid (also known as ‘window defect’). 
Hypofluorescence appears in vascular 
filling defects and blockage of fluorescence. 
In Stargardt disease, substantial blockage 
of the background fluorescence is caused 
by the accumulation of lipofuscin in the RPE 
cells, which causes the characteristic ‘dark 
choroid’ sign.
Clinical classification of selected inherited retinal dystrophies
It is challenging to provide a straightforward classification that compromises all inherited 
retinal dystrophies, since this group includes a wide spectrum of clinical phenotypes that 
show overlapping characteristics. However, retinal dystrophies can be stratified in stationary 
diseases, such as congenital stationary night blindness and achromatopsia, and progressive 
dystrophies. The latter is generally subdivided in peripheral (generalized) dystrophies that 
have early peripheral involvement, such as retinitis pigmentosa and choroideremia, and 
central degenerations. The central degenerations can be divided in those that affect the 
posterior pole, the macular dystrophies, and those that initiate in the macula and eventually 
affect the peripheral retina as well, e.g. cone dystrophy and cone-rod dystrophy. However, 
many macular dystrophies can be considered pan retinal disorders based on the molecular 
pathology, which makes this classification confusing.
This section provides the overall clinical features of the progressive dystrophies that 
are subject of this thesis: retinitis pigmentosa, cone-rod dystrophy, Stargardt disease, and 
dominant cystoid macular dystrophy.
Retinitis pigmentosa
Retinitis pigmentosa (RP) is a group of progressive retinal dystrophies in which the rod 
photoreceptors are more or equally affected than the cone photoreceptors (rod-cone 
dystrophies). RP is the most common retinal dystrophy with an incidence of approximately 
1 in 4000,25,108-110 and shows impressive variation in age of onset, progression rate, retinal 
appearance and visual function.
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1Despite this high variability, RP does have a set of characteristics that are generally preserved throughout all the RP phenotypes. These ‘classic’ RP symptoms include night 
blindness (nyctalopia) in the early phase of the disease, which is followed by relative defects 
in the midperipheral visual field. When the disease progresses, the peripheral visual field 
defects become more prominent and lead to tunnel vision, whereas central vision is often 
spared until end-stage disease.25,111 The classic ophthalmoscopic features include intraretinal 
pigment deposits in a bone-spicule configuration that are mainly visible in the midperiphery, 
a waxy pale optic disc, and attenuated arterioles.25,108,110 The bone-spicule pigmentation 
arises from RPE that migrates into the neuroretina in response to photoreceptor cell death,112 
whereas loss of ganglion cell axons after death of the parent cells causes the atrophic 
appearance of the optic disc.113 The attenuation of the retinal vasculature is thought to arise 
from a decrease in metabolic demands.113,114 In end-stage disease profound chorioretinal 
atrophy can be present in the (mid)periphery and sometimes the posterior pole as well. The 
ERG typically shows affected rod function that exceeds or is equal to cone dysfunction. 
However, the phenotype of RP is highly variable, and many forms of RP dissociate from the 
typical phenotype, as is highlighted in chapters 2 and 3 of this thesis.
The vast majority of RP is restricted to the retina. However, 20-30% of RP forms also 
include symptoms in other tissue than the retina, which results in syndromic disease.25 The 
most prevalent forms of syndromic RP include Usher syndrome (RP with variable degrees 
of neurosensory hearing loss) and Bardet-Biedl syndrome (RP with obesity, polydactyly, 
hypogonadism, renal failure, and cognitive impairment).115,116 However, to what extend the 
various tissues are affected is highly variable, and can depend on the type of genetic defect. 
Indeed, some patients with mutations in the Bardet-Biedl genes only have retinal disease.117
Up to date, 84 genes are associated with nonsyndromic RP phenotype that cause 
disease in autosomal recessive, autosomal dominant and X-linked inheritance patterns 
when mutated (RetNet, available at https://sph.uth.edu/retnet/), and are involved in many 
different pathways (Appendix 1 and Table 1.1). In general, patients with X-linked RP exhibit 
more severe disease compared to autosomal recessive and dominant disease. Autosomal 
recessive inheritance is thought to account for 50-60% of RP patients, whereas the autosomal 
dominant and X-linked patterns are described in 30-40% and 5-15%, respectively. However, 
these proportions assume that all isolated cases are autosomal recessive, which is not the 
case since 15% of the isolated RP patients have mutations in X-linked RP genes RPGR 
and RP2.118 Furthermore, these two genes also carry mutations in 8.5% of families that were 
initially thought to have autosomal dominant inheritance.119 In only a few cases, mitochondrial 
and digenic inheritance are found.120-122
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Table 1.1. Overview of the functional characteristics of the genes known up to date to cause non-
syndromic retinitis pigmentosa. 
Gene  
symbol Protein Function Inheritance Ref
Ciliary structure and transport
ARL2BP ADP-ribosylation 
factor-like 2 binding 
protein
May play a role in trafficking of ciliary 
proteins and factors
Recessive 123
BBS1* BBS1 protein Participates in the formation of a stable 
protein complex (the BBSome) involved in 
vesicular trafficking to the ciliary
membrane
Recessive 117,124
C2orf71 Chromosome 2 open 
reading frame 71
The protein localizes to primary cilia, exact 
function unknown
Recessive 125,126
C8orf37 Chromosome 8 open 
reading frame 37
The protein localizes to the base of cilia 
in retinal photoreceptors and RPE cells; 
exact function unclear 
Recessive 127,128
KIZ Kizuna centrosomal 
protein
Stabilizes the ciliary centrosomes Recessive 129
MAK Male germ-cell 
associated kinase
Involved in regulation of retinal cilium and 
spermatogenesis
Recessive 130-132
RP1 Microtubule-
associated protein
Ciliary microtubule formation and 
stabilisation
Recessive /
Dominant
133-135
RP2 Plasma membrane 
associated protein
Photoreceptor ciliary transport, as well 
as in the interaction between plasma 
membrane and cytoskeleton
X-linked 136
RPGR Retinitis pigmentosa 
GTPase regulator
Trafficking of proteins in the connecting 
cilium
X-linked 137,138
TOPORS Topoisomerase I 
binding arginine/
serine rich protein
May play a key role in regulating 
primary cilia-dependent photoreceptor 
development and function
Dominant 139,140
TTC8 Tetratricopeptide 
repeat domain 8
Localizes to the connecting cilium in 
photoreceptors; interacts with PCM1, a 
protein involved in ciliogenesis
Recessive 141,142
TULP1 Tubby-like protein 1 Possibly involved in transport of rhodopsin 
from inner to outer segment
Recessive 143-145
Retinal development
CRX* Cone-rod otx-like 
photoreceptor 
homeobox 
transcription factor
Activator of retinal genes Dominant 146,147
FAM161A Family with 
sequence similarity 
161 member A
Expressed in photoreceptors, involved in 
development of retinal progenitors during 
embryogenesis
Recessive 148,149
NEK2 NIMA (never in 
mitosis gene 
A)-related kinase 2
Plays an important role in regulation of 
cell cycle progression through localization 
to the centrosomes and interaction with 
microtubules
Recessive 150
NR2E3 Nuclear receptor 
subfamily 2
Ligand-dependent transcription factor Recessive / 
Dominant
151-153
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Gene  
symbol Protein Function Inheritance Ref
NRL Neural retina lucine 
zipper
Retinal transcription factor which interacts 
with CRX, promotes transcription of 
rhodopsin and other retinal genes, 
and is required for rod photoreceptor 
development
Recessive / 
Dominant
154,155
SEMA4A Semaphorin 4A 
(semaphorin B)
Involved in neuronal development and/
or immune response; enhances T-cell 
activation
Dominant 156,157
SLC7A14 Solute carrier family 
7 member 14
Potential cationic transporter protein with 
an unknown ligand
Recessive 158
ZNF513 Zinc finger protein 
513
Possible transcriptional regulator involved 
in retinal development
Recessive 159
Retinal homeostasis
CA4 Carbonic anhydrase 
IV
pH regulation of retina and choriocapillaris Dominant 160
CERKL Ceramide kinase-like Involved in neuronal cell survival and 
apopotosis in retinal ganglion cells
Recessive 161
KLHL7 Kelch-like 7 protein Plays a role in the ubiquitin-proteasome 
pathway leading to protein degradation
Dominant 162
MERTK Mer tyrosine kinase 
proto-oncogene
RPE receptor involved in outer segment 
phagocytosis
Recessive 163
MVK* Mevalonate kinase Peroxisomal enzyme; a key early enzyme 
in isoprenoid and sterol synthesis
Recessive 164
USH2A Usherin Basement membrane protein; may 
be important in development and 
homeostasis of the inner ear and retina
Recessive 165-168
RNA splicing
DHX38* DEAH (Asp-Glu-Ala-
His) box polypeptide 
38
Putative RNA helicase involved in pre-
RNA splicing
Recessive 169
PRPF3 Precursor-mRNA 
processing factor 3
Member of the U4/U6-U5 tri-snRNP 
particle complex (spliceosome)
Dominant 170,171
PRPF31 Precursor-mRNA 
processing factor 31
Member of the U4/U6-U5 tri-snRNP 
particle complex (spliceosome)
Dominant 172
PRPF4 Precursor-mRNA 
processing factor 4
Member of the U4/U6-U5 tri-snRNP 
particle complex (spliceosome)
Dominant 173
PRPF6 Precursor-mRNA 
processing factor 6
Member of the U4/U6-U5 tri-snRNP 
particle complex (spliceosome)
Dominant 174
PRPF8 Precursor-mRNA 
processing factor 8
Member of the U4/U6-U5 tri-snRNP 
particle complex (spliceosome)
Dominant 175
RP9 PIM1-kinase 
associated protein 1
Has a role in pre-mRNA splicing and 
interacts with a U2-complex splice factor
Dominant 176
SNRNP200 Small nuclear 
ribonucleoprotein 
200kDa (U5)
Member of the U4/U6-U5 tri-snRNP 
particle complex (spliceosome)
Dominant 177,178
Structure and cytoskeletal
CRB1 Crumbs homologue 
1
Transmembrane protein, adherent 
junctions
Recessive 179
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Gene  
symbol Protein Function Inheritance Ref
EYS Eyes shut/
spacemaker 
(Drosophila) homolog
Extracellular matrix protein; likely to have a 
role in the modeling of retinal architecture.
Recessive 180
FSCN2 Retinal fascin 
homolog 2
Photoreceptor-specific paralog of fascin 
which crosslinks and bundles f-actin; 
proposed to play a role in photoreceptor 
disk morphogenesis
Dominant 181,182
IMPG2 Interphotoreceptor 
matrix proteoglycan 
2
Component of the retinal extracellular 
matrix; plays a role in the organization of 
the interphotoreceptor matrix and may 
promote the growth and maintenance of 
the light-sensitive photoreceptor outer 
segment
Recessive 183
PROM1 Prominin 1 5-transmembrane glycoprotein associated 
with plasma membrane evaginations in 
rod outer segments
Recessive 184,185
PRPH2 Peripherin-2 Outer disc segment membrane protein Dominant / 
Digenic
120,186,187
ROM1* Rod outer segment 
protein 1
Essential for disk morphogenesis; may 
also function as an adhesion molecule 
involved in stabilization and compaction of 
outer segment disks or in maintenance of 
rim curvature
Dominant / 
Digenic
120,188
Phototransduction
CNGA1 Rod cGMP-gated 
cation channel 
α-subunit
α-subunit of the cGMP-gated cation 
channel that enables sodium, calcium and 
magnesium influx in photoreceptor cells
Recessive 189
CNGB1 Rod cGMP-gated 
cation channel 
β-subunit
β-subunit of the cGMP-gated cation 
channel that enables sodium, calcium and 
magnesium influx in photoreceptor cells
Recessive 190-192
DHDDS Dehydrodolichyl 
diphosphate 
synthetase
Enzyme in the dolichol synthesis pathway 
and dolichol is involved in biosynthesis 
of N-linked oligosaccharide chains on 
proteins such as rhodopsin
Recessive 193
GUCA1B Guanylate cyclase 
activating protein 1B
a calcium-binding protein that activates 
photoreceptor guanylate cyclases
Dominant 194,195
PDE6A Rod cGMP-
phosphodiesterase 
α-subunit
Rod cGMP-phosphodiesterase hydrolyses 
cGMP to 5’-GMP
Recessive 196,197
PDE6B Rod cGMP-
phosphodiesterase 
β-subunit
Rod cGMP-phosphodiesterase hydrolyses 
cGMP to 5’-GMP
Recessive 196,197
PDE6G Rod cGMP-
phosphodiesterase 
γ-subunit
Inhibitory subunit of cGMP 
phosphodiesterase
Recessive 198
RHO Rhodopsin G-protein coupled photon receptor; 
activation of transducin after 
photoactivation
Dominant 199
SAG Arrestin Arrestin binds to activated rhodopsin 
(metarhodopsin II) to stop the activation of 
transducin
Recessive 77,199,200
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Gene  
symbol Protein Function Inheritance Ref
Retinoid metabolism
ABCA4 ATP-binding cassette 
protein A4
Photoreceptor disc membrane flippase
for all-trans-retinal
Recessive 201-203
LRAT* Lecithin retinol 
acetyltransferase
Isomerization of all-trans-retinol to all-
trans-retinylester
Recessive 86,204
RBP3 Retinol binding 
protein 3
Binds and transports retinoids in the 
interphotoreceptor matrix between the 
RPE and photoreceptors
Recessive 205,206
RDH11* Retinol 
dehydrogenase 11
Oxidation 11-cis-retinol to 11-cis-retinal Recessive 207,208
RDH12 Retinol 
dehydrogenase 12
Reduction of all-trans-retinal to all-trans-
retinol
Dominant 207,209
RDH5* 11-cis retinol 
dehydrogenase 5
RPE microsomal enzyme involved in 
converting 11-cis retinol to 11-cis retinal
Recessive 207,210,211
RGR RPE-vitamin A 
G-protein coupled 
receptor
Binds all-trans retinal which light converts 
to 11-cis retinal in the RPE
Recessive 212
RLBP1* Retinaldehyde 
binding protein
11-cis-retinaldehyde carrier in visual cycle Recessive 90
RPE65 Vitamin A trans-cis 
isomerase
Isomerization of all-trans-retinylester to 
11-cis-retinol
Recessive 204
Other
BEST1 Bestrophin 1 Transmembrane oligmeric chloride 
channel in the basolateral plasma 
membrane of the RPE
Recessive / 
Dominant
213,214
CLRN1 Clarin 1 4-transmembrane protein with a possible 
role in hair cell and photoreceptor 
synapses
Recessive 215,216
EMC1* Endoplasmatic 
reticulum membrane 
protein complex 
subunit 1
Component of the endoplasmic reticulum; 
unknown function
Recessive 217
GPR125* G protein-coupled 
receptor 125
Unknown function Recessive 217
IDH3B NAD(+)-specific 
isocitrate 
dehydrogenase 3 
beta
Catalyzes conversion of isocitrate to 
α-ketogluterate in the citric acid cycle in 
mitochondria
Recessive 218
IMPDH1 Inosine-5’ 
monophosphate 
dehydrogenase 
type I
Guanine nucleotide synthesis Dominant 219
KIAA1549* KIAA1549 protein Unknown function Recessive 217
PRCD Progressive rod-
cone degneration 
protein
Unknown function Recessive 220,221
SPATA7* Spermatogenesis 
associated protein 7
Localized in spermatocytes and multiple 
retinal layers; function unknown
Recessive 222
* Genes that have been described in non-syndromic RP, but that are not specified as a specific ‘type’ 
of RP. Therefore, these types are not included in Appendix 1.
38  |  Chapter 1
Cone-rod dystrophy
In contrast to RP, patients with cone-rod dystrophy (CRD) reveal progressive photoreceptor 
degeneration in which cone dysfunction exceeds rod dysfunction. CRD occurs in 
approximately 1 in 30,000-40,000.223-225 Symptoms generally initiate during childhood, and 
predominantly include decrease of visual acuity and central vision, photophobia and color 
vision abnormalities. Complaints of night blindness may develop later on in the disease.225,226
Retinal features may precede clinical symptoms, and include macular pigmentary 
changes that vary from mild granular pigment alterations to macular atrophy in a bull’s eye-like 
pattern. In later stages of the disease macular intraretinal pigment deposits and attenuation 
of the arterioles can become apparent, as well as subtle bone spicule pigmentation in 
the periphery.225 In this, the end-stage retinal abnormalities can mimic the retinal appearance 
of RP.
Perimetry examinations reveal central scotomas that enlarge with progression of 
the disease. Eventually concentric peripheral constriction may become apparent. ERG 
examination, crucial for the diagnosis of CRD, demonstrates a decrease of cone-driven 
responses that exceeds the decrease of rod-driven responses. Again, the difference between 
CRD and RP in end-stage disease can be difficult since ERG rod and cone responses may 
be non-recordable in both diseases. This highlights the importance of proper history taking 
in those cases that visit the ophthalmologist in the advanced disease stage.
Mutations in 26 genes have been associated with cone-rod dystrophies (RetNet, available 
at https://sph.uth.edu/retnet/), and include autosomal recessive, autosomal dominant and 
X-linked inheritance patterns, although CRD cases are often isolated.
Stargardt disease
Karl Stargardt described the first families with Stargardt disease (STGD1) in 1909.5 STGD1 is 
the most common macular dystrophy with an incidence of 1 in approximately 10,000.227 The 
disease typically presents within the first two decades of life,5 but the disease may manifest 
in early childhood (< 5 years of age) to the elderly (60 years of age)) (see chapters 8 and 9 
of this thesis).228 Patients with STGD1 usually note bilateral decrease in visual acuity that 
generally progresses to levels of 20/200. The fundoscopic features include irregular yellow-
white fundus flecks, and macular atrophic lesions with a so-called ‘beaten bronze’ appearance 
or a bull’s eye pattern.229-231 In end-stage disease, intraretinal pigment depositions can be 
present. The ERG responses can be normal or reveal moderate to severe abnormalities of 
both cone- and rod-driven responses.230 FA imaging reveals a darker appearance of the 
choroid (‘dark choroid sign’) that is thought to originate from the accumulation of lipofuscin in 
the RPE cells masking the background fluorescence from the choroid.229,232,233
STGD1 has been linked to mutations in the ABCA4 gene, which encodes an adenosine 
triphosphate (ATP)-binding cassette transporter (ABCR) expressed specifically in the cones 
and rods of the retina.201,234 Defects in ABCR function cause the accumulation of all-trans-
retinal and its cytotoxic derivatives in photoreceptors and RPE cells, ultimately causing 
General introduction   |  39
1RPE cell death and the subsequent loss of photoreceptors.
235 The inheritance follows the 
autosomal recessive pattern. Numerous mutations in ABCA4 have been described, each 
with their own effect on the ABCR function. Based on this, Van Driel et al. and Maugeri et al. 
proposed a model that links phenotype severity to the degree of residual ABCR function.236,237 
Even within the STGD1 phenotype, a spectrum of disease severity has been observed, which 
also may relate to the residual ABCR function.
Dominant cystoid macular dystrophy
Dominant cystoid macular dystrophy (DCMD) is an autosomal dominant retinal dystrophy 
that has the hallmark feature of cystoid intraretinal fluid collections in the posterior pole, 
which appear before other retinal abnormalities become apparent.238,239 The disease usually 
initiates in the first or second decade of life, and leads to progressive loss of central vision 
due to degeneration of the central retina. Patients with DCMD generally have moderate to 
high hyperopia.240-242
The disease is extremely rare. Up to now, only a limited number of patients have been 
described in literature, including one large Dutch family with a common ancestor that probably 
lived in the early 18th century,240 one unrelated American family of Greek ancestry,243 and one 
American and one Spanish patient.244
The causative gene has not been identified yet, but the disease has been linked to the 
locus (p15-p21) on chromosome 7.245 Further details on the clinical phenotype and genetics 
of DCMD are provided in chapter 10.
Introduction in molecular genetics
Long before the discovery of deoxyribonucleic acid (DNA) and the modern dogmas of 
genetics, it was known that certain diseases, including retinal disease, run within families. 
Molecular genetics has been thriving over the last decades, and mutations in many different 
genes, more than 200 to date, have been associated with retinal disease. Thanks to our 
current understanding of molecular genetics and inheritance patterns, we are able to explain 
diseases up to the level of molecular pathways. The following section provides a basic 
overview of the structure and function of DNA, inheritance patterns, the different genetic 
assessment techniques and genetic context of retinal dystrophies.
DNA structure and function
The research of J. Watson, F. Crick, M. Wilkin and R. Franklin led to the discovery of the 
double helix structure of DNA.246,247 The double helix is composed of two complementary 
strands build from 5-carbon sugar with attached phosphate groups that each carries a 
linear array of the purine bases guanine (G) and adenine (A), and of the pyrimidine bases 
cytosine (C) and thymine (T). A unit of a sugar with phosphate group and the base is called 
a nucleotide (Figure 1.12). A single DNA molecule (i.e. chromosome) can reach a length up 
to 250 million nucleotide pairs long.248
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Figure 1.12. Schematic illustra-
tion of the molecular structure 
of DNA and its building blocks. 
A, The building blocks of DNA, 
called nucleotides, are composed 
of a sugarphosphate backbone 
and a base. B, The sugarphos-
phate backbone link to create 
a sequence of bases. C, Two 
strands of DNA with complemen-
tary bases are linked by hydro-
gen-bonds. This molecule has a 
double helix configuration as visu-
alized in panel D. (Adapted from: 
Alberts et al. Essential Cell Biol-
ogy, 4th edition, Garland  Science, 
2014.249)
From DNA to protein
The genetic information is contained within the sequence of the nucleotides. Genes refer to 
the parts of the genetic code that are translated into proteins. The human genome contains 
approximately 25,000 genes, which together constitute 2% of the total DNA. The remaining 
98% does not encode proteins, but does carry vital information for maintaining the structure 
of DNA, or for regulating gene expression.250-254 Within each gene, the coding sequences, 
called the exons, are interrupted by sequences of noncoding DNA, the introns.
The process driving gene expression can roughly be divided in three steps: transcription, 
ribonucleic acid (RNA) splicing, and translation (Figure 1.13). Transcription is the process 
in which the DNA data is translated into RNA data. RNA is structurally similar to DNA, but 
is usually single-stranded, has a backbone made of ribose instead of deoxyribose, and 
contains the uracil pyrimidine base instead of thymine that is present in DNA.255 During 
transcription, RNA polymerases create an RNA strand complementary to one of the DNA 
strands. In this process, the whole gene including both exons and introns is encoded into 
precursor messenger RNA (pre-mRNA).
Before the pre-mRNA molecule leaves the nucleus, a process of RNA splicing removes the 
intronic RNA from the molecule. The resulting RNA molecule only contains the information of 
General introduction   |  41
1
Figure 1.13. Schematic illustration of transcrip-
tion, splicing and translation. The pre-mRNA 
contains data of the exons and introns of the 
transcripted gene. During the RNA splicing 
process, the intronic RNA is removed. Sub-
sequently, the mRNA is exported to the cyto-
plasm, where the translation to a protein takes 
place. (Source: Alberts et al. Essential Cell Biol-
ogy, 4th edition, Garland Science, 2014.249)
Figure 1.14. Schematized 
representation of alterative 
splicing of the α-tropomyosin 
gene. Each mRNA subtype 
leads to an isoform of the 
α-tropomyosin gene that are 
expressed in specific tissues. 
(Source: Alberts et al. Essential 
Cell Biology, 4th edition, 
Garland Science, 2014.249)
the exons, and is referred to as messenger RNA (mRNA, Figure 1.13). The splicing process 
is not completely static: alternative splicing occurs in approximately 60% of genes.248 In 
alternative splicing, specific exons are not included in the mRNA, and therefore lead to 
multiple different mRNA molecules from a single gene (Figure 1.14), which are translated into 
protein subtypes, called isoforms.
Isoforms can be either ubiquitously expressed, or tissue-specific. The process of alternative 
splicing provides the opportunity to further increase the already enormous coding potential 
of the human genome. To stabilize the molecule, promote export to the cytoplasm and mark 
the RNA molecule as a mRNA , the 5’ end is capped with a guanine nucleotide bearing a 
methyl group, and the 3’ end is elongated by a series of repeated adenine nucleotides that 
generally is a few hundred nucleotides long (poly-A-tail).249
The last step in the process from DNA to protein, translation, takes place in the cytoplasm, 
where ribosomes are located. The mRNA travels into the cytoplasm, where ribosomes bind 
to the molecule. These ribosomes enable transient binding of transport RNA (tRNA), which 
are special RNA molecules that carry amino acid, to the mRNA. The mRNA code is read in 
sequences of 3 nucleotides, called codons. When the ribosome encounters the start codon, 
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the tRNA molecules complementary to this codon binds. Subsequently, the ribosome reads 
the next codon and the complementary tRNA binds to this codon, after which the amino acid 
of the first tRNA is attached to the amino acid of the second tRNA (Figure 1.15). This process, 
creating a strain of amino acids, continues until a stop codon is encountered in the mRNA 
sequence. The stretch of amino acids subsequently is folded and finalized, which results in 
the newly produced protein.
Genetic defects
The genetic code directly determines the sequence of amino acids of a protein (see section 
above). Although the body has extremely efficient DNA repair mechanisms, changes in the 
genetic code occur. If changes in the genetic code are located in exons they may change 
the amino acid sequence, and with that the protein. Intronic changes are thought to be less 
pathogenic, although they may have effects on splicing and regulatory processes.
There are a wide variety of changes that can occur in the genetic code. Based on the 
frequency of the genetic change, the difference is made between polymorphisms (frequency 
>1% in the general population) and mutations (<1% in the general population). In monogenetic 
diseases, like the majority of IRDs, mutations are the underlying molecular cause leading to 
disease, although polymorphisms can be of influence on the clinical phenotype, e.g. modifier 
effects.
Mutations can either involve a single nucleotide (point mutation) or multiple nucleotides, 
which may extend up to large stretches of nucleotides or even whole exons. In this thesis, 
the mutations are often named after their effect on the protein instead of the specific genetic 
change. Examples are silent mutations (or synonymous mutations) that do not alter the 
amino acid sequence, missense mutations that cause a change of the amino acid, and 
nonsense mutations that result in a stop codon and cause a premature termination of the 
protein (Figure 1.16). Insertions and deletions (also abbreviated as ‘indels’) of one or multiple 
nucleotides result in a frame shift if the number of inserted or deleted nucleotides is not 
dividable by 3. This often results in a different stretch of amino acids and often a premature 
stop (Figure 1.16). Splice site mutations alter the sequence of the DNA in the exon-intron 
boundary area, affecting the location where the spliceosome adheres to initiate splicing. This 
often results in aberrant splicing.
The pathogenicity of a mutation is determined by its effect on the protein function. 
Nonsense mutations are generally considered to be pathogenic, since they cause a 
premature truncation of the protein, functional areas of the protein are often lost. Splice 
site mutations are also considered pathogenic, since altered splicing also often disrupts 
the correct composition of the mRNA molecule, and thus leads to the formation of no or 
a non-functional protein. Indels are considered pathogenic if a frame shift or a premature 
truncation of the protein occurs. Missense mutations, on the other hand, have a less clear-cut 
pathogenicity profile. Several factors are involved in the effects that missense mutations have 
on protein function, such as the differences in physical properties of the exchanged amino 
acids (Figure 1.16), the location of the amino acid change (whether it is located in a functional 
domain of the protein or not), and if the affected residue is conserved during evolution. For 
most of these factors computerized, or so-called in silico, prediction algorithms are available, 
e.g. the Polyphen-2 score, the Grantham score, SIFT and the PhyloP score.256-259
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Figure 1.15. Schematic illustration of the translation process. The 
small and large ribosomal subunits bind to the mRNA, followed 
by the binding of tRNA molecules that carry an amino acid to 
the vacant A-site of the ribosome. The close relationship of the 
A and P sites only allow bondage of base pairs with codons 
that are contiguous, with no stray bases in between, which 
ensures preservation of the correct reading frame throughout 
the synthesis of the protein. Subsequently, the polypeptide chain 
(amino acid #3) is uncoupled from the tRNA at the P site and 
joined to the amino acid linked to the tRNA at the A site. Next, 
the ribosomal subunits translocate one codon, which ejects the 
tRNA at the E-site. This process is continued until a stop codon 
is encountered. (Source: Alberts et al. Essential Cell Biology, 4th 
edition, Garland Science, 2014.249)
Inheritance patterns
The vast majority of the IRDs follow one of the Mendelian 
inheritance patterns. The autosomal recessive inheritance 
pattern is most common among IRDs. In this pattern both 
alleles, which are the maternal and paternal copies of the 
same gene, are affected. Mutations can be homozygous 
(both alleles carry the same mutation) or compound 
heterozygous (both alleles are affected but by different 
mutations). In the autosomal dominant inheritance pattern, 
a mutation on one of both alleles is sufficient to cause 
disease. Autosomal dominant diseases generally manifest 
in each generation of a pedigree, since the chance 
of passing on the mutated allele is 50%. In X-linked 
diseases, the mutation is located on the X-chromosome. 
These diseases generally behave like recessive disease: 
if one normal allele is present, no disease occurs. 
X-linked inherited diseases therefore generally only 
affect males, since males only carry one X-chromosome 
whereas females carry two. Female carriers usually have 
no complaints, although they may show subtle retinal 
changes. However, semi-dominant X-linked RPGR-
associated RP cases have been described, in which female carriers were equally affected as 
the male patients.260
Other inheritance patterns that have been observed in IRDs are mitochondrial and 
digenic inheritance.120-122
Genetic heterogeneity
In the past few decades, many genetic causes of IRDs have been uncovered. In that time, 
the exceptional heterogeneity of the genetic background of IRDs became clear. Nowadays, 
over 200 genes have been known to carry mutations that lead to an IRD phenotype, where 
multiple genes can be involved in a single clinical subtype of IRD, for example 68 genes 
involved in non-syndromic RP. On the other hand, a single gene can cause different 
phenotypes depending of the mutation in that gene, for example PRPH2 that can cause 
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autosomal dominant RP, as well as macular dystrophies such as central areolar choroidal 
dystrophy and various pattern dystrophies (Figure 1.17) (RetNet, available at https://sph.uth.
edu/retnet/). In addition to the enormous number of genes involved in IRDs, the mutational 
variation is enormous. Only few more recurrently observed (founder) mutations are known. 
This extreme genetic heterogeneity complicates molecular genetic analyses in IRDs.
Genetic assessment techniques
Since the dawn of modern genetics, many techniques for genetic analysis have been 
developed. The most basic type of genetic analysis is Sanger sequencing, developed by 
two time Nobel price winner Frederik Sanger in 1977.262 Sanger sequencing determines 
the sequence of nucleotides based on selective incorporation of chain-terminating 
Figure 1.16. Illustration of the effects of missense and nonsense mutations, as well as insertions and 
deletions that often cause a shift of the reading frame. Arg, arginine; Glu, glutamic acid; Gly, glycine; 
Lys, lysine; Phe, phenylalanine; Thr, threonine; Tyr, tyrosine. The asterisk marks the mutated nucleotide.
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dideoxynucleotides by DNA polymerase during in vitro DNA replication,262,263 and is regarded 
as the golden standard in DNA sequencing. This method has been the main technique 
for DNA sequencing for over 25 years. In the past few years, however next-generation 
sequencing (NGS) techniques have supplanted Sanger sequencing, although the latter is 
still used to confirm mutations discovered with NGS technology.
Many different techniques are currently available for genetic analysis, each with its own 
advantages and disadvantages. Sanger sequencing is the most precise method available. 
However, it is costly, labor-intensive and time-consuming when used in sequencing of large 
numbers of genes. To analyze mutations in multiple genes in a cost-effective manner, the 
Figure 1.17. Clinical symptoms of non-syndromic monogenic retinal diseases and their causative 
genes. Clinical diagnoses are indicated by colored circles. Gene symbols in the overlapping areas show 
that mutations in the same gene can lead to different phenotypes. CD, cone dystrophy; CRD, cone-
rod dystrophy; CVD, color vision defects; LCA, Leber congenital amaurosis; MD, macular dystrophy; 
NB, night blindness; RP, retinitis pigmentosa. (Adapted from Berger W, Kloeckener-Gruissem B, 
Neidhardt J. The molecular basis of human retinal and vitreoretinal diseases. Prog Retin Eye Res. 2010 
Sep;29(5):335-75.261)
46  |  Chapter 1
micro-array chip was developed. This chip enabled screening of the presence (or absence) of 
specific mutations in different genes. In the field of IRDs, micro-array chips using the arrayed 
primer extension technique (Figure 1.18) are available for Stargardt disease (ABCA4), Leber 
congenital amaurosis (multiple genes) and autosomal recessive and dominant RP (multiple 
genes).264-266 Whole exome sequencing is a new technique that enables sequencing of the 
exons of all genes in the human genome simultaneously. This had large consequences on 
the costs, labor and time necessary to perform genetic analysis in multiple genes, which all 
decreased tremendously.
In daily practice, Sanger sequencing is used if mutations in a specific gene are suspected. 
If the mutations causative to the phenotype could be situated in multiple genes, as is the case 
of most RP and CRD cases, high-throughput NGS techniques like whole exome sequencing 
are more adequate. Micro-array chips have been used to test the patient’s DNA on certain 
specific mutations that are known to cause disease (Figures 1.18). However, since the 
number of genes and mutations in IRDs has grown significantly (Figures 1.19), this method 
has become inadequate and costly compared to NGS techniques (see Chapter 7).
Figure 1.18. Outline of the arrayed primer extension (APEX) technique. Step 1: A primer of 25 nucleotides 
specific for a nucleotide sequence just next to the variant nucleotide of interest are linked to a glass slide. 
Step 2: hybridization of fractionated wild-type or mutant genomic sequences amplified by polymerase 
chain reaction (PCR). Step 3: primer-extension using fluorescently labeled dideoxynucleotides. Step 4: 
separation of template DNA and detection of specific fluorescent dye and thereby the variant nucleotide 
of interest.
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Figure 1.19. Impression of the number of IRD genes identified and IRD loci mapped over the last 34 
years. (Source: RetNet, the Retinal Network, available at: https://sph.uth.edu/retnet/)
Aims and outline of this thesis
The growing number of genes involved in retinal dystrophies has increased our understanding 
of these diseases enormously. However, it also complicated the health care in these 
patients, especially for general ophthalmologist and geneticists. The main objective of this 
thesis was to improve our clinical and genetic knowledge on IRDs by providing detailed 
clinical descriptions of several subtypes of IRDs, as well as associate these phenotypic 
characteristics to the molecular genetic defects. This knowledge is important to counsel 
patients and their families, select the technique for genetic analysis, interpret molecular 
genetic findings, as well as to select patients amenable for future therapeutic trials.
Chapter 1 provides the basic aspects of the anatomy of the retina and choroid, as well as the 
physiologic processes that lead to vision. It discusses clinical tests and their value in clinical 
assessment of a patient. The reader is additionally introduced in the field of IRDs, and the 
general clinical aspects of the retinal dystrophies discussed in this thesis are considered. In 
addition, this chapter describes the basics of molecular genetics and the genetic context of 
IRDs.
The clinical characteristics of patients with RP associated to mutations in the IMPG2 genes 
are discussed in Chapter 2. In this form of RP, the general symptoms of night blindness and 
tunnel vision are complicated with a decrease in central vision due to relatively early macular 
involvement. This macular disease often displays as a bull’s eye maculopathy prior to further 
loss of macular tissue and a central atrophy becomes apparent. In this chapter we also 
discuss possible genotype-phenotype correlations.
Chapter 3 describes the clinical findings in MAK-associated RP, and also includes an 
overview of the retinal dystrophies caused by ciliary genes that cause both syndromic and 
nonsyndromic disease when mutated, and possible genotype-phenotype correlations. The 
MAK gene encodes a protein that plays a role in the connecting cilium of photoreceptor cells, 
and therefore defects in MAK are considered a form of ciliopathy. Ciliopathic disease can be 
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associated with syndromic disease, but MAK-associated RP appears not to be associated 
with syndromic symptoms.
In Chapter 4, the clinical characteristics of retinal disease caused by mutations in another 
ciliary gene, C8orf37, are discussed. Mutations in C8orf37 can give rise to either a form 
of RP with macular atrophy during childhood or adolescence, or a rather classic form of 
CRD. Interestingly, in one family postaxial polydactyly has occurred, which may indicate that 
mutations in C8orf37 may cause syndromic disease, and patients with this mutation should 
be carefully examined for extraocular abnormalities. Again, we provide possible correlations 
between the genetic and the phenotypic findings.
The clinical spectrum of disease caused by mutations in the ABHD12 gene is represented 
in Chapter 5. Nonsense mutations in this gene causes the PHARC-syndrome, which 
includes polyneuropathy, hearing loss, ataxia, retinitis pigmentosa and cataract. The chapter 
describes missense mutations in ABHD12, as well as the clinical spectrum that ranges from 
the complete PHARC syndrome phenotype to non-syndromic retinal degeneration.
Chapter 6 evaluates the clinical spectrum of USH1G-associated disease. Mutations in 
this gene have been associated with Usher syndrome type 1, which is characterized by 
congenital neurosensory hearing loss, vestibular areflexia and RP. This study describes a 
Dutch family with sensorineural hearing loss caused by compound heterozygous missense 
and nonsense mutations in USH1G in absence of retinal degeneration.
The efficiency of the arrayed-primer extension (APEX) microarray screening for autosomal 
recessive RP is discussed in Chapter 7. Since the dawn of modern genetics, many genes 
involved in autosomal recessive RP have been described, which complicates genetic 
analysis. In 2006, APEX microarray screening was a cost-efficient technique to screening 
multiple genes for mutations simultaneously. However, better alternatives for genetic analysis 
of autosomal recessive RP became available with the dawn of NGS techniques.
In Chapter 8, we describe the clinical features of early-onset STGD1 patients that present 
with visual complaints before the age of 10. These patients often present with early foveal 
atrophy and progress to visual acuity levels of hand movements, in contrast to patients with a 
classic STGD1 phenotype that presents during adolescence or early adulthood and progress 
to visual acuity levels ranging from 20/200 to finger counting. The clinical characteristics and 
genetic findings of early-onset STGD1 are provided and discussed in this chapter.
Chapter 9 evaluates the clinical characteristics of the foveal sparing phenomenon in patients 
with STGD1. This phenomenon mainly occurs in late-onset Stargardt, and is characterized 
by a relative preservation of the visual acuity, although visual acuity ultimately deteriorates by 
the end-stage of the disease when the foveola degenerates. The clinical findings and natural 
history of foveal sparing in STGD1 provided in this study are clinically relevant to counsel 
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1patients and their family members. Furthermore, this patient cohort may be promising candidates for future therapeutic trials.
The clinical phenotype of DCMD is presented in Chapter 10. It describes three grades of 
the disease based on the longitudinal data of multimodal imaging and electrophysiological 
findings in 97 Dutch patients, which is vital for counseling of patients and family members. In 
addition, therapeutic options in DCMD are discussed, as well as underlying pathophysiological 
processes.
Chapter 11 describes the set-up of the RD5000 database (RD5000db), the first multi-center, 
web-based database that includes anonymized detailed clinical data as well as selected 
genetic details in the Netherlands. The RD5000db has been created to enhance clinical and 
genetic studies on IRDs, as well as select patients for future clinical trials.
In Chapter 12, the studies described in this thesis are further discussed, integrated and 
place in a broader perspective.
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Abstract
Purpose. To provide the first detailed clinical description in patients with retinitis pigmentosa 
(RP) caused by recessive mutations in IMPG2.
Methods. This international collaborative study includes 17 RP patients with inherited retinal 
disease caused by mutations in IMPG2. The patients were clinically (re-)examined, including 
extensive medical history taking, slit-lamp biomicroscopy, ophthalmoscopy, perimetry, 
electroretinography (ERG), optical coherence tomography (OCT), fundus autofluorescence 
(FAF) imaging, fundus photography, and color vision tests. The main outcome measures 
included mean age at onset, initial symptom, best-corrected visual acuity, fundus appearance, 
perimetry results, ERG responses, OCT images, FAF imaging, color vision test reports and 
DNA sequence variants.
Results. The mean age at onset was 10.5 years (range: 4–20 years). Initial symptoms included 
night blindness in 59% of patients, a decreased visual acuity in 35% and visual field loss in 
6%. Fundus abnormalities were typical of RP: optic disc pallor, attenuated vessels, bone 
spicules and generalized atrophy of the retina and choriocapillaris. Additionally, we observed 
macular abnormalities in all patients, ranging from subtle mottling of the macular pigment 
epithelium (two patients), a bull’s eye maculopathy (7 patients) to macular chorioretinal 
atrophy (7 patients).
Conclusions. Mutations in IMPG2 cause a severe form of RP with symptoms manifesting in 
the first two decades of life. IMPG2-associated RP is frequently accompanied by macular 
involvement, ranging from mild pigment alterations to profound chorioretinal atrophy. The 
resulting decrease in central vision in combination with the severe tunnel vision leads to 
severe visual impairment in patients with IMPG2-associated RP.
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Introduction
Retinitis pigmentosa (RP) is a group of diseases featuring progressive degeneration of rod 
and cone photoreceptor cells and retinal pigment epithelium (RPE), and is considered the 
most commonly inherited retinal dystrophy with an estimated prevalence of approximately 
1:4000.1-3 RP typically starts with night blindness followed by loss of the peripheral visual 
field that leads to tunnel vision, whereas visual acuity often remains normal until the late 
stages.3, 4 Hallmark fundus abnormalities in RP are bone-spicule pigmentation, a waxy pale 
optic disc and attenuation of retinal vessels. Electroretinography (ERG) responses reveal 
rod and cone dysfunction, where rod abnormalities often are observed earlier in the course 
of the disease. However, wide variability in terms of disease onset, progression rate and 
degeneration patterns are observed in RP.4, 5
The genetic background underlying RP is also very heterogeneous. Inheritance modes 
observed in RP include autosomal-recessive (30% of patients), autosomal-dominant (20%), 
X-linked (10%), mitochondrial (<1%) patterns, and few cases of digenic RP.6-9 However, 
the remaining 40% of patients are isolated cases.10 Autosomal recessive RP is currently 
associated with mutations in 42 different genes (RetNet, https://sph.uth.edu/retnet/), which 
provide a molecular genetic explanation for approximately 50% of all recessive RP cases.11 
The proteins encoded by these genes are involved in a broad range of cellular functions, 
including phototransduction, the visual (retinoid) cycle, transport along the connecting cilium, 
cell to cell signaling or synaptic interaction, gene regulation, cell- or cytoskeletal structure, 
cell-cell interactions and outer segment phagocytosis.4, 10, 12
Recently, mutations in the IMPG2 gene have been implicated in autosomal recessive RP.13 
This gene encodes the interphotoreceptor matrix proteoglycan-2 (IMPG2), formerly known 
as IPM 200 or SPACRCAN,14 which is localized in the retinal extracellular matrix (also known 
as the interphotoreceptor matrix, IPM). The IPM is a viscous substance mainly composed 
of glycoproteins and proteoglycans that fills the space between individual photoreceptor 
cells and between photoreceptors and the RPE.15, 16 For many years the IPM was considered 
merely a fixating medium,17 but in the last few decades multiple functions of the IPM have 
been reported, including important functions in intercellular communication, regulation 
of neovascularisation, cell survival, membrane turnover, photoreceptor differentiation 
and maintenance, retinoid transport, matrix turnover and the precise alignment of the 
photoreceptor cells to the optical light path.14, 18, 19 Both rod and cone photoreceptor cells 
synthesize IMPG2 and secrete the protein into the IPM,20 where it binds to other proteins like 
hyaluronan, and also seems to be anchored in the plasma membrane of the photoreceptor 
cells, thereby fixating the photoreceptors in the IPM.21 Additionally, IMPG2 is thought to 
have calcium binding potential, which suggests it has an important role in sequestering 
extracellular calcium released by photoreceptors in response to light.21
Knowledge of the natural course of IMPG2-related RP is of significant importance for 
prognosis counseling as well as genetic counseling. Furthermore, this knowledge is vital in 
the view of emerging therapy trials, in terms of patient selection as well as the assessment 
of treatment effects. In this international collaborative study, we aim to provide a detailed 
overview of the clinical findings in patients with IMPG2-associated RP.
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Methods and patients
Subjects and genetic analysis
The specialized ophthalmogenetic centers of the Radboud university medical center (RACvH, 
CBH and BJK), the Rotterdam Eye Hospital (LIvdB), the Erasmus University Medical Center 
Rotterdam (CCWK), the Hadassah-Hebrew University Medical Center in Jerusalem (EB), the 
Seconda Università degli Studi di Napoli (FS) and the Shifa College of Medicine in Islamabad 
(RQ) participated in this study. As described previously,13 six families of Israeli, Palestinian, 
Pakistani, Italian or Dutch origin were found to carry causative mutations in IMPG2 (families 
A-F, Figure 2.1). Additionally, we selected four more families after identification of causative 
IMPG2 mutations in a targeted next-generation sequencing experiment in 100 Dutch RP 
probands (family G),22 or whole exome sequencing (families H, J, K, Figure 2.1).
Figure 2.1. Pedigrees of the families that were included in this study. Where relatives were available 
(families A, B, C, F, G, and H),the mutation segregates with the disease. Plus signs denote the wild 
type allele, square boxes indicate men, circles indicate women, and affected individuals are pointed 
out in black. The arrows indicate the probands. Double lines point out consanguineous marriages, the 
numbers indicate the degree of consanguinity. The dagger(†) indicates the patients diagnosed with RP 
not included in this study, due the lack of clinical data.
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 Exome sequencing was performed using the 5500xl Genetic Analyzer of Life Technologies™ 
(Life Technologies, Applied Biosystems, Foster City, CA, U.S.A.) and the Agilent SureSelectXT 
Human All Exon 50Mb amplification kit (Agilent Technologies Inc., Santa Clara, CA, U.S.A.). 
Data was analyzed with LifeScope™ software (version 2.1; Life Technologies, Applied 
Biosystems, Foster City, CA, U.S.A.). All mutations were confirmed with Sanger sequencing.
We adhered to the tenets of the Declaration of Helsinki and obtained approval for this 
study from the Institutional Ethics Committee from the Radboud university medical center. 
Approval included permission to use the documented medical data and, when indicated, 
clinically re-assess affected individuals and to obtain blood for the purposes of DNA 
extraction and genetic analysis. We obtained informed consent from all participants prior to 
the collection of blood samples and additional ophthalmologic examinations.
Clinical analysis
We collected the available clinical data from the medical files of all patients. Nine patients were 
clinically re-evaluated after the identification of causative IMPG2 mutations. Medical history 
was registered with a focus on the age at onset, initial symptoms and the overall course of 
the retinal disorder. The age at onset was defined as the age at which the initial symptom was 
noticed by the patient. Additionally, we questioned patients about the presence of syndromic 
features, which generally occur in 20-30% of RP patients.4 This questionnaire included 
the presence of hearing and balance abnormalities, renal failure, cardiac and respiratory 
anomalies, polydactyly, obesity, cognitive impairment, fertility disorders, hypogonadism and 
dental anomalies.
Clinical examination included best-corrected visual acuity (BCVA), slit-lamp 
biomicroscopy, and ophthalmoscopy. Additional examinations were performed if feasible. 
Goldmann (kinetic) perimetry was performed in 11 patients using targets V-4e, III-4e, I-4e, 
I-3e, I-2e and I-1e. In two patients (F-II:1 and F-II:2) perimetry was restricted to analysis of 
the central 30 degrees of the visual field with the Humphrey perimeter (Carl Zeiss Meditec, 
Jena, Germany). In all but one patient (F-II:2), full-field ERG was performed according the 
guidelines of the Internationals Society for Clinical Electrophysiology of Vision (ISCEV).23 
Results were compared to the local reference values. We evaluated color vision in six 
patients using the Farnsworth Dichotomous Test (Panel D-15) and/or the Hardy-Rand-Rittlers 
(HRR) test. Fundus photographs of the central retina (Topcon TRC50IX, Topcon Corporation, 
Tokyo, Japan) were obtained in 15 patients. Fundus autofluorescence images (Spectralis™, 
Heidelberg Engineering, Heidelberg, Germany) of the central retina were acquired in eight 
patients using a confocal scanning laser ophthalmoscope (cSLO) with an optically pumped 
solid state laser (488 nm) for excitation. Spectral-domain optical coherence tomography 
(SD-OCT, Spectralis™, Heidelberg Engineering, Heidelberg, Germany) could be performed 
in 13 patients. In three patients a high resolution OCT was not available and a time-domain 
OCT (Stratus, Carl Zeiss Meditec, Jena, Germany) was obtained. No OCT images were 
available for the remaining 4 patients. In eight Dutch patients with high-resolution SD-OCT 
images (mean age: 51 years, range: 23-67 years), we quantified thickness of the total retina 
at the foveola and at 0.25, 0.5, 1, 1.5, 2 and 2.5 mm eccentricity from the foveola in the right 
eye using the thickness graphs in the Heidelberg Eye Explorer Software (version 1.6.4.0; 
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Heidelberg Engineering, Heidelberg, Germany). In seven of these patients, we quantified the 
foveal volume by measuring the retinal volume within the central 3 mm2 using the thickness 
map in the Heidelberg Eye Explorer Software (version 1.6.4.0; Heidelberg Engineering, 
Heidelberg, Germany). A normal dataset of retinal thickness and foveal volume in individuals 
without (vitreo)retinal disease was obtained from 25 age-matched Dutch individuals (mean 
age: 46 years, range: 27-62 years) for reference purposes.
Results
Ten families with a total of 17 affected individuals were included in this study. The pedigrees 
of all families are depicted in Figure 2.1. An overview of the clinical findings in all 17 patients 
is provided in Table 2.1.
Clinical evaluation
The most recent examination of the 17 RP patients was performed at a mean age of 49 years 
(range: 23-67 years). The mean age at onset was 10.5 years (range: 4–20 years), and night 
blindness was the most frequent initial symptom occurring in 10 patients (59%). Other initial 
symptoms were decrease in visual acuity (35%) and loss of visual field (6%). In the patients 
who initially revealed a decreased visual acuity, normal BCVA were measured prior to the 
decrease in visual acuity, which excludes refractive amblyopia. In one patient (A-II:6), the 
diagnosis of RP was made during a routine ophthalmologic consultation when he was 12 
years old. At that time, he had not noticed any symptoms associated with RP, but later in the 
course of the dystrophy night blindness manifested as the first symptom at age 24. In eight 
patients, an extended clinical follow-up period varying from 14 to 48 years was available 
(mean: 29 years). The course of the BCVA for each of these patients during follow-up is 
represented in Figure 2.2. None of the patients showed extra-ocular abnormalities that are 
indicative of syndromic RP.
Refractive errors included mild to high myopia (range of spherical equivalents: plan to -12.00D; 
Table 2.1). Significant lens opacities were observed in 13 patients, most often subcapsular 
posterior cataracts (seven patients (41%), Table 2.1). Six patients had experienced cataract 
surgery, most often in the fourth decade (5 of 6 patients). Ophthalmoscopy revealed the 
classic RP features, including bone spicule pigmentation at the (mid)periphery, attenuated 
vessels, waxy pallor of the optic disc and atrophy of the RPE and choriocapillaris in all RP 
patients. In one patient (A-II:5) marked sheathing of the peripheral retinal vessels was noted 
(Figure 2.3A). In addition, all patients revealed macular abnormalities ranging from subtle 
changes, such as mottling of the macular RPE as observed in C-II:2 and J-II:1, to profound 
macular atrophy as was observed in seven patients (mean age: 57 years, range: 36-66, 
Figure 2.3B). A bull’s eye maculopathy (BEM) was a distinctive ophthalmoscopic feature 
in six patients, which mainly was observed during the fifth and sixth decades of life (mean 
age: 51 years, range: 32-67 years, Figures 2.3C, 2.3D, and 2.4A). Since the exact onset of 
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the BEM could not be ascertained, we were unable to define the interval in which the BEM 
had been present in these patients. Progression of a BEM to atrophy covering the whole 
fovea was observed in the follow-up data of patient G-II:1.
Perimetry revealed visual field constriction resulting in tunnel vision of 20° or less in nine 
patients (mean age: 48 years, range: 23-66 years; Figure 2.5). Macular involvement was 
apparent by a gradual decrease in central sensitivity, which we observed in 10 patients 
(mean age: 40 years, range: 23-66 years). We observed paracentral scotomas in two 
patients (C-II:2 and C-II:3) with a relatively intact (mid)peripheral visual field (Figure 2.5C). 
Additionally, paracentral scotomas were present in patients F-II:1 and F-II:2, in whom only the 
central 30° were analyzed with the more sensitive static perimeter (Table 2.1). ERG responses 
were nonrecordable in 11 patients (mean age: 51 years). In five patients (mean age: 31 years) 
a severely reduced photoreceptor dysfunction was seen in a rod-cone pattern. Evaluation 
of color vision resulted in an isolated tritan defect in patients A-II:6, G-II:1 and G-II:2 at age 
24, 40 and 39, respectively, whereas patients C-II:2 and C-II:3 demonstrated strong protan, 
deutan and tritan defects at age 33 and 36, respectively. In patient A-II:5 we did not detect 
color vision defects.
Figure 2.2. Graph showing the change in visual acuity (y-axis) related to the age in years (x-axis) in 
patients carrying mutations in the IMPG2 gene. Snellen visual acuity was transformed into logarithm 
of the minimal angle of resolution (logMAR) for visualisation purposes. A logMAR value of 1.9 was 
assigned to counting fingers (CF), 2.3 to hand movements (HM) and 2.7 to light perception (LP). When 
the visual acuity differed in both eyes, the visual acuity of the best eye was used. The improvement 
in visual acuity in patient A-II:5 was seen after cataract surgery; subsequently, the decrease in visual 
acuity was probably due to cystoid macular edema, which was successfully treated. The cause of the 
improvement in patient J-II:1 is unclear, since refractive, optical or retinal causes seemed absent.
70  |  Chapter 2
Ta
bl
e 
2.
1.
 C
lin
ic
al
 fi
nd
in
gs
 in
 p
at
ie
nt
s 
w
ith
 IM
P
G
2-
as
so
ci
at
ed
 re
tin
iti
s 
pi
gm
en
to
sa
 a
t t
he
ir 
m
os
t r
ec
en
t v
is
it.
Fa
m
ily
*
P
at
ie
nt
 ID
/A
aO
 
(y
)/A
ge
(y
)/
S
ex
In
iti
al
 
sy
m
pt
om
V
is
ua
l A
cu
ity
†
S
E
R
 (D
)‡
Le
ns
 S
ta
tu
s
O
ph
th
al
m
os
co
py
 R
es
ul
ts
E
R
G
 R
es
ul
ts
O
D
O
S
O
D
O
S
S
co
to
pi
c
P
ho
to
pi
c
A (W
01
-2
99
)
A
-I
I:1
/8
/5
9/
F
D
ec
re
as
e 
in
 
vi
su
al
 a
cu
ity
LP (2
.7
)
LP (2
.7
)
-4
.0
0
-4
.0
0
P
S
C
 
ca
ta
ra
ct
; 
ex
tra
ct
ed
 a
t 
37
y 
(R
E
) a
nd
 
38
y 
(L
E
)
B
E
M
, o
pt
ic
 d
is
c 
pa
le
ne
ss
, 
p
er
ip
ap
ill
ar
y 
at
ro
ph
y,
 v
es
se
l 
at
te
nu
at
io
n,
 R
P
E 
at
ro
ph
y 
an
d 
b
on
e 
sp
ic
ul
e 
pi
g
m
en
ta
tio
ns
 
in
 th
e 
p
er
ip
he
ry
.
N
R
(a
g
e 
8 
an
d 
27
)
N
R
(a
g
e 
8 
an
d 
27
)
A (W
01
-2
99
)
A
-I
I:5
/1
4/
45
/M
Lo
ss
 o
f 
vi
su
al
 fi
el
d
20
/2
00
(1
.0
)
LP (2
.7
)
-0
.2
5
-0
.2
5
P
S
C
 
ca
ta
ra
ct
; 
ex
tra
ct
ed
 a
t 
24
y 
(L
E
) a
nd
 
32
y 
(R
E
)
S
ub
tle
 B
E
M
, E
R
M
, 
p
er
ip
ap
ill
ar
y 
at
ro
ph
y,
 o
pt
ic
 
di
sc
 p
al
lo
r, 
at
te
nu
at
ed
 
ve
ss
el
s.
 P
er
ip
he
ry
: s
he
at
in
g 
of
 th
e 
ve
ss
el
s,
 R
P
E 
at
ro
ph
y 
an
d 
b
on
e 
sp
ic
ul
e 
pi
g
m
en
ta
tio
ns
.
S
R
(a
g
e 
14
 
an
d 
30
)
S
R
(a
g
e 
14
 
an
d 
30
)
A (W
01
-2
99
)
A
-I
I:6
/1
2/
44
/M
N
on
e,
 a
fte
r 
di
ag
no
si
s 
ni
gh
t 
bl
in
dn
es
s
20
/1
20
(0
.8
)
20
/4
00
(1
.3
)
pl
an
-0
.2
5
P
S
C
 
ca
ta
ra
ct
; 
ex
tra
ct
ed
 a
t 
32
y 
(b
ot
h 
ey
es
)
B
E
M
, p
er
ip
ap
ill
ar
y 
at
ro
ph
y,
 
pa
le
 o
pt
ic
 d
is
c,
 a
tte
nu
at
ed
 
ve
ss
el
s,
 R
P
E 
at
ro
ph
y 
an
d 
b
on
e 
sp
ic
ul
e 
pi
g
m
en
ta
tio
ns
 
in
 th
e 
p
er
ip
he
ry
.
S
R
(a
g
e 
12
 
an
d 
23
)
S
R
(a
g
e 
12
 
an
d 
23
)
B
 (M
O
L0
76
4)
B
-I
I:1
/ C
hi
ld
-
ho
od
/6
6/
F
D
ec
re
as
e 
in
 
vi
su
al
 a
cu
ity
LP (2
.7
)
LP (2
.7
)
-1
2.
00
-1
1.
75
P
S
C
 a
nd
 
nu
cl
ea
r 
ca
ta
ra
ct
Po
st
er
io
r s
ta
ph
yl
om
a,
 
m
ac
ul
ar
 a
tro
ph
y,
 o
pt
ic
 d
is
c 
pa
le
ne
ss
, a
tte
nu
at
ed
 v
es
se
ls
, 
R
P
E 
at
ro
ph
y 
w
ith
 b
on
e 
sp
ic
ul
es
 in
 p
er
ip
he
ry
N
R
N
R
B (M
O
L0
76
4)
B
-I
I:2
/ C
hi
ld
-
ho
od
/6
0/
F
D
ec
re
as
e 
in
 
vi
su
al
 a
cu
ity
H
M
(2
.3
)
H
M
(2
.3
)
-8
.2
5
-5
.5
0
P
S
C
 c
at
ar
ac
t
M
yo
pi
c 
ch
an
g
es
, R
P
E 
at
ro
ph
y 
in
 p
os
te
rio
r p
ol
e,
 
op
tic
 d
is
c 
pa
llo
r, 
at
te
nu
at
ed
 
ve
ss
el
s,
 R
P
E 
at
ro
ph
y 
an
d 
b
on
e 
sp
ic
ul
es
 in
 p
er
ip
he
ry
.
N
R
N
R
B
 (M
O
L0
76
4)
B
-I
I:3
/ C
hi
ld
-
ho
od
/5
2/
F
D
ec
re
as
e 
in
 
vi
su
al
 a
cu
ity
C
F
(1
.9
)
C
F
(1
.9
)
-3
.0
0
-3
.2
5
M
ild
 P
S
C
 
ca
ta
ra
ct
R
P
E 
at
ro
ph
y 
in
 p
os
te
rio
r 
p
ol
e,
 p
al
lo
r o
f t
he
 o
pt
ic
 d
is
c,
 
at
te
nu
at
ed
 v
es
se
ls
, R
P
E 
at
ro
ph
y 
an
d 
b
on
e 
sp
ic
ul
es
 in
 
th
e 
p
er
ip
he
ry
.
N
R
N
R
IMPG2-associated retinitis pigmentosa displays relatively early macular involvement  |  71
2
Fa
m
ily
*
P
at
ie
nt
 ID
/A
aO
 
(y
)/A
ge
(y
)/
S
ex
In
iti
al
 
sy
m
pt
om
V
is
ua
l A
cu
ity
†
S
E
R
 (D
)‡
Le
ns
 S
ta
tu
s
O
ph
th
al
m
os
co
py
 R
es
ul
ts
E
R
G
 R
es
ul
ts
O
D
O
S
O
D
O
S
S
co
to
pi
c
P
ho
to
pi
c
C (W
08
-1
37
8)
C
-I
I:2
/8
/3
3/
M
N
ig
ht
 
bl
in
dn
es
s
20
/5
0
(0
.4
)
20
/5
0
(0
.4
)
-5
.5
0
-7
.0
0
C
le
ar
M
ot
tli
ng
 o
f m
ac
ul
ar
 R
P
E,
 
op
tic
 d
is
c 
pa
llo
r, 
su
bt
le
 
p
er
ip
ap
ill
ar
y 
at
ro
ph
y,
 v
es
se
l 
at
te
nu
at
io
n,
 m
id
p
er
ip
he
ra
l 
b
on
e 
sp
ic
ul
es
.
N
R
N
R
C (W
08
-1
37
8)
C
-I
I:3
/8
/3
6/
M
N
ig
ht
 
bl
in
dn
es
s 
an
d 
d
ec
re
as
ed
 
co
lo
r v
is
io
n
20
/5
0
(0
.4
)
C
F
(1
.9
)
-4
.0
0
-4
.5
0
S
m
al
l 
op
ac
iti
es
M
ac
ul
ar
 a
tro
ph
y 
w
ith
 p
ig
m
en
t 
ch
an
g
es
, p
er
ip
ap
ill
ar
y 
at
ro
ph
y,
 w
ax
y 
op
tic
 d
is
c,
 
b
on
e 
sp
ic
ul
e 
pi
g
m
en
ta
tio
ns
 
in
 th
e 
m
id
p
er
ip
he
ry
.
N
R
N
R
D (N
A
P1
)
D
-I
I:1
/2
0/
65
/F
N
ig
ht
 
bl
in
dn
es
s
H
M
(2
.3
)
H
M
(2
.3
)
N
P
N
P
P
S
C
 c
at
ar
ac
t
M
ac
ul
ar
 a
tro
ph
y,
 p
al
lo
r o
f t
he
 
op
tic
 d
is
c,
 a
tte
nu
at
io
n 
of
 th
e 
ve
ss
el
s,
 R
P
E 
at
ro
ph
y 
an
d 
b
on
e 
sp
ic
ul
e 
in
 th
e 
p
er
ip
he
ry
.
N
R
N
R
72  |  Chapter 2
Ta
bl
e 
2.
1.
 C
lin
ic
al
 fi
nd
in
gs
 in
 p
at
ie
nt
s 
w
ith
 IM
P
G
2-
as
so
ci
at
ed
 re
tin
iti
s 
pi
gm
en
to
sa
 a
t t
he
ir 
m
os
t r
ec
en
t v
is
it.
 (c
on
tin
ue
d)
G
ol
dm
an
n 
P
er
im
et
ry
O
C
T 
R
es
ul
ts
A
u
to
flu
o
re
sc
en
ce
 R
es
ul
ts
Fo
llo
w
-u
p 
(y
)
N
P
S
ev
er
el
y 
th
in
ne
d 
re
tin
a,
 g
en
er
al
iz
ed
 lo
ss
 
of
 th
e 
ou
te
r r
et
in
a,
 c
en
tra
l R
P
E 
re
si
du
e 
w
ith
 p
ar
af
ov
ea
l R
P
E 
at
ro
ph
y
N
P
48
C
on
st
ric
te
d 
to
 1
0°
 w
ith
 m
od
er
at
el
y 
se
ns
iti
vi
ty
 lo
ss
.
G
en
er
al
iz
ed
 lo
ss
 o
f r
efl
ec
ta
nc
e 
of
 th
e 
ou
te
r r
et
in
al
 la
ye
rs
, i
rr
eg
ul
ar
 re
fle
ct
iv
e 
sp
ot
s 
ju
st
 a
b
ov
e 
th
e 
R
P
E 
re
fle
ct
iv
e 
ba
nd
, 
lo
w
er
ed
 p
ar
af
ov
ea
l R
P
E 
re
fle
ct
an
ce
, E
R
M
 
w
ith
 m
in
im
al
 tr
ac
tio
n 
in
fe
rio
r o
f t
he
 fo
ve
a.
Ir
re
gu
la
r h
yp
oA
F 
in
 th
e 
m
ac
ul
a,
 
no
rm
ofl
uo
re
sc
en
t a
sp
ec
t s
ur
ro
un
di
ng
 th
e 
m
ac
ul
a 
gi
vi
ng
 th
e 
im
pr
es
si
on
 o
f a
 h
yp
er
A
F 
rin
g,
 m
ot
tle
d 
as
p
ec
t o
f h
yp
oA
F 
in
 th
e 
m
id
p
er
ip
he
ry
.
28
C
on
st
ric
te
d 
to
 1
0°
 w
ith
 m
od
er
at
el
y 
se
ns
iti
vi
ty
 lo
ss
.
G
en
er
al
iz
ed
 lo
ss
 o
f t
he
 o
ut
er
 re
tin
al
 la
ye
rs
, 
R
P
E 
re
fle
ct
an
ce
 fa
irl
y 
in
ta
ct
, e
xp
ec
t f
or
 in
 
th
e 
te
m
p
or
al
 p
ar
af
ov
ea
.
G
ra
nu
la
r h
yp
oA
F 
as
p
ec
t o
f t
he
 m
ac
ul
a,
 
p
er
ifo
ve
al
 d
ee
p 
hy
p
oA
F 
si
gn
al
 g
iv
in
g 
th
e 
im
pr
es
si
on
 o
f a
 b
ul
l’s
 e
ye
-li
ke
 a
sp
ec
t, 
no
rm
ofl
uo
re
sc
en
t a
sp
ec
t s
ur
ro
un
di
ng
 th
e 
m
ac
ul
a 
gi
vi
ng
 th
e 
im
pr
es
si
on
 o
f a
 h
yp
er
A
F 
rin
g,
 m
ot
tle
d 
as
p
ec
t o
f h
yp
oA
F 
an
d 
la
rg
er
 
hy
p
oA
F 
le
si
on
s 
in
 th
e 
m
id
p
er
ip
he
ry
.
19
C
on
st
ric
te
d 
V
F 
up
 to
 le
ss
 th
an
 5
°.
S
ev
er
el
y 
th
in
ne
d 
ce
nt
ra
l r
et
in
a.
N
P
0
C
on
st
ric
te
d 
V
F 
up
 to
 5
°.
S
ev
er
e 
th
in
ni
ng
 o
f c
en
tra
l r
et
in
a,
 a
tro
ph
y 
of
 th
e 
ch
or
io
ca
pi
lla
ris
.
H
yp
oA
F 
m
ac
ul
a 
an
d 
p
er
ip
ap
ill
ar
y 
re
gi
on
, 
gr
an
ul
ar
 h
yp
oA
F 
as
p
ec
t o
f m
id
p
er
ip
he
ry
.
0
Pe
rip
he
ra
l i
sl
an
d
N
P
N
P
0
M
ild
ly
 d
ec
re
as
ed
 s
en
si
tiv
ity
 w
ith
 a
bs
ol
ut
e 
na
sa
l p
ar
ac
en
tra
l s
co
to
m
as
N
P
N
P
0
M
ild
ly
 d
ec
re
as
ed
 s
en
si
tiv
ity
, r
el
at
iv
e 
an
d 
ab
so
lu
te
 s
co
to
m
as
 in
 th
e 
m
id
p
er
ip
he
ry
, 
te
m
p
or
al
 p
ar
ac
en
tra
l s
co
to
m
a.
N
P
N
P
0
N
P
N
P
N
P
0
IMPG2-associated retinitis pigmentosa displays relatively early macular involvement  |  73
2
Ta
bl
e 
2.
1.
 C
lin
ic
al
 fi
nd
in
gs
 in
 p
at
ie
nt
s 
w
ith
 IM
P
G
2-
as
so
ci
at
ed
 re
tin
iti
s 
pi
gm
en
to
sa
 a
t t
he
ir 
m
os
t r
ec
en
t v
is
it.
 (c
on
tin
ue
d)
Fa
m
ily
*
P
at
ie
nt
 ID
/A
aO
 
(y
)/A
ge
(y
)/
S
ex
In
iti
al
 
sy
m
pt
om
V
is
ua
l A
cu
ity
†
S
E
R
 (D
)‡
Le
ns
 S
ta
tu
s
O
ph
th
al
m
os
co
py
 R
es
ul
ts
E
R
G
 R
es
ul
ts
O
D
O
S
O
D
O
S
S
co
to
pi
c
P
ho
to
pi
c
F (R
P4
9)
F-
II:
1/
12
/2
3/
M
N
ig
ht
 
bl
in
dn
es
s
20
/1
20
(0
.8
)
20
/4
0
(0
.3
)
-1
.0
0
-3
.0
0
C
le
ar
Pa
ra
fo
ve
al
 a
tro
ph
y,
 th
e 
op
tic
 d
is
c 
pa
llo
r (
LE
 >
 R
E
), 
na
rr
ow
 v
es
se
ls
, f
ew
 
b
on
e 
sp
ic
ul
es
 in
 th
e 
m
id
p
er
ip
he
ry
.
N
R
N
R
F (R
P4
9)
F-
II:
2/
10
/3
2/
F
N
ig
ht
 
bl
in
dn
es
s
20
/1
20
(0
.8
)
20
/1
00
(0
.7
)
-5
.7
5
-6
.5
0
C
le
ar
B
E
M
, E
R
M
, w
ax
y 
pa
llo
r o
f t
he
 
op
tic
 d
is
c,
 v
es
se
l a
tte
nu
at
io
n 
(R
E 
>
 L
E
), 
b
on
e 
sp
ic
ul
e 
pi
g
m
en
ta
tio
ns
, 
g
en
er
al
iz
ed
 re
tin
al
 d
eg
en
er
at
io
n.
N
P
N
P
G
G
-I
I:1
/1
7/
60
/M
N
ig
ht
 
bl
in
dn
es
s
20
/3
00
(1
.2
)
20
/3
00
(1
.2
)
-2
.0
0
-3
.0
0
C
le
ar
M
ac
ul
ar
 a
tro
ph
y,
 p
er
ip
ap
ill
ar
y 
at
ro
ph
y,
 b
on
e 
sp
ic
ul
e 
pi
g
m
en
ta
tio
ns
, 
w
ax
y 
op
tic
 d
is
c,
 n
ar
ro
w
 v
es
se
ls
, 
g
en
er
al
iz
ed
 c
ho
rio
re
tin
al
 a
tro
ph
y.
N
R
S
R
G
G
-I
I:2
/1
6/
59
/F
N
ig
ht
 
bl
in
dn
es
s
20
/3
0
(0
.2
)
20
/4
0
(0
.3
)
-6
.0
0
-7
.0
0
C
N
 c
at
ar
ac
t
B
E
M
, p
er
ip
ap
ill
ar
y 
at
ro
ph
y,
 w
ax
y 
op
tic
 d
is
c,
 n
ar
ro
w
 v
es
se
ls
. P
er
ip
he
ry
: 
b
on
e 
sp
ic
ul
e 
pi
g
m
en
ta
tio
ns
 a
nd
 
ch
or
io
re
tin
al
 a
tro
ph
y.
N
R
(a
g
e 
37
)
N
R
(a
g
e 
37
)
H
H
-I
I:6
/1
7/
46
/F
N
ig
ht
 
bl
in
dn
es
s
C
F
(1
.9
)
20
/2
00
(1
.0
)
-5
.0
0
-3
.7
5
C
at
ar
ac
t 
ex
tra
ct
ed
 a
t 
ag
e 
35
 (R
E
) 
an
d 
39
 (L
E
)
S
m
al
l c
en
tra
l a
re
a 
w
ith
 s
pa
re
d 
R
P
E,
 
fo
ve
a 
da
rk
 c
om
pa
re
d 
to
 p
er
ifo
ve
a,
 
bu
t n
o 
ev
id
en
t b
ul
l’s
 e
ye
, m
od
er
at
e/
se
ve
re
 p
al
lo
r o
pt
ic
 d
is
c,
 s
ev
er
el
y 
at
te
nu
at
ed
 v
es
se
ls
, P
er
ip
he
ry
: b
on
e 
sp
ic
ul
es
 a
nd
 d
ru
se
no
id
 d
ep
os
its
.
N
R
(a
g
e 
34
)
N
R
(a
g
e 
34
)
J
J-
II:
1/
4/
23
/F
D
ec
re
as
e 
in
 v
is
ua
l 
ac
ui
ty
20
/4
0
(0
.3
)
20
/4
0
(0
.3
)
P
la
n
P
la
n
M
ild
 c
or
tic
al
 
op
ac
iti
es
M
ot
tle
d 
m
ac
ul
a,
 m
od
er
at
e 
pa
llo
r, 
m
od
er
at
e 
at
te
nu
at
ed
 v
es
se
ls
, R
P
E 
at
ro
ph
y 
an
d 
b
on
e 
sp
ic
ul
es
 a
nt
er
io
r o
f 
va
sc
ul
ar
 a
rc
ad
es
.
S
R
(a
g
e 
18
)
S
R
(a
g
e 
18
)
K
K
-I
I:1
/4
/6
7/
F
D
ec
re
as
e 
in
 v
is
ua
l 
ac
ui
ty
20
/4
00
(1
.3
)
20
/4
00
(1
.3
)
-4
.2
5
-3
.5
0
P
se
ud
op
ha
ki
a 
in
 R
E,
 m
ild
 
ca
ta
ra
ct
 in
 L
E
B
E
M
, p
al
lo
r o
f t
he
 o
pt
ic
 d
is
c,
 
p
er
ip
ap
ill
ar
y 
pi
g
m
en
ta
tio
n,
 s
ev
er
el
y 
at
te
nu
at
ed
 v
es
se
ls
, R
P
E 
at
ro
ph
y 
an
d 
in
tra
re
tin
al
 b
on
e 
sp
ic
ul
e 
pi
g
m
en
ta
tio
ns
 in
 th
e 
m
id
p
er
ip
he
ry
.
S
R
(a
g
e 
24
)
W
N
L
(a
g
e 
24
)
74  |  Chapter 2
Table 2.1. Clinical findings in patients with IMPG2-associated retinitis pigmentosa at their most recent 
visit. (continued)
Goldmann Perimetry OCT Results
Autofluorescence 
Results Follow-up (y)
Constricted to 20° 
with residue inferior. 
Sensitivity very mildly 
decreased.
Fairly intact foveal laminar 
retinal architecture, confluence 
of the bands corresponding to 
the ellipsoid inner segments 
and the RPE, ELM reflectance 
is only present in the fovea, 
thinned ONL outside the fovea, 
minimal CME in the LE, the RPE 
seems fairly intact except for 
irregular thinning the fovea and 
RPE loss in the peripapillary 
region; profound loss of the outer 
retinal, RPE and choriocapillaris 
reflectance in the midperiphery.
Two small hypoAF 
spots in the otherwise 
hyperAF macula, subtle 
hyperAF ring around 
macula, granular 
aspect with sporadic 
hypoAF lesion just 
anterior of the vascular 
arcades, prominent 
blockage of AF by bone 
spicules.
34
Constricted to <10°, 
moderately decreased 
central sensitivity, small 
inferotemporal residues
Severely thinned central retina, 
small central residue of the ONL, 
fairly intact RPE reflectance in 
the fovea.
HyperAF macula, 
mottled aspect of 
hypoAF and larger 
hypoAF lesions just 
anterior of the vascular 
arcades, peripapillary 
hypoAF.
16
Constricted to 40° 
with temporal residual 
VF, mildly decreased 
central sensitivity in RE, 
severely decreased 
central sensitivity in LE
Loss of the bands corresponding 
the photoreceptor inner and 
outer segments, severely thinned 
ONL outside the fovea, irregular 
reflectance of presumably 
the ELM in the foveola. RPE 
reflectance intact in central 
retina.
Irregular hyperAF 
in macula (LE>RE), 
sporadic small hypoAF 
spots just anterior of the 
vascular arcades
14
NP Loss of the bands corresponding 
the photoreceptor inner and 
outer segments, severely thinned 
ONL in the central retina, RPE 
reflectance intact except for in 
the parafovea.
Mottled hypoAF aspect 
of the perifoveal region, 
hyperAF in the fovea, 
mottled hypoAF aspect 
just anterior of the 
vascular arcades.
41
AaO = Age at onset; BEM = bull’s eye maculopathy; CF = counting fingers; CME = cystoid macular 
edema; CN = corticonuclear; D = diopters; ELM = external limiting membrane; ERG = electroretinogram; 
ERM = epiretinal membrane; F = female HM = hand movements; IS = inner segments; LE = left eye; LP 
= light perception; M = male; MR = moderately reduced; NP = not performed; NR = nonrecordable; OCT 
= optical coherence tomography; ONL = outer nuclear layer; OS = outer segments; PSC = posterior 
subcapsular; RE = right eye; RPE = retinal pigment epithelium; SER = spherical equivalent refraction; 
SR = severely reduced; TD = time-domain; VF = visual field; y = years. *The family ID between brackets 
are those used before in reference 13. For readability issues, we preferred one letter family IDs. †The 
visual acuity is in noted in both Snellen visual acuity and logMAR visual acuity (between brackets). ‡If 
cataract surgery have been performed, the pre-surgery SER was noted.
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Figure 2.3. Fundus photographs (FP) and fundus autofluorescence (FAF) imaging of patients carrying 
mutations in IMPG2. A/F, FP of temporal superior region of the retina (A), showing sheating of the retinal 
vessels, and FAF imaging of the central retina (F), revealing irregular FAF signal in the macula and a 
granular hypoautofluorescent aspect of the RPE surrounding the posterior pole, in patient A-II:5 (age 45). 
B/H, FP composition (B), showing macular atrophy, and FAF images (H), revealing a hypoautofluorescent 
macula, a granular aspect with large confluent hypoautofluorescent lesions in the midperiphery, and 
peripapillary hypoautofluorescence, of patient G-II:1 (age 60). C/E, FP (C) and FAF image (E) of the 
central retina in patient A-II:6 (age 44). The FP reveals a bull’s eye maculopathy (BEM). The FAF image 
shows granular aspect of the macula, whereas deeper perifoveal hypoautofluorescence gives the 
impression of a BEM, mottled aspect of midperiphery with larger hypoautofluorescent lesions. D/G, FP 
(D) and FAF image (G) of the central retina in patient K-II:1 (age 67). The FP shows a BEM, whereas FAF 
reveals a mottled hypoautofluorescent aspect of the perifoveal region, hyperautofluorescence in the 
fovea, as well as a mottled aspect just anterior of the vascular arcades.
FAF images revealed macular involvement in all eight patients of whom FAF imaging 
was available. The macular aspects varied from hyperautofluorescence to profound 
hypoautofluorescent RPE lesions (mean age: 51 years, range: 23-67 years, Figures 2.3E-G, 
2.3I, 2.4B). Midperipheral changes include granular or mottled hypoautofluorescent changes 
that are spread to the vascular arcades. In some patients, large (confluent) hypoautofluorescent 
lesions were observed just anterior of the vascular arcades (Figures 2.3E, 2.3H). Evaluation of 
the central retinal structure with SD-OCT revealed loss of photoreceptors prior to RPE cell 
loss, which eventually result in moderate to severe retinal thinning (Figure 2.6A). The foveal 
volume in seven Dutch RP patients (mean age: 49 years, range: 23-67) was significantly lower 
compared to the foveal volume in 25 age-matched Dutch healthy controls (p<0.0001; Figure 
2.6B). In all patients with high-resolution SD-OCT except in G-II:2, the bands corresponding 
to the photoreceptor inner and outer segments were lost.24 The outer nuclear layer, containing 
the photoreceptor cell bodies, was concentrically lost and severely thinned where present. We 
observed concentric atrophy of the layer that corresponds to the RPE cells that progressed from 
the midperiphery. The central abnormalities in the RPE layer started in the parafoveal region, 
as was observed in four patients who also revealed a BEM (Figure 2.6D). In patient J-II:1, who 
displayed mottling in the macula, the RPE appeared normal on SD-OCT (Figure 6E). In later 
stages of the disease, we observed loss of the foveal RPE layer, which was highlighted by a 
increased beam penetration and choroidal reflection in patient E-II:4 and G-II:1 (Figure 2.6F). 
SD-OCT scans in the midperiphery revealed loss of the photoreceptor-RPE complex and 
intraretinal pigment deposits in patients G-II:1 and G-II:2 at age 60 and 59, respectively (Figure 
6G), whereas patient J-II:1 at the age of 23 only revealed photoreceptor loss (Figure 2.6H).
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Mutation analysis
A description of the molecular genetic findings in families A-F were reported earlier.13 In 
summary, sequence analysis of all 19 coding exons of IMPG2 led to the identification of 
10 different pathogenic variants in these 17 patients (Table 2.2). In the families with available 
family members, the homozygous or compound heterozygous mutations segregated 
completely with the RP phenotype (Figure 2.1).13
In addition to the mutations described earlier,13 four new pathogenic variants in IMPG2 
were identified. In family G, a targeted next generation sequencing approach that covered 
111 blindness genes resulted in two compound heterozygous mutations: a nonsense 
mutation (p.Arg127*), which is predicted to cause premature truncation of the IMPG2 protein, 
and a 4-base-pair deletion (c.3423-8_c.3423-5del) that affects the splice acceptor site 
(Table 2.2).22 Reverse transcriptase polymerase chain reaction analysis on RNA isolated 
from patient’s lymphoblastoid cells revealed that, instead of the regular splice acceptor 
site, a second splice site located upstream in the same intron is used that results in the 
inclusion of 80 additional nucleotides to IMPG2 mRNA, subsequently leading to a frameshift 
Figure 2.4. Multimodal imaging of the central retina in patient G-II:2 at the age of 59. A, Fundus 
photograph showing a bull’s eye maculopathy, attenuated vessels, peripapillary atrophy, pale optic 
disc, bone-spicule pigmentations and chorioretinal atrophy in the midperiphery. B, Autofluorescence 
imaging shows a subtle hyperautofluorescent ring around the macula, spots of decreased macular and 
peripheral autofluorescence and absence of autofluorescence corresponding with the peripapillary 
atrophy. C, SD-OCT reveals loss of the bands corresponding to the photoreceptor inner and outer 
segments in the macula. The external limiting membrane (ELM) is only present in the fovea. The RPE 
layer seems fairly intact, except for irregular thinning in the fovea and loss of RPE in the peripapillary 
region. D, Infrared en face image reveals the location of the SD-OCT image (green line).
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and premature termination of IMPG2 (Figure 2.7). cDNA products generated from RNAs 
isolated from cells grown under nonsense-mediated decay (NMD) suppressing conditions 
show subtle differences compared to those generated from RNAs isolated from cells grown 
under normal conditions. Growing cells under NMD-suppressing conditions did not yield an 
obvious difference in the amount of aberrantly spliced IMPG2, indicating that a truncated 
protein may be produced. The other novel mutations include a nonsense mutation (p.Tyr171*) 
and a missense mutation (p.Ser379Pro). The nonsense mutation is predicted to cause a 
premature truncation of IMPG2. The p.Ser379Pro missense mutation changes a highly 
conserved amino acid and is unanimously predicted to be pathogenic by multiple in silico 
prediction tools (SIFT: deleterious [score: 0], Polyphen-2: probably damaging [score: 1.000], 
Align GVGD: Class C65, MutationTaster: disease causing [probability: 0.994], Grantham 
score: 74, PROVEAN prediction: deleterious [score: -2.972]).
Discussion
The phenotype of IMPG2-associated RP
In this study we provide a detailed clinical description of the RP associated with mutations in 
IMPG2, a gene that recently was added to the long list of genes that may cause autosomal 
recessive RP when mutated.13 Most of the patients with IMPG2-associated RP demonstrated 
the classic RP symptoms: night blindness and progressive concentric loss of the visual field. 
However, six out of 17 patients mentioned a decrease in BCVA as the initial symptom, that 
could not be attributed to amblyopia. Loss of vision as initial symptom is not just a result of 
our electrically illuminated night-time environment that compensates for an impaired night 
vision,4, 5 but a consequence of macular abnormalities that are a prominent feature of this 
type of RP. Overall, the BCVA progressively decreased during the first four decades of life, 
Figure 2.5. Goldmann perimetry findings in the right eyes of patients J-II:1 (age 23, A), H-II:2 (age 35, 
B) C-II:3 (age 37, C) and G-II:2 (age 59, D). The colored lines indicate the outer borders of the isopters. 
The filled areas indicate scotomas for the isopter of that color.
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Figure 2.6. OCT examinations in patients with IMPG2-associated RP. A, Thickness of the total retina 
in eight Dutch patients (mean age: 49 years, range: 23-67). Shaded areas: normal limits (mean 
± 2 standard deviations) as measured in 25 controls (mean age: 46 year). B, Foveal volume (mm3) 
measured in the central 3 mm2 in these patients except patient A-II:1. The foveal volume in seven 
Dutch IMPG2-associated RP patients (mean age: 49 years, range: 23-67) was significantly lower than 
in 25 age-matched healthy Dutch controls (p<0.0001). The horizontal bars indicate the median of the 
corresponding cohort. C, SD-OCT scan of a normal central retina (age: 25). The hyperreflective bands 
correspond to the external limiting membrane (1), the ellipsoid photoreceptor inner segments (2), the 
photoreceptor outer segment/RPE contact cylinder region (3) and the RPE (4).24 D, SD-OCT of patient 
A-II:6 (age 44) that reveals generalized loss of the outer retinal layers, whereas the RPE reflectance is 
fairly intact expect for the irregular signal and thinning in the temporal parafovea (white arrowhead). 
E/H, SD-OCT in patient J-II:1 (age 23). The central retina (E) revealed normal bands corresponding to 
the RPE, whereas the photoreceptor bands are absent outside the fovea. The midperipheral retina (H) 
reveals loss of the photoreceptor inner and outer segments bands. However, no profound RPE atrophy 
or intraretinal pigment deposits were observed yet. F/G, SD-OCT of patient G-II:1 (age 60). The central 
retina (F) reveals generalized loss of photoreceptor inner and outer segments, a thinned ONL, and 
patchy loss/thinning of the foveal RPE. The midperipheral retina (G) shows profound loss of the outer 
retinal layers, RPE and choriocapillaris reflectance, as well as intraretinal pigment deposits. ONL, outer 
nuclear layer.
and subsequently deteriorates to levels lower than 20/300 during the fifth and sixth decade 
of life. The only exception was patient G-II:2, who still enjoyed a BCVA of 20/30 at the age 
of 59.
Thirteen of the 17 RP patients included in this study showed significant macular abnormalities: 
a BEM was observed in six patients (mean age: 51 years) and profound macular atrophy 
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in seven patients (mean age: 57 years). We hypothesize that the perifoveal atrophy, 
manifesting as a bull’s eye pattern, eventually progresses to macular atrophy with profound 
degeneration of photoreceptors and RPE, although this was only observed in patient G-II:1 
since longitudinal data of the other patients with macular atrophy were not available. The 
13 patients with macular involvement displayed a decreased central sensitivity and/or 
paracentral scotomas on visual field examination in addition to the concentric constriction 
that is typically seen in RP (Table 2.1, Figure 2.5). SD-OCT of the macula showed early loss of 
photoreceptor inner and outer segments prior to loss of the RPE layer in the central retina. On 
FAF imaging, macular hypoautofluorescence was observed, whereas hypoautofluorescence 
in the midperiphery generally had a granular aspect. In contrast to the significant macular 
involvement that was observed in the majority of patients, subtle macular FAF abnormalities 
appeared in patients C-II:2 and J-II:1. However, subtle macular FAF abnormalities have been 
observed in other forms of RP with intact central vision and therefore do not automatically 
predate loss of macular function.25
A BEM is a non-specific reaction of the posterior pole, which can occur in various diseases 
affecting the bipolar cell layer, photoreceptor cell layer or RPE.26 It is not often observed in RP, 
but has been reported in some specific forms of syndromic and nonsyndromic RP,27-31 and 
is associated with a faster deterioration of the visual acuity compared to RP without specific 
macular lesions.32 Concerning the BEM in IMPG2-associated RP, multimodal imaging 
revealed abnormalities in the photoreceptor and RPE cell layers. However, it is unclear 
why RPE abnormalities initially predominate in the perifoveal region, since the preceding 
abnormalities in the photoreceptor layer are ubiquitously present. Possible explanations may 
include topographical differences in metabolism and cell densities,33 the higher vulnerability 
of S (‘blue’) cone photoreceptors to retinal disease compared to M and L cones,34 and the 
higher vulnerability of parafoveal rods to aging and light-induced damage.35-37 In patient G-II:2 
(age 59), we observed a prominent BEM due to hypopigmentation rather than atrophy of the 
Figure 2.7. Reverse transcription-PCR of IMPG2 mRNA of affected individuals of family G. Reverse 
transcription (RT)-PCR analysis of IMPG2 amplicon containing exons 16 and 17 in family G showing the 
consequence of the c.3423-8_3423-5del mutation. An extra band containing 80 additional nucleotides 
is visible in cDNA samples of both affected siblings (G-II:1 and G-II:2). To rule out the possibility of 
aberrant transcripts undergoing nonsense-mediated decay (NMD), part of the cells from each individual 
was cultured with cycloheximide (CH), an NMD-blocking agent. The amount of aberrant cDNA splice 
products generated from cells grown under NMD-suppressing conditions (G-II:1 CH and G-II:2 CH) 
show a slight increase compared to the products generated without NMD-suppressing conditions 
(G-II:1 and G-II:2). ML, 100-bp ladder; WT, wild-type control cDNA; H2O, negative control (water).
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perifoveal RPE, since there were only minor RPE changes on FAF imaging (Figure 2.4B) and 
mild changes of the band corresponding to the photoreceptor outer segment-RPE complex 
(Figure 2.4C). By contrast, other patients with BEM revealed perifoveal hypoautofluorescence 
indicating perifoveal RPE atrophy (Figure 2.3E and 2.3G). In late stages of the disease, 
profound macular hypoautofluorescence developed, which is indicative of RPE atrophy 
(Figure 2.3H). In the light of future therapeutic options for retinal dystrophies, knowledge 
of the natural course of IMPG2-associated retinal disease is necessary to select patients 
amenable for treatment and to correctly interpret the effect of therapeutic intervention.
Genotype-phenotype correlation
Bandah-Rozenfeld et al. only identified mutations with severe effects on the IMPG2 protein in 
RP patients, whereas a homozygous mild missense mutation was identified in one patient with 
a mild maculopathy.13 In families G-K, we identified two novel truncating nonsense mutations 
(families G and H), a deletion causing a splice defect (family G) and a missense mutation 
that is unanimously predicted to be pathogenic (family K). The function of IMPG2 is vital for 
retinal survival and function, since the majority of IMPG2 mutations that are identified in our 
patients can be considered true loss-of-function alleles. Until now only one homozygous 
mild (missense) mutation in IMPG2 has been described in a single patient with an isolated 
maculopathy and a mildly affected visual function.13 This might indicate that a minimal loss of 
function of the IMPG2 protein may result in mild or even absent retinal disease.
Each of the seven nonsense mutations lead to either mRNA breakdown because 
of nonsense-mediated decay, or predicted truncated IMPG2 proteins that all lack the 
transmembrane domain and the cytoplasmic tail. The in-frame deletion identified in family A 
(c.888-1554_908+274del; absence of 7 amino acids) is thought to result in a nonfunctional 
IMPG2 protein, as in a cellular transfection assay this mutant protein was retained in the 
endoplasmic reticulum, while IMPG2 is physiologically located in the cell membrane.13 The 
4-base-pair deletion of the splice acceptor site in family G (c.3423-8_c.3423-5del) was found 
to result in the use of an alternative splice acceptor site, and thereby also predict to result in 
the generation of a truncated protein that most likely has reduced or no remaining function. 
Interestingly, the p.Arg906* was present in 8 of 20 alleles (40%) in 10 Dutch patients, which 
may imply a founder mutation in the Dutch population.
Since the identified mutations cause (near-)complete loss of IMPG2 function, the clinical 
variation is limited in IMPG2-associated RP. The patients in family G, however, retained 
slightly better visual acuity and visual field compared to the other patients (Figure 2.2, 
Table 2.1). This could imply that the splice defect in this family results in an IMPG2 protein 
with some residual function. However, functional assays are needed to reveal the true effect 
of the c.3423-8_c.3423-5 deletion, since there also is evidence of modifying factors in this 
family (Table 2.1; Figures 2.2, 2.3B, 2.3H, and 2.4) that influence the intrafamilial differences.
The IMPG2 protein (SPACRCAN) is highly homologous to SPACR, the product of the 
interphotoreceptor matrix proteoglycan 1 (IMPG1) gene, which has been linked to benign 
concentric annular macular dystrophy (BCAMD) and vitelliform macular dystrophy (VMD).38, 
39 Interestingly, BCAMD includes parafoveal hypopigmentation and RP-like fundoscopic 
changes in the end-stage disease, although visual acuity is generally better preserved 
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than in the IMPG2-associated RP patients in this report.38 The IMPG1-associated vitelliform 
dystrophy is also associated with macular pathology, although this is characterized by 
accumulation of lipofuscin rather than a BEM.39
In conclusion, severe mutations in IMPG2 are the cause of an autosomal recessive RP 
phenotype that manifests in the early teens and is accompanied by atrophic maculopathy 
often in a bull’s eye pattern. In early disease stages, the maculopathy is characterized by mild 
RPE alterations, but in later stages of the disease a BEM and profound macular chorioretinal 
atrophy may occur. In most patients, the RP phenotype arising from mutations in the IMPG2 
gene is severe, because of the unfortunate combination of progressive constriction of the 
visual fields and maculopathy that occurs relatively early in the course of the disease.
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Retinitis pigmentosa caused 
by mutations in the ciliary 
MAK gene is relatively mild 
and is not associated with 
apparent extra-ocular features
3
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Abstract
Purpose. Defects in MAK, encoding a protein localized to the photoreceptor connecting 
cilium, have recently been associated with autosomal recessive retinitis pigmentosa (RP). 
The aim of this study is to describe our detailed clinical observations in patients with MAK-
associated RP, including an assessment of syndromic symptoms frequently observed in 
ciliopathies.
Methods. In this international collaborative study, 11 patients carrying nonsense or missense 
mutations in MAK were clinically evaluated, including extensive assessment of the medical 
history, slit-lamp biomicroscopy, ophthalmoscopy, kinetic perimetry, electroretinography 
(ERG), spectral-domain optical coherence tomography (SD-OCT), autofluorescence 
imaging, and fundus photography. Additionally, we used a questionnaire to evaluate the 
presence of syndromic features and tested the olfactory function.
Results. MAK-associated RP is not associated with syndromic features, not even with 
subclinical dysfunction of the olfactory apparatus. All patients experienced typical RP 
symptoms of night blindness followed by visual field constriction. Symptoms initiated between 
childhood and the age of 43 (mean: 23 years). Although some patients experienced vision 
loss, the visual acuity remained normal in most patients. ERG and ophthalmoscopy revealed 
classic RP characteristics, and SD-OCT demonstrated thinning of the overall retina, outer 
nuclear layer and photoreceptor-pigment epithelium complex.
Conclusion. Nonsense and missense mutations in MAK give rise to a non-syndromic 
recessive RP phenotype without apparent extra-ocular features. When compared to other 
retinal ciliopathies, MAK-associated RP appears to be relatively mild and shows remarkable 
resemblance to RP1-associated RP, which could be explained by the close functional relation 
of these proteins.
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Introduction
Retinitis pigmentosa (RP) comprises a group of inherited retinal dystrophies that share 
clinical characteristics but display an impressive heterogeneity in phenotype and genotype. 
Symptoms include progressive loss of night vision and peripheral visual field loss that results 
in tunnel vision. Eventually patients may lose central vision.1,2 Although normal in early stages, 
the fundus appearance in advanced RP reveals attenuated retinal vessels, waxy pallor of 
the optic disc, retinal pigment epithelium (RPE) atrophy and bone spicule pigmentations.1,2 
Full-field electroretinography (ERG) typically shows reduced responses, where rod-driven 
responses generally are equally or more affected than cone-driven responses.
Mutations in the MAK gene, which encodes male germ cell-associated kinase, have 
recently been associated with retinal degeneration in mice and autosomal recessive RP in 
humans.3-5 The MAK protein is involved in regulating ciliary length in many species,3,6,7 and 
non-functional MAK results in elongation of the photoreceptor connecting cilium, diminished 
ciliary transport (intraflagellar transport, IFT) and subsequent photoreceptor degeneration 
in mice.3
Diseases that involve dysfunction of the cilium are generally referred to as ciliopathies.8 
They include multi-organ syndromic phenotypes, since the mutated ciliary genes are 
expressed in multiple tissues,9-11 although mutations in ubiquitously expressed ciliary genes 
may also result in single-organ disease.12 Expression of MAK was first identified in murine 
testicular germ cells.13 Subsequently, expression in photoreceptors, olfactory receptors and 
in the epithelium of the respiratory tract and choroid plexus has been shown in mice.14,15 
Nevertheless, no syndromic features have been observed in Mak-/- mice.3
In a recent study, Stone and colleagues described the ophthalmic features observed 
in 24 MAK-associated RP patients. In that study, all but one patient were from Ashkenazi 
Jewish origin and carried a homozygous 353-base pair insertion in exon 9, which results 
in loss of the retina-specific isoform of MAK.16 Although the MAK exon 9 insertion is the 
most frequent cause of RP in Ashkenazi Jews, this insertion has so far not been identified in 
individuals from other origins.4,16 Detailed clinical features of RP patients carrying missense 
or nonsense mutations in MAK have not been described yet. In addition, the presence of 
syndromic features has thus far not been evaluated in any MAK-related RP patient.
In this report, we describe the clinical results of an international collaborative study that 
investigated the clinical characteristics and possible syndromic associations of 11 patients 
with RP caused by nonsense or missense mutations in MAK.
Patients and Methods
Patients
Eleven RP patients with mutations in MAK from 7 families were studied at Hacettepe University 
in Ankara, Turkey (by RKÖ, family A); the Radboud University Medical Centre in Nijmegen, 
the Netherlands (by RACvH, CBH and BJK, families B-D); the Rotterdam Eye Hospital in 
Rotterdam, the Netherlands (by LIvdB and FCCR, family E); the Hadassah-Hebrew University 
Medical Center in Jerusalem, Israel (by EB, family F) and the Goldschleger Eye Research 
Institute in Sheba Medical Center, Israel (by YR, family G).
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This study adhered to the tenets of the Declaration of Helsinki and informed consent was 
obtained from all participating patients prior to blood withdrawal and additional ophthalmologic 
examinations. Prior to this study, we obtained institutional review board approvals.
Genetic analysis
In six families (families A-F), MAK mutations were identified as described previously.4 Genetic 
analysis using Sanger sequencing of all exons and intron-exon boundaries of MAK in the 
probands of five genetically unsolved families of Iraqi origin resulted in the identification of a 
homozygous mutation in one family, which was included in this study. The most recent human 
genome variation society (HGVS) nomenclature was used (http://www.hgvs.org/mutnomen/).
Clinical analysis
Clinical data were collected from the medical records of these patients. Following the 
identification of causative MAK mutations, six patients (families B, C, D and E) were 
re-evaluated in addition to the data collected during routine visits over the years. Medical 
history was registered with a focus on age of onset, initial symptoms and overall course of 
the retinal disorder. Age of onset was defined as the age at which the initial symptom was 
first noticed by the patient. The initial symptom was defined as the first symptom noted by 
the patient.
The ophthalmic clinical examination included best-corrected visual acuity (BCVA), slit-
lamp biomicroscopy, ophthalmoscopy, and fundus photography. Goldmann perimetry 
was performed using targets V-4e, III-4e, I-4e, I-3e, I-2e and I-1e in all but two patients: 
patient A-IV:1 underwent a full-field 120 point screening test using the Humphrey Field 
Analyser II (Carl Zeiss, Dublin, CA, USA); perimetry was unavailable in case F-II:2. Fundus 
autofluorescence (FAF; Spectralis™, Heidelberg Engineering, Heidelberg, Germany) was 
performed in six patients with a confocal scanning laser ophthalmoscope. FAF images with 
a view of 30˚ and 55˚ on the central retina were acquired using a confocal scanning laser 
ophthalmoscope (cSLO) with an optically pumped solid state laser (488 nm) for excitation. All 
patients underwent a full-field ERG except for patient F-II:2. We performed ERG according 
the guidelines of the International Society for Clinical Electrophysiology of Vision (ISCEV).17 
Responses were evaluated using local reference values.
Retinal structure. We obtained cross-sectional images along the horizontal meridian of 
the central retina with commercially available Spectral-domain optical coherence tomography 
(SD-OCT) instruments (Spectralis™, Heidelberg Engineering, Heidelberg, Germany) in 
8 patients using a 20° single line scan covering the fovea. We quantified thickness of the total 
retina, the outer nuclear layer (ONL) and photoreceptor-RPE complex (PR+RPE) in 4 MAK-
related RP patients. For reference purposes, a normal dataset for the thickness of all three 
layers on SD-OCT was obtained from 25 age-matched individuals (mean age: 46  years, 
range  27-62 years) without retinal or vitreoretinal disease. Thickness measurements of 
the ONL and the PR+RPE were performed at the foveola and at 0.25, 0.5, 1, 1.5, 2 and 
2.5 mm eccentricity from the foveola using the thickness graphs in Heidelberg Eye Explorer 
software (Heidelberg Engineering, Heidelberg, Germany). The ONL was measured from the 
outer plexiform layer to the external limiting membrane (ELM); the RP+RPE thickness was 
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measured from the ELM to the Bruch membrane; and the total retinal thickness was measured 
from vitreous-retinal interface to the Bruch membrane complex (Figure 3.1). The reference 
lines that demarcate the layers were manually set and verified; all thickness measurements 
were performed by the same operator (R.A.C.v.H.). Postacquisition interpolation of normal 
data was performed with custom programs using MatLab (Version R2011a, The MathWorks 
Incorporated, Natick, MA, USA).
Figure 3.1. Illustration of the measured parameters on optical coherence tomography images. The outer 
nuclear layer (ONL) was measured from the outer border of plexiform layer (yellow line) to the external 
limiting membrane (ELM, green line). The thickness of the photoreceptor-RPE complex (PR+RPE) was 
measured from the ELM (green line) to the Bruch membrane (red line), and the total retinal thickness 
(RT) was measured from the vitreous-retinal interface (blue line) to the Bruch membrane (red line).
Evaluation of extra-ocular symptoms. To evaluate presence of syndromic features 
in the patients with MAK mutations, we questioned all patients about the presence of 
various extra-ocular manifestations covering deficiencies in most tissues that are usually 
involved in syndromic ciliopathies.10 This questionnaire investigated hearing and balance 
abnormalities, renal failure or anomalies, cardiac and respiratory anomalies, olfactory 
deficiencies, polydactyly, obesity, cognitive impairment, fertility disorders, hypogonadism 
and dental anomalies. Additionally, we assessed olfactory function in 6 patients using the 
University of Pennsylvania Smell Identification Test (UPSIT; Sensonics Inc, Haddon Heights, 
New Jersey, USA), because olfactory deficiencies frequently go unnoticed by patients and 
olfactory functioning might be affected based on the expression of MAK in murine olfactory 
receptors.14,18 UPSIT-scores were evaluated using the age-matched gender-stratified scoring 
keys provided in the manual.19
We avoided further invasive procedures to assess the testicular function, as 
spermatogenesis was normal in MAK knock-out mice, and sperm motility and male-derived 
litter sizes were only mildly reduced.20
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Figure 3.2. Revised pedigrees of six families included in this study. Where relatives were available 
(families A, D and E),the mutation segregates with the disease. Plus signs denote the wild type allele, 
square boxes indicate men, circles indicate women, and affected individuals are pointed out in black. 
An arrow indicates the proband. Double lines point out consanguineous marriages, the numbers above 
the double lines indicate the degree of consanguinity.
Results
Clinical characteristics
This study included a total of 11 patients (mean age: 50 years) from 7 families (Figure 3.2). 
Longitudinal data were available for seven patients (mean duration: 9.3 years). The mean 
age at onset was 30 years and ranged from childhood to the age of 54, but could not be 
reliably determined in three patients. The age at diagnosis (mean age: 38 years, range: 
20-57 years, n=10) was generally within the first decade after the onset of the disease. All 
patients noticed night blindness as initial symptom of their disease. In one patient (E-II:1), 
the molecular diagnosis preceded the visual symptoms after segregation analysis in her 
family. One year later, she noticed a slightly prolonged adaptation to darkness and minor 
constriction of her temporal visual field.
An overview of the clinical findings in these patients at the most recent examination is 
provided in Table 3.1. The course of the BCVA in the cases with follow-up data is shown in 
Figure 3.3. The mean BCVA was approximately 20/40 at a mean age of 50. BCVA was ≥20/50 
in at least one eye of 9 patients and ≥20/25 in 6 of these cases, including individuals in their 
seventh or eighth decade of life. We observed a vision impairing stromal haze, which was 
already reported at the age of 57, in the cornea of the right eye of patient B-II:9. The origin 
of this haze was not clear. Lens opacities were observed in patient C-II:3 (polar posterior 
cataract) and patient E-II:3 (mild posterior subcapsular cataract), whereas patients B-II:9, 
D-II:1 and F-II:4 underwent cataract extraction, the latter patient due to congenital cataract.
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Figure 3.3. Best corrected visual acuity (y-axis) related to age (x-axis) in seven patients with MAK-
related retinitis pigmentosa. If visual acuity differed between both eyes, the best visual acuity was used. 
Small variability in visual acuity was observed in the patients of families D and E. HM, hand movements.
Ophthalmoscopy revealed typical RP features including vessel attenuation, waxy pallor of 
the optic disc and bone spicules in all patients (Figure 3.4A-E). In early stages, the nasal 
and inferior quadrants were predominantly affected, whereas in later stages the retina in 
the superior quadrant became affected in a likewise fashion. The temporal retina showed 
less densely packed bone spicules in end-stage disease (Figure 3.4A-B and 3.4D-E). The 
macular region was unaffected in all patients except for patient B-II:9, who, at the age of 74, 
showed large atrophic chorioretinal lesions (Figure 3.4F) with a corresponding low visual 
acuity of hand movements in both eyes. An earlier examination, at the age of 57, revealed a 
bull’s eye maculopathy.
Autofluorescence imaging (mean age: 51, range: 41-63 years) revealed typical RP 
features (Figure 3.4G-H), including the hyperautofluorescent ring associated with the 
transitional zone where photoreceptor inner and outer segments are lost (Figure 3.4I-J),21,22 
and hypoautofluorescent lesions in the midperiphery. Electrophysiological rod- and cone-
driven responses were either severely reduced or non-recordable (Figure 3.5). In patients 
E-II:3 and F-II:5, the responses showed a rod-cone pattern, where rod-driven responses 
were more severely affected than cone-driven responses. ERG responses within the normal 
limits were obtained in patient E-II:1, although scotopic minimal responses were at the lower 
end of the normal spectrum.
Perimetric testing revealed that tunnel vision was a prominent feature in 6 patients (55%): 
constricted visual fields up to 10° were observed (Table 3.1). Visual field loss followed the 
patterns reported earlier,16 where no or minor temporal field defects are present in early 
stages of the disease, whereas in more advanced stages the field is constricted to a central 
residue. However, the course of visual field loss was highly variable: patients C-II:3, G-II:1 
and E-II:3 had an isolated central residual field (pattern 5) at age 25, 28 and 49, respectively, 
whereas E-II:1, D-II:1 and D-II:4 had a nearly complete visual field (pattern 1) at age 54, 55 
and 63, respectively. Details of visual fields are depicted in Figure 3.6. Central sensitivity 
remained relatively spared in 7 patients, which is in accordance with the observed visual 
acuity (Table 3.1).
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Figure 3.4. Fundus photographs and autofluorescence imaging in patients with MAK-related retinitis 
pigmentosa. A, Composition fundus photograph of the left eye of case D-II:4 (age 63) illustrating 
attenuated vessels, waxy pallor of the optic disc and bone spicule pigmentations in the nasal-superior 
midperiphery. B, Composition photograph of the left fundus in patient D-:II:1 (age 72) showing 
attenuated vessels, pallor of the optic disc and bone spicules in the midperiphery. C, Composition 
fundus photograph of the left eye in patient C-II:3 (age 41) revealing severely attenuated vessels, a 
pale optic disc amd sporadic bone spicules in superotemporal and superonasal midperiphery (black 
arrows heads). D/E, Composition fundus photos of the right eye in patient E-II:3 at age 44 (D) and age 
46 (E) highlighting the increase in bone spicule pigmentations in the nasal and inferior quadrants as 
well as the progression in atrophy of the RPE. F, Photograph of the left fundus in patient B-II:9 (age 74) 
showing large RPE lesions surrounding the fovea, as well as attenuated vessels, waxy pallor of the 
optic disc and bones spicule pigmentations. G/H, FAF images of the left fundi in patients D-II:4 at age 
63 (G) and E-II:3 at age 46 (H) revealing a hyperautofluorescent ring surrounding the normal appearing 
macula and fine hypoautofluorescent spots in the nasal and superior midperiphery. I, FAF image of the 
left fundus of case C-II:3 (age 43) revealing a hyperautofluorescent ring around the fovea and irregular 
hypoautofluorescent spots scattered throughout the posterior pole. J/K, OCT scans along the horizontal 
meridian of the central retina in patients D-II:4 at age 63 (J) and E-II:3 at age 46 (K) highlighting the 
remaining photoreceptors and the transitional zone (marked by white arrow heads).
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Retinal Structure
We observed profound loss of photoreceptor layer structure in the perimacular zone in six 
patients (mean age: 57; range: 28-74 years). In accordance to the findings at ophthalmoscopy 
and perimetry, photoreceptor loss was more advanced towards the fovea in the nasal retina 
compared to the temporal retina (Figure 3.4J). In later stages, loss of the photoreceptor layer 
temporal to the fovea occurred (Figure 3.4K).
Figure 3.5 ERG recordings of two patients with recordable 
responses. (patient E-II:3 at age 43 and G-II:1 at age 28). Only 
scotopic mixed (rod + cone) responses and photopic (cone) 
responses are depicted. Arrowheads indicate the moment of 
the light flash. Control shows normal responses of individuals 
with healthy retinas. Patient E-II:3 has severely reduced scotopic 
responses and photopic responses just within normal limits. 
Both dark-adapted and light-adapted responses of patient G-II:1 
show barely detectable responses of <10 microvolts. ERG, 
electroretinography; msec, millisecond; µV, microvolts.
Figure 3.6. Patterns of visual field loss by Goldmann kinetic perimetry. All fields are depicted as right 
eyes. Patterns are numbered according to Stone et al. (Stone et al. 2011). Pattern 1: Field show nearly 
full extent with the V-4e isopter and absolute scotoma, if present, are situated in the superotemporal 
quadrant. Pattern 4: isolation of the central field from the residual nasal field by a complete midperipheral 
scotoma. Pattern 5: only a residual small central island with V-4e and even smaller with I-4e. Fields are 
grouped by pattern. Patient ID and age are at the top of each map. Solid areas: absolute scotoma.
Thickness measurements are plotted in Figure 3.7; normal data were plotted (mean ± 2 SD) 
as reference for the data from the patients. The overall retina became thinned beyond the 
fovea in 3 RP patients, of which 2 patients also showed a thinned foveal retina. The OCT scan 
in patient D-II:4 was acquired slightly superior to the foveal dip, resulting in the thickened 
foveal retina depicted in Figure 3.7 (top panel). The other values in this patient were within the 
normal range due to the early stage of disease. Both ONL and PR+RPE layers were thinned 
beyond the fovea, except for patient C-II:3 in whom the foveal ONL and PR+RPE thinned 
as well. Thinning of the retinal, ONL and PR+RPE thickness in the fovea correlated with a 
decrease in visual acuity. We did not observe thickening of the ONL or PR+RPE layer.
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Figure 3.7. Retinal laminar architecture 
by OCT in MAK-related RP. Thickness 
of the overall retina, ONL and 
photoreceptor-RPE complex (PR+RPE) 
along the horizontal meridian in 
4  patients. In patient B-II:9 only the 
retinal thickness could be measured as 
unstable fixation led to low scan quality. 
Shaded areas: normal limits (mean ± 2 
standard deviations) as measured in 
25 individuals without vitreoretinal and 
retinal disease (mean age: 46 year). VA, 
visual acuity; HM, hand movements.
Evaluation of extra-ocular features
All patients were in good general 
health. No extra-ocular manifesta-
tions were reported in the ques-
tionnaire and, more specifically, 
no history of sub- or infertility was 
reported in both males included in 
this study. In the six patients tested 
with the UPSIT, the absolute ability 
to smell varied from complete loss 
(anosmia, patient B-II:9) to nor-
mal olfactory function (normosmia, 
patient D-II:4). However, the 
 absolute ability to smell decreases 
with age in normal individuals 
while variance of olfactory function 
widens, and anosmia is observed 
in a portion of the normal elderly 
above the age of 60.19 Compared to age-matched controls, the olfactory function of the six 
patients tested in this study were all within the normal limits, although often at the lower end 
(Table 3.2). None of the patients complained about loss of their ability to smell or taste.
Table 3.2. UPSIT-scores and interpretation of 6 patients with MAK-associated RP.
Patient Age UPSIT-score Percentile*
Absolute olfactory function  
corrected for age and gender
B-II:9 74 15/40 7th Anosmia
C-II:3 41 32/40 13nd Mild microsmia
D-II:1 72 26/40 17th Moderate microsmia
D-II:4 63 36/40 53rd Normosmia
E-II:1 54 33/40 17th Mild microsmia
E-II:3 49 33/40 6th Mild microsmia
* = percentiles indicate the percentage of normal individuals that reach an equal or lower score as the 
patient. UPSIT, University of Pennsylvania Smell Identification Test.
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Discussion
MAK has recently been added to the expanding list of genes associated with autosomal 
recessive RP.4,5 Pathologic mutations in MAK cause abnormal elongation of the cilium, which 
eventually results in photoreceptor cell death.3 Defects in genes involved in ciliary structure 
or transport are known to cause syndromes that include retinal dystrophy.10,23-25 The exclusion 
of syndromic abnormalities in MAK-associated RP is therefore important. Previously, Stone 
and co-workers described the retinal phenotype in a genetically homogeneous group of 
almost exclusively Ashkenazi Jewish patients.16 The RP patients in this study carry causative 
mutations different from the specific insertion described in MAK, and were not of Ashkenazi 
Jewish ancestry.
The MAK-associated retinal phenotype
The retinal phenotype of the patients in this study is typical for RP and starts with night 
blindness and subsequent progressive constriction of the visual field. Visual acuity can 
remain relatively normal up to late age due to prolonged survival of the central retina, as 
was observed by Stone and colleagues.16 However, in cases B-II:9, C-II:3 and F-II:2, visual 
acuity decreased to 20/50 or less in both eyes at the age of respectively 74, 41 and 57 years, 
although in case of C-II:3 this may also be explained by visually disturbing cataracts.
In MAK-associated RP, visual field loss was initially restricted to the temporal field that 
gradually progressed to loss of the entire (mid)peripheral field, and ends with a isolated 
central residue. These perimetric findings correlate with the patterns described earlier in 
MAK-related RP by Stone et al, although we observed only three of five patterns and end-
stage pattern 5 was reached at an earlier age by patients C-II:3 and G-II:1 (Figure 3.6).16
SD-OCT imaging clearly demonstrated the overall thinning of the retina, as well as 
thinning of the ONL and PR+RPE, whereas foveal thickness initially is spared. PR+RPE 
thickening that could accompany the elongation of the connecting cilium to twice its normal 
length, which was present in rod photoreceptors of MAK knock-out mice,3 was not observed 
in our patients. This absence of retinal thickening may signify the absence of these structural 
abnormalities in human photoreceptors, although it cannot be excluded that such thickening 
lies beyond the resolution of current OCT systems.
Genotype-phenotype analysis
All but one (B-II:9) patients demonstrated the slowly progressive, central-preserving retinal 
phenotype. Accordingly, the mutations identified in our patients (Table 3.3) all affect the 
kinase activity that is crucial for normal functioning of the MAK protein.4 Nonsense mutations, 
which are generally assumed to have more detrimental effects on protein function than 
missense changes, were identified in family A. However, the phenotype in patient A-IV:1 
did not significantly differ from that in the other families. The p.Asn130His and p.Gly13Ser 
mutations, identified in B-II:9 and C-II:3 respectively, alter amino acids that are universally 
conserved across all known kinases,26 and these mutant forms of MAK show virtually no 
kinase activity in vitro.4 However, the distinct retinal differences between these two patients 
suggest differences in the total mutational load elsewhere in the genome.
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Variants in other retinal genes may have modified the phenotype in patient B-II:9. Prior 
to the identification of MAK mutations in patient B-II:9, targeted next generation sequencing 
in 111 known blindness genes had been performed (individual 9535 in this study).27 
A heterozygous genetic variant was found in GPR98, which might have a modifying effect 
on the disease. Alternatively, modifier effects from variants in other (retinal) genes that were 
not analyzed in the targeted next generation sequencing approach might be involved in 
the phenotype in patient B-II:9 since the atrophic macular phenotype deviates significantly 
from the relative preservation of macular function observed in the other patients. Additional 
genetic analysis with e.g. whole exome sequencing may reveal pathologic mutations other 
than those present in MAK.
Although the absence of syndromic features is not uncommon in ciliary retinal disorders,12 
the question remains why syndromic features are absent while multiple tissues express MAK. 
Tissue-specific isoforms can result in disease features in only one tissue, and a retina-specific 
isoform of MAK, which includes an extra exon (exon 12 in that transcript) that is regulated by 
exon 9, has been described.5 However, none of the MAK mutations identified in our patients 
were located in either exon 9 or 12. Other explanations may include variance in levels of 
gene expression among tissues and the high metabolic rate of the retina compared to other 
tissues, potentially making the retina more prone to disruptive processes. Alternatively, we 
cannot completely rule out that we missed very subtle extra-ocular features.
Table 3.3. Genetic findings in the patients included in this study.
Patient ID
Allele 1 Allele 2
ConsanguinityMutation Effect Mutation Effect Exon
A-IV:1 c.718C→T p.Gln240* c.718C→T p.Gln240* 8 First cousins
B-II:9 c.388A→C p.Asn130His c.388A→C p.Asn130His 6 First cousins
C-II:3 c.37G→A p.Gly13Ser c.37G→A p.Gly13Ser 2 First cousins
D-II:1 c.79G→A p.Gly27Arg NI r.0 2 No
D-II:4 c.79G→A p.Gly27Arg NI r.0 2 No
E-II:1 c.79G→C p.Gly27Arg c.542T→C p.Ile181Thr 2, 7 No
E-II:3 c.79G→C p.Gly27Arg c.542T→C p.Ile181Thr 2, 7 No
F-II:2 c.497G→A p.Arg166His c.497G→A p.Arg166His 7 Yes
F-II:4 c.497G→A p.Arg166His c.497G→A p.Arg166His 7 Yes
F-II:5 c.497G→A p.Arg166His c.497G→A p.Arg166His 7 Yes
G-II:1 c.497G→A p.Arg166His c.497G→A p.Arg166His 7 First cousins
NI, not identified.
MAK-related RP vs. ciliopathies
To date, mutations in 34 ciliary genes have been associated with both syndromic and non-
syndromic retinal disease (RetNet, available at https://sph.uth.edu/retnet/). Non-syndromic 
retinal disease is caused by defects in twenty-four of these genes and the associated retinal 
phenotypes are summarized in Table 3.4 (except for the MAK-associated phenotype). Besides 
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MAK, 13 ciliary genes are exclusively associated with non-syndromic retinal disease, without 
being associated with syndromic disease as well. Although detailed descriptions of most 
phenotypes associated with ciliary gene defects are lacking, we observed a remarkable 
clinical variability among non-syndromic ciliary retinal disease, ranging from relatively mild 
phenotypes like pericentral retinal dystrophy and occult macular dystrophy, to severe early-
onset retinal degeneration phenotypes such as Leber congenital amaurosis (Table 3.4).
Non-syndromic RP forms caused by ciliary genes generally initiate during the first two 
decades of life and demonstrate reduced visual acuity as an early feature. Accordingly, 
profound macular atrophy is observed in a subset of these RP forms (Table 3.4). Mild RP 
phenotypes without early macular involvement are observed in retinal disease associated 
with mutations in RP1, RP1L1, TOPORS or C2orf71,28-33 which generally are adult-onset and 
characterized by a slow decline in visual acuity. Since RP1, RP1L1 and TOPORS are the only 
ciliary genes that cause non-syndromic dominant RP known to date, the classic dogma that 
dominantly inherited RP is milder compared to recessive and X-linked RP also applies when 
only ciliary RP is considered.2
Like these dominantly inherited phenotypes, MAK-associated recessively inherited 
RP resides at the mild end of the spectrum of diseases caused by ciliary genes. It shows 
remarkable resemblance to the phenotype observed in patients with RP1 mutations in respect 
to the course of visual acuity loss, the patterns of retinal degeneration and visual field loss 
as described by Jacobson and colleagues.28 Underlying mechanisms for the regional retinal 
variations have been optioned to lie in topographic characteristics in gene expression,34-37 but 
further studies are necessary on this subject. The resemblance in phenotypes is especially 
intriguing as RP1 and MAK are functionally related: both proteins localize to the outer 
segment axoneme in murine photoreceptors and RP1 is a phosphorylation target of MAK.3 
Omori et al. suggested that phosphorylation of RP1 may influence microtubule stability and 
regulation of ciliary length.3 Moreover, if lack of RP1 phosphorylation is the direct cause 
of MAK-associated RP, this would also be in accordance with the absence of syndromic 
features, since RP1 is expressed in the retina only.38
In conclusion, we observed slowly progressive, autosomal recessive RP without 
syndromic features in patients with various nonsense or missense mutations in MAK. Visual 
acuity usually remains intact, although modifier effects may have negative consequences on 
central vision. MAK-associated RP is at the mild end of the ciliopathic RP phenotypes and 
shows remarkable resemblance to the retinal phenotype observed in RP1-related RP. Thus, 
defects in proteins that act in the pathway that involves MAK and RP1, may lead to relatively 
mild retinal phenotypes.
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Abstract
Purpose. To provide the clinical features in patients with retinal disease caused by C8orf37 
gene mutations.
Methods. Eight patients – four diagnosed with retinitis pigmentosa (RP) and four with cone-
rod dystrophy (CRD) – carrying causal C8orf37 mutations were clinically evaluated, including 
extensive medical history taking, slit-lamp biomicroscopy, ophthalmoscopy, kinetic perimetry, 
electroretinography (ERG), spectral-domain optical coherence tomography (SD-OCT), 
fundus autofluorescence imaging (FAF) and fundus photography.
Results. In families A and D, respectively, one and three patients showed a classic RP 
phenotype with night blindness followed by concentric loss of visual field. Severe visual loss 
to light perception occurred early in the course of the disease. The symptoms initiated during 
infancy (family A) or adolescence (family D). Ophthalmoscopy revealed macular atrophy, 
bone spicules, attenuated vessels and waxy pale optic discs. SD-OCT showed profound 
photoreceptor degeneration and FAF demonstrated atrophy of the retinal pigment epithelium 
(RPE). ERG responses were non-recordable in these patients.
In families B and C, the patients were diagnosed with CRD. Initial symptoms were 
photophobia or loss of visual acuity and occurred during infancy (family B) or adolescence 
(family C). Ophthalmoscopy and FAF revealed profound macular RPE atrophy, SD-OCT 
demonstrated macular photoreceptor degeneration. ERG responses were severely reduced 
in a cone-rod pattern or non-recordable. Interestingly, both patients in family B demonstrated 
polydactyly.
Conclusions: Mutations in C8orf37 give rise to an early or adolescent-onset autosomal 
recessive CRD or RP phenotype with early macular atrophy. The occurrence of postaxial 
polydactyly in one family suggests a syndromic phenotype, which may indicate C8orf37 has 
a ciliary function.
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Introduction
Retinitis pigmentosa (RP) and cone-rod dystrophy (CRD) are inherited photoreceptor 
dystrophies, which are genetically and clinically highly heterogeneous. RP is the most 
common photoreceptor dystrophy with a prevalence of approximately 1 in 4,000 individuals,1-3 
whereas CRD is less frequent with an estimated prevalence of 1 in 40,000 individuals.4, 5 Both 
conditions are characterized by progressive degeneration of photoreceptors, although in 
different patterns. In RP, rod photoreceptor degeneration usually starts prior to the loss of the 
cone photoreceptors, causing primary symptoms like night blindness and peripheral visual 
field loss. Ophthalmoscopic characteristics include attenuated vessels, peripheral bone 
spicule pigmentation, waxy pallor of the optic disc and peripheral chorioretinal atrophy.3, 
6 In CRD, the cone photoreceptors usually degenerate prior to the rod photoreceptors, 
which the patients perceives as photophobia, loss of visual acuity and central scotomas. 
Ophthalmoscopic features initially include macular retinal atrophy and pigment deposits, 
whereas in later stages mild attenuated vessels and bone spicule pigmentations in the 
periphery may be present, mimicking RP. These two photoreceptor degeneration patterns 
can be distinguished by performing an electroretinography (ERG). In RP, the rod-driven 
(scotopic) responses are equally or more severely reduced than cone-driven (photopic) 
responses,7, 8 whereas in early CRD there are normal rod responses and substantially 
reduced cone responses, although rod responses will deteriorate as the disease progresses.
Mutations in many different genes have been associated with either CRD or RP. CRD 
as well as RP display all Mendelian modes of inheritance.6 Also, digenic and mitochondrial 
inheritance have been described for RP.9-11 Until now, mutations in 36 genes have been 
associated with non-syndromic autosomal recessive (ar) RP.12 Proteins of these genes 
are involved in phototransduction, retinoid (vitamin A) metabolism, transport along the 
connecting cilium, intercellular signaling or synaptic interaction, interphotoreceptor matrix, 
gene regulation and phagocytosis,6, 11, 13 which emphasizes that RP should be defined as 
a spectrum of dystrophies with a similar phenotype. For CRD, mutations in six genes have 
been described to date.12 Mutations in two of these genes (ABCA4 and CERKL) can also 
cause autosomal recessive RP.14, 15 Taken together, it is estimated that mutations in these 40 
genes are causative for ~ 50-60% of all autosomal recessive RP and CRD cases,13 but new 
genes are still being discovered.
 Recently, causative mutations in the C8orf37 gene have been described in both 
autosomal recessive RP and CRD patients.16 Sequence analysis of all six coding exons of 
the C8orf37 gene led to the identification of four different pathogenic variants in these eight 
affected individuals.16 C8orf37 is ubiquitously expressed in adult human tissues, but is highly 
expressed in brain, heart and retinal tissues. The function of the C8orf37 protein is not known 
yet, but immunolocalization studies showed that it is localized at the base of the connecting 
cilium, suggesting a ciliary function.16
Mutations in C8orf37 are known to cause CRD or RP, but specific clinical features have not 
yet been described. A detailed clinical description of the patients with mutations in C8orf37 
may help to provide insight into the gene’s function and improve patient counseling on the 
prognosis of the disease. Furthermore, this type of knowledge is crucial to the emerging new 
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field of gene therapy, not only to select patients amenable for treatment, but also to determine 
the effects of the treatment they may receive.
Methods
Subjects and genetic analysis
Patients with inherited photoreceptor dystrophies were referred to specialized ophthalmic 
centers and examined at the Radboud University Nijmegen Medical Centre (by CBH 
and BJK), Hadassah-Hebrew University Medical Center in Jerusalem, Israel (by EB), the 
Goldschleger Eye Research Institute (by YR) or the Institute for Ophthalmic Research in 
Tuebingen, Germany (by SH).
Subsequently, genetic analysis was performed in all cases. After the discovery of a 
causative homozygous C8orf37 mutation using homozygosity mapping and targeted next 
generation sequencing (NGS) in a German RP patient (A-IV:1), further genetic analysis 
was performed in ~400 families with autosomal recessive RP, CRD, or Leber congenital 
amaurosis. This resulted in three more families from the Netherlands or Israel with causative 
mutations in C8orf37.16 In total, four families including eight affected individuals were selected 
for this clinical study (Table 4.1).
We adhered to the tenets of the Declaration of Helsinki and informed consent was 
obtained from all participating patients prior to the collection of a blood sample and additional 
ophthalmologic examinations. Prior to this study, we obtained approval from the Institutional 
Ethics Committee from the Radboud University Nijmegen Medical Centre.
Clinical analysis
Clinical data were collected from the medical records of these patients. Following the 
identification of causative C8orf37 mutations, all patients were re-evaluated in addition to the 
data accumulated over the years. Medical history was registered with a focus on age of onset, 
initial symptoms and overall course of the retinal disorder. Age of onset was defined as the age 
at which the initial symptom was first noticed by the patient. We asked all patients about the 
presence of syndromic features, which are generally present in 20-30% of retinal dystrophy 
patients. These questions concerned the presence of hearing and balance abnormalities, 
renal failure, cardiac and respiratory anomalies, polydactyly, obesity, cognitive impairment, 
fertility disorders, hypogonadism and dental anomalies. The clinical examination included 
best-corrected visual acuity (BCVA), slit-lamp biomicroscopy, ophthalmoscopy and fundus 
photography. Goldmann (kinetic) perimetry was performed in 6 patients. In patients A-IV:1 
and D-IV:4 perimetry proved impossible due to severe visual impairment. Cross-sectional 
images of the central retina were obtained with a commercially available Spectral-domain 
optical coherence tomography (SD-OCT) instrument (Spectralis, Heidelberg Engineering, 
Heidelberg, Germany; Cirrus, Carl Zeiss Meditec, Jena, Germany) by performing a volume 
scan (15° x 20°) through the fovea. Central foveal thickness was measured at the foveola 
using Heidelberg Eye Explorer software (version 1.6.4.0, Heidelberg Engineering, Heidelberg, 
Germany) or the Cirrus Software (version 5.1.1.6, Carl Zeiss Meditec, Jena, Germany). Fundus 
autofluorescence (FAF; Spectralis, Heidelberg Engineering, Heidelberg, Germany) could be 
performed in six patients. A full-field ERG was performed in all patients except patient D-IV:4. 
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ERGs were performed using Dawson-Trick-Litzkow (DTL) electrodes and the Espion Visual 
Electrophysiology System (Diagnosys, LLC, Lowell, USA) in the Institute for Ophthalmic 
Research Tuebingen, Germany; DTL-electrodes and the RETI-port system (Roland Consults, 
Stasche & Finger GmbH, Brandenburg an der Hazel, Germany) in the Radboud University 
Nijmegen Medical Centre, The Netherlands; Bipolar Burien Allen electrodes and the UTAS 
SunBurst™ Color LED Ganzfeld (LKC technologies, Gaithersburg, MD) in Goldschleger 
Eye Research Institute, Israel; and monopolar corneal electrodes (Henkes-type, Medical 
Workshop B.V., Groningen, The Netherlands) and the computerized UTAS 3000 system (LKC 
technologies, Gaithersburg, MD) in the Hadassah-Hebrew University Medical Center, Israel. 
ERGs were assessed according to local standard values. All centers followed the guidelines 
of the International Society for Clinical Electrophysiology of Vision (ISCEV).17
Results
We included a total of eight patients from four families in this study. An overview of the 
clinical findings in these patients is provided in Table 4.1. In families A and D, the affected 
individuals were diagnosed with RP, whereas in the other families (B and C) the patients 
were diagnosed with CRD. Additionally, both patients from family B mentioned postaxial 
polydactyly in their medical history, including one additional finger and toe on the right 
hand and foot respectively. In the other families, no extra-ocular abnormalities suggesting 
syndromic RP or CRD were observed.
In the RP families (A and D), the mean age of onset was approximately 12 years and 
ranged from infancy to the age of 18. The initial symptom in these patients was either loss 
of visual acuity (n=2) or night blindness (n=1) in these patients, although both symptoms 
occurred within a year after the onset of the disease in these patients. In one patient (D-IV:1), 
the exact initial symptom could not be determined as night blindness and visual acuity loss 
occurred simultaneously. After the onset of the disease, visual acuity deteriorated to hand 
movements or light perception within the following two decades (range: 8-17 years). No 
nystagmus was observed. Early stages of posterior subcapsular cataract were present in the 
patients of family D, whereas the lens of patient A-IV:1 was clear. Ophthalmoscopy displayed 
the classic RP features of bone spicule pigmentation, attenuated vessels and pallor of 
the optic disc as well as profound atrophic lesions in the macular RPE, along the vascular 
arcades and peripapillary region (mean age 40 years; Figure 4.1A and D). Correspondingly, 
autofluorescence imaging showed hypoautofluorescent lesions in these areas (Figure 4.2A 
and G), whereas OCT examination showed generalized loss of the photoreceptor-retinal 
pigment epithelium (RPE) complex (Figure 4.2B and H).
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4Figure 4.1. Fundus photographs of patients carrying mutations in C8orf37. A, Fundus photograph of the central retina in the right eye of patient A-IV:1 (age 37) showing profound retinal degeneration, 
waxy pallor of the optic disc, attenuated vessels, irregular pigmentations in the macula, as well as 
bone spicule-like pigmentation in the mid-periphery. B, Fundus photograph composition of right eye 
of patient B-V:7, aged 26, revealing macular atrophy as well as slightly attenuated arterioles and areas 
of ongoing chorioretinal atrophy. One round pigmentation can be found along the inferior vascular 
arcade. C, Fundus photograph of the central retina in the right eye of patient C-II:1 (age 36) showing 
profound macular atrophy and intraretinal irregular pigmentation, as well as attenuated arterioles. D, 
Fundus photograph composition of patient D-IV:1 at age 39 (right eye) reveals macular atrophy and 
pigmentation clumps, as well as pallor of the optic disc, attenuated vessels, paravascular atrophy of the 
retinal pigment epithelium and abundant bone spicules.
On ERG examination, both rod- and cone-driven responses were nonrecordable in all patients 
(mean age 33 years). Perimetry (patients D-IV:1 and D-IV:3) showed a severely constricted 
visual field with approximately 5° remaining using target V-4e (mean age 41 years).
In the two CRD families (B and C), the mean age of onset was approximately seven 
years and, like in the RP patients, ranged from infancy to the age of 18. Either photophobia 
(n=2) or loss of visual acuity (n=2) was mentioned as initial symptom. In the three decades 
following the onset of the disease, all four CRD patients developed loss of visual acuity 
that gradually decreased to low vision levels of 20/60 to counting fingers. These patients 
showed eccentral fixation, no nystagmus or nystagmoid wandering eye movements were 
present. Biomicroscopy revealed no cataract was present in these patients. Ophthalmoscopy 
revealed macular RPE atrophy as well as (mild) attenuation of the vessels (mean age 33 years; 
Figure 4.1B and C). In patient C-II:2, pigment changes due to extra-ocular surgery for retinal 
detachment were observed. Autofluorescence imaging showed focal hypoautofluorescent 
lesions in the macula (Figure 4.2C and E), whereas OCT examination showed generalized 
photoreceptor degeneration (Figure 4.2D and F). Initially, cone-driven responses were more 
severely affected than the rod-driven responses, which were nonrecordable and severely 
reduced respectively. In the affected individuals of family C, the mixed dark-adapted 
recordings showed negative waveforms. In later stages, rod-driven responses also became 
nonrecordable in the patients from family B (mean age 34 years). Perimetry was difficult to 
perform, but concentric restriction of the visual field was present (mean age 34 years). A 
central scotoma was found in only one patient (B-V:1).
Thinning of the central neuroretina was observed in all patients, except for A-IV:1 and 
C-II:1. The central foveal thickness (CFT) was 74 micron on average (mean age 36 years; 
Table 4.1), whereas CFT generally is ~230 micron in healthy individuals as found by Tick and 
colleagues.18
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Discussion
Inherited retinal dystrophies are highly variable in their clinical presentation, even when more 
or less specific phenotypes such as RP and CRD are considered. This clinical heterogeneity 
is for a large part the result of the many different genes and mutations that are involved. In 
addition, incompletely understood genetic and environmental modifying factors influence 
the disease phenotype. Recently, mutations in the C8orf37 gene have been linked to an 
autosomal recessive retinal dystrophy.16 This report provides an overview of the clinical 
features of the C8orf37-associated retinal dystrophy.
The eight patients in this study presented either with a CRD phenotype or an RP phenotype 
with early macular involvement. Macular atrophy is an early feature of CRD. It usually does not 
occur in classic RP until the very end stage of disease, although it is observed in some specific 
forms of RP.19-22 The RP patients in our study demonstrated a profound loss of vision in an 
early stage of the disease, and some even mentioned loss of visual acuity as initial symptom, 
although night blindness followed visual loss only by a couple of months. Ophthalmoscopy, 
OCT and FAF examination revealed profound atrophy of the photoreceptor-RPE complex in 
the maculae of the RP patients. Contrary to the CRD patients, RP patients developed tunnel 
vision. Perimetry examination in patients D-IV:1 and D-IV:3 did not show an absolute central 
scotoma, but a remaining central visual field residue of 5° with decreased sensitivity.
The disease progression rate was high in all patients in this study: end stage disease was 
reached within two decades after the onset in the RP patients and within three decades 
in the CRD patients. Presently, at a mean age of 36 years, most CRD and RP patients 
demonstrate severely atrophic retinas as a final common end stage. In the light of gene 
therapy development, knowledge about the natural course of C8orf37-associated diseases 
is important. When available, early treatment before severe damage to the retinal architecture 
occurs, is essential in these patients.23 The high rate of disease progression makes early 
evaluation of treatment effect possible. Unfortunately, gene therapy will probably not be 
developed in the near future, as the estimated frequency of C8orf37 mutations as a cause of 
RP/CRD is low (<1%), and a suitable (animal) model is lacking.
Interestingly, C8orf37 is one of few genes that can cause both autosomal recessive RP and 
CRD. Until now, this has only been described in two other genes: ABCA4 and CERKL. For 
ABCA4, it is hypothesized that the level of dysfunctional ABCA4 protein is instrumental in 
the degeneration pattern, causing either Stargardt disease, CRD or RP.24-26 Although the 
phenotype associated with CERKL mutations was originally characterized as RP,15, 27 most 
patients that have been described until now are diagnosed with CRD.28-31 This is in accordance 
with the observation that the CERKL protein is mainly localized in cone photoreceptors of 
mouse retinae.32 The C8orf37 gene is expressed in both rod and cone photoreceptors.16 This 
fits with the involvement of both types of photoreceptors, but does not explain the pattern 
of photoreceptor degeneration. Within the 4 families, we did not observe differences in 
degeneration patterns. This suggests a connection between the degeneration pattern and a 
genetic cause, as family members carry identical C8orf37 mutations and are likely to share 
modifier alleles as well. Here, the correlation between phenotype and genotype is mainly 
Clinical characteristics of C8orf37-associated retinal disease  |  125
4
Figure 4.2. (Auto)fluorescence imaging and corresponding SD-OCT examinations in patients with 
mutations in C8orf37. A, B. Autofluorescence (A) and SD-OCT (B) image of the right eye of patient 
A-IV:1 (age 37) showing macular hypoautofluorescence and numerous hypoautofluorescent lesions in 
the perimacular region (A), as well as severe thinning of the retina temporal of the macula (B). C, D. 
Autofluorescence (C) and SD-OCT (D) imaging of the right eye of patient B-V:7 (age 26) reveals foveal 
hypoautofluorescence, parafoveal hyperautofluorescence, numerous irregular hypoautofluorescent 
spots in the perimacular region (C), and severe thinning of the foveal thickness and profound loss of the 
photoreceptor layer with preservation of the RPE cells (D). E, F. Fluorescence angiography (E) and OCT 
(F) image of the central retina in the left eye of patient C-II:2 at the age of 30 (no autofluorescence was 
performed) showing hypofluorescence in the macula (E), and loss of photoreceptor outer segments, 
thinning of the retina and atrophy of the choriocapillaris (F). G, H. Autofluorescence (G) and OCT (H) 
image of the central retina in the right eye of patient D-IV:1 (age 39) reveals hypoautofluorescence in 
macula indicating atrophy as well as atrophic lesions along the vascular arcades (G) and severe thinning 
of the retina with profound loss of the photoreceptor-RPE complex (H). Green lines indicate the location 
of the corresponding OCT examination. Image quality varies as result of unstable eccentric fixation.
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theoretical as the exact effects of the mutations on the C8orf37 protein and its function are 
not known. However, our previous study localized the protein to the ciliary rootlet of the 
connecting cilia in mouse photoreceptors and to the base of the primary cilia of human RPE 
cells, indicating a ciliary function.16
Ciliopathies are diseases characterized by the dysfunction of the cilium,33 which may lead 
to either multi-organ syndromic phenotypes or to single organ diseases.34 The presence of 
postaxial polydactyly in patients B-V:1 and B-V:7 is interesting in view of the probable ciliary 
function of C8orf37, as it is one of the cardinal features of Bardet-Biedl syndrome (BBS), 
a ciliopathy characterized by retinal degeneration, obesity, polydactyly, hypogonadism, 
renal dysfunction and cognitive impairment.34 Retinal degeneration is a hallmark of many 
syndromic ciliopathies,35, 36 although mutations in retina-specific ciliary genes may also lead 
to non-syndromic RP.37, 38 One-third of non-syndromic retinal dystrophies involve defects in a 
ciliary protein.38 Ubiquitously expressed ciliary genes, like C8orf37 and for example RPGR, 
are more likely to cause syndromic phenotypes. Also in RPGR-associated disease, most of 
the patients demonstrate isolated RP,39 although systemic symptoms have been identified 
occasionally.40, 41
Figure 4.3 ERG recordings of all patients with recordable 
responses. (patient C-II:1 at age 36 and C-II:2 at age 30). Only 
scotopic mixed (rod + cone) responses and photopic (cone) 
responses are depicted. Arrowheads indicate the moment of 
the light flash. Control shows normal responses of individuals 
with healthy retinas. Both patients have severely reduced 
scotopic responses and nonrecordable photopic responses. 
The dark-adapted responses of patient C-II:1 show negative 
ERG waveforms. The dark-adapted responses of patient C-II:2 
only show a negative ERG waveform in the left eye. ERG, 
electroretinography; msec, millisecond; µV, microvolts.
Besides the postaxial polydactyly in individuals B-V:1 and 
B-V:7, we did not identify other syndromic features in these 
individuals. In the other patients no syndromic abnormalities 
were observed, although we could not perform detailed 
additional examinations to exclude subclinical symptoms. 
Polydactyly generally occurs in 5 to 19 per 10000 live births.42 We cannot exclude coincidental 
co-existence but the polydactyly in this family only occurred in the siblings affected with CRD. 
This strengthens the hypothesis of associations between the retinal phenotype and polydactyly. 
In the remaining patients, we could identify other features previously linked to ciliopathies: 
electronegative ERG waveforms in patients C-II:1 and C-II:2 (Figure 4.3), which have been 
described in BBS1-associated BBS,43, 44 and the early occurrence of macular atrophy.21, 22, 43-46 
These data indicate that mutations in C8orf37 may be able to cause both syndromic and non-
syndromic phenotype, similar to other ciliary genes such as USH2A,47 BBS1,48 and RPGR.39-41
In conclusion, mutations in C8orf37 cause autosomal recessive CRD or RP with early 
macular involvement. The dystrophies start in the first two decades of life and progress 
relatively fast to a common phenotype of end-stage retinal degeneration. Although the exact 
function of C8orf37 is not known yet, its immunolocalization, associations and interactions with 
other proteins and presence of polydactyly in one of our families suggest a ciliary function.
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From Syndromic to Nonsyndromic Retinal Degeneration
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Abstract
Objective. To identify the genetic causes underlying autosomal recessive retinitis pigmentosa 
(arRP) and to describe the associated phenotype.
Design. Case series.
Participants. Three hundred forty-seven unrelated families affected by arRP and 33 unrelated 
families affected by retinitis pigmentosa (RP) plus noncongenital and progressive hearing 
loss, ataxia, or both, respectively.
Methods. A whole exome sequencing (WES) analysis was performed in 2 families 
segregating arRP. A mutational screening was performed in 378 additional unrelated families 
for the exon-intron boundaries of the ABHD12 gene. To establish a genotype-phenotype 
correlation, individuals who were homozygous or compound heterozygotes of mutations in 
ABHD12 underwent exhaustive clinical examinations by ophthalmologists, neurologists, and 
otologists.
Main Outcome Measures. DNA sequence variants, best-corrected visual acuity, visual field 
assessments, electroretinogram responses, magnetic resonance imaging, and audiography.
Results. After a WES analysis, we identified 4 new mutations (p.Arg107Glufs*8, p.Trp159*, 
p.Arg186Pro, and p.Thr202Ile) in ABHD12 in 2 families (RP-1292 and W08-1833) previously 
diagnosed with nonsyndromic arRP, which cosegregated with the disease among the family 
members. Another homozygous mutation (p.His372Gln) was detected in 1 affected individual 
(RP-1487) from a cohort of 378 unrelated arRP and syndromic RP patients. After exhaustive 
clinical examinations by neurologists and otologists, the 4 affected members of the RP-1292 
had no polyneuropathy or ataxia, and the sensorineural hearing loss and cataract were 
attributed to age or the normal course of the RP, whereas the affected members of the 
families W08-1833 and RP-1487 showed clearly symptoms associated with polyneuropathy, 
hearing loss, cerebellar ataxia, RP, and early-onset cataract (PHARC) syndrome.
Conclusions. Null mutations in the ABHD12 gene lead to PHARC syndrome, a 
neurodegenerative disease including polyneuropathy, hearing loss, cerebellar ataxia, RP, 
and early-onset cataract. Our study allowed us to report 5 new mutations in ABHD12. This 
is the first time missense mutations have been described for this gene. Furthermore, these 
findings are expanding the spectrum of phenotypes associated with ABHD12 mutations 
ranging from PHARC syndrome to a nonsyndromic form of retinal degeneration.
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Introduction
Retinitis pigmentosa (RP; Mendelian Inheritance in Man, 268000) is the most common 
form of inherited retinal dystrophies affecting 1 in 4000 persons.1 Symptoms include night 
blindness in the early phase of the disease, the development of tunnel vision, and a slowly 
progressive decrease in central vision.2 On examination, patients have decreased visual 
acuity and constricted visual fields accompanied by the classic fundus appearance with dark 
pigmentary clumps in the midperiphery and perivenous areas, attenuated retinal vessels, 
and waxy optic disc pallor. However, the disease onset, progression, retinal appearance, 
and visual function may vary significantly among patients and even within a family.
Retinitis pigmentosa usually is restricted to the eye; however, in 20% to 30% of cases, it 
is associated with nonocular signs leading to more than 30 different syndromes.3 The most 
frequent syndromic RP form is Usher syndrome, in which retinal degeneration is associated 
with hearing impairment, accounting for approximately 10% to 20% of all RP cases.
Retinitis pigmentosa is also a very heterogeneous genetic disorder; the disease can be 
inherited as an autosomal dominant trait (approximately 20% of cases), as an autosomal 
recessive trait (30% of cases), or as an X-linked trait (10% of cases). Approximately 40% 
of patients with RP are isolated cases, although this percentage varies when considering 
different populations.1,4 Non-Mendelian inheritance patterns such as digenic, mitochondrial, 
or de novo mutations have been reported, accounting for a small proportion of cases.3 To 
date, mutations in 41 genes have been described as causing nonsyndromic autosomal 
recessive RP (arRP), and mutations in 56 genes have been identified as being responsible 
for autosomal recessive syndromic retinal dystrophy, including Bardet-Biedl and Usher 
syndromes.5 However, mutations in these genes account for the disease in little more than 
half of all patients.1,6 Although the functions of some of these genes have been studied 
extensively, it is difficult to establish a precise genotype phenotype correlation because 
mutations in different RP genes can cause overlapping clinical phenotypes.7
Recently, a novel form of syndromic RP, a neurodegenerative disease including 
polyneuropathy, hearing loss, cerebellar ataxia, retinitis pigmentosa, and early-onset cataract 
(PHARC; Mendelian Inheritance in Man, 612674), has been described.8 Manifesting typically 
in the late teens, PHARC syndrome is an autosomal recessive progressive and degenerative 
disease. Although the phenotype is quite variable, even within a family, it is observed that 
the hearing loss, the cataract, and the RP are presented in all adult patients described so 
far.8-10 Null mutations in the ABHD12 gene, encoding α-β hydrolase 12 protein, have been 
associated with this syndrome in a total of 12 unrelated families,9,10 as well as with a less 
aggressive phenotype without polyneuropathy that was considered to be a variant of PHARC 
syndrome in a single family.11 In this study, after a whole exome sequencing (WES) analysis, 
we identified 5 new mutations in ABHD12 in 3 families affected with arRP, one of  hich did 
not present any systematic abnormalities, after careful evaluation of neurologic and auditory 
function. In addition, this is the first report of missense mutations in ABHD12, thereby 
expanding the spectrum of mutations and phenotypes that range from PHARC syndrome to 
a nonsyndromic form of retinal degeneration.
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Methods
Patient Recruitment
Patients diagnosed with RP were recruited from the Biobank of the Fundación Jiménez Díaz 
Hospital, Madrid, Spain, and from the department of Ophthalmology, Radboud University 
Medical Center, Nijmegen, The Netherlands. Diagnostic criteria of RP included night 
blindness, peripheral visual loss, or both, with visual field loss and poor visual acuity in 
advanced stages of the disease.
A total of 347 unrelated families with arRP or sporadic RP (346 Spanish families and 
1  Dutch family) and 33 unrelated families affected with RP plus noncongenital and 
progressive hearing loss, ataxia, or both were selected. Informed consent was obtained from 
all patients and family members or their legal guardians involved in the study. All procedures 
were reviewed and approved by the ethics committees of our institutions and adhered to the 
tenets of the Declaration of Helsinki.
One hundred seventy-six unrelated individuals of Spanish origin without RP family history 
were screened as controls to evaluate the frequency of the missense mutations p.Thr202Ile 
and p.His372Gln found in these studied Spanish families. The occurrence of the missense 
variant that was identified in a Dutch family (p.Arg186Pro) was assessed in an in-house 
exome database consisting of more than 500 unrelated individuals.
Peripheral blood samples of index cases and their family members were collected in 
EDTA (ethylenediaminetetraacetic acid) tubes. DNA was extracted from peripheral blood 
leukocytes with an automated DNA extractor (model BioRobotEZ1; Qiagen, Hilden, Germany) 
following the manufacturer’s instructions, or with a standard salting out procedure.
Genetic Analysis
Next Generation Sequencing. Whole exome sequencing was performed in the index cases 
of the RP-1292 and the W08-1833 families as previously described.12,13
Sanger Sequencing Analysis. Bidirectional automatic sequencing was performed to 
confirm and segregate the obtained results by WES in the RP-1292 and W08-1833 families, 
to screen the ABHD12 gene for mutations in a total of 378 additional arRP families, and to 
determine the frequency of one of the missense variations in the control population. Exons 
and exon-intron boundaries of the ABHD12 gene (RefSeq NM_001042472) were analyzed 
using 14 oligonucleotide primer pairs designed using Primer3 software (available at: www.
cgi.com; accessed July 13, 2012). Sequences and annealing temperatures are available 
from the authors on request.
Sequencing results were analyzed by using Staden Package software version 1.7.0 
(available at: staden.sourceforge.net; accessed February 4, 2014) by assembling the 
sequenced contigs and then visualizing the aligned sequences of the exons. High-
Resolution Melting Analysis. High-resolution melting analysis was developed specifically 
and optimized for the mutational scanning of one of the new missense mutations to evaluate 
the frequency of the missense variation in the control population. The methodological 
optimization was performed as described previously.14 Polymerase chain reaction conditions 
are available from the authors by request. The high-resolution melting (HRM) curve analysis 
was performed using the LightCycler 480 Gene Scanning Software (Hoffmann-La Roche, 
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Basel, Switzerland). Melting curves were normalized and temperature adjusted, and finally, 
a difference plot was generated.
Prediction of the Pathogenic Effect of the Missense Variations. The pathogenicity of the 
new variants found in this study was established by the following criteria:
1. Cosegregation in the family.
2. Absence in 176 Spanish healthy control individuals.
3. Amino acid conservation for the missense mutations, which was determined using 
31 orthologs of the ABHD12 protein belonging to different evolutionary branches. The 
BLINK tool (available at: http://www.ncbi.nlm.nih.gov/sutils/blink/; accessed February 
4, 2014) and the Jalview Alignment Editor program (available at: http://www.jalview.org; 
accessed February 4, 2014) were used to analyze the multiple sequence alignments. If 
a residue did not change throughout the species, it was considered highly conserved; 
if the variant residue was present in fewer than 3 species, the change was considered 
moderately conserved; if it was present in 3 to 5 ortholog proteins, it was considered to 
be weakly conserved; otherwise, it was classified as nonconserved.
4. Pathogenicity prediction with in silico tools, including PolyPhen-2 (Polymorphism Pheno-
typing version 2; available at: http://genetics.bwh.harvard.edu/pph2/; accessed February 
4, 2014), SIFT (available at: http://sift.jcvi.org/; accessed February 4, 2014), and Mutation 
Taster (available at: http://www.mutationtaster.org/; accessed February 4, 2014) bioinfor-
matics programs.
5. Three-dimensional structure prediction to determine the possible structural changes in 
the mutant ABHD12 protein. The structure prediction was performed using Project HOPE 
(available at: http://www.cmbi.ru.nl/hope/home/; accessed February 4, 2014) taking the 
protein sequencing Q8N2K0 providing by UniprotKB (Universal Protein Resource) data-
base.15
Clinical Examination
Ophthalmic Evaluation. Ophthalmic examinations were performed including visual acuity, 
intraocular pressure, ocular motility, pupillary reaction, biomicroscopic slit-lamp examination, 
and dilated fundus examination. Visual function was evaluated by static perimetry and Ganzfeld 
electroretinography according to the International Society for Clinical Electrophysiology of 
Vision.16
Hearing Evaluation. Hearing assessment was performed by pure tone audiometry, 
speech-audiometry, and otoscopic examination.
Neurologic Evaluation. A complete neurologic examination was carried out including 
cranial nerves, mental status examination, sensory system, extrapyramidal and pyramidal 
system, cerebellum, peripheral nervous system, individual muscle testing, and evaluation 
of speech and language. To determine if the patients had cerebellar atrophy, magnetic 
resonance imaging was performed.
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Figure 5.1. A, Pedigrees of the 3 studied families with ABHD12 mutations. The index case is indicated 
with an arrow. Sanger sequencing confirmed the mutations identified by whole exome sequencing 
(WES) and revealed their complete cosegregation with the disease. The chromatograms of a mutant and 
a control individual are depicted for each variant (arrows). B, Cross-species comparison of 3 regions of 
ABHD12 indicates that the 3 identified missense mutations affect highly conserved residues. C, Three-
dimensional structural model of ABHD12. The Ile amino acid residue at position 202 (purple) may lead 
to distortion of the active site (yellow) of the other monomer. For variant p.His372Gln, the Gln amino 
acid residue at position 372 (red) does not seem to impair the predicted structure of the protein. The 
His residue is shown in orange. For variant p.Arg186Pro, the change, Arg (green) to Pro (red), seems 
to disturb the predicted structure of the protein. The hydrogen bonds and hydrophobic interactions 
are shown in yellow. D, Intron-exon structure of ABHD12 and location of all mutations identified so 
far. Mutations previously associated with polyneuropathy, hearing loss, cerebellar ataxia, retinitis 
pigmentosa, and early-onset cataract (PHARC) syndrome or PHARC-like syndrome are shown in black. 
Red exons indicate the α-β hydrolyze domain of the protein. The mutations identified in this study and 
associated with PHARC syndrome or nonsyndromic retinitis pigmentosa are shown in red.
Results
Genetic Analysis
A Spanish family with 4 affected siblings (Figure 5.1A) with arRP was recruited. Previously, 
known mutations associated with arRP were discarded using a commercial genotyping 
microarray (AsperBiotech AS; Tartu, Estonia). In addition, whole genome homozygosity 
mapping using a 6.0 Affymetrix SNP array (Affymetrix AS; Santa Clara, CA) excluded the 
presence of IBD regions. To identify the genetic defect underlying the arRP in this family, a 
WES analysis was performed. The WES analysis, after sequencing on a HiSeq2000 platform 
(Illumina Inc., San Diego, CA) for the index case of the RP-1292 family (Figure 1A) yielded total 
of approximately 7254 Mb (raw data), among which approximately 4298 Mb were mapped to 
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the target region with a mean depth of x114.4. As a result, 98.7% of the target regions were 
covered at least x4, with 92.0% covered at least x20. After the WES analysis, 65,444 variants 
were identified after mapping the reads to the human genome reference sequence (National 
Center for Biotechnology Information build 36.1). Prioritization of possibly pathogenic changes 
was performed as follows. We first selected 138 nonsynonymous variants comprised within 
the coding sequence of 160 known genes associated with hereditary retinal degenerations 
and then excluded DNA variants that had more than 2% frequency within the general 
population (dbSNP version 130; database http://www.ncbi.nlm.nih.gov/SNP/) resulting in 
30 variants. Notably, among the variants identified in the known retinal degeneration genes, 
a missense change (p.Leu1970Phe; c.5908C/T) in the ABCA4 gene previously associated 
with both Stargardt disease17 and age-related macular degeneration18 was identified as 
heterozygous. However, no other mutation in this gene that could account for the autosomal 
recessive mode of inheritance was found. Then, we considered only 15 variants in genes 
carrying 2  such changes within their sequence (1 homozygous variant or 2 compound 
heterozygous variants) and cross-checked our results manually with the literature, newest 
single nucleotide polymorphism databases, and so forth. After applying these filters, we were 
left 1 novel homozygous mutation (p.Val349Asp) in the NPHP4 gene, previously associated 
with Senior-Loken syndrome,19 and 1 novel homozygous mutation (p.Glu224*) in the GPR98 
gene, underlying Usher syndrome type 2.20 Both homozygous variants in the NPHP4 and 
GRP98 genes were false positives after their confirmation by Sanger sequencing. For the 
ABHD12 gene, one of them was a 1-base pair deletion (c.319delA) in exon 3, resulting in 
a frameshift and a stop codon after 8 residues (p.Arg107Glufs*8). The other one was a 
C-to-T substitution at nucleotide 605 in exon 6 (c.605CàT) causing an amino acid change 
at codon 202 (p.Thr202Ile).
In parallel, a sporadic Dutch case of the family W08-1833 (Figure 5.1A), which initially 
was considered to have nonsyndromic retinal degeneration, was analyzed by WES in a 
molecular diagnostic setting.13 Only variants in genes in which mutations previously were 
described to be causative for inherited retinal dystrophies were analyzed. In the index case, 
this prefiltering step yielded 724 variants. After the removal of variants present in more than 
1% of our in-house exome sequencing database and including only those variants that affect 
exons or canonical splice sites, only 12 variants were left. Two compound heterozygous 
variants in ABHD12 (p.Trp159* and p.Arg186Pro) were the only 2 variations that were in line 
with an autosomal recessive mode of inheritance, and thus were considered to be the prime 
candidates underlying retinal dystrophy in this family. One of them was a G-to-A substitution 
at nucleotide 447 in exon 4 (c.447GàA) resulting in a stop codon (p.Trp159*), and the other 
one was a G-to-A substitution at nucleotide 557 (c.557GàA) causing an amino acid change 
at codon 186 (p.Arg186Pro).
Sanger sequencing of the specific regions confirmed the presence of the variants 
identified by WES in both index cases and affected members, which cosegregated with the 
disease in the families according to a recessive pattern of inheritance (Figure 5.1A). After 
this finding, a mutation analysis of the ABHD12 gene was performed by Sanger sequencing 
in 345 additional Spanish patients affected with nonsyndromic arRP. The study of all the 
exons and intron-exon boundaries (RefSeq NM_001042472) was performed in the index 
cases. Family RP-1487 carried a novel homozygous missense mutation (c.1116CàG) in exon 
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12, leading to an amino acid change at codon 372 (p.His372Gln). Sanger sequencing in 
all family members of pedigree RP-1487 confirmed that inheritance of this mutation was 
compatible with that of a pathogenic recessive allele (Figure 5.1B).
Throughout this study, we identified 3 novel missense variants. Pathogenicity of these 
variants first was assessed by cosegregation with the disease in the families and by their 
absence in a total of more than 500 Dutch individuals for c.557GàA and in 352 healthy 
control Spanish chromosomes in the case of thec.605CàT and c.1116CàG variations. We 
also considered amino acid conservation in 31 different ABHD12 proteins across evolution 
in combination with a functional prediction in silico analysis. The 3 variants, p.Arg186Pro, 
p.Thr202Ile, and p.His372Gln, accordingly were classified as most likely damaging by 3 
bioinformatic prediction tools (Table 5.1).
The mutation p.Arg186Pro changes a highly conserved and positively charged amino 
acid (arginine) into a neutral residue (proline; Figure 5.1B). As shown in Figure 5.1C, the R168 
is located in one of the central helices in the protein. The 3-dimensional structure analyses 
showed that when the arginine residue changes to a proline, the hydrogen bonds and the 
hydrophobic interactions are lost. Besides that, the proline disturbs the helix, which may 
affect other residues. This means that the mutation severely affects the structure.
The mutation p.Thr202Ile changes a small, hydrophilic, and highly conserved residue 
(threonine; Figure 5.1C) into a bigger and hydrophobic one (isoleucine). A 3-dimensional 
structure analysis by Project HOPE showed, after analyzing multiple different models, that 
the best model seems to be in a dimer conformation. As shown in Figure 5.1C, the mutation 
is located far away from the putative active site in its own monomer. However, it is located 
close to the active site in the other monomer, and therefore it could prevent dimerization or 
interactions with other proteins.
The variant p.His372Gln changes a highly conserved and positively charged amino acid 
(histidine) into a neutral residue (glutamine; Figure 5.1C). However, possibly in virtue of the 
similar sizes of histidine and glutamine, the change did not seem to impair the predicted 
structure of the protein (Figure 5.1D). Nevertheless, the p.His372 involves 1 of the 3 charge-
relay residues in ABHD12 supporting the hypothesis that p.His372Gln is functionally 
deleterious. Moreover, a recent study has shown that site-directed mutagenesis of residues 
of the catalytic triad abolished the enzymatic activity of ABHD12.21
Table 5.1. In Silico Predictions of Novel Missense Variants.
Exon 
No.
Nucleotide 
Change AA Change
Conser-
vation
Polyphen 
Prediction
SIFT  
Prediction
Mutation Taster 
Prediction
5 c.557G/A p.Arg186Pro HC Probably 
damaging
Deleterious Disease causing
6 c.605C/T p.Thr202Ile HC Probably 
damaging
Affects protein 
function
Disease causing
12 c.1116C/G p.His372Gln HC Probably 
damaging
Affects protein 
function
Disease causing
AA = amino acid; HC = highly conserved, considering 31 orthologs of the ABHD12 protein belonging to 
different evolutionary branches; SIFT = sorting tolerant from intolerant.
Novel variants described in this study. Nucleotide numbering is based on RefSeq DNA accession 
number NM_001042472
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Table 5.2. Clinical features of patients with mutation in the ABHD12 gene. (continued)
Sensory and 
Motor  
Neuropathy
Pyramidal Tract 
Signs
Sensorineural 
Hearing Loss
Ataxia MRI of brain
Preserved 
strength; present 
tendon reflexes; 
decreased 
vibration sense 
in lower limbs; no 
paresthesia 
Normal flexor 
and extensor 
plantar response; 
preserved reflexes 
Age-related BE 
(Presbyacusis) 
Normal gait; no 
dysmetria and 
dysarthria 
Normal 
cerebellum and 
brainstem; minimal 
cerebral atrophy 
Preserved 
sensitivity; slightly 
loss of strength 
right upper limb; 
present tendon 
reflexes; no 
paresthesia 
Normal flexor 
and extensor 
plantar response; 
preserved reflexes 
Age-related RE 
(Presbyacusis) 
Dysmetria in lower 
limbs; gait with a 
slightly wide base 
Normal except for 
some minimal old 
residual ischemic 
injuries in semovial 
centers and 
left cerebellum 
hemisphere 
Preserved 
strength and 
sensitivity; present 
tendon reflexes; 
no paresthesia 
Flexor and 
extensor plantar 
response; 
preserved reflexes 
Not referred NCD Gait somewhat 
unstable without 
a wide base; no 
adiadocokinesia 
NCD 
Preserved 
strength and 
sensitivity; present 
reflexes; no 
paresthesia 
Normal flexor 
and extensor 
plantar response; 
preserved reflexes 
Age-related BE 
(Presbyacusis) 
Normal gait with 
a normal base 
width; slight 
dysarthria; no 
dysmetria; mild 
distal postural 
tremor 
Normal except 
for some minimal 
residual ischemic 
injuries in white 
matter 
No tremor; no 
pes cavus; 
Hypoesthesia 
distal symmetric to 
touch and pain 
No hyperreflexia; 
Achilles reflex 
abolished 
Sensorineural 
hearing loss BE 
(37y) 
Normal gait; no 
dysmetria and 
dysarthria. 
Cerebral and 
cerebellar atrophy 
Preserved 
strengths, 
decreased 
peripheral 
sensitivity; no 
achilles tendon 
reflex, low arm 
reflexes, normal 
knee tendon reflex 
Normal plantar 
response 
Decreased 
sensitivity in 1500-
8000 Hz range to 
levels of ~40dB. 
Wide based gait. 
Heel-knee sign 
clearly atactic, 
stuttering speech. 
No dysmetria. 
Normal 
cerebellum 
ID, identification; YR, years; ERG, electroretinogram; BMC, biomicroscopy; MRI, magnetic resonance 
imaging; NB, night blindness; VA visual acuity; NR, non recordable; LE, left eye; PSC, posterior 
subcapsular cataract; BE, both ears; RE, right ear; RE, right eye; RPE, retinal pigment epithelium; NCD, 
no clinical data.
Clinical Examination
Three of the 4 affected individuals of family RP-1292 (II:4, II:5, and II:7) and the index 
cases of the families RP-1487 (II:2) and W08-1833 (II:1) were examined comprehensively 
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by ophthalmologists, otologists, and neurologists. The clinical features of the patients are 
summarized in Table 5.2. All of the affected individuals presented with an RP phenotype 
characterized by a symptom-free period in the first 2 decades of life. Night blindness was the 
first symptom, followed by central visual field loss and reduction of visual acuity.
At the time of the last ophthalmologic examination, in all mutated cases, visual fields 
were reduced symmetrically from 10° to absolute scotoma and the visual acuity varied 
depending on the different stages of macular involvement. Posterior subcapsular cataract 
was found in all the affected individuals carrying ABHD12 mutations. Fundi showed changes 
typical of RP with pale disc, narrowed vessels, and bone spicule pigmentation, although 
the latter were absent in individual II:1 of family W08-1833. In addition, some patients had 
macular retinal pigment epithelium degeneration of various degrees (Figure 5.2A). Full-field 
electroretinography was nonrecordable or substantially reduced in all cases.
For family RP-1292, patient II:4 reported recent hypoacusis (a 78-year-old woman), 
whereas siblings II:6 (a 72-year-old woman) and II:7 (a 66-year-old man) did not report 
hearing loss. The II:5 individual (a 75-year-old man) had severe hearing loss in the left 
ear because of the presence of a cholesteatoma. Audiograms of the patients II:4 and II:7 
showed sensorineural hearing loss of both ears for higher frequencies (>2000 Hz), whereas 
patient II:5 had hearing loss only in the right ear (Figure 5.2B). After clinical examination, the 
diagnosis for the 4 patients was an age-related hearing loss or presbyacusis.
Neurologic examination of the 4 affected individuals of the RP-1292 family revealed no 
signs of peripheral polyneuropathy or ataxia. None of the patients showed pes cavus or 
hammertoes. The strength and sensitivity were preserved in every case. All the reflexes were 
present and the gait was normal, except for individual II:5. None of them reported balance 
problems. Magnetic resonance imaging scans did not show an indication of cerebellar 
atrophy in any case, except for individual II:5, who showed a localized abnormality in the left 
cerebellum interpreted to be caused by a previous ischemic event (Figure 5.2C). No patient 
showed evidence of polyneuropathy or ataxia.
After an exhaustive clinical examination at 38 years of age, the index case of the RP-1487 
family was found to have bilateral hearing loss. An audiogram of the patient showed slight 
hearing loss for low frequencies (<1000 Hz) and moderate hearing loss for median and higher 
frequencies (>2000 Hz) for the right ear and moderate hearing loss in all frequencies for the 
left ear. Currently, she is wearing a hearing aid. Bilateral cataract surgery was performed 
at 21 years of age. She also demonstrated some features of motor and sensory peripheral 
neuropathy. The electroneurographic study was consistent with a moderate demyelinating 
sensorimotor polyneuropathy in the upper and lower limbs. Cerebral and cerebellar atrophy 
were observed on magnetic resonance imaging (image not available).
Patient II:1 from family W08-1833 did not report any neurologic symptoms, but a detailed 
neurologic examination revealed a wide-based gait, peripheral sensitivity loss at the lower 
extremities, and low tendon reflexes. Signs of ataxia were observed in stuttering speech, an 
ataxic heel-knee sign, and intentional tremor at the finger-to-nose test, although no structural 
abnormalities of the cerebellum were observed on magnetic resonance imaging examination 
(Figure 5.2C). Audiography revealed significantly decreased sensitivity of frequencies higher 
than 1500 Hz to levels of 40 dB or lower in both ears (Figure 5.2B).
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Figure 5.2. Phenotype of patients from the RP-1292 and W08-1833 families with mutations in the 
ABHD12 gene. A, Spectrum of fundus findings in different individuals. Funduscopy of 3 patients of 
the RP-1292 family (II:4, II:5, and II:7) shows pale optic discs, attenuation of retinal vessels, and bone 
spicule pigmentation. Funduscopy of patient II:1 of the W08-1833 family shows pallor of the optic 
disc, attenuation of the arterioles, and parafoveal atrophy with bull’s-eye appearance B, Pure-tone air 
conduction audiograms of the patients. The grey areas are the hearing ranges for normal individual at 
70 to 79 years of age (women), 70 to 79 years of age (men), and 60 to 69 years of age (men), respectively, 
as reported by Cruickshanks et al.32 Family RP-1292: for patients II:4 (female) and II:7 (male), the 
audiogram shows age-related hearing loss. Audiogram of the patient II:5 (male) shows hearing loss of 
the right ear. Family W08-1833: audiogram of the patient II:1 shows sensorineural hearing loss of both 
eyes. C, Magnetic resonance imaging (MRI) scans. Family RP-1292: for patient II:4, MRI scan shows 
minimal cerebral atrophy (white arrow), whereas in patient II:5, some injuries in the left cerebellum 
hemisphere consistent with the consequence of an ischemic event (white arrow) are present. Patient II:7 
has a minimal abnormality probably resulting from an ischemic injury (white arrow). Family W08-1833: 
for patient II:1, no structural abnormalities of the cerebellum are observed.
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Discussion
The ABHD12 gene is located on chromosome 20p11.21 and contains 13 exons, encoding a 
protein of 398 amino acids. The protein includes 1 α-β hydrolase domain that spans amino 
acids 171 to 335 and contains 3 active sites located in residues 246, 333, and 372. In 
vitro, the ABHD12 enzyme hydrolyzes 2-arachidonoyl glycerol, the main endocannabinoid, 
by converting it into metabolites arachidonate and glycerol.21,22 However, in vivo it is only 
responsible for a small fraction of the 2-arachidonoyl glycerol hydrolase activity in mouse 
brain, showing that in the mouse brain, ABHD12 is a major lysophosphatidylserine lipase.
In Abhd12 knockout mice, auditory and motor defects and neuroinflammatory responses 
develop. These results suggested that the accumulation of the lysophosphatidylserine 
could contribute to the PHARC phenotype.23 ABHD12 is differentially expressed in 
various cell types and cellular compartments,23-25 being highly expressed in microglia. 
Endocannabinoids are implicated in microglia-mediated neuroinflammation, and the 
dysregulated lysophosphatidylserine metabolism produces microglial and neurobehavioral 
abnormalities.23 Moreover, microglia dysfunction is known to be involved in neurodegenerative 
diseases26 and in retinal dystrophies,27 although further studies are mandatory to elucidate 
how the loss of the ABHD12 function results in the wide spectrum of phenotypes we are 
describing here.
After an exhaustive review of the literature (PubMed: abhd12; accessed January  17, 
2014; http://www.ncbi.nlm.nih.gov/pubmed/?term=abhd12 ) and consultation of the 
databases (HGMD Professional 2013.4 and Eye Diseases-LOVD version 2.0; both accessed 
January 17, 2014) available for mutations in the ABHD12 gene, it has been observed that a 
total of 7 different mutations in the ABHD12 gene have been identified so far as causes of 
PHARC syndrome.9,10,11 All of them are interpreted as null mutations leading to an abolished 
or a severely reduced activity of the encoded enzyme. In our study, we identified 5 new 
mutations in the ABHD12 gene. Two of them were null mutations (p.Arg107Glufs*8 and 
p.Trp159*). As is the case with the previously described mutations, these changes also may 
result in a null allele, whereas the 3 novel missense changes, p.Arg186Pro, p.Thr202Ile, and 
p.His372Gln, may result in a reduced, although not completely abolished, activity of the 
ABHD protein. Taking this hypothesis into account and considering what is known about 
other retinal dystrophies, it is reasonable to expect that mutations in the ABHD12 gene may 
result in a range of disease, from lethal multisystem disorders associated with null alleles 
to a milder spectrum of manifestations from mutations with a hypomorphic character.28,29 
However, after a thorough clinical examination of the patients with mutations in the ABHD12 
gene identified in this study, we could not establish a clear genotype-phenotype correlation.
Although the affected members of the RP-1487 and W08-1388 families showed a 
moderate form of PHARC syndrome including sensorineural hearing loss, cataract, RP, 
and polyneuropathy, none of the patients from the RP-1292 family demonstrated symptoms 
that are distinctive of PHARC, and all of them indeed maintained the initial diagnosis of 
nonsyndromic RP even at later stages of life.
All the modest nonocular abnormalities, such as cataract, hearing loss, and ischemic 
injury, detected in the patients of the RP-1292 family were not debilitating and could be 
attributed to other age-related complications. It is well known that the development of the 
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cataract, most prevalent being the posterior subcapsular cataract, in the RP population is 
more frequent than in the general population and also that the age of onset is earlier. However, 
this is usually present at mid stage in the progression of the disease.2,30,31 The affected 
individuals from families RP-1487 and W08-1388 demonstrated a cataract at the same age 
or earlier than they demonstrated RP, whereas all affected members of the RP-1292 family 
demonstrated posterior subcapsular cataract at a very advanced age, an occurrence that is 
compatible with the natural course of RP or with the age of the patients.
Coinciding with the features described in PHARC syndrome, the patients II:2 (RP1487) 
and II:1 (W08-1388) showed a sensorineural hearing loss in the twenties and early thirties, 
respectively. However, in accordance with the report by Cruickshanks et al,32 where it was 
demonstrated that hearing loss is a very common problem affecting older adults, 3 of 4 
affected individuals for the RP-1292 family showed hearing loss that was diagnosed as age 
related (presbyacusis) by the clinical specialists. However, the gait with a slightly wide base 
present in individual II:5 of the RP-1292 family is most likely the consequence of ischemic 
injuries in the left cerebellum.
Based on these results, it is not possible to establish a clear genotype-phenotype 
correlation for ABHD12 mutations, and it is not clear if less detrimental mutations cause a 
less severe phenotype. Alternatively, the highly heterogeneous clinical differences observed 
in the patients with mutations in the ABHD12 gene may suggest the involvement of genetic 
modifiers, as has been described previously in other cases for retinal dystrophies.33-36 
However, because one of the families presented in this study carries a missense mutation in 
the ABHD12 gene and has members with nonsyndromic RP, we could not completely deny 
the possibility that hypomorphic mutations lead to milder disease. Overall, a larger number of 
patients with missense mutations in this gene need to be assessed clinically, which should be 
coupled further with functional analysis of the mutant proteins to draw definitive conclusions 
on the genotype-phenotype correlation.
In conclusion, this study allowed us to report 5 new variations in the ABHD12 gene, 
representing the first time missense mutations have been described. We have determined, 
using a WES analysis followed by an exhaustive clinical examination, that mutations in the 
ABHD12 gene can cause a wide spectrum of phenotypes ranging from PHARC syndrome to 
a nonsyndromic form of retinal degeneration.
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Abstract
Currently, six genes are known to be associated with Usher syndrome type I and mutations 
in most of these genes can also cause nonsyndromic hearing loss. The one exception is 
USH1G, which is currently only known to be involved in Usher syndrome type I and atypical 
Usher syndrome.
Here we present clinical and genetic data of a Dutch family with autosomal recessively 
inherited hearing loss. The hearing loss had an early onset with a downsloping audiogram 
configuration. Slight progression of the hearing loss was seen in both affected individuals. 
Compound heterozygous mutations in USH1G were found to segregate with the hearing loss 
in this family, a missense (c.310AàG, p.Met104Val) and a frameshift mutation (c.780insGCAC, 
p.Tyr261Alafs*96). Extensive ophthalmic and vestibular examinations demonstrated no 
abnormalities that are usually associated with Usher syndrome type I.
This is the first family presented with nonsyndromic hearing loss caused by mutations in 
USH1G. Our findings expand the phenotypic spectrum of mutations in USH1G.
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Introduction
Usher syndrome is the most common cause of combined hereditary hearing and vision 
loss.1 It is clinically and genetically heterogeneous, but it is mainly characterized by bilateral 
sensorineural hearing loss and retinitis pigmentosa (RP). Vestibular dysfunction is seen in 
part of the cases. Based on severity of hearing loss and presence or absence of vestibular 
dysfunction, Davenport and Omenn distinguished three types in 1977.2 Type I is characterized 
by congenital, stable, severe to profound hearing loss, vestibular areflexia and RP that has an 
onset before puberty. Type II can be distinguished from type I based on severity of hearing 
loss (moderate - severe), absence of vestibular dysfunction and a later onset of RP. Type III is 
characterized by progressive hearing loss, variable vestibular dysfunction and variable onset 
of RP.1,3 Up to now, twelve loci are known for Usher syndrome and for ten of these loci the 
involved genes have been identified. Eight loci are known for Usher syndrome type I and the 
six causative genes are: MYO7A, CDH23, USH1C, PCDH15, USH1G and CIB2.4
Like in Usher syndrome, clinical and genetic heterogeneity are also seen in autosomal 
recessive nonsyndromic hearing loss, for which 49 genes have been identified so far.4 
Interestingly, five genes known to be involved in Usher syndrome type I, MYO7A, CDH23, 
USH1C, PCDH15 and CIB2, are also involved in nonsyndromic hearing loss: DFNB2, DFNB12, 
DFNB18A, DFNB23, and DFNB48, respectively. These DFNB phenotypes are generally 
characterized by prelingual, severe to profound hearing loss, occasionally including minor 
retinal abnormalities not typical for RP.5-8 Exceptions are DFNB2, which is reported to have a 
more variable onset age,9,10 and DFNB12 which can also present with moderate hearing loss, 
but with a progressive nature.11,12
USH1G is located at chromosome 17q25.1 and encodes the protein SANS. Mutations in 
this gene have, up to now, only been described to cause Usher syndrome type I or atypical 
Usher syndrome.13-15 The latter is characterized as atypical since the patients did not suffer 
from visual problems. Ophthalmic examination, however, revealed bone spicules and atrophy 
of the retinal pigment epithelium (RPE), which was characterized as late-onset RP.13,14 To 
our knowledge there are no reports that describe hereditary non-syndromic sensorineural 
hearing loss caused by mutations in USH1G. In this study, we report a Dutch family with 
nonsyndromic sensorineural hearing loss caused by compound heterozygous missense and 
frameshift mutations in USH1G.
Material and methods
Clinical examinations
A non-consanguineous Dutch family (W08-2221) was studied. The pedigree demonstrates 
that hearing loss is present in only one generation, which may indicate an autosomal recessive 
inheritance pattern (Figure 1). This study was approved by the local medical ethics committee. 
All participants signed an informed consent, which additionally was used to retrieve relevant 
data from other medical centers. All family members of the second generation completed a 
questionnaire on hearing and balance. Hearing impaired participants underwent complete 
ear, nose and throat examination including otoscopy and external ear inspection to exclude 
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external ear deformities, previous surgery and other possible causes of hearing impairment. 
A computed tomography (CT) scan of the temporal bone was performed in individual II.1 in 
order to exclude cochlear malformations.
Genetic analyses and molecular modeling
Peripheral blood was drawn from all family members for genetic analysis. Genomic DNA 
was isolated from lymphocytes according to standard procedures. Single Nucleotide 
Polymorphism (SNP) genotypes of individuals II.1 and II.4 were determined by use of the 
Affymetrix® Genome-Wide Human SNP Array 6.0. All SNP array experiments were performed 
and data was analyzed according to the manufacturer’s protocol. Genotype calling and 
calculation of the regions of homozygosity was performed with the Affymetrix® Genotype 
Console Software v2.1 with use of default settings. The segregation of the genotypes for 
each previously reported nonsyndromic, recessive deafness gene was visually evaluated.
Haplotype analysis of Variable Number Tandem Repeat (VNTR) markers was used to 
evaluate the family for involvement of OTOGL, PTPRQ, STRC, GJB3 and SYNE4. VNTR 
marker analysis was performed as described before by Schraders et al.16
We performed Sanger sequence analysis for genes associated with autosomal recessive 
hearing impairment in shared genotype regions, TRIOBP, SOX10, GIPC3, MSRB3, TECTA, 
BSND, WHRN, TPRN, SLC26A4, SLC26A5, GRXCR1, PJVK, TMC1 and USH1G. The effect 
of the missense mutation on the surface and structure of the SANS protein was predicted 
by using a hybrid model of the protein constructed by the automatic script in YASARA.17 The 
structure of the area surrounding amino acid residue 104 is based on the Protein Data Bank 
file 1n0r, which has a sequence identity of 41% with SANS.
Audiometry
Pure tone audiometry was performed, according to current standards to determine hearing 
thresholds at frequencies of 0.25, 0.5, 1, 2, 4 and 8 kHz. To exclude conductive hearing 
impairment, both air and bone conduction thresholds were determined. Speech recognition 
scores were measured by using standard Dutch phonetically balanced consonant-vowel-
consonant word lists. The maximum phoneme recognition score (mean value of both ears) 
was obtained from monaural performance versus intensity curves. The mean value of both 
ears was plotted against age and mean pure tone average (PTA) at 1, 2 and 4 kHz. These 
curves were compared to the curves of presbyacusis patients.18
We additionally tested acoustic reflexes, as well as loudness scaling and speech 
perception thresholds in individual II.1. Acoustic reflexes were measured at the contralateral 
ear as well as at the ipsilateral ear at 0.5, 1, 2 and 4 kHz up to the loudness discomfort level. 
Loudness scaling and speech perception thresholds in noise were evaluated as described 
before.19,20 The results of these examinations were compared to those of normal hearing 
individuals, retrieved from our own clinic, and to those of presbyacusis patients.19
Prism 5.0 (Graphpad Software Inc., San Diego, CA, USA) was used to evaluate 
progression of hearing loss, speech recognition scores and loudness scaling by means of 
regression analysis.
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Vestibular examination
Vestibular function was evaluated by electronystagmography in individual II.1. This involved 
calorisation and a rotary chair testing using the velocity-step test. A smooth pursuit, a 
gaze, an optokinetic test and saccadic tests were performed to confirm normal vestibule-
oculomotor function and to exclude the presence of possible central lesions. To determine 
the reactivity and possible vestibular preponderance of both individual vestibuli bithermal 
(30 and 44˚C) water irrigation of the external auditory canal was used for calorisation. For 
the velocity step test, the patient was seated in a rotary chair with the head ante-flexed 
at 30˚ to obtain a horizontal position of the horizontal semicircular canals. The chair was 
accelerated and when the rotatory nystagmus had subsided during constant rotation, the 
chair was suddenly stopped. This was done for both directions in order to calculate the 
possible presence of directional preponderance (asymmetry). Analyses were performed as 
described previously.21
Ophthalmic evaluation
Retinal function was evaluated in detail in individual II.1. We performed history taking 
and standard ophthalmic examination including best-corrected visual acuity (BCVA), slit-
lamp biomicroscopy and ophthalmoscopy. Goldmann perimetry was performed using 
targets V-4e, III-4e, I-4e, I-3e, I-2e and I-1e. In addition to fundus photography (Topcon 
TRC50IX, Topcon Corporation, Tokyo, Japan), we obtained 30˚ x 30˚ and 55˚ x 55˚ fundus 
autofluorescence (FAF) images (Spectralis, Heidelberg Engineering, Heidelberg, Germany). 
Cross-sectional images of the central and peripheral retina were obtained with a commercially 
available Spectral-domain optical coherence tomography (SD-OCT) instrument (Spectralis, 
Heidelberg Engineering, Heidelberg, Germany) using a 20°x15˚ 19-line volume scan 
covering the fovea as well as a 20˚ single line scan in the superior midperiphery. The patient 
underwent a full-field electroretinography (ERG) performed according the guidelines of the 
International Society for Clinical Electrophysiology of Vision (ISCEV).22 Additionally, color 
vision was evaluated using Hardy-Rand-Rittler (HRR) plates.
Figure 6.1. Pedigree of W08-2221. Squares indicate males, circles females. Solid symbols depict 
affected individuals, clear symbols mean unaffected. WT means wild type. The genotypes of individuals 
II.2 and II.3 are not shown because of privacy reasons.
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Results
Clinical evaluation
Family W08-2221 consists of parents and four siblings of whom two are hearing impaired: a 
female (II.1) and a male (II.4). Hearing loss was noted since the age of four in both siblings. 
Physical examination did not demonstrate any dysmorphic features suggestive of syndromic 
disease. A CT scan of the temporal bones in individual II.1 did not show any abnormalities.
Genetic analyses and molecular modeling
Autozygosity mapping revealed 22 homozygous regions larger than one Mb including one 
known gene for recessive deafness, STRC. For 17 other known autosomal recessive deafness 
genes the genotypes segregated with the hearing loss upon manual inspection of the SNP 
genotypes. OTOGL, PTPRQ, STRC, GJB3 and SYNE4 were excluded by haplotype analysis 
of flanking VNTR markers. Mutation analysis was performed for the other genes by Sanger 
sequencing and three rare variants were identified. A heterozygous synonymous variant was 
detected in TRIOBP (c.4809TàC; p.= (p.Asp1603Asp), NM_001039141.2) and two variants 
in USH1G (NM_173477.2). One novel variant, c.780insGCAC, which causes a frameshift and 
a predicted premature stop codon (p.Tyr261Alafs*96), and a missense variant (c.310AàG; 
p.Met104Val). The USH1G variants segregated with the hearing loss in the family (Figure 6.1) 
and were not present in 350 Dutch control alleles. The insertion was also not present in the 
exome variant server (EVS), while the c.310GàA variant was identified in 4 out of 13002 
European American and African American alleles.23 The amino acid substitution p.Met104Val 
is predicted to be benign by Polyphen2 (score 0.066; range 0-1 with 0= benign and 1= 
probably damaging).24 SIFT predicts that the substitution affects protein function (score 0.03; 
a score < 0.05 predicts the change to be damaging and >0.05 predicts it to be tolerated).25 
Mutation taster predicts the substitution to be disease causing with a probability of 0.99 (0-1).26
Molecular modeling predicts that substitution of methionine for valine in the third ankyrin 
domain of SANS causes a change at the surface of this domain, and therefore possible 
loss of hydrophobic contacts but no change in structure of the domain (Figure 6.2A). For 
comparison, modeling of a previously described missense mutation (p.Leu48Pro) in patients 
with Usher syndrome type Ig was performed.27 This missense mutation is predicted to cause 
a disturbance of the protein structure (Figure 6.2B). Ankyrin domains are mainly formed by 
helical structures, and proline is known to disrupt helical structures. Therefore, it is expected 
that this missense mutation changes the helical structure of the protein and hence affects 
protein function (Figure 6.2B).
Audiometric evaluation
Figure 6.3A demonstrates the deterioration of air conduction thresholds of individual II.1 over 
time. Air conduction thresholds did not differ from bone conduction thresholds. At onset, her 
hearing loss was moderate, but over time it progressed to severe. The audiogram configuration 
was initially flat to gently downsloping, but over time the curve became steeper downsloping, 
demonstrating significant progression especially in the high frequencies (Table 6.1). When 
speech perception scores were plotted against age, scores began to deteriorate after the 
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age of 20 years. When speech perception scores were plotted against PTA1, 2, 4kHz, individual 
II.1 clearly performed better than presbyacusis patients (Figure 6.4).
Patient II.4 also showed a moderate hearing loss and progression was less outspoken over 
time than in case II.1. Audiogram configuration remained flat to gently downsloping (Figure 
6.3B) but progression was significant at 0.25, 4 and 8 kHz (Table 6.1). Speech recognition 
scores plotted against age were comparable to those of individual II.1 and remained stable. 
However, individual II.4 had just reached the age at which the scores of individual II.1 began 
to deteriorate. When the scores were plotted against PTA1, 2, 4kHz, they were comparable to 
those of individual II.1.
Acoustic reflexes were absent in individual II.1. Loudness scaling of II.1 showed a steeper 
loudness growth than one would expect from normal hearing individuals for both 0.5 kHz 
and 2 kHz. The signal to noise ratio was worse than the average ratio of normal hearing 
individuals and presbyacusis patients.
Figure 6.2. (A) Molecular modeling of missense variants in SANS. Close-up of the third ankyrin domain 
with wild type amino acid (methionine) in green and the variant (valine) in red. The change of methionine 
to a valine at position 104, leads to a change at the surface of the ankyrin domain. (B) Close-up of the 
first ankyrin domain with wild type (leucine) in green and the variant (proline) in red. Insertion of a proline 
for a leucine at position 48 causes a change in structure, due to the interference with the helix structure 
of the ankyrin domain.
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Table 6.1. Annual deterioration thresholds
0.25 (kHz) 0.5 (kHz) 1 (kHz) 2 (kHz) 4 (kHz) 8 (kHz)
II.1 -0.25 0.09 -0.25 -1.51 -1.71 -1.60
p NS NS 0.02 <0.0001 <0.0001 <0.0001
II.4 -0.82 -0.25 -0.09 -0.51 -1.17(0.0001) -2.02 
(0.0001)
p 0.03 NS NS NS
Results of longitudinal regression analysis of individual binaural mean air conduction thresholds in dB/yr.
NS = not significant.
Figure 6.3. Longitudinal binaural mean air conduction threshold data of family members II.1 (A); aged 
4.8-25.6 years and II.4 (B); aged 4.9-20.3 years. Age (years) is shown with a symbol key.
Vestibular evaluation
Patient II.1 complained of motion sickness. She showed a spontaneous nystagmus of 3 deg/s 
to the left, which was considered to be non-significant. Recording of the optokinetic nystagmus 
and results of all vestibule-oculomotor tests were normal. During the velocity step test, gain 
and start speed were slightly higher than normal; time constant and Gesamtamplitude were 
normal. Results of calorisation were normal as well. There was a slight asymmetry between 
both labyrinths, to the detriment of the right vestibulum. Based on these results, vestibular 
function was considered normal.
Ophthalmic evaluation
Both patients had no visual complaints, including absence of night blindness, visual field loss 
and decrease in central vision. Patient II.1 presented with amblyopia of the right eye, with 
a suboptimal visual acuity of 20/30 after occlusion therapy, whereas visual acuity reached 
20/12 in the left eye. Ophthalmic examination revealed normal anterior segments and retinas. 
There were no signs of RP: no bone spicules, no attenuation of the retinal vasculature, no 
(waxy) pallor of the optic disc or degeneration of the RPE were observed (Figure 6.5A). FAF 
images revealed normal autofluorescence of the RPE (Figure 6.5B) and SD-OCT revealed 
normal retinal architecture, including intact photoreceptor layer reflectance in the macula 
and midperiphery (Figure 6.5D and 6.5E). Additionally, Goldmann perimetry showed normal 
visual field sizes and sensibility levels and HRR plates were named correctly. Rod- and cone-
derived responses on full-field ERG were normal in both eyes.
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Figure 6.4. (A) Longitudinal regression analysis 
of mean monaural phoneme recognition 
score (% correct) related to age (year) of 
both affected family members. Scores of II.1 
are indicated in grey circles, the regression 
line is a dashed grey curve. Scores of II.4 are 
indicated as black squares, the regression line 
is black and solid. The dashed curve indicates 
nonlinear regression of presbyacusis patients. 
(B) Longitudinal regression analysis of mean 
monaural phoneme recognition score (% 
correct) related to PTA1, 2, 4 kHz (dB HL). Same 
legend as figure 6.4A.
We concluded that subject II.1 had normal 
retinal appearance and function in both 
eyes. The amblyopia found in this patient 
was not considered to be a (prodromal) 
symptom of an Usher syndrome phenotype.
Figure 6.5. Multi-modal imaging of the right eye of patient II.1 at age 25. (A) Fundus photography of 
central fundus of the right eye showing no abnormalities. (B) Fundus autofluorescence imaging of the 
right eye with normal autofluorescence levels in the posterior pole. (C) Infra-red en face image of the 
posterior pole of the right eye. The green lines indicate the location of the optical coherence tomography 
(OCT) images depicted in panels D and E. (D) OCT image of the central retina of the right eye depicting 
the fovea, which reveals no retinal abnormalities and especially a normal photoreceptor layer and retinal 
pigment epithelium (RPE). (E) OCT image of the midperipheral retina of the right eye revealing normal 
retinal architecture.
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Discussion
Here, we present, to our knowledge, the first cases of non-syndromic autosomal recessively 
inherited hearing loss caused by mutations in USH1G. The moderate hearing loss has an 
onset during early childhood. Mild progression of hearing loss, especially in the higher 
frequencies, was observed. Resulting in a downsloping audiogram configuration. Although 
it was only performed in one individual, results of psychophysical examination were in line 
with a cochlear, sensorineural hearing loss. No vestibular abnormalities were detected. 
During ophthalmic examination of patient II.1, no retinal pathology was observed, especially 
no signs of RP which is a clinical hallmark for Usher syndrome. This absence of ophthalmic 
abnormalities made us characterize the phenotype in individual II.1 as nonsyndromic. 
However, while absent at the age of 25 years, RP may develop at a later age, which is highly 
atypical for type I Usher syndrome. Atypical USH1G-associated Usher syndrome has been 
described by Kalay et al. and Bashir et al. in patients with retinal abnormalities, but without 
visual problems.13,14 However, these retinal abnormalities were already observed in patients 
younger than individual II.1.
Of the six known Usher syndrome type I genes, five were already known to be involved 
in nonsyndromic autosomal recessive hearing loss, except for USH1G.5,7,28-30 A number 
of explanations have been given for the fact that mutations in these genes either lead to 
syndromic or nonsyndromic hearing loss. Ouyang et al. illustrated the importance of tissue-
dependent alternative splicing as a cause of phenotypic heterogeneity in Usher syndrome 
type 1c, since harmonin has isoforms that are only expressed in the inner ear and not in 
the retina.8 However, to our knowledge, only one isoform is currently known for the USH1G 
encoded protein SANS.
The difference between Usher syndrome type 1f and DFNB23 has been correlated to the 
mutational effect and residual function of specific protein domains. Only missense mutations 
that do not affect calcium binding and rigidification of protocadherin15 (PCDH15) cause 
DFNB23 thus far.5,28,31 Missense mutations are more likely to result in residual protein function 
than truncating mutations. Furthermore, Riazuddin et al. hypothesize that some residual 
function of myosin VIIA is retained in DFNB2 and that no residual function of the protein will 
be found in Usher syndrome type 1b,7 which was also hypothesized for CDH23 (DFNB12 and 
Usher syndrome type 1d).6,30
Families have been described with Usher syndrome type Ig carrying USH1G missense 
mutations that are expected to result in residual protein function. Therefore, we assume that 
the differences of the genotypic spectrum depend on the extent of residual protein function. 
In addition, other factors are probably also involved in the heterogeneity of the phenotypic 
spectrum of USH1G-associated disease.
When compared to other USH1G genotypes, the genotype described here mostly 
resembles the genotype of a German family described by Weil et al.27 In this family, one allele 
contains a missense mutation (c.143TàC) which leads to a substitution of proline for leucine 
(p.Leu48Pro) in the first ankyrin domain. The second mutation (c.186-187delCA) is predicted 
to lead to a truncated protein (p.Ile63Leufs*71). The phenotype in the affected members of 
this German family deviates from that in family W08-2221 as the former demonstrates an 
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Usher syndrome type I phenotype. As shown by modeling, the change of methionine to valine 
at position 104 only alters the surface of SANS, and not the overall structure (Figure 6.2A). 
This may result in a reduction or loss of binding of one or more interactions partner of SANS. 
The p.Leu48Pro substitution is predicted to lead to a more severe structure alteration and 
predicted loss of hydrophobic contacts (Figure 6.2B). This may interfere more with interaction 
partners than the slight surface change caused by p.Met104Val. Interacting with other 
proteins is essential for the function of SANS, since it is a scaffold protein and is known to 
bind with multiple proteins of the Usher interactome.32 Furthermore, the p.Leu48Pro mutation 
might affect binding of one or more proteins that are essential in both inner ear and retina 
whereas the p.Met104Val might affect the interaction with protein(s) that are only essential 
in cochlear function. To our knowledge, no interaction partners for the ankyrin domains of 
SANS have been identified.
Questions now rise on the prevalence of nonsyndromic hearing loss based on mutations in 
USH1G. One is probably less vigilant on USH1G as a causal gene for nonsyndromic hearing 
loss since it has not been described before to be associated with a nonsyndromic type of 
the disease. We assume that more patients with USH1G-associated isolated hearing loss will 
be identified in the future, especially as the c.310AàG mutation has been found in 0.03% of 
alleles in the EVS database. We demonstrate that several different phenotypes can trigger 
one to consider USH1G as the causative gene: when a patient presents with Usher syndrome 
type I or with atypical Usher syndrome, but most certainly also when a patient presents with 
a nonsyndromic, autosomal recessive, slightly progressive hearing loss.
Conclusion
We describe, to our knowledge, the first family with nonsyndromic sensorineural hearing 
loss based on mutations in USH1G. The hearing loss has an onset during early childhood, 
is progressive and has a downsloping audiogram configuration. Ophthalmic and vestibular 
abnormalities are absent. More knowledge on interaction partners and how they bind to 
SANS will probably clarify the heterogeneous spectrum of phenotypes found with mutations 
in USH1G in the near future.
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Abstract
Purpose. To determine the efficacy of multiple versions of a commercially available arrayed 
primer extension (APEX) microarray chip for autosomal recessive retinitis pigmentosa (arRP).
Methods. We included 250 probands suspected of arRP who were genetically analyzed with 
the APEX microarray between January 2008 and November 2013. The mode of inheritance 
had to be autosomal recessive according to the pedigree (including isolated cases). If the 
microarray identified a heterozygous mutation, we performed Sanger sequencing of exons 
and exon-intron boundaries of that specific gene. The efficacy of this microarray chip with 
additional Sanger sequencing approach was determined by the percentage of patients that 
received a molecular diagnosis. We also collected the data of the genetic tests other than 
the APEX analysis for arRP to provide a detailed description of the molecular diagnoses in 
our study cohort.
Results. The APEX microarray chip for arRP identified the molecular diagnosis in 21 (8.5%) 
of the patients in our cohort. Additional Sanger sequencing yielded a second mutation in 
17 patients (6.8%), thereby establishing the molecular diagnosis. In total, 38 patients (15.2%) 
received a molecular diagnosis after analysis by the microarray and additional Sanger 
sequencing approach. Further genetic analyses after a negative result of the arRP microarray 
(n=107) resulted in a molecular diagnosis of arRP (n=23), autosomal dominant RP (n=5), 
X-linked RP (n=2) and choroideremia (n=1).
Conclusions. The efficacy of the commercially available APEX microarray chips for arRP 
appears to be low, most likely caused by the limitations of this technique and the genetic 
and allelic heterogeneity of RP. Diagnostic yields up to 40% have been reported for NGS 
techniques that, as expected, thereby outperform targeted APEX analysis.
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Introduction
Retinitis pigmentosa (RP) is a group of hereditary diseases with an incidence of approximately 
1:4000.1-4 Although the clinical variation is high, RP is generally characterized by complaints 
of night blindness and peripheral visual field loss caused by progressive rod photoreceptor 
degeneration. In later stages of the disease cones may also degenerate, which results in 
a decrease of central and color vision. The disease can be transmitted in all Mendelian 
patterns, including autosomal recessive in 50%–60% of RP patients, autosomal dominant 
in 30%–40% and X-linked in 5%–15%.1 Additionally, mitochondrial inheritance has been 
described in <1% of RP patients,5 and a few digenic cases have been reported.6,7 To date, 
over 2,300 mutations in 45 genes have been associated with autosomal recessive RP (arRP; 
RetNet, https://sph.uth.edu/retnet/).8 This allelic and genetic heterogeneity complicates 
mutation detection in RP patients, since the phenotype is often not specific enough to link 
the disease to a particular gene. In addition, only just over 50% of the arRP cases can be 
linked to mutations in these genes.9,10
Over time, multiple genotyping techniques have been developed to identify causative 
mutations in genes associated with RP, such as single-strand conformation analysis,11 
denaturing high-performance liquid chromatography (HPLC),12 resequencing microarrays,13 
and arrayed primer extension (APEX) analysis.14-16 Recently, next-generation sequencing 
(NGS) has shown its potential in identifying causative mutations in a selected gene set 
(targeted NGS)17 and in the whole exome.18
Diagnostic genetic testing in nonsyndromic RP patients using the APEX microarray 
technology has been popular since it is a relatively low cost technique that enables screening 
of numerous mutations in multiple genes simultaneously. In the last decade, APEX chips 
have been developed for mutation analysis of the ABCA4 gene in autosomal recessive 
Stargardt disease or cone-rod dystrophy,16,19 as well as for multiple gene microarrays for 
Leber congenital amaurosis (LCA),15,20 Bardet-Biedl syndrome (BBS),21 Usher syndrome,22 
and autosomal dominant and recessive RP.23 The efficacy with which these APEX chips lead 
to a molecular diagnosis is variable for the different disorders.
Identification of the genetic cause in these patients has become more important over 
time. It not only allows for a more accurate prognosis and appropriate genetic counseling 
for patients and their families, but also provides crucial information with regard to upcoming 
genetic therapies. The aim of this study was to evaluate the efficiency of the microarray chip 
for arRP in a cohort of recessive and isolated RP probands.
Methods
Patients
For this study, we selected unrelated patients from the Departments of Ophthalmology of the 
Radboud University Medical Center (Nijmegen, The Netherlands), Erasmus Medical Center 
(Rotterdam, The Netherlands) and the Rotterdam Eye Hospital (Rotterdam, The Netherlands) 
that were clinically suspect for RP and have been analyzed with an arRP microarray 
between January 2008 and November 2013. The microarray screenings were requested 
by the ophthalmologist who examined the patient when RP was suspected based on the 
simultaneous occurrence of at least two of the following criteria: (1) a history of night blindness 
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and/or peripheral visual field loss, (2) a positive family history for RP, (3) perimetric results 
compatible with RP and (4) reduced responses on electroretinography (ERG). We included 
the probands of families that were suspected of RP with an autosomal recessive inheritance 
pattern as well as isolated cases; families with presumed dominant or X-linked inheritance 
patterns were excluded. Only probands were included; other patients within the same family 
were excluded, as well as patients with insufficient clinical data. For this retrospective study 
the local ethics committee ruled that approval was not required and, according to the tenets 
of the Declaration of Helsinki, all participants gave informed consent for the use of their data.
For the selection procedure described above, we collected data from the medical records, 
including history and age of onset, best corrected visual acuity (BCVA), fundus appearance 
and full-field electroretinography (ERG) results. Full-field ERG was performed according the 
International Society for Clinical Electrophysiology of Vision (ISCEV) standards.24
Table 7.1. Overview of the genes analyzed by the latest APEX microarray chip for autosomal recessive 
retinitis pigmentosa (version 6.0).
Gene symbol Full gene name
Number of mutations 
included in chip
ABCA4 ATP-binding cassette, sub-family A (ABC1), member 4 1
AIPL1 Aryl hydrocarbon receptor interacting protein-like 1 1
CERKL Ceramide kinase-like 5
CNGA1 Cyclic nucleotide gated channel alpha 1 5
CNGA3 Cyclic nucleotide gated channel alpha 3 1
CNGB1 Cyclic nucleotide gated channel beta 1 3
CNGB3 Cyclic nucleotide gated channel beta 3 1
CRB1 Crumbs homolog 1 114
EYS Eyes shut homolog 68
GRK1 G protein-coupled receptor kinase 1 1
IMPG2 Interphotoreceptor matrix proteoglycan 2 6
LRAT Lecithin retinol acyltransferase (phosphatidyl-choline-
retinol O-acyltransferase)
3
MERTK C-mer proto-oncogene tyrosine kinase 14
PDE6A Phosphodiesterase 6A, cGMP-specific, rod, alpha 22
PDE6B Phosphodiesterase 6B, cGMP-specific, rod, beta 28
NR2E3 Nuclear receptor subfamily 2, group E, member 3 31
PROM1 Prominin 1 2
RBP3 Retinol binding protein 3, interstitial 1
RDH12 Retinol dehydrogenase 12 (all-trans/9-cis/11-cis) 45
RGR Retinal G protein coupled receptor 7
RHO Rhodopsin 2
RLBP1 Retinaldehyde binding protein 1 13
RP1 Retinitis pigmentosa 1 3
RPE65 Retinal pigment epithelium-specific protein 65kDa 100
SAG S-antigen; retina and pineal gland (arrestin) 4
TULP1 Tubby like protein 1 25
CLRN1 Clarin 1 12
USH2A Usher syndrome 2A 192
Total: 28 Total: 710
ATP, adenosine triphosphate; cGMP, cyclic guanosine monophosphate; kDA, kiloDalton.
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Genetic microarray chip analyses
DNA was extracted from leukocytes acquired from peripheral venous blood samples 
according to automated nucleic acid isolation based on magnetic bead technology 
(Chemagic MSM I, Perkin Elmer chemagen Technologie GmbH, Baesweiler, Germany). 
We performed mutational screening using a commercially available genotyping microarray 
chip based on APEX technology (Asper Biotech, Tartu, Estonia) according to a protocol 
described previously.15 An APEX reaction is based on a single base extension principle, 
which provides highly specific discrimination without allele-specific hybridization. In a single 
multiplex reaction, hundreds to thousands of variants can be analyzed simultaneously. The 
microarray chips used in this study included known pathogenic mutations in the coding 
regions and adjacent intronic sequences of genes associated with arRP.
The microarray chip initially included 501 mutations in 16 genes in 2006,25 but was regularly 
updated as new mutations were being discovered. The latest version (version 6.0) included 
710 mutations in 28 genes (Table 7.1). During the inclusion period of this study, five versions 
of this array have been used: versions 4.0 (between January and April 2008), 4.1 (between 
April 2008 and February 2009), 5.0 (between February 2009 and September 2010), 5.3 
(between September 2010 and July 2012), and 6.0 (between July 2012 and November 
2013). Sanger sequencing was performed to confirm each mutation that was identified by 
the microarray chip. If only a single heterozygous mutation in a certain gene was found, all 
exons and intron-exon boundaries of this gene were analyzed with Sanger sequencing in 
search for the mutation on the second allele. The pathogenicity of a mutation was determined 
by our in-house protocol based on the criteria described by Cotton et al,26 which evaluates 
pathogenicity by evolutionary conservation of the altered nucleotide (phylogenetic profiling 
[PhyloP] score), the nature of the change at the amino acid level (Grantham score), and 
information from online in silico prediction tools SIFT and Polyphen-2. The effects of mutations 
on splice sites, if applicable, were determined by five predictor programs (SpliceSiteFinder-
like, MaxEntScan, NNSPLICE, GeneSplicer, en Human Splicing Finder) as provided in Alamut 
Visual (various versions, Interactive Biosoftware, Rouen, France). Reference sequences as 
provided by Alamut Visual (Interactive Biosoftware, Rouen, France) have been used. Genes 
and mutations were annotated according the HGNC and HGSV nomenclature, respectively. 
The efficiency of each version of the microarray chip was determined by the number of 
patients that had a molecular diagnosis after the analysis with the microarray chip. Patients 
were considered to have a molecular diagnosis when it was plausible that both alleles had 
been identified by a variant that was predicted to be pathogenic, meaning that the variants 
were predicted to significantly reduce or nullify the function of the protein. Identification of 
two pathogenic mutations (in combination with the presence of the RP phenotype) was 
considered pathogenic; segregation analysis – to evaluate if the identified mutations are 
situated on separate alleles –was performed in some but not all families.
Further genetic analyses
To further evaluate the molecular diagnoses found in our study cohort, we also collected data 
of the genetic tests that have been performed after a negative result of the arRP microarray chip 
in these patients. The tests included targeted NGS (n=16), microarray analyses for autosomal 
dominant RP, LCA, BBS, Usher syndrome, and ABCA4 mutation analysis (n=28), or Sanger 
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sequencing of selected genes (n=88). The microanalyses have been performed using the 
microarray chips available from Asper (Asper Biotech, Tartu, Estonia). Targeted NGS was 
performed by sequencing the exome with a 5500xl Genetic Analyzer (Life Technologies™, 
Carlsbad, CA) after DNA enrichment with the Agilent SureSelectXT Human All Exon 50Mb 
Kit (Agilent Technologies, Santa Clara, CA). Data was analyzed by LifeScope™ software (Life 
Technologies™, Carlsbad, CA). Afterwards, the variants of 160 genes known to be involved 
in retinal disease were selected and ordered on predicted pathogenicity. All mutations 
identified have been confirmed by Sanger sequencing.
Results
We included 250 probands (136 males, 54%) with the clinical diagnosis isolated or arRP. 
Seven patients were analyzed with the microarray version 4.0, 12 patients with version 4.1, 
86 with version 5.0, 98 with version 5.3 and 47 with version 6.0. All mutations identified by the 
microarray chip were subsequently confirmed with Sanger sequencing.
Combining the results of all versions of the microarray chip, we identified mutations 
in 68 patients (27.7%). A total of 21 arRP patients (8.5%) received a confirmed molecular 
diagnosis by means of identification of homozygous or two heterozygous pathogenic 
mutations. In 47 patients (18.8%) a single heterozygous pathogenic mutation was detected. 
In the vast majority (182 patients, 72.8%) however, the microarray analysis did not reveal any 
causative mutation (Table 7.2). Additional Sanger sequencing when a heterozygous mutation 
was identified by the microarray chip resulted in a second pathogenic mutation in 17 patients 
(6.8%, Table 7.2). The microarray missed two (11.8%) of these mutations, which results in a 
maximum sensitivity of 95.7%. However, to determine the exact sensitivity all genes tested on 
the microarray chip should be sequenced. In total, the microarray screening with additional 
Sanger sequencing approach identified the molecular diagnosis in 38 (15.2%) of the arRP 
patients. Table 7.2 summarizes the numbers of patients with two, one or no mutation after 
microarray screening for each microarray version, as well as the numbers of solved cases 
after additional Sanger sequencing.
Table 7.2. Efficacy in the identification of the genetic cause of autosomal recessive retinitis pigmentosa 
by the Asper micro-array chip with and without additional Sanger sequencing for this disease.
Chip  
ver-
sion 
Num-
ber of 
patients
Number of cases after microarray analysis (%) Number of genetically 
solved cases by additional 
Sanger sequencing (%)†Genetically solved* Heterozygous No mutations
4 7 0 (0) 0 (0) 7 (100) 0 (0)
4.1 12 3 (25) 2 (16.7) 7 (58.3) 0 (0)
5 86 4 (4.7) 20 (23.3) 62 (72.1) 4 (4.7)
5.3 98 11 (11.2) 16 (16.3) 71 (72.4) 11 (11.2)
6 47 3 (6.4) 9 (19.1) 35 (74.4) 2 (4.3)
Overall 250 21 (8.5) 47 (18.8) 182 (72.8) 17 (6.8)
*Patients were considered genetically ‘solved’ if homozygous or compound heterozygous mutations 
were identified. Segregation analysis was performed in some but not all families.
† Number of patients in whom the mutation on the second allele was identified by Sanger sequencing 
after identification of a heterozygous mutation by microarray screening.
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In this study, we identified 65 different mutations in 12 genes (Table 7.3). Most mutations were 
identified in USH2A (48.5%), PDE6A (17.6%) and CRB1 (10.3%). Of the 65 variants identified 
in this study, 39 (60%) were missense mutations, 10 (15.4%) had effects on splicing, 9 (13.8%) 
caused a premature stop (nonsense mutations), and 7 (10.8%) resulted in a shift of the open 
reading frame. Fifty-nine mutations are (likely to be) pathogenic, whereas 6 mutations appear 
to have no significant effects on protein function (Table 7.3). These mutations may have 
been included based on non-published in-house databases of collaborators. The other eight 
mutations were identified by Sanger sequencing.
Further genetic analyses
Additional genetic tests were performed in 107 patients (43.6%) subsequent to the microarray 
analysis for arRP. An overview is provided in Table 7.4. The tests were selected based on 
the lack of family history or the acquisition of new history and ocular examination details after 
running the arRP APEX. These genetic tests resulted in a molecular diagnosis in 31 patients 
(30%), including arRP in 23 patients (21.5%), autosomal dominant RP in five patients (4.7%), 
X-linked RP in two patients (1.9%) and choroideremia in one patient (0.9%). The targeted 
NGS approach that covered 160 genes associated with hereditary blindness resulted in a 
molecular diagnosis in 12 patients (75%, Table 7.4).
Table 7.3. Mutations identified by microarray chip analysis and additional Sanger sequencing in the 
patients included in this study.
cDNA 
mutation 
(reference 
sequence)
Effect (RNA/
protein)
EVS minor 
allele  
frequency 
in %†
Predicted  
pathogenicity‡
Frequency of 
variant in this 
cohort (%) Reference
CERKL (NM_001030311.1) 1 (0.8)
c.847C>T p.Arg283* 0.048 Pathogenic 1 (0.8) 27,28
CLRN1 (NM_174878.2) 1 (0.8)
c.149_ 
152delins8 p.Ser50fs 0.008 Pathogenic 1 (0.8) 29,30
CNGA1 (NM_000087.3) 3 (2.5)
c.94C>T p.Arg32* NA Pathogenic 2 (1.7) 31
c.959C>T p.Ser320Phe NA Probably pathogenic 1 (0.8) 32
CRB1 (NM_201253.1) 11 (9.2)
c.613_619del p.Ile205fs NA Pathogenic 1 (0.8) 33,34
c.614T>A p.Ile205Lys NA Probably pathogenic 1 (0.8) This study
c.614T>C p.Ile205Thr 0.038 Possibly pathogenic 1 (0.8) 35,36
c.1602G>T p.Lys534Asn NA Probably pathogenic 1 (0.8) 17
c.1892A>G p.Tyr831Cys NA Probably pathogenic 2 (1.7) This study
c.2234C>T p.Thr745Met 0.008 Probably pathogenic 2 (1.7) 37
c.2681A>G p.Asn894Ser 0.008 Possibly pathogenic 1 (0.8) 25,38
c.2842+5G>A splicing NA Possibly pathogenic 1 (0.8) 37
c.2945C>A p.Thr982Lys NA Probably pathogenic 1 (0.8) 39
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cDNA 
mutation 
(reference 
sequence)
Effect (RNA/
protein)
EVS minor 
allele  
frequency 
in %†
Predicted  
pathogenicity‡
Frequency of 
variant in this 
cohort (%) Reference
EYS (NM_001142800.1) 2 (1.7)
c.9405T>A p.Tyr3135* NA Pathogenic 2 (1.7) 40
NR2E3 (NM_014249.2) 5 (4.2)
c.119-2A>C splicing NA Possibly pathogenic 3 (2.5) 29
c.227G>A p.Arg76Gln 0.032 Probably pathogenic 1 (0.8) 29,30
c.932G>A p.Arg311Gln 0.024 Probably pathogenic 1 (0.8) 29
PDE6A (NM_000440.2) 21 (17.5)
c.304C>A p.Arg102Ser 0.015 Probably pathogenic 10 (8.3) 25,41,42
c.769C>T p.Arg257* 0.015 Pathogenic 1 (0.8) 43
c.878C>T p.Pro293Leu 0.361 Possibly benign 1 (0.8) 41
c.937del p.Ile313fs NA Pathogenic 1 (0.8) This study
c.1032C>T
p.Ser344Ser 
(splicing) NA Possibly pathogenic 1 (0.8) This study
c.1171G>A p.Val391Met 1.699 Possibly pathogenic 4 (3.3) 41
c.1705C>A p.Gln569Lys 0.015 Probably pathogenic 1 (0.8) 41
c.1963C>T p.His655Tyr 2.091 Possibly benign 2 (1.7) 44
PDE6B (NM_000283.3) 9 (7.5)
c.220C>T p.Arg74Cys 0.038 Pathogenic 1 (0.8) 45
c.655T>C p.Tyr219His 0.538 Probably pathogenic 2 (1.7) 17
c.1107+3A>G splicing 0.015 Probably pathogenic 1 (0.8) 17
c.1401+4_ 
1401+48del splicing NA Possibly pathogenic 1 (0.8) This study
c.1798G>A p.Asp600Asn NA Possibly pathogenic 2 (1.7) 42
c.2503+5G>C splicing NA Possibly pathogenic 1 (0.8) 17
c.2503+2T>C splicing NA Probably pathogenic 1 (0.8) This study
PROM1 (NM_006017.2) 1 (0.8)
c.1354dup p.Tyr452fs 0.049 Pathogenic 1 (0.8) 46
RDH12 (NM_152443.2) 4 (3.3)
c.379G>T p.Gly127* NA Pathogenic 4 (3.3) 47
RPE65 (NM_000329.2) 3 (2.5)
c.271C>T p.Arg91Trp 0.015 Probably pathogenic 1 (0.8) 48,49
c.963T>G p.Asn321Lys 0.077 Possibly pathogenic 1 (0.8) 50,51
c.1069dup p.Asn356fs NA Pathogenic 1 (0.8) 52
USH2A (NM_206933.2) 59 (49.2)
c.486-14G>A Splicing 0.008 Probably pathogenic 1 (0.8) 53
c.949C>A
p. Arg317Arg 
(Splicing) NA Possibly pathogenic 1 (0.8) 54-58
c.1256G>T p.Cys419Phe 0.008 Pathogenic 3 (2.5) 55,57,59
c.1876C>T p.Arg626* NA Pathogenic 1 (0.8) 55
c.2276G>T p.Cys759Phe 0.154 Pathogenic 16 (13.3) 35,60-64
c.2299delG p.Glu767fs*21 0.176 Pathogenic 3 (2.5) 65
c.2522C>A p.Ser841Tyr 0.531 Possibly pathogenic 3 (2.5) 57,66
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cDNA 
mutation 
(reference 
sequence)
Effect (RNA/
protein)
EVS minor 
allele  
frequency 
in %†
Predicted  
pathogenicity‡
Frequency of 
variant in this 
cohort (%) Reference
c.3368A>G p.Tyr1123Cys NA Probably pathogenic 1 (0.8) 67
c.5728C>T p.Gln1910* NA Pathogenic 1 (0.8) This study
c.5975A>G p.Tyr1992Cys 0.361 Possibly pathogenic 2 (1.7) 64
c.6049+1G>A Splicing NA Pathogenic 1 (0.8) This study
c.7054C>T p.Pro2352Ser NA Probably pathogenic 1 (0.8) This study
c.8723_ 
8724del p.Val2908fs NA Pathogenic 2 (1.7) 54
c.9262G>A p.Glu3088Lys 0.450 Probably benign 2 (1.7) 64
c.9413G>A p.Gly3138Asp NA Probably pathogenic 1 (0.8) This study
c.9433C>T p.Leu3145Phe 0.008 Probably benign 1 (0.8)
EVS
(rs267598373)
c.9815C>T p.Pro3272Leu NA Possibly pathogenic 1 (0.8) 68,69
c.10073G>A p.Cys3358Tyr 0.054 Probably pathogenic 1 (0.8) 25,64
c.10525A>T p.Lys3509* NA Pathogenic 1 (0.8) 17
c.10561T>C p.Trp3521Arg NA Probably pathogenic 1 (0.8) 58,64
c.11677C>A p.Pro3893Thr 1.653 Probably benign 2 (1.7) 58,70
c.12328T>G p.Tyr4110Asp NA Probably pathogenic 1 (0.8) This study
c.12343C>T p.Arg4115Cys 0.077 Probably pathogenic 5 (1.7) 54,58,70
c.13274C>T p.Thr4425Met NA Probably pathogenic 3 (2.5) 17,54,58,70
c.14803C>T p.Arg4935* 0.015 Pathogenic 1 (0.8) 53,64,71
c.15091C>T p.Arg5031Trp 1.284 Probably benign 1 (0.8) 58
c.15377T>C p.Ile5126Thr 2.422 Probably pathogenic 1 (0.8) 11,64,72
c.15433G>A p.Val5145Ile 0.408 Pathogenic 1 (0.8) 35,62-64
†The overall allele frequency as provided in the Exome Variant Server in both European and African 
Americans.
‡The pathogenicity of the mutations was determined by our in-house protocol based on the criteria 
described by Cotton et al26, which evaluates pathogenicity by evolutionary conservation of the amino 
acid (phylogenetic profiling [PhyloP] score), the nature of the change (Grantham score), and information 
from online in silico prediction tools SIFT and Polyphen-2.
* indicates a premature stop.
EVS, Exome Variant Server (available at http://evs.gs.washington.edu/EVS/); NA, not available.
Discussion
Only a decade ago, microarray screening boosted diagnostic genetic analysis in genetic 
heterogeneous disorders such as RP by facilitating reliable fast analysis of multiple genes 
simultaneously with much lower costs than Sanger sequencing of the same genes. 
Nowadays, high-throughput NGS techniques like exome sequencing have become available 
and are selectively used in a diagnostic setting. The microarray technique, however, remains 
in a prominent position in the diagnostic genetic analysis of RP, since NGS is currently only 
available for a small number of patients and has long lead times (>6 months). Therefore, 
we evaluated the efficiency of the microarray screening in arRP and isolated RP cases to 
determine its place in the array of diagnostic genetic tests currently available.
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The low efficacy of 15.2% solved cases after microarray screening and additional Sanger 
sequencing found in this study can be attributed to the method’s limitations in covering the 
genetic and clinical characteristics of autosomal recessive and simplex RP. First, the chip 
only analyzes a fixed set of mutations. The latest version of the chip includes 710 mutations 
in 28 genes, whereas over 2,300 mutations in 45 genes are associated with arRP nowadays8 
(and RetNet, https://sph.uth.edu/retnet/). Therefore, more frequent updates and inclusion of 
less frequent genes and mutations are necessary to increase the chip’s efficacy, although 
this is costly and laborious to implement. Secondly, the APEX microarray approach does 
not identify variants other than the set of mutations present on the array. This rigid approach 
lowers the chance of mutation identification for arRP patients, since the frequency of private 
mutations is generally relatively high because of the immense mutational heterogeneity 
in arRP.
In addition to the disadvantages of the test itself, the heterogeneity of genetic and clinical 
characteristics of autosomal recessive and simplex RP complicates genetic analysis, since 
the correlation between a phenotype and a specific mutations in specific gene may be weak. 
Moreover, isolated RP cases, which are generally considered autosomal recessive, may 
also have an autosomal dominant or X-linked modes of inheritance. For instance, X-linked 
RP caused by mutations in RPGR or RP2 account for 15% of male isolated cases with 
retinal degenerative disease,73 and de novo mutations in genes known to follow a dominant 
inheritance pattern account for 1-2% of isolated RP.17,74 This is exemplified by the discovery of 
mutations in dominant and X-linked RP genes in seven isolated patients in the current study 
(Table 7.4). An approach that enables genetic analysis of autosomal recessive, dominant and 
X-linked cases simultaneously, such as NGS, would therefore be preferable.
The microarray chip analyses defects in the genes that are relatively frequently mutated 
in arRP. Yet, this contributes little to the chip’s efficacy since mutations in the majority of 
genes account only for 1-2% or less of arRP cases.1,8,75 Furthermore, the older versions of the 
chip included mutations that are considered benign (c.9262G>A in USH2A and c.878C>T in 
PDE6A, Table 7.3). These variants probably have been detected in arRP cases previously, 
and have subsequently been added to the array, without a functional assessment of their 
pathogenicity, especially in case of missense mutations. Recently, it has become clear that 
using in silico prediction tools and especially databases with allele frequencies in large 
normal cohorts, like the Exome Variant Server (EVS), provide insight in the pathogenicity 
of a missense mutation, and should be used if functional assessment is missing. These 
benign mutations lower the microarray’s efficiency, and should ideally be removed from the 
chip. The two benign mutations identified with the microarray in this study were not on later 
versions of the chip.
In contrast to the microarray approach, NGS techniques such as whole exome sequencing 
can handle the heterogeneity of arRP and provide a thorough genetic analysis. NGS has 
been reported to identify the genetic cause in 19% to 40% of arRP cases (and 50% to 
82% of RP cases in general), which is significantly higher than the 15.2% solved cases 
after microarray screening and additional Sanger sequencing found in this study.10,17,39,76-81 In 
whole exome sequencing, all coding sequences (the exons) of all genes in the genome are 
sequenced, which enables the identification of known and novel mutations in known arRP 
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genes. Mutations in genes that have not yet been associated with arRP can also be identified 
by this approach. In whole genome sequencing all genetic material is sequenced including 
the exons as well as the introns, the non-coding sequences. This approach theoretically can 
solve even more arRP patients, for instance through the identification of intronic pathologic 
mutations, which have been described in retinal degeneration.82-85 Yet, the increasing 
number of DNA variants that will become available when employing these techniques poses 
a significant challenge to data interpretation.
Future perspectives of genetic testing in RP
The genetic and allelic heterogeneity and often nonspecific clinical appearance of RP 
complicates diagnostic genetic testing. Although APEX microarray analysis has been 
the most efficient diagnostic tool for RP for years, the introduction of NGS techniques in 
diagnostics have shown to be superior by identifying causative mutations in up to 40% of arRP 
cases.10,17,39,76-78 However, NGS comes with its own difficulties, such as data management and 
analysis of the large data sets, and confirming pathogenicity of identified variants.10,17,78 The 
latter is crucial since the large number of genes involved in arRP increases the risk of finding 
a pathogenic variant that is not causative, especially when considering that each person may 
be carrying ~1,500 variants in their coding sequence affecting protein function,86 and, when 
considering retinal degeneration genes, clear-cut heterozygous pathogenic null mutations 
were reported in 1 out of 4 to 5 healthy controls that were analyzed with whole genome 
sequencing.87 Furthermore, costs of data management and storage may rise with the use of 
whole genome sequencing and the development of ‘third generation’ technologies, due to 
massive data sets.88 The sequencing costs in NGS have been high initially, but the expenses 
have diminished over the years, especially since this technique became commercially 
available. Currently, the costs of diagnostic NGS have reduced to levels just above those 
of the APEX microarray analysis. Therefore, we conclude NGS is by far more cost-effective 
and efficient than the microarray analysis in patients with arRP and should be the diagnostic 
genetic analysis of preference.
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Abstract
Objective. To describe the phenotype and genotype of patients with early-onset Stargardt 
disease.
Design. Retrospective cohort study.
Participants. Fifty-one Stargardt patients with age at onset ≤10 years.
Methods. We reviewed patient medical records for age at onset, medical history, initial 
symptoms, best-corrected visual acuity (BCVA), ophthalmoscopy, fundus photography, 
fundus autofluorescence (FAF), fluorescein angiography (FA), spectral-domain optical 
coherence tomography (SD-OCT), and full-field electroretinography (ffERG). The ABCA4 
gene was screened for mutations.
Main outcome measures. Age at onset, BCVA, fundus appearance, FAF, FA, SD-OCT, ffERG, 
and presence of ABCA4 mutations.
Results. The mean age at onset was 7.2 years (range: 1–10 years). The median times to 
develop BCVA of 20/32, 20/80, 20/200 and 20/500 were 3, 5, 12, and 23 years, respectively. 
Initial ophthalmoscopy in 41 patients revealed either no abnormalities or foveal RPE changes 
in 10 and 9 patients, respectively; the other 22 patients had foveal atrophy, atrophic RPE 
lesions, and/or irregular yellow-white fundus flecks. FA revealed a “dark choroid” in 21 out 
of 29 patients. In 14 out of 50 patients, foveal atrophy occurred before flecks developed. 
FAF showed centrifugal expansion of disseminated atrophic spots, which progressed to 
the eventual profound chorioretinal atrophy. SD-OCT revealed early photoreceptor damage 
followed by atrophy of the outer retina, RPE, and choroid. On ffERG in 26 patients, 15 had 
normal amplitudes, and 11 had reduced photopic and/or scotopic amplitudes at their first 
visit. We found no correlation between ffERG abnormalities and the rate of vision loss. 
Thirteen out of 25 patients had progressive ffERG abnormalities. Finally, genetic screening of 
44 patients revealed ≥2 ABCA4 mutations in 37 patients and single heterozygous mutations 
in 7 patients.
Conclusions. In early-onset Stargardt, ophthalmoscopy can reveal no abnormalities or minor 
retinal abnormalities in early disease. Yellow-white flecks can be preceded by foveal atrophy 
and may be visible only on FAF. Although ffERG is insufficient for predicting the rate of 
vision loss, abnormalities can develop. Over time, visual acuity declines rapidly in parallel 
with progressive retinal degeneration, resulting in profound chorioretinal atrophy. Thus, 
early-onset Stargardt lies at the severe end of the spectrum of ABCA4-associated retinal 
phenotypes.
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Introduction
Stargardt disease (STGD1) is the most prevalent inherited juvenile-onset retinal dystrophy, 
with a mean age at onset of 15.2 years.1, 2 The inheritance pattern of STGD1 is autosomal 
recessive, and the disease is characterized by the presence of irregular yellow-white 
fundus flecks in the posterior pole.2-4 Over time, the disease progresses to include macular 
depigmentation and chorioretinal atrophy. Typical STGD1 patients have normal—or near-
normal—panretinal cone and rod function on full-field electroretinography (ffERG); however, 
progressive abnormalities in photopic and scotopic amplitudes have been reported.5-7 
Blockage of choroidal fluorescence (the so-called “dark choroid” sign) on fluorescein 
angiography (FA) is present in 80% of STGD1 patients.8-10 The aforementioned yellow-white 
fundus flecks are hyperautofluorescent on fundus autofluorescence (FAF), presumably due 
to an accumulation of lipofuscin fluorophores in the retinal pigment epithelium (RPE).11, 12 
Spectral-domain optical coherence tomography (SD-OCT) can reveal changes in the outer 
nuclear layer, as well as photoreceptor loss, RPE abnormalities, and a general thinning of 
the retina.13
Mutations in the ABCA4 gene have been associated with a spectrum of retinal diseases 
ranging from mild phenotypes (for example, late-onset STGD1 with relatively preserved 
visual function) to severe, early-onset retinitis pigmentosa accompanied by a rapid loss of 
central and peripheral photoreceptors.14-16 The ABCA4 gene encodes the retina-specific 
ATP-binding cassette transporter (ABCR).17 ABCA4 is expressed in both cones and rods. In 
rod cells, the ABCR protein is localized at the rim of the outer segment discs, where ABCR 
transports all-trans-retinal from the lumen of the outer segment disc to the cytoplasm of 
the photoreceptor cell.18 The accumulation of all-trans-retinal—and its toxic derivatives—
eventually results in the death of RPE cells and photoreceptor cells.19-21 The ABCA4 gene has 
high mutation heterogeneity; more than 700 distinct mutations have been identified to date, 
with a wide range of effects on ABCR protein function. A model to correlate the phenotype 
with the functional severity of the ABCA4 mutation has been proposed.22, 23 According to this 
model, STGD1 results from mild to moderate ABCR impairment.
Among patients who are diagnosed with STGD1, the disease has remarkably wide 
clinical variability with respect to the general course of the disease, the retinal features, 
and the electrophysiological findings.5, 8, 14, 15 STGD1 has both genetic and clinical overlap 
with cone-rod dystrophy, and this may cause confusion among general ophthalmologists; 
indeed, diagnosing STGD1 can be challenging at an early age. Therefore, obtaining an 
accurate description of the full spectrum of ABCA4-associated retinal dystrophies—including 
STGD1—is essential for providing appropriate patient counseling and adequate disease 
management, and may have important implications for selecting patients to participate in 
gene therapy trials. Although clinical features of STGD1 patients with a very young onset 
have been described in heterogeneous cohorts,5, 7, 24, 25 there is lack of studies concerning 
the natural history of these patients. Here, we provide the first comprehensive description of 
the initial and longitudinal clinical and genetic characteristics of a large number of patients 
with early-onset Stargardt, which we defined as an age at onset ≤10 years.
186  |  Chapter 8
Methods
Patients and genetic analysis
The database of the Department of Ophthalmology at Radboud university medical center 
(Nijmegen, the Netherlands) contains 426 patients with a clinical diagnosis of STGD1. For 
258 of these patients, the ABCA4 gene was analyzed by the Department of Human Genetics 
at Radboud university medical center (Nijmegen, the Netherlands). Known mutations were 
screened using the arrayed-primer extension (APEX) microarray (Asper Biotech, Tartu, 
Estonia), and exon duplications and/or deletions were detected using multiplex ligation-
dependent probe amplification (MLPA, MRC-Holland P151/P152). If no mutations or only 
a single heterozygous mutation was identified, the exons and intron-exon boundaries were 
sequenced using the Sanger method to screen for mutations in the other allele. All identified 
mutations were confirmed using Sanger sequencing. In total, 199 patients contained ≥1 
mutation in the ABCA4 gene. Age at onset of disease was defined as the age at which 
symptoms were first noticed by the patient. If this information was not available, we used the 
patient’s age at which he/she first visited an ophthalmologist.
In this study, we included 51 patients with an age at onset ≤10 years and one of the 
following criteria: at least two ABCA4 mutations (n=37); one ABCA4 mutation and the 
presence of yellow-white flecks (n=7); or in absence of ABCA4 analysis, the presence of 
yellow-white flecks and either a dark choroid or an atrophic macular lesion (n=7).
This study was approved by the Institutional Ethics Committee and was performed in 
accordance with the Declaration of Helsinki. All patients provided informed consent prior to 
giving a blood sample and receiving additional ophthalmologic examinations.
Clinical evaluation
We defined the duration of disease as the time interval between the patient’s age at onset 
(defined as described above) and the age at the last visit. Best-corrected visual acuity 
(BCVA) was measured using a Snellen chart, then transformed into the logarithm of the 
minimal angle of resolution (logMAR) for subsequent analysis. A logMAR value of 1.9, 
2.3, or 2.7 was assigned to the patient’s ability to count fingers, detect hand movements, 
or perceive light, respectively.26 Fundus characteristics were documented for 41 patients 
using fundus photography (Topcon TRC-50IX, Topcon Corporation, Tokyo, Japan). FAF 
was performed in 32 patients using a confocal scanning laser ophthalmoscope (cSLO; 
Spectralis, Heidelberg Engineering, Heidelberg, Germany) fitted with an optically pumped 
solid-state laser (488-nm excitation). Atrophic chorioretinal lesions outside the fovea were 
stratified into the following two groups: 1) a patchy pattern consisting of mild disseminated 
hypoautofluorescent spots; and 2) sharply demarcated chorioretinal atrophic lesions with 
an absence of autofluorescence; the extent of these lesions was then classified as either 1) 
lesions that were limited to the posterior pole, or 2) lesions that extended beyond the vascular 
arcades. Cross-sectional images were obtained for 30 patients using SD-OCT (Spectralis, 
Heidelberg Engineering, Heidelberg, Germany). FA (Topcon TRC-50IX, Topcon Corporation, 
Tokyo, Japan; Spectralis, Heidelberg Engineering) was performed in 32 patients in order 
to determine the presence or absence of the “dark choroid” sign. FfERG was performed 
in 43 patients in accordance with the guidelines established by the International Society 
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for Clinical Electrophysiology of Vision (ISCEV)27 using either Dawson-Trick-Litzkow (DTL) 
electrodes or contact lens (CL) electrodes together with the RETI-port system (Roland 
Consults, Stasche & Finger GmbH, Brandenburg an der Havel, Germany). DTL and CL 
electrodes have similarly high signal stability.28 Based on the ffERG results, the patients were 
assigned to three groups as described previously5: group 1 consisted of patients with normal 
ffERG amplitudes; group 2 consisted of patients with reduced photopic amplitude (<5% of 
normal range: <78 µV [B-wave]) and normal scotopic amplitude; and group three consisted 
of patients with reduced photopic and scotopic amplitudes (<5% of normal range: <263 µV 
[B-wave]).
Statistical analysis
Data were analyzed using SPSS Statistics version 20.0 (IBM Corp., Armonk, NY). Kaplan-
Meier “survival” curves were used to analyze the interval between the age at onset and the 
age at which the following endpoints were achieved: mild visual impairment (≥0.2 logMAR, 
Snellen ≤20/32), moderate visual impairment (≥0.6 logMAR, Snellen ≤20/80), severe visual 
impairment (≥1.0 logMAR, Snellen ≤20/200), and blindness (≥1.4 logMAR, Snellen ≤20/500).29 
Cox regression analysis was used to compare the ffERG groups. Differences with a P-value 
≤0.05 were considered statistically significant.
Table 8.1. Summary of clinical and genetic characteristics of 51 early-onset Stargardt patients.
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Allele 1 Allele 2
15 3 14 1.00 (20/200) Yes NP N N c.4539+1G>T c.768G>T
16 9 11 1.10 (20/250) Yes No MR N NP
17 10 47 1.90 (CF) Yes Yes SR SR NP
18 7 48 2.30 (HM) Yes NP SR SR c.768G>T c.5461-10T>C
19 6 43 1.90 (CF) Yes NP SR SR c.768G>T c.5461-10T>C
20 8 33 1.10 (20/250) Yes No N N c.5161-5162delAC c.5882G>A
21 8 64 1.90 (CF) Yes NP ND ND c.2947A>G c.4506C>A
22 8 31 1.90 (CF) Yes NP SR SR NP
23 9 51 1.90 (CF) Yes Yes ND ND c.768G>T c.5461-10T>C
24 3 19 1.00 (20/200) Yes No ND N c.5461-10T>C c.6320G>A
25 9 16 1.30 (20/400) Yes NP MR N c.214G>A c.5461-10T>C
26 5 10 1.10 (20/250) Yes NP NP NP c.5762_5763dup c.2919-?_3328+?del
27 10 31 0.40 (20/50) NP(d ) NP(d ) NP NP c.455G>A c.5461-10T>C
28 9 19 0.72 (20/105) Yes NP N N c.5461-10T>C NI
29 1 28 1.90 (CF) Yes Yes SR N c.5585-10T>C NI
30 8 26 1.30 (20/400) Yes Yes N N c.5312+1G>A c.286A>G
31 10 22 1.90 (CF) Yes Yes SR N c.2588G>C c.4539+1G>T
32 9 15 0.80 (20/125) Yes Yes NP NP c.2588G>C c.4539+1G>T
33 7 18 1.15 (20/286) Yes NP N N c.1957C>T, c.6320G>A, c.3449G>A
34 10 31 1.15 (20/286) Yes Yes N N c.5461-10T>C c.5537T>C
35 7 11 0.80 (20/125) Yes NP N N c.818G>A NI
36 7 7 0.80 (20/125) No Yes N N c.872C>T;4224G>T c.2947A<G 
37 8 22 1.15 (20/286) Yes NP N N c.1822T>A c.5882G>A
38 10 13 0.52 (20/67) No No N N c.5882G>A c.5882G>A
39 10 16 1.15 (20/286) Yes No N N c.768G>T c.1822T>A
40 5 24 1.30 (20/400) Yes Yes MR MR c.768G>T c.5461-10T>C
41 6 22 1.90 (CF) Yes Yes ND ND c.1622T>C;3113C>T c.1622T>C;3113C>T
42 10 22 1.30 (20/400) Yes Yes MR N NP
43 7 19 1.10 (20/250) Yes NP N N NP
44 8 19 1.00 (20/200) Yes NP SR N NP
45 5 15 1.00 (20/200) Yes Yes MR N c.3335C>A c.5461-10T>C
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46 7 31 2.30 (HM) Yes No ND MR c.1822T>A c.5461-10T>C
47 9 20 0.85 (20/143) Yes NP N N c.122G>A c.286A>G
48 4 32 1.00 (20/200) Yes NP NP NP c.5882G>A NI
49 8 18 1.00 (20/200) Yes No SR ND c.286A>G c.286A>G
50 9 14 0.80 (20/125) No No ND SR c.4773+1G>A c.5461-10T>C
51 8 43 1.90 (CF) Yes No ND ND c.768G>T c.5113C>T
a Age, BCVA and ffERG at last examination. 
b The abbreviations reflect the B-wave amplitude: N, normal (equal to or above the lower 5% of the range 
for a normal population: photopic ≥78 µV, scotopic ≥263 µV); MR, moderately reduced (1-5% or normal 
range: photopic ≥69 µV and <78 µV, scotopic ≥ 195 µV and <263 µV); SR, severely reduced (<1% of 
normal range: photopic <69 µV, scotopic <195 µV; ND, not detectable (flat amplitudes). 
c Mean age at onset of the total cohort is used. dIn the patient's medical records fundus findings were 
described conform STGD1, but no detailed description or imaging was made and thus excluded from 
imaging analysis. Del, deletion; dup, duplication; NI, not identified; NP, not performed; y, years; CF, 
counting fingers; HM, hand movements.
Results
Results I: Initial clinical characteristics
A total of 51 patients (28 men and 23 women) were included in this study. The mean 
(±standard deviation) age at onset was 7.2 (±2.2) years (median: 8 years; range: 1-10 years).
Visual acuity. In each case, the initial symptom of the disease was a decline in visual acuity 
that was noticed by the patient, the patient’s parents, or the school physician. Where 
available (n=41 patients), the mean BCVA at the first visit to an ophthalmologist was 0.51 
(±0.36) logMAR (median: 0.48; range: 0-1.15), Snellen 20/65. In 13 patients, the vision loss 
was initially unexplained. Six of these 13 patients were diagnosed with functional vision 
loss, and six other patients were diagnosed initially with cone-rod dystrophy. Twenty-two 
of the 51 patients were diagnosed with STGD1 ≥3 years (range: 3-30 years) after the initial 
symptoms appeared.
Retinal features. Ophthalmoscopy performed at the first visit revealed no retinal abnormalities 
in 10 out of 41 patients. Nine additional patients had foveal RPE changes, and the remaining 
22 patients had foveal atrophy, atrophic RPE lesions that were not limited to the fovea, and/
or irregular yellow-white fundus flecks. FA in 29 patients revealed an absence of choroidal 
fluorescence (the so-called “dark choroid”) in 21 patients. In patient 4, FAF revealed subtle 
hyperautofluorescence of the fovea, and SD-OCT revealed thickening of what appeared to 
be the external limiting membrane (Figure 8.1A1,2,3). One year later, this patient developed 
several small parafoveal hyperautofluorescent flecks with no apparent abnormalities on 
ophthalmoscopy (Figure 8.1B2).
190  |  Chapter 8
Electrophysiologic findings. At their first visit, ffERG data was collected for 26 patients, and 
the patients were classified based on their findings. Group 1 (patients with normal photopic 
and scotopic amplitudes) contained 15 patients (58%), group 2 (patients with reduced 
photopic amplitude and normal scotopic amplitudes) contained 4 patients (15%), and group 
3 (patients with reduced photopic and scotopic amplitudes) contained 6 patients (23%). One 
patient could not be classified into one of these three groups because only the scotopic 
amplitudes were reduced moderately, although no pigmentary retinopathy was observed. 
We found no significant correlation between the ffERG group classification at the first visit 
and progression towards mild visual impairment (p=0.485), moderate visual impairment 
(p=0.309), severe visual impairment (p=0.203), or blindness (p=0.647).
Results II: Natural course
The mean disease duration was 17.1 (±14.5) years (median: 11 years; range: 0-56 years). 
The follow-up period ranged from a single examination in three patients to 47 years (mean: 
12.4±12.6; median: 9 years). The clinical and genetic characteristics of the patient cohort at 
the last examination are summarized in Table 8.1.
Visual acuity. A survival analysis yielded a median interval and 95% confidence interval (CI) 
between age at onset and a decline in BCVA to mild visual impairment, moderate visual 
impairment, severe visual impairment, and blindness of 3 (95% CI: 1.1-4.9), 5 (95% CI: 2.2-
7.8), 12 (95% CI: 9.3-14.7), and 23 (95% CI: 13.2-32.8) years, respectively (Figure 8.2). Mean 
patient age at the last recorded visit was 24.9 (±14.0) years (median: 20 years; range: 7-64 
years), and mean BCVA was 1.29 (±0.58) logMAR (median: 1.15; range: 0.20-2.30), Snellen 
20/386.
Figure 8.1. Kaplan-Meier curves showing the cumulative fraction in early-onset Stargardt with the 
following clinical endpoints: mild visual impairment (≥0.2 logMAR, Snellen ≤20/32, triangle), moderate 
visual impairment (≥0.6 logMAR, Snellen ≤20/80, square), severe visual impairment (≥1.0 logMAR, 
Snellen ≤20/200, circle), and blindness (≥1.4 logMAR, Snellen ≤20/500, star). Censored observations 
are depicted as vertical bars.
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Figure 8.2. Retinal imaging of patient 4 
(age at onset: 6 years; BCVA: 0.24 logMAR, 
Snellen 20/35; ABCA4 genotype: p.Thr983Ala 
and c.5461-10T>C (p.?)) at 7 (A1,2,3) and 8 
(B1,2,3) years of age. Initially, only subtle foveal 
hyperautofluorescence was present (A2); one 
year later, small parafoveal hyperautofluorescent 
flecks were present (the arrow in B2), 
despite a lack of apparent abnormalities on 
ophthalmoscopy. SD-OCT revealed foveal 
thickening of the band representing the external 
limiting membrane (the arrows in A3-B3).
Retinal features. We observed irregular 
yellow-white fundus flecks in 47 out of 50 
patients. These flecks were not always 
evident at the first examination, but they 
developed within an average of 2.9 (±4.1) 
years (median: 0 years; range: 0-17 years) 
of the first visit. The location of these flecks 
varied among the patients: in 10 patients, 
the flecks were present exclusively in the 
central macula; in 17 patients, the flecks 
were scattered throughout the posterior 
pole, but did not extend beyond the vascular arcades; finally, the remaining 20 patients 
presented with a fundus flavimaculatus pattern with numerous flecks in the central and mid-
peripheral retina. Foveal atrophy was reported in 38 patients and occurred within 1.9 (±3.3) 
years (median: 0 years; range: 0-13 years) of the initial visit. Finally, 14 patients developed 
foveal atrophy before the appearance of fundus flecks (Figure 8.3A1,2).
Long-term follow-up data revealed that the initial foveal atrophy progressed to more 
widespread chorioretinal atrophy. Over time, FAF imaging revealed centrifugal expansion 
of disseminated spots in 30 out of 32 patients with a mean timeframe of 9.8 (±10.5) years 
(median: 8 years; range: 0-40 years) (Figure 8.4B2). These spots extended beyond the 
vascular arcades in 24 of these 30 patients with a mean of 11.2 (±11.0) years (median: 
9.5 years; range: 0-40 years) following the first visit (Figure 8.4C2). In 22 out of 32 patients, 
the spots progressed to chorioretinal atrophic lesions after a mean period of 13.5 (±12.3) 
years (median: 10.5 years; range: 0-40 years) (Figure 8.4C2-D2). In 11 of these 22 patients, 
the confluence of these lesions extended beyond the vascular arcades after a mean period 
of 23.0 (±10.3) years (median: 23 years; range: 5-40 years) (Figure 8.4E2). These 11 patients 
who presented with the common phenotype of chorioretinal lesions beyond the vascular 
arcades at the final examination initially presented with flecks (n=3), foveal atrophy (n=4), or 
both flecks and atrophy (n=4) at their first examination.
Over time, SD-OCT showed thinning of the outer nuclear layer and loss of the ellipsoid 
zone, which preceded loss of the RPE/Bruch’s membrane complex. In addition, hyperreflective 
abnormalities in the outer retina were present (Figure 8.4A3). Progression occurred as 
an expanding loss of the outer nuclear layer, ellipsoid zone, RPE, and choriocapillaris 
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(Figure  8.4B-E3). Hyperreflective deposits in the inner layers of the fovea developed, 
corresponding to intraretinal pigmentations on fundus photography (Figure 8.4C1-C3).
Electrophysiologic findings. Follow-up data for 25 patients showed that four patients 
progressed from ffERG group 1 to group 2 within a mean of 10.5 (±4.4) years (range: 
7-16 years), and nine patients progressed from group 1 to group 3 within a mean of 27.7 
(±14.4) years (range: 3-47 years).
Results III: Mutation analysis
The ABCA4 gene was screened for mutations in 44 of the 51 patients; the remaining seven 
patients refused genetic analysis for personal reasons. In these 44 patients, mutations in the 
ABCA4 gene were identified in 81 of the 88 alleles (92%). Thirty-three of these patients had 
two ABCA4 mutations, seven patients had one mutation, three patients had three mutations, 
and one patient had four mutations. In total, 37 distinct mutations were identified; these 
mutations are summarized in Table 8.2. The c.768G>T mutation was identified in 25% of the 
44 patients and accounted for 13% of all identified mutations. The c.5461-10T>C mutation 
was identified in 36% of the patients and accounted for 22% of all identified mutations. 
The most prevalent ABCA4 mutation among Dutch patients with STGD1 (c.2588G>C)23 was 
identified in only 4% of the alleles. Table 8.3 summarizes the non-missense mutations that 
were identified in this study.
Figure 8.3. Fundus photographs and autofluorescence imaging of patient 37 (age at onset: 8 years; 
ABCA4 genotype: p.Phe608Ile and p.Gly1961Glu) at 15 (A1,2) and 22 years (B1,2) of age, showing isolated 
foveal pigment alterations and a hypoautofluorescent lesion (BCVA 0.52 logMAR, Snellen 20/66). Seven 
years later (B1,2), yellow-white parafoveal fundus flecks (the arrow in B2) developed (BCVA 1.15 logMAR, 
Snellen 20/283).
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Table 8.2. ABCA4 mutations in early-onset Stargardt patients.
Mutation Effect
Allele
ReferencesFrequency Percentage
c.122G>A p.Trp41* 1 1% 35
c.214G>A p.Gly72Arg 1 1% 32
c.286A>G p.Asn96Asp 4 5% 36
c.443-?_570+?del p.Arg149fs 1 1% This study
c.455G>A p.Arg152Gln 1 1% 32, 37
c.656G>C p.Arg219Thr 1 1% 38
c.768G>T p.Val256Val/p.? 11 13% 16, 23, 32, 39
c.818G>A p.Trp273* 1 1% This study
c.872C>T p.Pro291Leu 1 1% 34
c.1622T>C p.Leu541Pro 2 2% 1, 16, 32, 40
c.1822T>A p.Phe608Ile 4 5% 1, 23
c.1957C>T p.Arg653Cys 1 1% 32, 41
c.2588G>C p.Gly863Ala/p.DelGly863 3 4% 16, 18, 23, 32, 42
c.2919-?_3328+?del p.Ser974_Gly1110delinsCys 2 2% 23
c.2947A>G p.Thr983Ala 3 4% 34
c.3113C>T p.Ala1038Val 2 2% 16, 31, 32, 40, 43
c.3335C>A p.Thr1112Asn 1 1% 23
c.3449G>A p.Cys1150Tyr 1 1% This study
c.3813G>C p.Glu1271Asp 1 1% This study
c.3874C>T p.Gln1292* 1 1% 34
c.4224G>T p.Trp1408Cys 1 1% This study 
c.4462T>C p.Cys1488Arg 1 1% 1, 8, 44, 45
c.4506C>A p.Cys1502* 1 1% 34
c.4539+1G>T p.? 3 4% 1, 23, 43, 44
c.4773+1G>A p.? 1 1% This study 
c.5113C>T p.Arg1705Trp 1 1% 34
c.5161_5162del p.Thr1721fs 1 1% 23, 36
c.5312+1G>A p.? 1 1% 46
c.5461-10T>C p.? 19 22% 16, 23, 47
c.5537T>C p.Ile1846Thr 1 1% 23, 45
c.5585-10T>C p.? 1 1% 48
c.5714+5G>A p.? 1 1% 1, 23, 32, 41, 43
c.5762_5763dup p.Ala1922fs 1 1% 34
c.5882G>A p.Gly1961Glu 5 6% 18, 31, 32, 44, 49
c.6320G>A p.Arg2107His 2 2% 8, 31, 40, 45, 50
c.6411T>A p.Cys2137* 1 1% 34
c.6543_6578del p.Leu2182_Phe2193del 1 1% 1
References are shown for mutations that have been reported previously. *, stop signal; del, deletion; fs, 
frame shift.
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Figure 8.4. Overview of the natural course of retinal disease in early-onset Stargardt based on findings 
obtained from five separate patients using fundus photography, autofluorescence (FAF), and spectral-
domain optical coherence tomography (SD-OCT). Early-onset Stargardt includes foveal atrophy 
and parafoveal hyperautofluorescent fundus flecks (A1,2) in an early disease stage. SD-OCT reveals 
hyperreflective abnormalities in the outer retina, loss of the ellipsoid zone, and thinning of the outer 
nuclear layer (A3). The initial foveal atrophy and parafoveal flecks then extend centrifugally (B1,2), 
and disseminated hypoautofluorescent spots appear (B2). SD-OCT reveals progression of the foveal 
atrophy, with thinning of the RPE/Bruch’s membrane complex (B3). Further in the course of the disease, 
the disseminated hypoautofluorescent spots become chorioretinal atrophic lesions, the central atrophy 
expands further (C1,2), and pigmentations (C1) are visible as hyperreflective deposits on SD-OCT (C3). 
Over time, confluence of these lesions evolves centrifugally (D1,2), extending beyond the vascular 
arcades (E1,2), with further retinal thinning and atrophy of the choriocapillaris (D3-E3) visible on SD-OCT. 
A1,2,3: patient 1 at age 17; B1,2,3: patient 31 at age 22; C1,2,3: patient 40 at age 24; D1,2,3: patient 8 at age 
36; E1,2,3: patient 5 at age 57.
Table 8.3. Characteristics of the non-missense ABCA4 mutations identified in our cohort study.
Mutation Protein effect SIFT Polyphen-2 Grantham PhyloP
c.3449G>A p.Cys1150Tyr Not tolerated Benign 194 3.19
c.3813G>C p.Glu1271Asp Not tolerated Possibly damaging 45 6.10
c.4224G>T p.Trp1408Cys Not tolerated Probably damaging 215 5.86
The outcome of two protein prediction programs (SIFT: tolerated or not tolerated; PolyPhen: benign, 
possibly damaging, probably damaging), together with Grantham (>60 pathogenic) and PhyloP 
conservation score (>2.5 pathogenic), were used to form the final conclusion. Mutations are proposed 
to be pathogenic when ≥2 categories point to pathogenicity.
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Discussion
In this study, we examined the clinical and genetic characteristics of patients with early-onset 
Stargardt, a disease that lies within the spectrum of retinal phenotypes linked to mutations 
in the ABCA4 gene. Whenever a spectrum of disorders contains overlapping phenotypes as 
the rule rather than an exception, any cutoff point used to define a particular disease within 
that spectrum will be arbitrary. Therefore, we arbitrarily defined “early-onset Stargardt” as 
occurring with an age at onset ≤10 years of age; this definition enabled us to avoid including 
patients with a more typical STGD1 phenotype. Only 4% of the 51 patients in our early-onset 
Stargardt cohort had visual acuity ≤0.30 logMAR, Snellen <20/40 (measured at age 8 and 
18 years of age in these two patients), compared to 14-37% of patients with typical STGD1 
and 59% of patients with late-onset STGD1.5, 14, 24 As patients with a relatively good visual 
acuity tended to return less often than those with progressive problems, these data may 
have overrepresented more severe cases. The majority of our patients for whom full-field 
ERG (ffERG) data were available developed abnormal ffERG amplitudes, consistent with a 
previous report by Fujinami et al.7 However, we found no significant correlation between the 
ffERG group classifications (which were based on the nature of the ffERG abnormalities) at 
the age at onset and the speed of vision loss in this early-onset Stargardt cohort. This finding 
differs from STGD1 cohorts that included patients with later ages at onset.5, 6 Our findings 
indicate that early-onset Stargardt can be considered a distinct severe subtype of STGD1 
that is characterized by early foveal abnormalities and the rapid loss of visual function; in 
contrast, in late-onset STGD1, foveal sparing is common, and visual acuity is often preserved 
to a relatively advanced age.14
The diagnosis of early-onset Stargardt
The natural course of early-onset ABCA4-related retinal disease in our cohort reflects a broad 
clinical spectrum both at the time of onset and at follow-up, with varying degrees of ffERG 
abnormalities and yellow-white flecks and/or atrophy at a variety of locations. Thus, each 
combination of electrophysiological and fundoscopic findings could be considered a unique 
phenotype at a specific time point. Moreover, these phenotypes changed during the course 
of the disease, suggesting progression of the disease. Because both fundoscopic and 
electrophysiological criteria have been proposed for establishing a descriptive diagnosis (for 
instance, Stargardt disease and cone-rod dystrophy), each individual patient can potentially 
receive several diagnoses at one time point and at follow-up. Importantly, receiving several 
diagnoses can be extremely confusing to both the patient and the referring ophthalmologist.
Nevertheless, we found that the spectrum of fundus presentations in this early-onset 
retinal dystrophy ultimately converges to a single clinical and functional endpoint that 
includes profound chorioretinal atrophy and severe vision loss. Therefore, we propose that 
one diagnosis of “early-onset Stargardt” should be given to patients with early-onset central 
retinal dystrophy and ABCA4 gene mutations. This approach will provide the patient with the 
benefit of receiving a single diagnosis throughout his/her entire life.
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Genotype-phenotype correlation
Because early-onset Stargardt can be considered a severe phenotype, severe combinations 
of mutations are expected in these patients. In our cohort, the c.768G>T and c.5461-10T>C 
mutations were significantly more prevalent (present in 25% and 36% of our patients, 
respectively) than in other STGD1 cohorts (8% and 5%, respectively).30, 31 The c.768G>T 
mutation is predicted to cause a splice defect that leads to nonsense-mediated decay 
due to absence of the corresponding mRNA; this mutation is therefore considered to be 
a severe pathogenic mutation. In addition, a founder effect has been suggested for this 
mutation due to the allele frequency of 8% among Dutch patients with STGD1.30 On the 
other hand, the c.5461-10T>C mutation does not appear to be pathogenic, as heterologous 
expression of this mutation failed to reveal a splicing defect.32 However, this mutation is rare 
among control patients but is present in 5% of patients with general STGD1. Therefore, the 
c.5461-10T>C mutation may be in linkage disequilibrium with another, currently unidentified 
severe pathogenic mutation.31 Equally important, the most prevalent ABCA4 mutation among 
Dutch patients with STGD1—c.2588G>C, which was reported in approximately one-third 
of typical STGD1 cases33—was present in only 4% of the ABCA4 alleles in our cohort of 
patients with early-onset Stargardt. To date, no homozygous carriers of this mutation have 
been identified,23 supporting the hypothesis that this is a relatively mild mutation. The low 
prevalence of this presumably mild mutation in our cohort is consistent with a previously 
proposed genotype-phenotype model that correlates the degree of residual ABCR activity 
with the severity of the phenotype.17, 23
We identified ABCA4 mutations in all of our patients who received genetic screening; 
in contrast, the detection rate in routine clinical practice is 73%.34 This difference can be 
explained—at least in part—by the inclusion criteria; patients who lacked a detected ABCA4 
mutation, only would have been included if yellow-white flecks and either a dark choroid 
or an atrophic macular lesion were present. However, our database did not contain such 
patients who received genetic screening and had an early-onset disease. This finding 
supports the notion that early onset is highly predictive for identifying ABCA4 mutations,34 
possibly because of the relatively higher percentage of severe mutations, which are more 
readily identified and/or recognized.
It remains unclear why the fovea is affected early in the course of STGD1 in some patients, 
whereas it can be spared—even for many decades—in other patients carrying compound 
heterozygous mutations, including one severe ABCA4 mutation.14, 15 Other factors must 
therefore play a role in the development of foveal atrophy in early-onset Stargardt; possible 
factors can include pathogenic mutations or single-nucleotide polymorphisms in genes other 
than ABCA4, as well as aberrant cellular processes. For example, the accumulation of all-
trans-retinal in photoreceptor cells can directly increase cellular stress, thereby triggering 
apoptotic signaling pathways.35 Next-generation sequencing of all retina-specific genes may 
help identify the genetic factors that determine whether or not the fovea is involved early in 
the course of STGD1.
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Clinical significance of early-onset Stargardt
Although diagnosing STGD1 at an early age is challenging, delaying diagnosis can have 
serious consequences. For example, 22 of the patients in our study did not receive the 
correct diagnosis for at least three years, and vision loss was initially unexplained in 13 
patients. Recognizing early-onset Stargardt early in the disease course enables the timely 
start of potential measures—such as sunlight protection and low-vision counseling—and 
can prevent the inappropriate prescription of vitamin A supplements. Therefore, patients who 
are suspected of having early-onset Stargardt should be examined thoroughly using FAF 
and SD-OCT, particularly when no abnormalities (or mild foveal abnormalities) are present 
in a child with central vision loss that is otherwise unexplained. This diagnosis should also 
be confirmed by screening for the presence of ABCA4 mutations. Finally, in light of future 
therapeutic options such as gene therapy for treating ABCA4-related retinal disorders, 
obtaining a thorough understanding of the phenotypic spectrum and clinical course of 
STGD1 is essential for identifying the patients who will benefit most from these treatments.
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Abstract
Purpose. To provide a clinical and genetic description of a patient cohort with Stargardt 
disease (STGD1) with identifiable foveal sparing.
Methods. Patients with retinal atrophy (defined as an absence of autofluorescence) that 
surrounds the fovea by at least 180° and does not include the fovea were defined as having 
foveal sparing; eyes with visual acuity (VA) worse than 20/200 were excluded. We reviewed 
the medical files and extracted data regarding medical history, VA, ophthalmoscopy, static 
perimetry, fundus photography, spectral-domain optical coherence tomography (SD-OCT), 
fluorescein angiography (FA), fundus autofluorescence (FAF), and electroretinography 
(ERG). We screened each patient’s ABCA4 gene for mutations.
Results. Seventeen eyes with foveal sparing were identified in 13 unrelated patients. In 4 eyes, 
the fovea gradually became atrophic after the initial foveal sparing. The mean age at onset 
was 51 years (range: 32-67 years). VA was 20/40 or better in all foveal sparing eyes, and 20/25 
or better in 41%. FAF imaging revealed hyperautofluorescent flecks and parafoveal retinal 
atrophy, SD-OCT revealed sharply delineated atrophy, and perimetry revealed parafoveal 
scotomas with intact foveal sensitivity. Finally, genetic screening identified mutations in 19 of 
the 26 ABCA4 gene alleles.
Conclusions. Foveal sparing occurs mainly in patients with late-onset STGD1 and represents 
the milder end of the clinical spectrum in STGD1. The anatomy, metabolism, and biochemistry 
of the retina, as well as genetic variations in genes other than ABCA4, can influence the 
etiology of foveal sparing. Identifying these fovea-protecting factors will facilitate the future 
development of strategies designed to treat STGD1.
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Introduction
Within the retina, the macula provides the highest visual acuity and contains the highest density 
of cones.1, 2 Therefore, a loss of central vision is a hallmark feature of macular dystrophies. 
There are, however, exceptions to this rule. Foveal sparing is an intriguing phenomenon in 
which retinal atrophy surrounds a relatively preserved fovea, leaving central visual acuity 
largely unaffected. Although foveal sparing has been reported in a variety of conditions, 
including Stargardt disease (STGD1),3-5 mitochondrial retinal dystrophy associated with 
the m.3243A>G mutation,6 and geographic atrophy in age-related macular degeneration 
(AMD),7-11 its etiology remains poorly understood.
STGD1 is an autosomal recessive retinal dystrophy that typically presents within the 
first two decades of life.12 Although the clinical presentation of STGD1 varies widely, it is 
usually characterized by a progressive loss of central vision, irregular yellow-white fundus 
flecks, and the so-called “beaten bronze” atrophic macular lesions.13-15 STGD1 has been 
linked to mutations in the ABCA4 gene, which encodes an adenosine triphosphate (ATP)-
binding cassette transporter (ABCR) expressed specifically in the cones and rods of the 
retina.16, 17 Defects in ABCR function cause the accumulation of all-trans-retinal and its 
cytotoxic derivatives (e.g., diretinoid-pyridinium-ethanolamine) in photoreceptors and retinal 
pigment epithelial (RPE) cells, ultimately causing RPE cell death and the subsequent loss of 
photoreceptors.18
Mutations in ABCA4 have been linked to a spectrum of phenotypes ranging from mild 
macular dystrophy to severe early-onset panretinal dystrophy.3, 19-22 We previously postulated 
that disease severity may be correlated to the functional severity of the particular mutation 
in the resulting ABCR protein.19, 23-25 The substantial clinical variability among patients with 
STGD1—including an age at onset of the symptoms that can range from 5-72 years of age, 
diverse fundoscopic features, diverse electrophysiological findings, and a variable time 
course of vision loss—suggests the presence of several strong modifying factors.3,13, 14
Recently, Fujinami et al. reported the clinical and molecular genetic findings of a cohort of 
STGD1 patients with relatively preserved foveal structure and function (based on seemingly 
normal autofluorescence at the fovea). Their study revealed the presence of two basic—
yet distinct—STGD1 phenotypes, namely STGD1 patients with foveal sparing and STGD1 
patients with early-onset foveal atrophy.26 However, the onset of foveal involvement in STGD1 
can vary substantially and can occur in later disease stages, for example in late-onset 
STGD1.3 This heterogeneity complicates the selection of homogeneous cohorts for clinical 
studies to investigate the subtype of STGD1 patients with foveal sparing.
Here, we report the clinical characteristics and the natural course of foveal sparing in 
a cohort of STGD1 patients with foveal sparing, and we explore the mechanisms that may 
underlie this phenomenon.
Methods
Patients and genetic analysis
The patient selection process is depicted in Figure 9.1. The database of the Department of 
Ophthalmology at Radboud University Medical Center (Nijmegen, the Netherlands) contains 
425 clinically suspected cases of STGD1. For 257 of these patients, an ABCA4 genetic screen 
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for known mutations was performed in the Department of Human Genetics at Radboud 
University Medical Center (Nijmegen, the Netherlands) using arrayed primer extension 
analysis (APEX) microarrays (Asper Biotech, Tartu, Estonia). Because STGD1 is autosomal 
recessive, if the Asper microarray screen revealed only one mutation in a given patient, we 
sequenced the exons and intron-exon boundaries in ABCA4 to identify the mutation in the 
second allele. All mutations were confirmed using Sanger sequencing. The presence of one 
or two mutations in the ABCA4 gene confirmed the diagnosis of STGD1 in 198 patients. 
For our study, we selected cases in which foveal sparing was documented using fundus 
photography and/or fundus autofluorescence (FAF) imaging. Patients with RPE atrophy 
(defined as an absence of autofluorescence surrounding the fovea by least 180°) that did not 
include the fovea were defined as having foveal sparing. Eyes with visual acuity of 20/200 or 
worse were presumed to have little or no foveal function and were therefore excluded. Twelve 
unrelated STGD1 patients with foveal sparing in at least one eye were included in this study. 
We also included one additional patient who initially presented with foveal sparing; in this 
patient, the fovea became atrophic as the disease progressed. To exclude pseudo-Stargardt 
pattern dystrophy,27 the PRPH2 gene was sequenced in all 13 patients.
This study was performed in accordance with the tenets of the Declaration of Helsinki, 
and all participating patients gave their informed consent prior to providing a blood sample 
and receiving additional ophthalmologic examinations.
Clinical examination
Clinical data were collected from the medical records of the 13 eligible patients. The data 
collected included the patient’s age at onset, medical history, initial symptoms, and the 
overall course of the retinal disorder. Age at onset was defined as the age at which the initial 
symptoms were noted by the patient. We defined the duration of symptomatic disease as 
the time from the age at onset to the patient’s current age. In the patients who were initially 
asymptomatic, the age at their first visit to the ophthalmologist was used to define disease 
duration.
The standard ophthalmic examination included a measurement of best-corrected visual 
acuity (BCVA) using Snellen visual acuity charts and ophthalmoscopy. The central visual 
field was assessed using a Humphrey perimeter (Carl Zeiss Meditec, Jena, Germany) using 
central 10-2, 24-2, or 30-2 threshold tests in two, two, and four patients, respectively. Fundus 
photography (Topcon TRC50IX, Topcon Corporation, Tokyo, Japan) was performed in ten 
patients. Fluorescein angiography (FA) was performed in ten patients to screen for the presence 
of the dark choroid sign. Full-field electroretinography (ffERG; 8 patients) and multifocal ERG 
(mfERG; 7 patients) were performed using Dawson-Trick-Litzkow (DTL) electrodes and the 
RETI-port system (Roland Consults, Stasche & Finger GmbH, Brandenburg an der Havel, 
Germany). Both the ffERG and mfERG recordings were performed in accordance with the 
guidelines of the International Society for Clinical Electrophysiology of Vision (ISCEV).28
Cross-sectional images were obtained using spectral-domain optical coherence 
tomography (SD-OCT; Heidelberg Engineering, Heidelberg, Germany) in 12 patients; a 
20°x15° 19-line scan covering the fovea was used. Total retinal thickness, outer nuclear layer 
(ONL) thickness, and photoreceptor-RPE (PR+RPE) complex thickness were measured at 
the foveal dip and at 0.25, 0.5, 1, 1.5, 2, and 2.5 mm eccentric distances using Heidelberg 
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Eye Explorer software (Version 1.6.4.0, Heidelberg Engineering, Heidelberg, Germany). ONL 
thickness was measured from the outer plexiform layer to the external limiting membrane 
(ELM), PR+RPE thickness was measured from the ELM to Bruch membrane, and total retinal 
thickness was measured from the vitreous-retinal interface to RPE-Bruch membrane complex. 
Clinically normal values for total retinal thickness, ONL thickness, and PR+RPE thickness 
were obtained from 25 age-matched individuals (mean age: 46 years; range: 27-62 years) 
with no retinal or vitreoretinal disease; we performed a post-acquisition interpolation of the 
normal data using custom programs (MatLab R2011a, The MathWorks Inc., Natick, MA).
We acquired FAF images using a confocal scanning laser ophthalmoscope (cSLO, 
Spectralis, Heidelberg Engineering, Heidelberg, Germany). After the pupil was dilated, 
30° and/or 55° field-of-view FAF images were obtained from all patients (except case 11) using 
an optically pumped solid-state laser with 488-nm excitation. Two independent observers 
(authors R.A.C.v.H. and N.M.B.) measured the size of the atrophic lesions (determined using 
the absence of autofluorescence) as described previously.29
Figure 9.1. Flow-chart depicting the selection 
process of Stargardt patients with foveal sparing for 
inclusion in the study. FAF, fundus autofluorescence; 
FP, fundus photography; STGD1, Stargardt disease.
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Figure 9.2. Fundus photographs of three patients with STGD1. A, Fundus photograph of the right eye 
of patient 4 (at age 60), showing fundus flavimaculatus flecks and parafoveal atrophy of the retinal 
pigment epithelium (RPE). B, Fundus photograph of the left eye of case 5 (at age 45), showing fundus 
flavimaculatus flecks and parafoveal atrophy of the RPE. C, Mosaic of fundus photographs of the right 
eye of case 12 (at age 73), showing profound central atrophy of the RPE; this patient previously had 
foveal sparing.
Results
Clinical characteristics
Of the 198 patients with a confirmed diagnosis of STGD1, 13 unrelated patients (7%) had 
foveal sparing. The clinical characteristics of these 13 patients (including all 26 eyes) are 
summarized in Table 9.1. This cohort included five women and eight men; all 13 patients 
were of Caucasian descent, with a mean age at onset of 52 years (range: 32-67 years). The 
mean disease duration was 9 years (range: 1-34 years). These patients were diagnosed 
between the age of 39 and 82 years (mean: 57 years). None of the patients were using 
hydroxychloroquine at the time of the study, nor had they used this drug in the past.
Foveal sparing was present in 17 of the 26 eyes (65%), and five of the 13 patients (38%) 
had bilateral foveal sparing. In seven of the patients with unilateral foveal sparing, five of 
the contralateral eyes had no signs of RPE atrophy or parafoveal atrophic RPE lesions that 
surrounded the fovea by less than 180°. In the remaining two eyes, and in both eyes in 
patient 12, the fovea degenerated after initial foveal sparing (Table 9.1).
Nine of the 13 patients (69%) initially experienced a decline in visual acuity. Other initial 
symptoms included paracentral scotoma in four patients (31%), metamorphopsia in two 
patients (15%), and nyctalopia in one patient (8%). Two patients (patients 2 and 13; 15%) 
initially experienced no visual complaints, but were referred to our department because of 
fundus abnormalities found during ophthalmologic screening for glaucoma or thyroid eye 
disease; after nine and six years, respectively, these two patients experienced a perceived 
decrease in visual acuity (Table 9.1). BCVA was 20/40 or better in all 17 eyes with foveal 
sparing; 7 of these 17 eyes (41%) had a BCVA of 20/25 or better. In the four eyes in which 
atrophy ultimately affected the fovea, BCVA had decreased to ≤20/200 from an initial acuity 
of 20/25 to 20/40 when the fovea was spared.
In 12 patients, a fundus examination revealed irregular flavimaculatus flecks scattered 
throughout the posterior pole and occasionally extending anterior to the vascular arcades 
(Figures 9.2A-B and 9.3A). One patient had small perifoveal yellow-white dots. Patient 12, 
who had bilateral foveal degeneration, developed extensive chorioretinal atrophy of the 
posterior pole and the midperiphery during the patient’s 26 years of follow-up (Figure 9.2C). 
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Masking of the choroidal background fluorescence (i.e., a so-called “dark choroid”) was 
evident on FA imaging in seven patients, four of whom carried a single heterozygous ABCA4 
mutation (Tables 9.1 and 2). The flavimaculatus flecks were visible as an irregular pattern of 
hyperfluorescence and hypofluorescence on FA imaging (Figure 9.3B), and they appeared 
as hyperautofluorescent flecks on FAF imaging (Figures 9.3C and 9.4). The chorioretinal 
atrophy corresponded with sharply delineated areas that included both an absence of 
autofluorescence and structural thinning of the outer retinal layers on OCT (Figure 9.3D). 
Static perimetry revealed sharply delineated absolute parafoveal scotomas (Figure 9.4) with 
subnormal foveal sensitivity (median: 35 dB; range: 20-39 dB). Foveal sensitivity was not 
measurable (<0 dB) in patient 12, which is consistent with the anatomical findings and other 
functional results obtained from this patient.
Figure 9.3. Multimodal imaging of the right fundus of patient 3 at age 62. A, Fundus photograph showing 
irregular flavimaculatus flecks and atrophy of the central retinal pigment epithelium (RPE); note that the 
fovea is spared. B, Fluorescein angiograph showing the “dark choroid” sign, hyperfluorescence, visible 
choroidal vessels due to window defects, and a normal-appearing fovea. C, Fundus autofluorescence 
image showing hyperautofluorescent flecks and RPE atrophy with foveal sparing. The green horizontal 
line indicates the scanning level of the optical coherence tomography (OCT) scan in panel D. D, An 
OCT scan through the fovea clearly shows the preserved cone photoreceptors in the fovea surrounded 
by atrophy of the outer retina and RPE.
The results of the ffERG recordings in ten eyes with foveal sparing are summarized in 
Table  9.1. In these ten eyes, photopic amplitude was normal in seven eyes (70%) and 
moderately reduced in three eyes (30%), and scotopic amplitude was normal in eight eyes 
(80%) and moderately reduced in two eyes (20%). In the four eyes that developed an atrophic 
fovea after initial foveal sparing, the photopic and scotopic amplitudes were either normal or 
severely reduced (Table 9.1).
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Figure 9.4. Natural course of fundus and perimetric changes in STGD1 with foveal sparing. FAF imaging 
can be used to identify the three stages that occur in foveal sparing. In stage 1, confluent parafoveal 
RPE lesions surround the macula, leaving several connections of intact RPE with the surrounding vital 
RPE (stage 1; A, C). Over time, the RPE atrophy progresses, and the lesions interconnect, leaving 
only one isthmus of RPE (stage 2; E, G). Further disease progression leads to an isolated fovea that 
is surrounded completely by RPE atrophy (stage 3; I, K). Eventually, RPE atrophy overcomes foveal 
resistance, leading to foveal degeneration (post-foveal sparing; L, N). Static perimetry examination 
reveals absolute perifoveal scotomas with intact foveal sensitivity in all eyes with foveal sparing (B, D, 
F, H, J). Large absolute scotomas with diminished foveal sensitivity were observed in the post-foveal 
sparing eyes (M, O). A/B, FAF (A) and 24-2 perimetry (B) in patient 13 at age 63. C/D FAF (C) and 30-2 
perimetry (D) in patient 4 at age 60 and 61, respectively. E/F FAF (E) and 10-2 perimetry (F) in patient 3 
at age 64 and 65, respectively. G/H, FAF (G) and 24-2 perimetry (H) in patient 5 at age 45. I/J, FAF (I) 
and 30-2 perimetry (J) in patient 8 at age 66 and 65, respectively. K, FAF in patient 6 at age 58. L/M, 
FAF (L) and 30-2 perimetry (M) in patient 10 at age 53. N/O, FAF (N) and 30-2 perimetry (O) in patient 
12 at age 73.
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 In three patients (patient 5, right eye; patient 8, left eye; and patient 13, left eye), the scotopic 
amplitude was reduced more markedly than the amplitude of photopic flash responses, 
although none of these patients had peripheral pigmentary retinopathy. No clear correlation 
was found between ffERG response and disease duration, visual acuity, or fundoscopic 
characteristics. We also measured mfERG in eight eyes with foveal sparing and found that 
the P1-response amplitudes in the central two rings (representing the foveal retina) were 
relatively intact compared to the outer three rings, which showed severely reduced responses.
Figure 9.5. OCT analysis of Stargardt patients with foveal sparing. Panels A through E show the 
structural aspects of the macula in a healthy individual (A; age 51), case 2 (B; age 60), case 3 (C; age 
45), case 8 (D; age 65), and case 10 (E; age 53). The white arrows in panel D indicate the locations 
of signs resembling outer retinal tubulation. The black arrowheads in panels C, D, and E indicate the 
locations of abrupt photoreceptor layer disturbances without gradual outer and/or inner segment loss. 
The white arrowhead in panel C indicates the presence of microcysts in the inner nuclear layer. F, 
Summary of thickness measurements of the total retina (top panel), ONL (middle panel), and PR+RPE 
(lower panel). The gray shaded areas show the distribution (mean ± 2SD) of the total retinal, ONL, and 
PR+RPE thickness in 25 age-matched healthy individuals (mean age: 46 years). ONL, outer nuclear 
layer; PR+RPE, photoreceptor-retinal pigment epithelium complex.
Retinal structure
SD-OCT imaging was performed in 12 patients and revealed highly localized damage to 
the lamellar architecture of the macula. We observed parafoveal atrophy of photoreceptors 
and RPE cells with sharp borders, represented by a loss of the bands associated with 
the ELM, the ellipsoid inner segments, and the RPE (Figure 9.5B-E).30 These bands were 
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present in the fovea, however, although many of the bands that corresponded to the ELM 
and ellipsoid inner segments were irregular. In addition, the longer outer segments—which 
are characteristic of cone photoreceptors in the foveal dip—were not observed in any 
of these 12  eyes (Figure  9.5A-D). In three eyes, we observed signs reminiscent of outer 
retinal tubulation at the border of the atrophic lesions (Figure 9.5D), although no rosette-like 
structures (as described by Zweifel and colleagues) were observed.31 Microcystoid macular 
edema was present in three eyes (Figure 9.5C), and epiretinal gliosis with retinal wrinkling 
extending over the fovea was observed in one eye.
An analysis of the retinal lamellar architecture revealed that the overall retinal thickness in 
the foveal and parafoveal regions was generally decreased (Figure 9.5F). The thickness of 
both the ONL and PR+RPE layers was normal at the foveal center in most patients. However, 
in the parafoveal region, the PR+RPE was usually nearly absent, whereas the ONL was 
progressively thinner in this region (Figure 9.5F).
Natural course of foveal sparing
An analysis of the longitudinal FAF data, which were available for six patients, enabled us 
to investigate the natural course of foveal sparing. In general, fundus flavimaculatus flecks 
were observed in the early stages, in some cases even before symptoms developed. Within 
one to two decades of diagnosis (range: 10-18 years), one or more sharply delineated 
parafoveal RPE atrophic areas appeared (Figure 9.4A). Over time, these lesions expanded 
and reached confluence around the fovea, thus producing the foveal sparing phenotype. 
We observed three distinct stages in the development of foveal sparing; these stages 
characterize the natural course of the phenomenon. In stage 1, parafoveal atrophic lesions 
emerge, with several intact RPE connections between the fovea and the surrounding vital 
RPE (Figure 9.4A and 9.4C). In stage 2, the atrophic RPE lesions interconnect, leaving only 
a single isthmus of RPE, thus resulting in a “peninsula-like” appearance (Figure 9.4E and 
9.4G). Stage 3 is characterized by an isolated fovea that is surrounded completely by RPE 
atrophy (Figure 9.4I and 9.4K). We measured the expansion rate of the atrophic lesions in 
four patients using the FAF follow-up data (Table 9.2). The rate of expansion ranged from 
0.832 to 2.363 mm2/year in these patients, and the rate was positively correlated to the size 
of the atrophic lesions. Given this wide range of expansion rates, it is unclear how long foveal 
sparing is present before the foveal structure and function become significantly affected 
by the profound atrophy; however, we observed that the foveal structure and function were 
relatively preserved for up to six years in patients 8 and 12. Eventually, the remaining foveal 
tissue became progressively smaller, and atrophy of the central fovea was observed in four 
eyes (in patients 10, 11 and 12, Figures 9.4L, 9.4N and 9.5E); this was accompanied by a 
decline in central vision to 20/200 or worse.
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Table 9.2. Results of progression analysis on fundus autofluorescence (FAF) imaging during follow-up 
in STGD1 patients with foveal sparing.
ID
Age at 
initial visit 
(years)
Duration follow-up
Eye
Atrophy at 
initial visit 
(mm²)*
Atrophy at 
follow-up 
(mm2)*
Expansion 
during 
follow-up 
(mm²)*
Progres-
sion rate 
(mm²/ 
year)*Days Years
P1 57 597 1.6 Right 3.517 4.877 1.36 0.832
P2 59 842 2.3 Right 11.792 15.770 3.978 1.726
Left 11.202 16.43 5.228 2.268
P8 63 1657 4.5 Right 16.308 27.027 10.719 2.363
P9 62 420 1.1 Right 3.570 4.601 1.031 0.897
*Measurements were performed by two authors (RACvH and NMB), and the average of the two 
measurements are shown. Mean interobserver variance was 2.7% (range: 0.4%-9.8%).
Genetic analysis and mutation screening
An examination of the pedigrees of the 13 unrelated patients with foveal sparing revealed 
a recessive inheritance pattern in five patients; the other eight patients appeared to be 
isolated cases. Mutations in the ABCA4 gene were identified in 19 of the 26 alleles (73%, 
Table 9.3). We identified compound heterozygous mutations in six patients (46%) and single 
heterozygous mutations in the other seven patients (54%). In total, 13 different ABCA4 variants 
were identified, including nine missense mutations, two splice site mutations, one nonsense 
mutation, and one synonymous variant that affects splicing.23 Each of these variants has 
been described previously (Table 9.3).
The mutational effects of five of the identified mutations have been reported previously 
(Table 9.4). Although functional data regarding the effects of the other eight mutations is not 
available, we can speculate on the functional effect of the nonsense mutation (p.Gln1292*). 
Assuming that the resulting mRNA is not subject to nonsense-mediated decay, the resulting 
truncated protein will lack the second extracytoplasmic domain and the nucleotide-binding 
domain, which are involved in substrate and ATP binding, respectively.32 Table 9.5 summarizes 
the identified missense mutations in ABCA4, including allele frequencies in the exome 
variant server (EVS) and scores obtained from selected predictive tools. No differences in 
phenotype were observed between patients carrying severe mutations and patients carrying 
mild mutations. Finally, no pathogenic mutations in the PRPH2 gene were identified in this 
cohort, thereby excluding the possibility of pseudo-Stargardt pattern dystrophy.27
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Table 9.3. ABCA4 mutations in STGD1 patients with foveal sparing
ID
Allele 1 Allele 2
ReferencesDNA variant Effect DNA variant Effect
P1 c.5461-10T→C Unknown NI NA 35, 36
P2 c.3113C→T p.Ala1038Val c.3874C→T p.Gln1292* 16, 37, 38, 58
P3 c.5461-10T→C Unknown c.5537T→C p.Ile1846Thr 23, 35, 39, 58
P4 c.4363T→C p.Cys1455Arg NI NA 40
P5 c.1822T→A p.Phe608Ile c.4685T→C p.Ile1562Thr 23, 40, 41
P6 c.768G→T Splice defect c.3113C→T p.Ala1038Val 16, 23, 37
P7 c.5196+1G→T Splice defect NI NA 45, 58
P8 c.3874C→T p.Gln1292* NI NA 38
P9 c.5461-10T→C Unknown NI NA 35, 58
P10 c.1822T→A p.Phe608Ile NI NA 23, 41
P11 c.286A→G p.Asn96Asp NI NA 43
P12 c.1805G→A p.Arg602Gln c.4462T→C p.Cys1488Arg 37, 39, 42-44
P13 c.3874C→T p.Gln1292* c.1928T→G p.Val643Gly 38, 45
NI, not identified. * = nonsense mutation. NA, not applicable
Discussion
Here, we present the clinical characteristics of 13 STGD1 patients with foveal sparing in 
one or both eyes. The majority of these patients were diagnosed with late-onset STGD1; 
only three patients developed symptoms prior to the age of 45 (Table 9.1). In eyes with 
foveal sparing, visual acuity was relatively preserved; nevertheless, most of the patients 
experienced some loss of vision, which caused them to seek ophthalmologic care. In 
these instances, ophthalmoscopy readily revealed advanced retinal disease, with yellow-
white irregular pisciform flecks and profound RPE atrophy adjacent to the fovea. Automated 
perimetry revealed perifoveal scotomas of various sizes with intact foveal sensibility. This 
combination of mild vision loss together with profound retinal abnormalities is typical among 
STGD1 patients with foveal sparing.
Recently, Fujinami et al. reported the clinical and molecular findings of a cohort of Stargardt 
patients with a foveal sparing phenotype.26 In their study, the authors included STGD1 
patients with a functional fovea, irrespective of the presence of parafoveal RPE atrophy; thus, 
they studied a heterogeneous cohort of 40 patients. In contrast, in our cohort we defined 
foveal sparing as profound RPE atrophy that surrounded the fovea by at least 180 degrees 
and spared the fovea’s structure and function. This clinical presentation is an rare finding 
among STGD1 patients, and our strict selection criterion resulted in a small but homogeneous 
cohort with a consistent phenotype and excluded STGD1 patients with late-onset disease 
that initiated with foveal atrophy. Moreover, our definition of foveal sparing is consistent with 
previously reported cases of foveal sparing in patients with other degenerative diseases.6, 8, 
33, 34 Despite the differences between our cohort and that the cohort described by Fujinami et 
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al., the visual acuity and electrophysiology findings in their paper are similar to the findings 
in our study; nevertheless, none of our patients were carriers of the ABCA4 p.Arg2030Gln 
missense mutation, which was suggested previously to be prevalent among STGD1 patients 
with foveal sparing.26
Table 9.4. Functional implications of ABCA4 mutations
DNA variant (Effect)
Type of 
mutation
No. of 
Alleles
Predicted Effect on ABCR  
function
Classification 
of Mutations
c.768G→T (splice 
defect)
Splice site 1 No protein produced23 Severe
c.1805G→A 
(p.Arg602Gln)
Missense 1 No protein function due to 
mislocalization of the protein 
to the inner segment of the 
photoreceptor42
Severe
c.3113C→T 
(p.Ala1038Val)
Missense 2 Decreased ATP binding and 
ATPase activity37
Mild/Moderate
c.4462T→C 
(p.Cys1488Arg)
Missense 1 Decreased ATPase activity, 
reduced all-trans-retinal binding37, 44
Mild/Moderate
c.5461-10T→C 
(Unknown)
Splice site 3 Splice site intact, but presumed 
to be linked with an unidentified 
pathologic ABCA4 mutation (linkage 
disequilibrium)59
Unknown
ATP, adenosine triphosphate; ATPase, adenosine triphosphatase.
The etiology of foveal sparing
In our study, screening the ABCA4 gene identified 19 pathogenic mutations that were 
described previously in STGD1 and/or other ABCA4-associated retinopathies (Table 9.3);16, 
23, 35-45 interesting, however, foveal sparing was not described in any of the patients who 
were previously reported to carry these mutations. In a previously proposed model that links 
phenotype severity to the degree of residual ABCR function,23, 24 late-onset STGD1 with foveal 
sparing was placed at the mild end of the spectrum of ABCA4-associated retinopathies.3 
Indeed, none of our STGD1 patients with foveal sparing had two ABCA4 variants that are 
associated with a severe loss of ABCR function. However, our knowledge regarding the 
functional consequences of ABCA4 mutations identified to date is limited (Table 9.4). It can 
be extremely difficult to assess the effect of most missense variants using in silico predictions 
and allele frequencies in healthy individuals, for whom this information is often incomplete 
(Table 9.5); in addition, assessing the combined effect of carrying two ABCA4 variants is 
particularly difficult. Functional assays are needed in order to form definitive conclusions 
regarding the effects of these mutations.
Because foveal sparing can be present in phenotypes that are independent of ABCA4 
mutations, including AMD and mitochondrial retinal dystrophy,6, 8-12, 17, 20, 25, 44, 45 genetic 
factors other than ABCA4 mutations are likely involved. These factors could include single-
nucleotide polymorphisms (SNPs) and even mutations in retina-specific genes other than 
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ABCA4, which suggests that a digenic or triallellic trait—in combination with the identified 
ABCA4 mutations—may underlie the degenerative pattern observed in our patients. 
Moreover, anatomical, metabolic, and/or biochemical factors may underlie foveal sparing. 
For example, the average peak density of cones in the fovea is 199,000 cones/mm2, but can 
range from 98,200 to 324,100 cones/mm2.2 The initial number of cones in the fovea cones 
may play a role in the development of foveal sparing; however, adaptive optics imaging 
techniques—which can provide the resolution needed to determine photoreceptor density in 
vivo—are not generally available in most ophthalmology practices. Another factor to consider 
is that S (“blue”) cone photoreceptors, which are absent in the foveal center, seem to be more 
vulnerable to retinal disease than M and L cones, although this selective vulnerability has not 
been reported in STGD1.46, 47 Moreover, parafoveal rods appear to be more vulnerable than 
cones to the effects of aging and all-trans-retinal – mediated damage.48-50 This difference 
may arise from the sole dependence of rods on the RPE for replenishing 11-cis-retinal; in 
contrast, cones are also supplied by Müller cells.51 Furthermore, cone cells have a slower 
turnover rate of outer segments compared to rods,52 although this does not necessarily 
result in higher all-trans-retinal levels in RPE cells, as regeneration is faster in cones than in 
rods.51 Macular pigments, which can filter out high-energy light, may also serve a protective 
role, given that light exposure is crucial in the pathogenesis of STGD1.53, 54 In addition, rod-
derived cone viability factor (RdCVF), which is believed to prevent cone degeneration,55 may 
also play a role. Importantly, the absolute levels of macular pigments and RdCVF may differ 
between STGD1 patients with foveal sparing and STGD1 patients without foveal sparing.
Differential diagnosis and clinical significance of foveal sparing
When forming a diagnosis, foveal sparing – associated clinical entities other than late-
onset STGD should be considered, including geographic atrophy in AMD, mitochondrial 
retinal dystrophy associated with the m.3243AàG mutation, central areolar choroidal 
dystrophy, and pseudo-Stargardt pattern dystrophy.6, 9, 10, 27, 29 Importantly, misdiagnosing 
this condition can lead to inappropriate genetic counseling (these diseases display unique 
inheritance patterns) and/or an inaccurate estimate of the prognosis. Furthermore, in the 
event of an incorrect diagnosis of AMD, prescribing vitamin A – rich nutritional supplements 
can accelerate the accumulation of all-trans-retinal – derived toxins and increase the rate 
of disease progression, as shown in the retinas of homozygous Abca4-knockout mice.56 
STGD1 with foveal sparing can be diagnosed based on the presence of characteristic 
pisciform flecks together with RPE atrophy surrounding the fovea, a “dark choroid” sign on 
FA, and genetic analysis of the ABCA4 gene. FAF imaging can clearly highlight the fundus 
flecks, which appear as hyperautofluorescent flecks, and RPE atrophy, which appears as an 
absence of autofluorescence. Retinal dystrophies that closely resemble STGD1 can follow 
other patterns of inheritance—for example, due to mutations in mitochondrial DNA—or can 
be autosomal dominant, with variable penetrance and expression. The fact that the “dark 
choroid” sign is present in approximately 85% of patients with STGD157 suggests a pivotal 
role for genetic analysis in the diagnosis of retinal dystrophies.
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In conclusion, foveal sparing is a clinical phenomenon that occurs primarily in patients 
with late-onset STGD1 and is associated with the relative preservation of visual acuity, 
although visual acuity ultimately deteriorates by the end-stage of the disease. STGD1 patients 
with foveal sparing may be promising candidates for future therapeutic trials, as delayed 
degeneration of the fovea increases the time window for applying therapeutic interventions 
such as gene therapy. Although the mechanisms that underlie foveal sparing are currently 
unclear, expanding our knowledge of the metabolic and biochemical processes that lead to 
foveal sparing can facilitate the development of therapeutic strategies aimed at preserving 
foveal function.
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Abstract
Objective. To describe the clinical characteristics and long-term follow-up in patients with 
autosomal dominant cystoid macular dystrophy (DCMD).
Design. Retrospective case series study.
Participants. Ninety-seven patients with DCMD.
Methods. Extensive ophthalmic examination, including visual acuity (VA), fundus photography, 
fluorescein angiography (FA), fundus autofluorescence (FAF) imaging, optical coherence 
tomography (OCT), color vision testing, dark adaptation testing, full-field electroretinography 
(ERG), and electro-oculography (EOG). Blood samples were obtained for DNA extraction 
and subsequent haplotype analysis.
Main Outcome Measures. Age at onset; VA; fundus appearance; characteristics on FA, FAF, 
OCT, ERG, and EOG.
Results. Cystoid fluid collections (CFCs) were the first retinal abnormalities detectable in 
DCMD, developing during childhood. At long-term follow-up, the CFCs decreased in size 
and number, and eventually disappeared with concurrent development of progressive 
chorioretinal atrophy and hyperpigmented deposits in the posterior pole. DCMD could be 
classified into 3 stages, based on characteristics on ophthalmoscopy, FAF, FA and OCT, as 
well as on results of electrophysiology. The staging system correlated with age and VA. In 
stage 1 DCMD (20 patients, 22%), patients were generally under the age of 20 and presented 
with CFCs with fine folding of the internal limiting membrane and mild pigment changes. In 
stage 2 DCMD (48 patients, 52%), the CFCs tended to decrease in size, and moderate 
macular chorioretinal atrophy developed. Patients with stage 3 DCMD (24 patients, 26%) 
were generally over the age of 50 and showed profound chorioretinal atrophy, as well as 
coarse hyperpigmented deposits in the posterior pole. Most patients were (highly) hyperopic 
(72 patients, 92%). All DCMD patients shared the disease haplotype at the DCMD locus at 
7p15.3.
Conclusions. DCMD is a progressive retinal dystrophy, characterized primarily by early-
onset cystoid fluid collections in the neuroretina, which distinguishes this disorder from other 
retinal dystrophies. The phenotypic range of DCMD can be classified into three stages. The 
genetic locus for this retinal dystrophy has been mapped to 7p15.3, but the involved gene is 
currently unknown.
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Introduction
Dominant cystoid macular dystrophy (DCMD) is an autosomal-dominantly inherited retinal 
disorder that primarily affects the macula.1, 2 A hallmark feature and presenting symptom 
of DCMD is the appearance of cystoid intraretinal fluid collections (CFCs) in the macula 
that resemble cystoid macular edema before any other visible retinal abnormalities appear. 
The onset of these CFCs is generally in the first or second decade of life. Most patients 
with DCMD have moderate to high axial hyperopia.3-5 As the disease progresses, the CFCs 
diminish, and progressive central vision loss develops between 20-50 years of age due to 
progressive chorioretinal atrophy.1, 5
DCMD has been linked to a genetic interval on chromosome 7p15-p21,6 but the causative 
gene has not been identified to date. DCMD has also been abbreviated as CYMD (OMIM 
153880). In the Netherlands, one large family with DCMD is known and extensive genealogical 
studies revealed a common Dutch ancestor, who supposedly lived in the early 18th century.4 
In addition to this large Dutch family, one unrelated American family from Greek ancestry,7 
and an American and a Spanish patient,8 have been described with presumed DCMD.7, 9
Little is known about the spectrum and variability of fundus abnormalities in DCMD, 
as well as the visual outcome. We report the clinical characteristics and follow-up data 
of the large Dutch DCMD family with 97 affected family members. Based on multimodal 
imaging and electrophysiological studies, we propose a clinical classification system for 
DCMD in 3 stages. In addition, we evaluate the therapeutic options and discuss a possible 
pathophysiologic disease sequence.
Figure 10.1. Diagram showing that all dominant cystoid macular dystrophy patients in The Netherlands 
belong to 1 large pedigree with a common ancestor.
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Methods
Clinical Assessment
This study included 97 patients with DCMD, who were all examined at the Institute of 
Ophthalmology of the Radboud University Medical Center (Nijmegen, the Netherlands) 
between October 1958 and August 2013. All patients belong to one large pedigree, 
descending from one common Dutch ancestor (Figure 10.1).4 Most patients originated from 
the southeast region of the Netherlands. Patients received the diagnosis of DCMD based 
on the aspect of the lesions on ophthalmoscopy, fluorescein angiography (FA) and optical 
coherence tomography (OCT).4 In addition, genealogical research and haplotype analysis 
confirmed the diagnosis DCMD.
The medical history, age at onset, (best-corrected) Snellen visual acuity (VA), fundus 
appearance, including slit-lamp examination, fundus examination by indirect ophthalmoscopy, 
and fundus photography, as well as results of electrophysiological testing were retrieved 
from medical records. To analyze the course of the visual acuity over time, we recorded 
the age at which the decrease in VA exceeded 20/40, 20/60, and ≤ 20/200 for survival 
analyses. Fundus autofluorescence (FAF) imaging was performed with a confocal scanning 
laser ophthalmoscope (Spectralis; Heidelberg Engineering, Heidelberg, Germany; excitation 
light 488 nm). FAF follow-up images were available in 9 patients. Based on ophthalmoscopy 
and/or autofluorescence, mild atrophy of the retinal pigment epithelium (RPE) was defined 
as indistinct granular hypopigmented RPE changes, and profound atrophy was defined 
as sharply demarcated areas of chorioretinal atrophy in the macula, corresponding with a 
decrease and absence of autofluorescence. Spectral-domain OCT (Spectralis™, Heidelberg 
Engineering, Heidelberg, Germany) was performed using the “Macular Thickness Map” 
protocol provided by the manufacturer (Heidelberg Eye Explorer Software, version 1.6.4.0; 
Heidelberg Engineering, Heidelberg, Germany). Follow-up OCT scans were available in 
14 patients to detect progression of retinal changes. Follow-up FA data were available in 
29 of them. In addition electro-oculography (EOG), full-field electroretinography (ERG), 
visual field analysis by means of Goldmann perimetry (stimuli V4e-III4e-I4e-I3e-I2e-I1e), 
dark adaptation, and color vision testing were performed in selected patients as described 
previously (Table 10.1).10 Altogether, follow-up data were available in 71 DCMD patients. 
Furthermore, 10 DCMD patients were invited for an additional, extensive clinical examination 
to complete the follow-up data resulting in a better appreciation of the disease course 
and characteristics. EOG and full-field ERG recordings were performed according to the 
standards of the International Society for Clinical Electrophysiology of Vision (ISCEV).11-13 EOG 
Arden ratios were registered and stratified as normal (≥1.8), mildly reduced (<1.8, but ≥1.5), 
or severely reduced (<1.5). Full-field ERG was defined as normal (equal to or above the lower 
5% of the range for a normal population: photopic ≥78 µV, scotopic ≥263 µV), subnormal in 
case of moderately reduced amplitudes of the B-wave (1-5% of normal range: photopic ≥69 
µV and <78 µV, scotopic ≥195 µV and <263 µV) or as abnormal in case of severely reduced 
amplitudes (<1% of normal range: photopic <69 µV, scotopic <195 µV). The study adhered 
to the tenets of the Declaration of Helsinki, and Ethics Committee approval was obtained. 
Informed consent was received from all examined subjects.
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Haplotype Analysis
Peripheral venous blood samples were obtained from 69 patients for analysis of the 
haplotypes at the previously described DCMD locus.6 The haplotypes at the DCMD locus 
were also determined in 52 unaffected family members. The genomic DNA was isolated 
as described elsewhere.14 Haplotype analysis was performed with microsatellite markers 
(D7S493 and D7S673) surrounding the genetic locus located at 7q15-p21.
Results
Clinical Findings
General characteristics. The study cohort included 97 patients, of which 55 were female 
(57%) and 42 male (43%), as well as 52 unaffected family members. The age at the first 
visit of the DCMD patients to our department ranged from 1 month to 72 years (median: 
27 years). The mean age at onset of visual symptoms was 12.9 years (range: 2–45 years), 
and showed a remarkable trend of a lower age at onset in younger generations (p=0.02). At 
first presentation, the fundus aspect ranged from no abnormalities or only an absence of the 
foveal reflex and mild pigment changes in the fovea (Figure 10.2A) to profound chorioretinal 
atrophy with extensive hyperpigmentation in the posterior pole (Figure 10.2M).
All patients experienced a certain degree of central vision loss, with a progressive decline, 
but the course of the VA loss was highly variable among patients as shown in Figure 10.3. 
The age at which patients reached the level of legal blindness (VA ≤20/200) in the better eye, 
despite optimal refractive correction, varied widely from 10 to 65 years (median: 43.5 years). 
Two patients (2%) became totally blind (no light perception) in 1 eye, at the age of 58 and 73, 
respectively, due to serous retinal detachment that resulted in phthisis bulbi despite several 
vitreoretinal procedures. In addition to vision loss, 7 patients (7%) reported difficulties with 
night vision, and 5 patients (5%) with advanced disease experienced (para)central scotoma. 
Four female patients (7%) noticed a more rapid and irreversible visual decline during 
hormonal events, like first menarche, pregnancy, and menopause.
Hyperopia was a frequent finding in DCMD patients. Information about the refractive 
error of the eye was available in 78 patients, of which 72 presented with hyperopia, with a 
mean hyperopic refraction of +5.78 diopters (D, range of spherical equivalents (SE): +1.00 to 
+13.00 D), of which 30 patients (38%) were highly hyperopic (SE ≥+6.00 D). The axial length 
measurements were available in 24 eyes of 12 patients, performed with A-scan ultrasound 
measurement. In all cases, the axial length was significantly below normal (mean: 19.6 mm; 
range: 18.6–21.0 mm).
Acute angle-closure glaucoma occurred in 6 patients (6%), at a mean age of 48 years 
(range: 42-58 years). Although normal intraocular pressure could be accomplished by 
either topical treatment, laser intervention, surgical treatment or a combination, all 6 patients 
experienced irreversible vision loss. In 1 patient with acute angle-closure glaucoma, laser 
iridotomy and iridectomy treatment had insufficient effect. Finally, this patient received a 
Baerveldt tube implant which resulted in hypotonia, causing a serous retinal detachment. 
This was treated with pars plana vitrectomy with oil tamponade and laser treatment. The 
retina eventually redetached, resulting in complete blindness with phtisis bulbi leading to 
evisceration of this eye. The other eye was treated preventively with laser iridotomy resulting 
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Figure 10.2. Clinical classification of dominant cystoid macular dystrophy (DCMD) into 3 stages: 
(A-F) stage 1 DCMD, (G-L) stage 2 DCMD, and (M-R) stage 3 DCMD. A, Color fundus photograph 
of a 15-year-old patient with stage 1 DCMD (visual acuity, 20/63; spherical equivalent [SE], +4.00 
diopters [D]; subjectively fluctuating vision for 4 years) showing cystoid fluid collections (CFCs) 
and fine pigment changes in the macula. B, Fluorescein angiogram (FA; early phase) showing mild 
hyperfluorescence of the foveal fluid collections. C, Fluorescein angiography (late phase) image 
showing hyperfluorescent CFCs located in the fovea and more diffuse hyperfluorescence in the 
macula. D, Fundus autofluorescence image showing areas of mildly increased autofluorescence at 
the cystoid areas and diffuse hyperautofluorescence within the vascular arcades. E, Horizontal optical 
coherence tomography (OCT) scan through the fovea (scanning plane indicated by black arrowhead in 
A) showing CFCs in the inner and outer nuclear layer. F, Six months before, only some small CFCs were 
visible on OCT at the same level as in (E), demonstrating the fluctuating course of the CFCs without 
any treatment intervention. G, Color fundus photograph of a 32-year-old patient with stage 2 DCMD 
(visual acuity, 20/100; SE, +1.50 D) showing pigment changes in the macula and mild residual CFCs. 
H, I, Fluorescein angiogram showing a central hyperfluorescent lesion caused by a retinal pigment 
epithelium (RPE) window defect and residual edema in the early (H) and late (I) phase, surrounded by 
mild, indistinct hyperfluorescence. J, Fundus autofluorescence image showing moderately decreased 
autofluorescence in the central macula, corresponding with atrophy of the RPE in the fovea on OCT (K) 
at the level of the black arrowhead in (G). L, horizontal OCT scan through the scanning plane indicated 
by the white arrowhead in (G) showing possible mild thickening of the outer nuclear layer, but an RPE 
layer that seemed largely intact.
in a prolonged normal intra-ocular pressure. One patient with a narrow anterior chamber 
angle was treated preventively with phaco-emulsification, but nevertheless acute glaucoma 
developed in 1 eye.
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Disease Spectrum and Clinical Classification. The spectrum of retinal abnormalities in 
this DCMD cohort could be subdivided generally into 3 stages by an experienced retina 
specialist (C.J.F.B.) based on ophthalmoscopy and supported by the findings obtained 
from multimodal imaging (Table 10.1). These 3 stages were delineated by analyzing 
ophthalmoscopic findings in combination with FA, FAF, and SD-OCT, which were available 
in 92 DCMD patients.
Stage 1 DCMD (20 patients, 22%; Table 10.1) was characterized by wrinkling of the internal 
limiting membrane, CFCs and mild granular pigment changes in the macula (Figure 10.2A). 
The CFCs were visible as mildly hyperautofluorescent areas in the fovea and perimacular 
area on fundus autofluorescence (Figure 10.2D); on OCT the CFCs were located in the 
inner and outer nuclear layer of the retina (Figure 10.2E). FA clearly showed an aspect of 
hyperfluorescent cystoid macular edema, and in 60% evidence of mild perifoveal capillary 
dilation was seen (Figure 10.2B and 10.2C). In 14 patients (70%) the CFCs gradually 
increased in size, number, and extent during follow-up, affecting the entire posterior pole. 
However, during this progression the degree of CFCs was highly variable, corresponding 
with intra-individual variability of the VA (Figure 10.2E-F and Figure 10.4A-E). In addition to 
the CFCs, in two patients with stage 1 DCMD the OCT also showed a serous detachment of 
the neuroretina with a fluctuating course.
The mean VA was 20/37 and decreased to less than 20/125 in only 4 patients (20%). In 
one patient with stage 1 DCMD and large CFCs who had a VA of 20/200, the VA recovered 
to 20/50 after remission of the cysts by treatment with acetazolamide.
(Figure 10.2. continued) M, Color fundus photograph of a 67-year-old patient with stage 3 DCMD 
(visual acuity, 20/800; SE, +7.00 D) showing profound chorioretinal atrophy in the macula with 
attenuated arterioles and coarse hyperpigmentations. N, O, Early- (N) and late- (O) phase FA showing 
early hypofluorescence and some late staining in the deeply atrophic central macula encircled by 
hyperfluorescence that seems to be diffuse edema, extending beyond the vascular arcade and optic 
nerve. P, Fundus autofluorescence image showing a large area of markedly decreased autofluorescence 
as a result of RPE atrophy in and beyond the macula. Q, Horizontal OCT scan (scanned through plane 
indicated by black arrowhead in (M)) showing chorioretinal atrophy in the macula, with hyperreflective 
lesions consistent with the hyperpigmentations on color fundus photograph (M). R, Vertical OCT scan 
through the fovea of the fellow (right) eye showing marked attenuation of the outer photoreceptor and 
RPE layers, although there appears to be a certain degree of persistent thickening of the inner and outer 
nuclear layer centrally in the macula.
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Figure 10.3. Kaplan-Meier survival curves of visual acuity (VA) of worse than 20/40 (a threshold of 
visual disability, according to the United States definition reflecting the legal inability to drive a car); 
VA of worse than 20/60 (a cutoff point for low vision defined by the World Health Organization criteria 
associated with increasing difficulties in reading without visual aids); VA of 20/200 or worse (a threshold 
of legal blindness according to World Health Organization criteria) related to age. The median ages at 
which the VA in our cohort exceeded 20/40, exceeded 20/60, and decreased to 20/200 or less were, 
34, 45, and 57 years, respectively.
In stage 2 DCMD (48 patients, 52%; Table 10.1), the CFCs tended to become progressively 
smaller over time (Figure 10.2K). Unlike stage 1 DCMD, only 5 cases showed evidence of 
perifoveal capillary dilatation on FA. Mildly atrophic lesions appeared in the macula, with a 
corresponding decrease in VA (Figure 10.2G, 10.2J and 10.2K).
In stage 3 DCMD (24 patients, 26%; Table 10.1), the macula was affected by profound 
chorioretinal atrophy (Figure 10.2M-R). In the macula and mid-peripheral retina, multiple 
coarse hyperpigmentations were present in all patients, who also showed attenuated 
arterioles in varying degrees (Figure 10.2N). In this advanced disease stage, CFCs were no 
longer present on OCT (Figure 10.2Q and 10.2R). A variable degree of small whitish punctate 
deposits in the vitreous were seen in stage 2 and 3 DCMD.
The VA decreased to the level of legal blindness in 18 patients (75%) with stage 3 
DCMD. Most patients (88%) were above the age of 50 years. The majority (77%) of the 
full-field ERG results were abnormal without selective cone or rod impairment in stage 
3 DCMD (Figure 10.5). The EOG and full-field ERG results in all stages are depicted in 
Table 10.1. An atypical phenotype was seen in 4 patients with stage 3 DCMD (17%). In 2 
patients (8%) a phenotype reminiscent of Coats’ disease developed at the age of 56 and 
61, respectively, consisting of an exudative serous retinal detachment with RPE atrophy and 
coarse hyperpigmentations (Figure 10.6A-B).  Furthermore, two patients (44 and 57 years) 
originating from two different branches of the pedigree, showed a retinal phenotype similar 
to end-stage retinitis pigmentosa, with  attenuated arterioles, peripheral pigment changes 
resembling bone spicules, a waxy-pale optic disc, in addition to advanced chorioretinal 
atrophy in the posterior pole (Figure 10.6C-D).
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Figure 10.4. Follow-up of 2 dominant cystoid macular dystrophy (DCMD) patients with cystoid fluid 
collections (CFCs) on (A) time-domain or (B-J), spectral-domain optical coherence tomography (OCT). 
A-E, Patient with stage 1 DCMD and fluctuation of CFCs without treatment over 7 years. The OCT 
follow-up data of the left eye shows the fluctuating natural course of CFCs. A, At 8 years of age, OCT 
clearly showing moderate CFCs in the inner and outer nuclear layers without visual symptoms (visual 
acuity [VA], 20/20; spherical equivalent [SE], +4.00 diopters [D]). During the ensuing years, she 
experienced vision loss with fluctuating vision. B, At 11 years of age, no fluid collections were present 
on OCT, but funduscopy showed fine pigment changes in the fovea with some wrinkling of the internal 
limiting membrane. The patient experienced fluctuating vision for 1 year (VA in this eye, 20/40). C, Two 
months after the image in (B) was obtained, mild CFCs recurred and her visual symptoms increased (VA 
decreased to 20/63). D, Three years after the image in (C) was obtained, the CFCs and vision symptoms 
decreased, whereas the VA increased to 20/50. E, Five months after the image in (D) was obtained, 
extensive and large CFCs recurred, associated with vision loss (VA, 20/63). F-J, Stage 1 DCMD patient 
treated with octreotide-acetate (20 mg intramuscular monthly) and oral acetazolamide (250 mg 1-4 
times daily), reducing the CFCs and showing a possible dose-dependent effect of acetazolamide on 
OCT follow-up of 1 year. 
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Figure 10.4. (continued) F, Nineteen-year-old patient with late stage 1 DCMD with mild CFCs causing 
visual symptoms before starting treatment (VA, 20/ 25; SE, +3.25 D). G, One year later, despite treatment 
with monthly intramuscular octreotide-acetate injections (20 mg) and oral acetazolamide 125 mg twice 
daily either separately or combined, CFCs increased with loss of vision (VA, 20/50). H, Increasing the 
dose of acetazolamide to 250 mg 3 times daily, in addition to octreotide-acetate treatment, resulted in 
a significant decrease of CFCs within 2 weeks, with an increase in VA to 20/32. I, The CFCs increased 
markedly within 2 weeks after lowering the dose of acetazolamide to 250 mg twice daily, with a 
corresponding vision loss (VA, 20/80). J, Raising the dose of acetazolamide to 250 mg 4 times daily 
resulted in a significant resolution of the CFCs within the next 2 weeks, with in an increase in VA to 20/50.
Figure 10.5. Representative full-field electroretinograms (ERGs) of 3 patients with dominant cystoid 
macular dystrophy (DCMD) showing normal, subnormal, and abnormal results of the rod, rod and cone, 
cone, and 30-hertz flicker ERG. Left, Normal full-field ERG results in a 15-year-old patient with stage 
1 DCMD (visual acuity [VA], 20/50; spherical equivalent [SE], +4.25 diopters [D]). Middle, Subnormal 
cone- and rod-driven responses on full-field ERG in a 67-year-old patient with stage 3 DCMD (VA, 
20/800; SE, +7.25 D). Right, Abnormal photopic and scotopic full-field ERG results in a 58-year-old 
patient with stage 3 DCMD (VA, 1/200; SE, +4.00 D).
Both patients showed fundoscopic signs of CFCs in their childhood. These two patients had 
difficulties with night vision, with markedly abnormal dark adaptation and marked constriction 
of the peripheral visual field on Goldmann perimetry. Full-field ERG showed no scotopic 
response and a decreased photopic response corresponding to a rod-cone dystrophy 
dysfunction pattern. Both patients had a subnormal EOG with mildly reduced Arden ratios. 
Both patients shared the genetic DCMD locus, and their affected parents showed a typical 
DCMD phenotype without these retinitis pigmentosa-like features.
The different stages of DCMD correlated significantly with age (r=0.871; p<0.001), VA (r=-
0.562; p<0.001), EOG test results (r=-0.404; p<0.001) and ERG findings (r=-0.590; p<0.001) 
(Table 10.1). During progression of the disease, electrophysiological testing became more 
abnormal and constriction of the peripheral visual field developed in stage 2 and stage 3 
DCMD. Of the 16 patients with stage 2 DCMD, 1 patient (6%) showed no abnormalities, 
11 patients (69%)
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Figure 10.6. Atypical cases of dominant cystoid macular dystrophy (DCMD). A-B, Coats-like exudative 
abnormalities in a 62-year-old DCMD patient (visual acuity [VA], light perception; spherical equivalent 
[SE], +4.25 diopters [D]). A, Composite color fundus photograph showing a serous retinal detachment 
with exudates superior to the upper vascular arcade and temporal pigment accumulations mimicking 
bone spicules. This patient experienced vision loss at the age of 30 years, with cystoid fluid collections 
(CFCs) in the macula. B, Horizontal optical coherence tomography scan through the scanning plane 
indicated by the black arrowhead in (A) showing retinal atrophy and a mild epiretinal membrane. C-D, 
Retinitis pigmentosa-like phenotype in a 44-year-old patient with stage 3 DCMD (VA, 20/63; SE, +7.00 
D) who also experienced night blindness and constriction of the peripheral visual fields. C, Composite 
color fundus photograph showing peripheral bone-spicule-like pigment changes, a waxypale optic 
disc, attenuated arterioles, and chorioretinal atrophy. Vision loss started at the age of 7 years with 
funduscopic foveal pigment changes and wrinkling of the internal limiting membrane. Because of loss 
of follow-up, no findings of CFCs are available, but in that period he experienced fluctuating vision loss. 
D, Optical coherence tomography scan through the fovea (black arrowhead in [C]) showing retinal 
pigment epithelium atrophy in the macula with some structural sparing of the fovea.
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demonstrated small central absolute scotomata / sensitivity loss, and 4 (25%) patients 
showed sensitivity loss of the central retina with mild constriction of the peripheral visual field 
(40-50° nasal and 60-80° temporal for the II4e isopter). All stage 3 DCMD patients showed 
central absolute scotomata (15° for the V4e isopter) of which 5 patients (63%) additionally 
showed a moderate constricted peripheral visual field in Goldmann perimetry (25-45° nasal 
and 45-65° temporal for the III4e isopter and 0-25° nasal and 30-35° temporal for the I4e 
isopter) and 2 (25%) presented with nyctalopia. These were the 2 patients with the retinitis 
pigmentosa-like phenotype (Figure 10.4C).
In all DCMD stages, dark adaptation testing could be normal as well as abnormal, but 
abnormal test results were most often present in DCMD stage 3 (6/8; 75%). In stage 1 and 
2 only 38% (3/8) and 33% (6/18), respectively, has an abnormal dark adaptation. From the 
15 patients with abnormal dark adaptation, 8 underwent Goldmann perimetry, which revealed 
a constricted peripheral visual field in 3 patients (38%), who also had pigment lesions in their 
peripheral retina. Abnormalities of color vision testing were seen in all DCMD stages, ranging 
from anomaloscopic diminished red-sensitivity in stage 1 (35%), to an acquired blue-yellow 
defect in stage 2 (76%) and 3 (100%), with an additional red-green defect when fixation 
became eccentric in 10/13 stage 3 DCMD patients (77%).
Follow-up. Follow-up data were available for 71 patients, with a mean follow-up time of 
17 years (range: 0.5-44 years). Fifteen patients (21%) progressed from stage 1 to stage 2 
after a mean follow-up time of 17 years (range: 4-28 years) and 9 patients (13%) progressed 
from stage 2 to stage 3 after a mean time of 23 years (range: 10-35 years) (Figure 10.7). 
Additionally, a progression from stage 1, via stage 2, to stage 3 was observed in 3 patients (4%) 
after a mean time of 32 years (range: 29-34 years).
The degree of CFCs was observed to decrease progressively with advancing disease 
stages, while chorioretinal atrophy and pigmentary abnormalities concurrently became more 
pronounced. Visual acuity, EOG and full-field ERG data of patients who progressed from one 
stage of DCMD to the next stage are summarized in Table 10.2.
Treatment. During the natural course of DCMD stage 1 and 2, the degree of CFCs varied 
largely over time in 26 patients (mean follow-up: 18 years; range 4-43 years) (Figure 10.4A-E), 
but the fluid collections could also be influenced by treatment (Figure 10.4F-J). In an attempt 
to reduce the CFCs, 16 patients with stage 1 or 2 DCMD used acetazolamide, a carbonic 
anhydrase inhibitor, generally for several years (mean 40 months; range 2-221 months). In 
10 of these patients (63%), oral administration of acetazolamide for several years (mean 
56 months; range 2-221 months) seemed to result in a reduction of CFCs on OCT, with an 
improvement of the VA (mean VA from 20/46 to 20/35). In 2 patients (13%), the treatment 
resulted in reduction of CFCs without VA improvement. The daily dose in which a significant 
reduction of CFCs was seen on OCT ranged from 125 mg twice a day to 250 mg four times 
daily.
Octreotide-acetate, a somatostatin analogue assumed to promote the removal of 
intraretinal edema across the RPE,15 was used in 16 patients with stage 1 or 2 DCMD for 
several years (mean 68 months; range 6-151 months).
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Figure 10.7. Long-term follow-up of dominant cystoid macular dystrophy (DCMD). A-D, Follow-up 
images showing (A, B) progression during stage 2 DCMD and (C, D) progression to stage 3 DCMD. A, 
Color fundus photograph of a 35-year-old patient with early stage 2 DCMD (visual acuity [VA], 20/160; 
spherical equivalent [SE], +7.00 diopters [D]) showing pigmentary changes of the retinal pigment 
epithelium and some small cystoid fluid collections (CFCs). At the age of 7 years, vision loss started and 
pigmentary changes and CFCs were seen. B, Ten years later, a central atrophic lesion developed with 
absence of CFCs. C,D, Follow-up color fundus photographs showing progression from stage 2 to stage 
3 DCMD. C, Color fundus photograph of a 38-year-old patient with stage 2 DCMD (VA, 20/100; SE, 
+5.50 D) showing mild atrophic hypopigmentation and a central spot of hyperpigmentation.D, Thirty-
five years later, a progression to profound chorioretinal atrophy with marked hyperpigmentations and 
some arteriolar attenuation was seen. The VA at this stage was 20/400.
Table 10.2. Follow-up results of patients who progressed to another stage of Dominant Cystoid Macular 
Dystrophy
Stage 
progres-
sion Stage
VA EOG* Full-field ERG †
Mean Normal
Mildly 
reduced
Severely 
reduced Normal
Subnor-
mal Abnormal
1 à 2 1 20/25 6/8 2/8 0/8 2/2 0/2 0/2
2
20/63
2/8 5/8 1/8 2/2 0/2 0/2
2 à 3 2 0/9 6/9 3/9 2/5 2/5 1/5
3 20/300 0/9 3/9 6/9 0/5 0/5 5/5
*Electro-oculography Arden ratios were stratified as normal (>1.8), mildly reduced (<1.8 but _1.5), 
or severely reduced (<1.5). †Full-field electroretinography results were defined as normal in cases 
of normal amplitudes of the B-wave (photopic, >78 mV; scotopic, >263 mV), subnormal in cases of 
moderately reduced amplitudes (photopic, >69 mV and <78 mV; scotopic, >195 mV and <263 mV), or 
as abnormal in cases of severely reduced amplitudes (photopic, <69 mV; scotopic, <195 mV).
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In 12 patients (75%), octreotide-acetate administered 20 mg intramuscular monthly for 
several years (mean 84 months; range 14-151 months) seemed effective in reducing CFCs 
and improving the VA with a mean increase in VA of 20/125, but in two patients (13%) side 
effects like nausea, diarrhea, fatigue and cholelithiasis were present, resulting in cessation 
of this treatment in 1 patient. Four patients (25%) treated with octreotide-acetate stopped the 
treatment because of the lack of effect on VA. In 3 of them, no effect on CFCs was detectable 
on OCT.
During six years of follow-up, in three patients with stage 1 DCMD who were treated, the 
mean VA increased from 20/34 to 20/25, whereas in four patients with stage 1 DCMD who 
were not treated, the mean VA decreased from 20/29 to 20/35. In stage 2 DCMD patients, 
the mean VA decreased from 20/51 to 20/67 in 12 treated patients with a follow-up of 17 years 
and in 12 untreated patients, the mean VA decreased from 20/54 to 20/87 during 15 years 
of follow-up.
Haplotype Analysis
Linkage analysis previously showed that DCMD is linked to the interval D7S493 – D7S526 
at 7p15-p21,6 but the disease-associated gene and mutation have not yet been identified. 
In 69 of the 97 clinically affected DCMD patients (71%), the haplotypes at the DCMD locus 
were analyzed, and all carried the disease-associated haplotype. The genetic DCMD locus 
seemed to be completely penetrant. Haplotype analysis in the 52 clinically unaffected family 
members revealed the absence of the DCMD haplotype in all. One DCMD patient with the 
genetic DCMD locus was also tested for the BEST1 gene, but he showed no mutations in 
this gene.
Discussion
Clinical characteristics and staging of Dominant Cystoid macular dystrophy
Dominant cystoid macular dystrophy is a unique retinal dystrophy, because the appearance 
of CFCs in the macula is the first and most prominent abnormality at the onset of the disease, 
resembling cystoid macular edema.16 The spectrum of severity of DCMD ranges from an 
absence of the foveal reflex with mild CFCs and some pigment changes in the macula early 
in the course of the disease, to profound chorioretinal atrophy in the posterior pole in the late 
stage of DCMD. In this study, we propose a clinical classification system for DCMD into three 
stages. This classification system is based on ophthalmoscopy and multimodal imaging, and 
correlates well with age, VA and results on EOG and full-field ERG (Table 10.1). We observed 
an evolution of DCMD through the proposed stages, supporting that DCMD is a progressive 
disease.
The age at onset of visual symptoms in DCMD is generally in childhood, but seems 
to vary depending on the generation. The apparently earlier age at onset in more recent 
generations may be due to an increased awareness and earlier screening of younger family 
members as a result of their affected father or mother.
All patients show a gradual decrease in VA, and most progress to visual disability at a 
relatively early age. In advanced DCMD, the VA generally evolves to finger counting (20/800), 
or even worse when relatively rare complications such as serous retinal detachment or 
acute angle-closure glaucoma occur. Due to the short axial length of the eye, glaucoma 
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can accompany the retinal abnormalities, and (high) hyperopia is present in most DCMD 
patients, similar to other retinal dystrophies such as the bestrophinopathies which are caused 
by mutations in the BEST1 gene.17, 18
The finding that EOG abnormalities generally preceded photopic and scotopic 
dysfunction on full-field ERG indicates that impaired RPE function occurs earlier in the course 
of DCMD, whereas the panretinal photoreceptor function is affected later in the disease.1 
Since half of the stage 1 DCMD patients with macular CFCs had normal EOG results, primary 
panretinal RPE dysfunction with dysfunctional ionic homeostasis, as observed in BEST1-
related dystrophies such as Best vitelliform macular dystrophy and autosomal recessive 
bestrophinopathy,17 is presumably not present in DCMD. Presence of primary CFCs without 
reduced EOG might be explained by primary dysfunction of a cell population other than the 
RPE and photoreceptors, such as the Müller cells.
In addition to the large DCMD family described in the present study, two cases and 
one small family with features of DMCD have been described.7-9 The clinical findings of a 
Spanish patient with presumed DCMD are consistent with DCMD stage 2.9 In an American 
DCMD family from Greek ancestry,7 the EOG results in affected patients were normal, and 
none of the examined children of affected family members, 10 to 18 years of age, showed 
any abnormalities. This does not support an autosomal dominant mode of inheritance, and 
rather suggests a different disease than the typical DCMD phenotype observed in our large 
Dutch family.
Differential diagnosis
Several other retinal diseases with early-onset CFCs should be considered in the differential 
diagnosis of DCMD, such as X-linked juvenile retinoschisis, retinitis pigmentosa, phenotypes 
associated with mutations in the BEST1 gene, and uveitis. In the absence of a genetic 
association with the DCMD locus in a patient with presumed DCMD, one should review the 
clinical evidence for DCMD carefully, and consider the possibility of one of the following 
clinical entities associated with early-onset CFCs.
X-linked juvenile retinoschisis, which is inherited in an X-linked pattern in contrast to 
DCMD, gives rise to vision loss in boys at a young age and progresses to atrophy and 
alterations of the RPE,19 like in DCMD. The “cystoid” schisis cavities are mainly situated in the 
inner and outer nuclear layer,20 like the CFCs in DCMD, but the schisis cavities in X-linked 
juvenile retinoschisis often become confluent, with only small strands of tissue bordering 
these spaces on OCT, and without apparent fluorescein leakage into the schisis spaces on 
FA, in contrast to the CFCs in DCMD.21 Also, a typical radial pattern is visible in the fovea 
on FAF and red-free images in X-linked juvenile retinoschisis cases, which is not observed 
in DCMD. The full-field ERG in X-linked juvenile retinoschisis characteristically shows an 
“electronegative” aspect,19 in contrast to DCMD.
Like stage 3 DCMD, retinitis pigmentosa can present with hyperpigmentation in the (mid)
peripheral fundus, and cystoid macular edema.22 However, compared to DCMD, patients 
with retinitis pigmentosa experience night blindness early in the course of the disease, and 
retinitis pigmentosa patients characteristically show early arteriolar attenuation and bone-
spicule pigmentary changes, with a rod-cone dysfunction on full-field ERG that outweighs 
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EOG abnormalities. In contrast to bone-spicule hyperpigmentation in retinitis pigmentosa, 
the hyperpigmented abnormalities in DCMD are typically more coarse and mainly located in 
the posterior pole.
Phenotypes associated with BEST1 gene mutations – inherited either autosomal 
dominantly or recessively - can have somewhat similar retinal lesions and abnormalities, like 
an abnormal EOG that outweighs full-field ERG abnormalities, hyperopia and CFCs in the 
macula.16-18 In contrast to DCMD, all patients with BEST1-related dystrophies have a severely 
abnormal EOG at onset, and BEST1-related fundus abnormalities usually include highly 
autofluorescent yellowish deposits in the macula.17
Posterior uveitis should also be considered, since DCMD can be accompanied by a 
variable degree of whitish punctate deposits (although these are not cells) in the vitreous 
body in stage 2 and 3 disease. Finally, the clinical characteristics of vascular causes of 
cystoid macular edema such as diabetic retinopathy, retinal venous occlusions, as well as 
age-related macular degeneration,23 allow an easy distinction from DCMD.
Genetic Background
Dominant cystoid macular dystrophy is inherited autosomal dominantly, but the associated 
gene and mutation have not yet been identified.6 We show that the genetic defect in DCMD 
appears to be completely penetrant in the large family in this study. The KLHL7 gene, causing 
autosomal dominant retinitis pigmentosa,24 is located within the critical interval of the DCMD 
locus, which might explain why two DCMD patients in our study exhibited abnormalities 
and phenotypic characteristics of retinitis pigmentosa (Figure 10.6C-D). However, no coding 
variant in the coding region of the KLHL7 gene was detected in our DCMD family. This, 
however, does not exclude the presence of a deep intronic mutation or a mutation affecting a 
regulatory element of the KLHL7 gene. Alternatively, due to the distinct disease characteristics 
between the families described by Friedman et al and our DCMD family, it is plausible that 
another gene at the DCMD locus can be involved in the disease rather than KLHL7. Further 
analysis of all genes located within the DCMD locus at the genomic and at a transcriptional 
level using next-generation sequencing technologies may identify the causative mutation of 
DCMD in the near future. Identification of the associated gene can provide insight into the 
pathogenesis of the disease, and may improve our understanding on the development of 
hyperopia and cystoid fluid collections in other rare and common retinal diseases.
Pathophysiology and treatment
Cystoid fluid accumulation in the macula is the first clinically visible abnormality in DCMD. 
This indicates that the CFCs in DCMD are the direct result of the primary genetic defect and 
its immediate pathophysiological consequences. Interestingly, a histopathological study on 
2 donor eyes of a 78-year-old American patient with presumed DCMD has been published.25 
Large intraretinal cystoid spaces were observed in the macula, with mildly attenuated retinal 
vessels, atrophy and marked disorganization of the inner nuclear layer. The large cyst-like 
spaces within the inner nuclear layer were surrounded by Müller cell fibers and pigment-
laden cells with remnants of photoreceptor segments, and degeneration of Müller cells 
was seen. Based on these findings, the authors suggested a primary pathologic process 
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affecting Müller cells in DCMD.25 These histopathological findings correlate well with the 
clinical findings in our DCMD cohort, which could support primary Müller cell dysfunction in 
DCMD.8 If this is the case, DCMD would be a rare example of retinal dystrophy that results 
from a genetic defect that primarily affects Müller cell function. The gene defect in DCMD 
might interfere with capillary permeability, resulting in a disturbance of the inner blood-retinal 
barrier and early CFCs.
It is also possible that CFCs in DCMD are the result of primary dysfunction of the RPE, 
as the EOG becomes abnormal early in the course of the disease. It is unlikely that the 
photoreceptors are primarily affected, at least on the panretinal level, as the full-field ERG 
remains normal for a long time. Cystoid macular edema in the outer neuroretinal layers, such 
as in the course of retinitis pigmentosa, is presumed to be caused by a dysfunction of the 
outer blood-retina barrier.26-28 In DCMD, CFCs located in the outer nuclear layer are possibly 
induced by dysfunction of the RPE layer, comparable to cystoid macular edema that occurs 
in retinitis pigmentosa.29
Cystoid macular edema in the inner neuroretinal layers, such as in pseudophakic macular 
edema and diabetic retinopathy, is predominantly caused by a failure of the inner blood-retinal 
barrier.27, 30 The CFCs located in the inner nuclear layer in DCMD could also be caused by a 
dysfunctional macular inner blood-retinal-barrier, which depends on Müller cells, astrocytes, 
and pericytes.27 This could be supported by the fundoscopic and fluorescein angiographic 
finding of perifoveal capillary dilation early in the course of the disease.
We suggest that the Müller cells, the RPE, or both, may be the primarily affected cells in 
DCMD, resulting in CFCs early in the course of the disease.
Previous studies in patients with retinal dystrophies showed that treatment with 
acetazolamide reduced intraretinal fluid collections,18, 22, 31-34 although the effect can be dose-
dependent,18 but the exact mechanism is unclear. Boon et al. suggested that acetazolamide 
may interact with carbonic anhydrase subtypes XIV and II in the RPE and Müller cells, resulting 
in intracellular acidification with consequently Cl- transport in the RPE, with water following 
passively.18 Treatment with acetazolamide has previously been shown to be ineffective in 
treating CFCs in most DCMD patients at a daily dose of 250 mg,35 but we now demonstrate 
that the effect can be dose dependent in DCMD, as treatment with higher doses can indeed 
be effective in DCMD patients. A possible rebound effect that has been postulated in half 
of the retinitis pigmentosa patients with cystoid macular edema treated with acetazolamide 
for 8 to 12 weeks,31 was present in only 2 of the 16 DCMD patients after 1.5 and 6 years of 
treatment with acetazolamide. Treatment seems be most effective in DCMD patients with 
stage 1 and has a less strong influence on the long term VA in stage 2 DCMD patients.
In conclusion, we describe the clinical spectrum, which can be subdivided into three clinical 
stages, in the largest DCMD cohort to date. CFCs are a hallmark feature in earlier disease, 
but during progression the CFCs diminish and chorioretinal atrophy develops. Haplotype 
analysis using microsatellite markers at the DCMD locus at 7p15.3 confirmed the diagnosis, 
and the disease was fully penetrant in our DCMD cohort. Future studies will be directed 
towards determining the causative gene by next-generation sequencing at a genomic and 
transcriptional level. The elucidation of the causative gene and pathogenesis in DCMD will 
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not only give important insight into this intriguing and peculiar retinal dystrophy, but the 
findings can also shed a light on the pathogenesis of hyperopia and cystoid macular edema 
in other retinal dystrophies, uveitis, diabetic macular edema or following ophthalmic surgery, 
and provide a new target for treatment.
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Abstract
Inherited retinal diseases (IRDs) represent a clinical and genetic heterogeneous group of 
chorioretinal disorders. The frequency of persons affected by an IRD due to mutations in the 
same gene varies from 1 in 10,000 to less than 1 in a million. In order to perform meaningful 
genotype-phenotype analyses for rare genetic conditions, it is necessary to collect data 
from sizable populations. Although several standardized functional tests are widely used, 
ophthalmologic data are usually stored in local databases and not in multi-center databases 
that are linked with other centers. In order to be able to register ophthalmologic data of 
all Dutch patients with IRDs into one database, we developed the RD5000 database 
(RD5000db) that can harbor all ophthalmological and selected genetic data. Authorization 
rights for the management, data entry and data sharing have been set-up, rendering this 
database into a user-friendly, secure and widely used repository that will facilitate future 
studies into molecular genetics and therapies for IRDs. RD5000db has the potential to grow 
into a European standard for the registration of data from IRDs.
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Introduction
Inherited retinal diseases (IRDs) constitute a clinically heterogeneous group of disorders 
that involve degeneration of the photoreceptors, retinal pigment epithelium (RPE) and/or 
choroid.1-4 The incidence rates vary from 1 in 10,000 (for Stargardt disease) to less than 
1 in a million for rare clinical subtypes.5-9 The diseases affect both sexes, and include major 
causes of blindness in children and young adults worldwide, although some patients remain 
asymptomatic until middle-age. The phenotypic variability is caused by genetic defects in a 
large number of genes. In the last 25 years, over 200 genes associated with both syndromic 
and nonsyndromic IRDs (RetNet, available at https://sph.uth.edu/retnet/) were identified.4, 10, 11
The internet offers several public and license-protected databases that contain genetic 
data on IRDs, such as the Leiden Open (source) Variation Databases (LOVDs, available 
at http://www.lovd.nl/3.0/home), the Human Gene Mutation Database (HGMD, available at 
http://www.hgmd.org/), and the retina international mutation database available at http://www.
retina-international.org/sci-news/databases/mutation-database/). Still, databases containing 
clinical data are, to our knowledge, not publically available. Instead, most specialized medical 
centers use a database exclusively accessible by that specific center. This lack of publically 
available clinical data is most likely due to privacy legislation and medical ethics. On the 
other hand, there are websites that provide an overview of genetic and clinical features of 
IRDs published in literature, such as the Retinal Network (RetNet, available at https://sph.uth.
edu/retnet/) and the Online Mendelian Inheritance in Man (OMIM, available at http://www.
omim.org/).
Since incidence rates are low in IRDs, national collaborations are the first step to get an 
overview of cohort sizes, the distribution of certain genetic defects and the matching clinical 
features. This will also be important to identify persons for (gene) specific therapeutic trials. 
In this light, 11 Dutch ophthalmic centers collaborated in a project named RD5000§ to set up 
a database with anonymized clinical and genetic data: the RD5000 database (RD5000db, 
available for members at http://www.RD5000db.nl). To obtain larger cohort sizes for studies 
on specific genotypes, phenotypes or genotype-phenotype correlations, international 
expansion of the database is possible and desirable.
Objectives of the RD5000 database
To our knowledge, the RD5000db is the first multi-centered, web-based database available 
in the field of inherited retinal diseases. Main objectives are (1) standardization of clinical and 
genetic data registration, (2) pseudo-anonymized (‘pseudomized’) storage of data, and (3) 
web-based, controlled data sharing among participating medical centers. The pseudomized 
character of the data storage lies in the absence of personal characteristics that could lead 
to the identification of a specific patient, and the presence of a center specific internal patient 
identification number. This results in anonymized data for the centers that have access to 
the database, and personalized data for the patient’s medical center that also owns the 
source data files. Data access by other centers is controlled: only a few general features 
§ The name ‘RD5000’ was based on the estimated prevalence of 5000 patients with inherited retinal 
diseases in the Netherlands.
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are commonly available in a ‘catalogue’; access to all other details can be granted either for 
clinical reasons (e.g. when the patient attends an ophthalmologist or geneticist in another 
center participating in RD5000db) or research reasons (e.g. for a specific research question; 
see Data access below). This controlled access allows the professionals to be in charge of 
the data to be shared.
Database design
We reviewed literature on existing databases in the field of ophthalmic retinal disease. The 
Ophthabase database (used in Tuebingen, Germany) was used for database structure and 
lay-out.12 Additionally, the biobank of the string-of-pearls initiative (The Netherlands, Dutch: 
Parelsnoer initiatief) was used for their way of structuring multicenter data entry and access 
to patient data (see Data access).13 Additionally, jurisdiction and expert opinion on national 
privacy legislation and patient data were obtained.
Source code. The source code of Ophthabase® (developed by Institute for Ophthalmic 
Research, Tübingen, Germany, as part of EVI-GENORET Project) was generously provided 
for further development. HTML design and data model of Ophthabase ® were used as a 
starting point for RD5000db and were altered to the specifications of RD5000db by the 
company First8 (www.first8.com). RD5000db is built in Java 1.7 (Oracle Corporation, 
Redwood Shores, CA, USA) and runs on an Apache Tomcat 7.0 (The Apache Software 
Foundation, Forest Hill, MD, USA) application server and uses PostgreSQL 8.4 (EnterpriseDB 
Corporation, Bedfort, MA, USA) as a relational database. The web interface is built using 
Apache Wicket 6 (The Apache Software Foundation, Forest Hill, MD, USA) and uses Spring 
Core (Pivotal Software, Palo Alto, CA, USA) framework to interact with services, which 
contain the business logic. Hibernate (Red Hat Inc., Raleigh, NC, USA), which implements 
the Java Persistence application programming interface 2 standard, is used to query the 
database. Spring Security (Pivotal Software, Palo Alto, CA, USA) is used for authorization 
and authentication and is used to implement the roles and rights system. Access from the 
web is always redirected from http to https which uses SSL (Secure Socket Layer) to ensure 
encrypted transportation of the data over the internet.
Data entry. The RD5000db is set up as a research database that contains pseudomized 
patient data. The internal IDs are used to relate the data stored in RD5000db to information in 
the medical files of the centers in which the patient is treated (pseudomisation). Although no 
personal data that could identify a patient is stored in the database, initials, date of birth and 
gender are entered to construct a hash code that is used to identify double entries. Since 
only the hash code is stored, the initials and date of birth are not accessible, but the year of 
birth and gender remain visible to users.
The data forms are organized around the pseudomized Basic Patient Data (Appendix 
Figure A11.1.2). The structure of RD5000db was based on the case report form (CRF) and 
standard operative procedures (SOPs) that were formulated by the RD5000 consortium, as 
well as on the data structure of Ophthabase.
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Figure 11.1. Visualization of data access in case patient data are entered from one, two or three centers. 
The numbers indicate the number of centers that have access to the patient’s data. If more than three 
centers are involved, the principle is followed analogously.
We designed five different data forms: patient history, genetics/DNA sample, clinical 
examinations, technical examinations and diagnoses forms. More details on the different 
data entry forms are provided in the Appendix 11.1 and Figures A11.1.1-A11.1.7 (available 
at the end of this chapter). Numerous clinical and technical examinations can be entered 
when follow-up data (longitudinal data) are available. Furthermore, image files of imaging 
techniques or examination reports can be uploaded to support the clinical data. The database 
allows patients to be registered in multiple centers that can all contribute to the data volume 
of a single the patient (Figure 11.1), which is not uncommon in The Netherlands. Family data 
are initially entered in the family history section of the history form (see Appendix 11.1). This 
data only include the number of affected individuals within the family, their relation to the 
patient and (if available) internal registration numbers of the parents. However, RD5000db 
provides the ability to assign family members that are entered in the database to a family ID 
in the Family tab (Appendix Figure A11.2.1).
Informed consent. We endeavored to enroll patients in the RD5000db with their approval to 
adhere to the tenets of the Declaration of Helsinki, although the data entered in the database 
is pseudomized and patient’s personal details are only available to the center the patient 
attends to (via the internal ID), which makes informed consent not obligatory. Nevertheless, 
we created an informed consent to obtain patient approval for data entry in the database.
Privacy. Due to the sensitive nature of the collected data we carefully considered how to 
handle privacy correctly according to the Dutch privacy regulations. At first the idea was 
to encrypt all the data using a public key infrastructure (PKI). In this set-up, only the super 
administrator of RD5000db would have access to the private key. However, in this approach 
maintenance by our hosting provider or ICT implementation party would be complicated. 
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The data were therefore anonymized in such a way that it is not possible to directly identify 
a patient. However, the center that a patient attends to can identify the patient by means of 
a separate registration system that is not connected in any physical or electronic way to the 
RD5000db application. In the RD5000db, this is possible by the internal ID that is linked 
to a patient in that specific center, hence, only members of that center can acquire the 
patient’s privacy sensitive details from their own center’s registration systems. Only a very 
limited amount of information is available to members of the other centers with access to the 
RD5000db. They can, however, obtain additional anonymous patient data upon permission 
from the review committee (see Data access).
Identifying double entries. We introduced a hash code based on date of birth, initials and 
gender to prevent double entry of a patient. However, this procedure has its limitations: initials 
are not always completely registered in the hospital’s registration systems and in some cases, 
names may be noted incorrectly on the medical files. For some individuals the distinction 
between first and family names is not clear, resulting in a different order of the initials that 
constructs a different hash code. Preventing double entry is however important, especially in 
these small groups of patients. When a double entry is suspected, the system administrator 
executes an audit trail based on year of birth, gender and diagnosis, and verifies personal 
details of the presumed double entries with the responsible physicians (who are generally 
from two different centers), before merging the entries.
Search engines. The RD5000db includes two search engines to explore patient data: the 
search engine of the database located on the Catalogue tab that searches all entries, and the 
search engine on the Patients tab that searches only patients accessible to the user (Figures 
A11.2.2 and A11.2.3). Both search engines are identical in composition, but differ in function. 
The Catalogue tab presents a limited set of data for all patients in the database, allowing 
the users to have an indication of the population that has been entered in RD5000db. This 
information can be used for formulating a research question and obtaining data access to 
other patients, the procedure of which is elaborated below (see Data access). The search 
function in the Patients tab provides the full data of the patients entered by the user’s centre, 
or of the patients the user has obtained access to.
Authorization roles. The hierarchy in authorization roles in RD5000db involves one system 
administrator, who has access to all data and roles of all users database-wide, and multiple 
center administrators, who have access to all data and roles of users in their center. Each 
center has two additional roles available: (1) writers, who can read, edit and add data to 
patients of their center, as well as add patients to the database and (2) readers, who have 
read-only access to data from patients of their center. Both the reader and writer roles can 
be assigned to multiple users.
The system administrator has the main supervising role in the system which includes 
organizational tasks, including add/delete roles of center administrators, handle requests 
to delete patients from the database, merge patient’s data in case of multiple entries of a 
single patient, change access rights per patient per form and search all patients (see Data 
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access). The center administrator has the supervising role within a center and takes care of 
communication to the system administrator, provides help to the users in his center, adds 
and removes users and changes user roles of his center, and provides passwords to users 
within the center.
Data access. The database is available at https://www.RD5000db.nl. To sign up to the 
database, the registration form has to be completed, including a specific center key (provided 
by the center administrator). After registration, a password will be sent to the user, to log into 
RD5000db and access patient data. By default, the user has access to all the patients linked 
to its own center. Which actions the user can perform, depends on the role assigned to him 
(see Authorization roles).
Patients linked to two or more centers can be accessed by each of these centers 
(Figure 11.1). Regulations on data management state that one center does not alter data 
entered by another center. Since technical and clinical examinations are stored as separate 
files for different time points, additional data can easily be added. Violations are tracked in 
the audit trails (see Audit Logging). When a patient with initials, date of birth and gender 
identical to an existing entry is entered into the database, users receive the double entry 
notification. After verification of the patient details, the system administrator can assign the 
patient to both centers.
For specific research questions, an RD5000db-user can receive access to the data of 
patients of other centers by formulating a research question application for the RD5000db 
review committee (Figure 11.2). The RD5000db review committee consists of RD5000-
members, one of each participating center. A positive decision from this committee enables 
the system administrator to grant the researcher access to the requested data (Figure 11.2). 
The access granted can be specified up to the level of specific forms (without access to the 
data on other forms of this patient). This same procedure is applicable in case an external 
researcher would wish to have data from the RD5000db. The only difference is that in case 
the requestis granted, data are sent in an export file to the external researcher instead of 
granting access to the database.
Data export. Patient data can be exported in two forms. Firstly, each single form can be 
exported in PDF format and can be stored in patient’s medical files if desired. Secondly, in 
the Reporting tab patient data can be exported to a Windows Excel® 2007 Worksheet format 
(.xslx), which enables further data analyses by various statistical programs. The Excel export 
file includes the data of all patients the user has access to. Any filtering of the data should 
be done after data export. The variables are organized in separate tabs of the worksheet 
based on the forms of the database. In each tab, the data are arranged based on RD5000 
ID. Longitudinal data, such as clinical and technical examination data of multiple visits, 
are presented in a single row per examination, each identified with the RD5000 ID and the 
examination date. Where value lists are used in the database, numeric values are present in 
the export worksheet, which can be identified using the codebook with the corresponding 
labels that is available in the last tab of the worksheet.
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A SPSS syntax document was written to simplify data import and management in SPSS 
(available for RD5000 members at http://www.RD5000.nl). By running the syntax, the data of 
all Excel worksheet tabs is imported into SPSS synthesizing one entry with correct labeling 
and subheadings. The syntax files is structured with subheadings, which enables selective 
use of parts of the syntax code.
Audit logging
All actions (inserts, updates and deletes) towards the database are stored in an audit log 
(also in the database). With this audit log, a registration is made that includes the details of 
the specific user, the time of the action, as well as the details of the actions. These details 
can be retrieved upon request.
Figure 11.2. Flowchart on the process to request access to data. Each center in principle only has 
access to the data entered by their own center. Colleagues from other centers obtain access to the data 
from other centers only after approval by a review committee which contains representatives of all data-
contributing centers. External researchers can only obtain data through this review committee. Upon 
authorization, the system administrator will give internal researchers access to the data, and provide the 
requested data to the external researchers in a report file.
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Current status and usability of the RD5000 database
The RD5000db was launched online at September 1st, 2012. In the meantime, 1,923 patients 
with retinal dystrophies have been registered in the database (reference date June 1st, 2014), 
with a mean age of 41 years (range: 1-102 years). In this cohort, 62 different diagnoses 
were made based on clinical phenotype and inheritance pattern. Clinical and/or technical 
examinations were registered for 469 patients (24.3%) with an average number of visits of 4.5 
(range: 1-17 for technical examinations and 1-22 for clinical examinations. Follow-up periods 
varied between 0-51 years. DNA samples were available for 1,235 patients (64.2%). Of 
these, 684 patients (35.6% of all entries) were genetically solved, and 188 additional patients 
(9.8% of all entries) carried putatively causative mutations, but have not yet been solved 
completely. Causative or putatively causative mutations were found in 77 different genes.
Time needed for entry of one patient is mainly dependent on the source data and the 
amount of details to be entered. Initially, comprehensive data entry takes up to 40 minutes per 
patient on average. However, for a trained person this time may be reduced to a maximum of 
25 minutes for a full data record.
Future plans
Data quality surveillance. In the near future, we will cope with some of the problems we 
encountered in the past two years. One issue of high priority is the double entry check that 
is intended to prevent the repeated entry of a patient. The current hash code that combines 
the patient’s initials, date of birth and gender has proven to be insufficiently solid, since 
we found 11 double entries up to now in 1,923 records. The entry of the initials has shown 
to be the most variable and inconsistent factor, since registrations in hospitals often are 
incomplete or incorrect. A solution may be the entry of a citizen identification number (Dutch: 
Burger Service Nummer, BSN) using Trusted Third Party (TTP) procedures, which warrants 
pseudomisation that complies with the strictest privacy legislations. Furthermore, standard 
procedures for checking data quality will be written, thereby preventing errors in the data 
entry, such as misspelled gene names and other free text fields. Finally, there is currently no 
compulsory minimal clinical dataset, which may be very useful for several research questions 
that rely on detailed clinical data. However, the data requirements will be different for each 
research question, complicating the definition of the minimal dataset.
Funding. Up to now, the costs for the development of RD5000db have been covered by 
Dutch blindness foundations. However, once the database is routinely used, it stands to 
reason that each participating center contributes an annual fee to host, maintain and update 
the database. Information about the set-up and maintenance costs for the database can be 
found in Appendix 11.3.
International expansion of the database. Currently, the RD5000db is available for 11 Dutch 
ophthalmologic centers. In the near future, we want to include data of a few international 
centers. RD5000db thereby has the potential to develop into a pan-European database for 
the detailed registration of clinical data. By increasing the number of patient records, its 
potential will grow significantly and facilitate many different studies in the fields of genetics, 
genotype-phenotype comparisons, and the application of novel therapies.
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Appendix 11.1: Data entry forms
The database structure is depicted in Figure A11.1.1 (available at: http://www.iovs.org/content/
suppl/2014/11/17/55.11.7355.DC1/IOVS-14-15317-s01.pdf). Patients are entered into the 
RD5000db database by the basic patient data form (Figure A11.1.2). Personal data including 
date of birth, initials and gender are registered at patient enrollment in RD5000db for the use 
of a check on double entries of a single patient. After registration of the patient, only the year 
of birth remains visible, whereas initials are not visible to users after the basic patient data 
form has been saved. Other details that are entered in this form are the centers the patient 
visited, including the patient’s internal registration number and responsible physician, with a 
maximum of three centers.
The patient history form (Figure A11.1.3) contains modules on the initial diagnosis, visual 
and general symptoms, ophthalmic history, medication and family history. Seven visual 
complaints most prevalent in IRDs and 16 syndromic features present in syndromic IRDs are 
documented, with the possibility to specify each complaint further with e.g. age at onset of 
this specific complaint or its location (if applicable). The module on family history registers 
data on the patient’s siblings, as well as the generations of the patient’s parents and children.
The genetics/DNA sample form (Figure A11.1.4) primarily states the presence of a DNA 
sample of this specific patient. Additionally, both causative and non-causative variants can 
be registered. If the effects of a mutation are not known, these variants are registered in the 
‘mutations of uncertain pathogenicity’ module. The correct module appears based on the 
conclusion of genetic analysis that was selected. The method used for genetic analysis can 
be specified further as well as version numbers of used gene sets, kits etc can be registered. 
Gene names are registered in HGNC nomenclature, whereas both complementary DNA 
changes and protein changes are noted for the variants/mutations.
In the clinical examination form (Figure A11.1.5), data of ophthalmic examinations are 
registered, including visual acuity (including subjective refractive error), fixation, eye motility, 
intra-ocular pressure and slit-lamp biomicroscopy of the anterior segment and posterior 
segments. Except for fixation and eye motility data, all data are entered for each eye 
separately. Each module contains a button to copy data of the right eye to the fields of the left 
eye, since IRDs are generally symmetrical. Data of the anterior and posterior segments are 
entered by a drop-down menu stating the options ‘normal’, ‘abnormal’ and ‘not applicable’. 
Additional fields to specify observations appear if the option ‘abnormal’ is selected. If the 
data entry fields do not cover the observed details, a free text field enables registration of 
these additional data.
The technical examination form (Figure A11.1.6) enables registration of data acquired 
from perimetry, color vision tests, full-field or multifocal electroretinography (ERG), electro-
oculography (EOG), dark adaptation, and commonly used imaging techniques, including 
fundus photography, optical coherence tomography (OCT), fundus autofluorescence (FAF) 
and fluorescein angiography (FA). Like the clinical examination form, all data are entered for 
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each eye separately and buttons to copy data from the right to the left eye fields are present. 
Furthermore, each module contains the option to upload a file, e.g. a scan of the perimetric 
results, the ERG graphs or digital files of imaging examinations.
The diagnoses form (Figure A11.1.7) enables registration of the diagnoses made in the 
patient. The final ophthalmic diagnosis is selected from an extended list of retinal diagnoses 
and syndromes. Other ophthalmic diagnoses or general relevant diagnoses can be entered 
from the 10th revision of the International Classification of Diseases (ICD-10).
Four different field types are used in the database: value lists, check boxes, radio buttons 
and iterate values/dates. The default value for most value lists is “Please select…”. All value 
lists contain a “not applicable” value, which means these data are not available, in contrast 
to “not known”, which should be used if the patient cannot provide the data. Radio buttons 
are only used in the technical examination form, mainly to specify if the examination referred 
to has been performed.
To enhance usability, we minimized the amount of mandatory fields. Mandatory fields 
include the examination date in both clinical and technical examination forms, because 
the saved forms are arranged by these dates. The technical examination form has multiple 
mandatory fields, which specify whether an examination has been performed or not.
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Figure A11.1. http://www.iovs.org/content/suppl/2014/11/17/55.11.7355.DC1/IOVS-14-15317-s01.pdf
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Figure A11.1.2: http://www.iovs.org/content/suppl/2014/11/17/55.11.7355.DC1/IOVS-14-15317-s02.pdf
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Figure A11.1.3: http://www.iovs.org/content/suppl/2014/11/17/55.11.7355.DC1/IOVS-14-15317-s03.pdf
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Figure A11.1.3: (Continued)
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Figure A11.1.3: (Continued)
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Figure A11.1.4: http://www.iovs.org/content/suppl/2014/11/17/55.11.7355.DC1/IOVS-14-15317-s04.pdf
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Figure A11.1.4: (Continued)
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Figure A11.1.5: http://www.iovs.org/content/suppl/2014/11/17/55.11.7355.DC1/IOVS-14-15317-s05.pdf
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Figure A11.1.5: (Continued)
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Figure A11.1.5: (Continued)
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Figure A11.1.6: http://www.iovs.org/content/suppl/2014/11/17/55.11.7355.DC1/IOVS-14-15317-s06.pdf
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Figure A11.1.6: (Continued)
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Figure A11.1.6: (Continued)
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Figure A11.1.6: (Continued)
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Figure A11.1.6: (Continued)
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Figure A11.1.7: http://www.iovs.org/content/suppl/2014/11/17/55.11.7355.DC1/IOVS-14-15317-s07.pdf
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Figure A11.1.7: (Continued)
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Figure A11.1.7: (Continued)
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Appendix 11.2: Supplemental figures
Figure A11.2.1: http://www.iovs.org/content/suppl/2014/11/17/55.11.7355.DC1/IOVS-14-15317-s08.pdf
Figure A11.2.2: http://www.iovs.org/content/suppl/2014/11/17/55.11.7355.DC1/IOVS-14-15317-s09.pdf
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Figure A11.2.3: http://www.iovs.org/content/suppl/2014/11/17/55.11.7355.DC1/IOVS-14-15317-s10.pdf
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Appendix 11.3: Costs
The basic technical set-up costs of the database, with Ophthabase as a basic structure, 
were approximately € 85,000. Based on the current use that includes 11 centers, the running 
costs are about € 1,000 per month, which warrants maintenance, system stability, regular 
back-up of the database and of the source code, security updates and support. On top of 
that, the consortium manager spends 6 hours per week on both organizational tasks of the 
consortium and system administration. Currently, the costs can be covered by the funding 
from Dutch blindness foundations.
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This thesis contains studies on phenotypic and molecular characteristics of a group of 
selected inherited retinal dystrophies (IRDs) and discusses the genotype-phenotype 
correlations. This chapter considers IRDs in a broader perspective, and discusses current 
and future perspectives on phenotypic evaluation, genotype-phenotype correlations and 
therapeutic possibilities. These items are subsequently integrated in the future management 
of patients with IRDs, which perfectly fits the personalized-medicine approach.
Clinical aspects of inherited retinal dystrophies
Clinical heterogeneity
One characteristic that applies to virtually all IRDs is heterogeneity. This is reflected in 
the tremendous number of genes and mutations involved, as well as the wide variation 
in phenotypes, even when one considers a single clinical entity like for example MAK-
associated retinitis pigmentosa (RP). This clinical heterogeneity has expanded over time due 
to an increase in clinical parameters. New multimodal applications have appeared such as 
fundus perimetry (microperimetry), which combines retinal en face imaging with perimetry 
to provide topographic retinal sensitivity levels, as well as the preferred point of fixation.1 In 
addition, new approaches for clinical examination have been developed and found their way 
into routine ophthalmic practice in the past few decades, like for example high-resolution 
(spectral domain) optical coherence tomography (OCT) and fundus autofluorescence (FAF) 
imaging.2-4 The OCT technique is currently refined by adaptive optics to increase the spatial 
resolution, up to cellular levels,5,6 and are applied in new examinations, like for example in 
OCT-based microangiography and OCT changes in retinal responses to light stimulation 
(functional OCT).5,7 These new techniques provide very detailed structural and functional 
information, which increases our understanding of the retinal physiology and the effects of 
certain genetic defects.
One desired test still missing in the pallet of retinal parameters is an objective 
measurement of topographic retinal function. Functional OCT aims at this, but focuses on 
(1) optical changes induced by light, an indirect parameter of photoreceptor function, and 
(2) retinal structure, which also does not always correlate with visual function. For example, 
RP patients with a central island of photoreceptors of 5-10˚ on OCT imaging often reveal a 
visual field extending to 40-50˚ degrees eccentricity. Multifocal electroretinography (mfERG) 
provides the macular neuronal action potential, which may be a more direct parameter of the 
functionality of photoreceptor, bipolar and ganglion cells, but it is easily disturbed by fixation 
losses and does not appreciate retinal structure. Performing mfERG with simultaneous retinal 
image tracking could provide a stable repeatable localization of the responses measured. 
Ideally, en face imaging, (functional) OCT and mfERG should be integrated to provide 
objective data on topographic retinal functionality. This data can be useful in follow-up of 
patients, and be of great value in the selection of patients and evaluation of treatment effects 
in therapeutic trials.
Genetic causes of clinical heterogeneity
IRDs are generally considered to be monogenic diseases: the disease is caused by 
defects in a single gene. However, we often cannot determine evident genotype-phenotype 
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correlations among IRD patients, and observe clinical variance between families and even 
within families. This may indicated the involvement of other (genetic) factors. Changes 
in so-called modifier genes have often been attributed to cause clinical variance in IRD 
patients.8-11 In this concept, all retinal genes could influence the retinal phenotype, since they 
harbor for instance heterozygous mutations (in genes that lead to disease with recessive 
inheritance patterns) or single nucleotide polymorphisms (SNPs) that may change the 
resilience of a specific pathway or the general retinal condition, and make the retina more or 
less susceptible to degeneration.
In light of this, it is debatable if retinal dystrophies, or any genetic disease, can be 
considered truly monogenic, since the genetic context is always of influence up to some 
degree. Of course, IRDs are considered monogenic because the causative genetic defects 
are identified in one specific gene that fits a Mendelian inheritance pattern and without these 
defects the retina would function as in normal-sighted individuals. However, the retina is a 
very complex tissue that survives and functions because of numerous proteins expressed 
from approximately 19,500 genes.12 SNPs occur in all individuals and clear-cut pathologic 
mutations occur in 1 out of 4-5 individuals in the general population,13 so this large number of 
genes involved in the retinal tissue implicates that modifier effects probably are of influence 
in each IRD patient. Yet, these modifier effects may be of different magnitude since one 
pathway may be imbalanced more easily compared to the other.
Genetic analysis by whole exome sequencing provides data on variants found in all 
retinal genes, and therefore on the ‘retinal genotype’ of a patient. However, knowledge on 
the functional consequences of these variants is often lacking. It is difficult and laborious to 
determine these effects, which may – especially in case of SNPs - be small or even nearly 
indifferent from normal protein function. Moreover, other factors such as differences in gene 
expression levels, epigenetics and nutritional status may have their share in determining 
the retinal phenotype apart from modifier effects. Much knowledge has to be gained on the 
factors influencing the retinal phenotype and mutual interactions between these factors. We 
are far from getting a complete genetic profile of each IRD patient, yet new techniques for 
genetic analysis like next-generation sequencing (NGS) enable analysis of whole pathways 
or all retinal genes known up to now. This may provide insight in the probable ‘multigenic’ 
character of these diseases, and lead to clear associations between the genetic findings 
and the phenotype. The large amount of data generated by NGS however complicates 
variant prioritization, but the main difficulty will be the low number of patients with 
comparable genetic and clinical features to verify findings, as in this approach the specific 
genetic combinations may be found in only a single patient. This may increase the need 
of international collaborations and international databases on genotypes and phenotypes. 
Additionally, bioinformatics may get a prominent role in verification of research findings by 
means of theoretic models, prediction tools and other bioinformatic approaches.
Another fascinating observation is that mutations in some genes can cause retinal disease in 
both rod-cone or cone-rod patterns, like we observed in C8orf37-associated retinal disease 
(see chapter 4), and also has been described among patients with mutations in CERKL, 
MERTK, CRX or PROM1.14-24 How can mutations in one gene result in almost opposite 
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degeneration patterns? To cause preliminary degeneration in rods (rod-cone pattern) or 
cones (cone-rod pattern), the gene needs to be expressed in both types of photoreceptors. If 
a gene is expressed in only one type of photoreceptor, for example rods, the rod degeneration 
is expected to preceed cone degeneration, since the cones degenerate secondarily due to 
the loss of rods in this scenario, resulting in a rod-cone dystrophy. This, however, still does not 
explain the difference in degeneration pattern among patients. Mutational differences would 
not directly result in opposite degeneration patterns, unless there are domains in the protein 
that are more important in either rods or cones. The same may occur if rods and cones have 
specific isoforms of the protein. Another explanation may be that the degeneration pattern is 
determined by variants in other genes involved in the same pathway. These pathways may 
differ in detail among rods and cones, which can result in a more pronounced degeneration in 
one of the photoreceptor cell types. However, we often lack data on protein function, isoforms 
expressed in the retina, or simultaneous defects in pathway-related genes. Further analysis 
of genetic changes in specific pathways, as well as analysis of corresponding features of 
such genes may provide insight in the origin of the differences in degeneration pattern.
Systemic features of inherited retinal dystrophies
Many syndromic forms of IRDs, especially RP and CRD, have been described in literature. 
These syndromes can be caused by mitochondrial and metabolic defects, but also may 
rise from defects in ciliary genes, which are genes involved in the structure and functioning 
of the hair-like cellular organelle called the cilium that is present in virtually each cell in the 
human body. First considered rudimentary, the cilium is recognized as essential in numerous 
tissues, such as the retina, the inner ear, the olfactory system, the kidneys, respiratory tract 
epithelium and the liver.25,26 In the retina, the connecting cilium and outer segment in the 
photoreceptors are highly modified primary cilia (see also chapter 1).
In patients with IRDs, extra-ocular features are often underappreciated, and evaluation of 
the presence of these symptoms almost seems to be academic. However, history taking with 
a focus on the most prevalent syndromic features related to IRDs can provide an impression 
if the IRD is syndromic. Mockel and colleagues provided a detailed overview of the extra-
ocular tissues that can be affected in syndromic forms of retinal degeneration.26 Most frequent 
symptoms include hearing and balance abnormalities, renal failure and nephronophthisis, 
cardiac and respiratory anomalies, olfactory deficiencies, polydactyly, obesity, cognitive 
impairment, fertility disorders, hypogonadism and dental anomalies. Presence of extra-
ocular symptoms can guide genetic analysis, although this may be of less importance with 
the introduction of NGS techniques. More importantly, syndromic disease may be applicable 
for symptomatic treatment, and patients should be referred to the right specialist if necessary.
The mere presence of an extra-ocular symptom, however, does not necessarily confirm 
the diagnosis of a syndromic disease, since extra-ocular symptoms also occur in the general 
population and patients may suffer from other pathology simultaneously to but independent 
from their retinal dystrophy. On the other hand, the absence of extra-ocular symptoms 
during history taking does not exclude syndromic disease either, since these extra-ocular 
symptoms may develop in a later disease stage than the ocular symptoms, or may be present 
subclinically. However, little is known of the prevalence of subclinical syndromic features 
General discussion  |  287
12
in IRD patients or the general population. Our studies on ABHD12-associated disease 
(chapter 5) and USH1G-associated disease (chapter 6) highlight that such disease often 
present as a phenotypic spectrum in which tissues can be affected to different degrees, 
which has also been observed in other ciliary genes such as USH2A, BBS1 and RPGR.27-33 
If syndromic features are present but the diagnostic criteria of none of the known syndromes 
is met, descriptive diagnoses are often used. If patients do meet the diagnostic criteria 
of a known syndrome, new genotype-phenotype associations may occur, such as Usher 
syndrome in patients with RPGR mutations. The use of NGS techniques and a focus on extra-
ocular symptoms may reveal such new associations.
Nomenclature of inherited retinal dystrophies
The nomenclature of IRDs is complicated and confusing, and is insufficient for the heterogenic 
nature of IRDs. The currently used nomenclature historically grew from clinical observations in 
an era in which the genetic causes were not known, and was already complicated by overlap 
in clinical appearance (e.g. RP with macular involvement and CRD) and misnomers (e.g. 
retinitis pigmentosa is not caused by inflammation or infection). The identification of many 
genes involved in IRDs illustrated the overlap in pathology (e.g. Stargardt disease (STGD1) 
and fundus flavimaculatus). This led to a ‘subtype classification’ of RP and CRD, where each 
gene causes a specific type of RP or CRD. Moreover, the lack of therapeutic consequences 
did not aid IRD nomenclature, although receiving the right diagnosis becomes vital now 
highly personalized gene-specific therapies are coming into perspective.
Diseases are generally classified by the combination of specific clinical features and 
a specific pathologic process. However, reported clinical observations did not always 
lead to classifications applicable in practice, as can be observed in the phenotypic and 
electrophysiological classifications that have been described in STGD1.34,35 Yet, these 
classifications do not seem to be able to provide a suitable classification for STGD1, since the 
pathologic process underlying the heterogeneous character is not understood completely. 
The clinical classification based on the age at onset that we optioned in our studies on STGD1 
(see chapter 8 and 9 of this thesis) is applicable in each patient, and seems to provide a 
general indication on severity of the disease. However, since no genetic associations with the 
clinical differences were found, this classification also lacks a pathologic background, and 
therefore probably can be improved.
An important, yet underappreciated, factor in nomenclature of IRDs is time. Clinical 
phenotypes of progressive IRD change during the patient’s life, which may complicate the 
correct diagnosing. If, for example, an electroretinogram (ERG) reveals a cone-rod pattern 
the differentiation between RP and CRD seems obvious, while in advanced disease, when 
the scotopic and photopic ERG responses often are equally reduced or nonrecordable and 
the fundus becomes more atrophic, differentiation between RP and CRD becomes more 
difficult. Additionally, an IRD may progress from one phenotype into a phenotype that does 
not fit the initial diagnosis, and, because of this, patients not incidentally receive multiple 
diagnoses during their lifetime. However, the pathologic process did not change, and 
therefore the diagnosis should not be changed, especially when genetically confirmed. For 
example, a 70-years-old patient with STGD1 with an atrophic posterior pole, pigmentary 
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changes and severely affected photopic ERG still has STGD1, although the phenotype would 
currently be classified as CRD.
Receiving the wrong diagnosis or multiple diagnoses can be very confusing for the patient, 
especially now patients have easy access to a huge amount of information on the Internet. 
Detailed history taking, perimetry, (previous) ophthalmic examinations, genetic testing, and 
advertency to the disease stage can help in providing the right diagnosis. In some IRD cases 
however, diagnosing is unclear despite of a thorough history taking and clinical evaluation, 
such as some of the patients with C8orf37-associated retinal dystrophies described in 
chapter 4. The diagnosis of RP with early macular involvement is mainly descriptive, while 
differentiation with early-onset CRD and Leber congenital amaurosis (LCA) is debatable.
The facts discussed above make it difficult to propose a more consistent method of 
nomenclature for the heterogeneous progressive IRDs. The overlap in clinical appearance 
tempts the use of universal terms like ‘photoreceptor dystrophy’, which, on the other hand, 
lacks any descriptive value of the clinical features of the disease. Slightly more specific 
terms such as ‘rod-cone dystrophy’ or ‘cone-rod dystrophy’ can be useful, although these 
electrophysiological classifications are not always obvious. The age of onset provides an 
indication of the progression rate of the IRD as well as the disease stage a patient is in when 
the age is known. This can be reflected in terms such as ‘early-onset’ or ‘late-onset’, although 
‘childhood-onset’, ‘adolescence-onset’ and ‘adult-onset’ are more specific and preferable. 
In light of the upcoming gene augmentation therapies, it seems vital to include the causative 
gene in the diagnosis, although this seems ambiguous since the retinal phenotype probably 
is the result of the variants in multiple retinal genes (see above). These factors – general 
diagnosis, onset and causative gene – can be used as a more systematic approach that is 
applicable in most patients. In this approach the nomenclature provides more information on 
the clinical and genetic features of the disease than the currently used subtype classification 
used in RP and CRD. However, new insights in the genetic background and their relation to 
the phenotype may provide a better classification of IRDs, i.e. based on the defective gene 
or pathway.
Management of IRD patients
Up to now, the management of patients with IRDs mainly involved a follow-up of the progression 
of visual field and visual acuity loss, (prenatal) genetic counseling, recommending the use 
of sunglasses and low-vision aids if necessary, and/or providing information on therapy trials 
and participation in these studies. Some studies suggested that treatment with vitamin A, 
fish oils (docosahexaenoic, DHA) or both resulted in a slower decline of ERG amplitudes 
and visual field in patients with RP.36-40 In 2013, however, a Cochrane systematic review by 
Rayapudi et al concluded that there is no clear evidence for benefit of treatment with vitamin 
A and/or DHA for RP patients.41 An important issue here is that these studies treated RP as 
if it was one disease. We know now that numerous genes are involved in the pathogenesis 
of RP, and that vitamin A suppletion could well be beneficial in one form of RP while being 
harmful in another. For example, vitamin A suppletion is harmful in patients carrying ABCA4 
mutations, due to the increased accumulation of toxic vitamin A derivates (especially A2E). 
Nevertheless, the studies on vitamin A suppletion mentioned above found a beneficial 
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effect despite the heterogeneous cohort, which implies that in some forms of RP vitamin 
A is beneficial. To what extend cannot be said, since the distribution of genetic causes in 
these cohorts is not known. Recently, studies involving administration of a specific vitamin 
A derivate in RP cases with defects in genes involved in the retinoid cycle (RPE65, LRAT) 
reported beneficial effects (see Upcoming treatments below).42-44
Several trials evaluated the effects of valproic acid (VPA) in RP patients. VPA is generally 
used as an anticonvulsant, migraine prophylaxis or in the treatment of bipolar disease. It 
inhibits histone deacetylase, downregulates complement proteins, and increases the 
levels of neurotrophic factors.45-50 Clemson et al initially reported beneficial effects of VPA 
administration in RP patients, although the scientific rationale and conclusions of this study 
were questioned.51-53 Several studies have been published since: some reporting beneficial 
effects, some reporting harmful effects.54-57 A study on the effects of VPA on Rd1 and Rd10 
mice found no beneficial effects on photoreceptor survival, while they observed harmful 
effects when administered in an early disease stage.58 Although the mechanisms in which 
VPA has its effect on the retina need to be elucidated, a randomized double-blinded trial with 
VPA in RP patients is currently ongoing (www.clinicaltrials.gov).
The management of IRDs further involves measures that help patients cope with their 
visual handicap. IRD patients should be encouraged to visit vision-rehabilitation clinics in 
which visual aids can be offered to improve (night) vision.59-61 For some patients and their 
family members it can be helpful to join a support group to discuss problems and solutions 
involved in living with a visual handicap. Other measures focus on other forms of ocular 
pathology that may accompany IRDs, whether or not associated with the retinal dystrophy, 
but that can be treated. Subcapsular posterior cataract, for instance, occurs in about 50% of 
RP patients.62-65 Patients with lens opacities that substantially affect distance or near vision 
can benefit of cataract extraction. Another example would be epiretinal membrane peeling 
in IRD patients when this condition causes loss of vision and/or metamorphopsia.66 Patients 
with cystoid macular edema (CME) may benefit from treatment with carbonic anhydrase 
inhibitors (CAIs).67-76 Treatment of CME with intravitreal steroids may as well be beneficial, but 
its efficiency seems to be limited over time.77-81 Intravitreal treatment with vascular endothelial 
growth factor (VEGF) antibodies has been reported to decrease CME in one study,82 but 
generally had no beneficial effect on the oedema.83-85 Moreover, intravitreal anti-VEGFs may 
theoretically be harmful in IRD patients, since VEGF levels are reportedly decreased in RP 
patients.86
Upcoming treatments
The insights in the genetic background of IRDs have led to a better understanding of the 
molecular defects causing the various diseases. This sourced a new era of research into 
therapeutic options for retinal disease that focus on repairing or passing by the specific 
genetic deficit, renew retinal photosensitivity or replace lost tissue. Each therapeutic approach 
has specific characteristics and focuses on specific patient populations. The therapeutic 
approaches that currently are under evaluation are briefly reviewed in the paragraphs below. 
Table 12.1 provides an overview of the clinical trials currently open to patients.
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Genetic therapy includes various approaches used to overcome or by-pass the genetic 
defect by gene augmentation, gene suppression or modulation of the splicing process, or 
delay retinal degeneration by introduction of genes expressing neuroprotective factors. An 
important factor in determining the approach necessary is the effect the mutations have on 
protein function, e.g loss-of-function effects, gain-of-function effects, or dominant-negative 
effects (the mutated protein has negative effects on the functional protein product of the 
other allele).87 Gene augmentation therapy (GAT) can be used in case of loss-of-function 
defects. GAT involves introduction of a wildtype cDNA copy of the mutated gene, which 
produces a functional protein and potentially restores the related pathways.88-90 In dominant-
negative effects GAT can be attributed to reach sufficient levels of the functional protein. 
Challenges that appeared in this approach are the limited cargo size of some of the viral 
vectors used, the level of transduction of viral vectors for photoreceptor and retinal pigment 
epithelium (RPE) cells, the route of drug delivery, immune responses against the viral vector, 
and duration of the therapeutic effect after a single administration.87 This strategy focuses on 
stopping disease progression (although improvement of visual function has been observed 
as well88), and therefore will be mainly applicable for patients with relatively intact retinal 
structure and/or good visual function.
Clinical studies on GAT for RPE65-associated retinal disease have shown remarkable 
effects,89 and probably receive FDA approval shortly. This really boosted the research on 
GAT for other diseases (Table 12.1), as well as genetic therapy in general.
GAT can also be used to elevate the expression of genes for neuroprotective factors in the 
retina, and thereby prolong the survival of photoreceptors regardless of their genetic defect. 
Factors that have been involved in this approach are ciliary neurotrophic factor (CNTF), brain-
derived neurotrophic factor (BDNF), glial-cell derived neurotrophic factor (GDNF), X-linked 
inhibitor of apoptosis (XIAP), and rod-derived cone viability factor (RdCVF).91-100 Advantages 
of this approach are that these factors are highly diffusible, and the therapeutic gene can 
be administered to any tissue close by the retina resulting in a paracrine effect.87 The main 
downside of this approach is that this therapy does not prevent retinal degeneration, which 
eventually occurs albeit at a later point in the disease course. This approach focuses on 
the patients with a fairly intact retina, although it may be beneficial in advanced disease 
as well, as CNTF has shown to be beneficial in geographic atrophy in age-related macular 
degeneration.101
In some dominantly inherited diseases with gain-of-function or dominant-negative effects, 
the mutated protein has negative effects on protein or cellular function. Introduction of a wild-
type cDNA copy of the mutated gene does not reduce this negative effect, and gene or 
allele silencing is essential. Suppression of the mutated gene or allele can be reached by 
the use ribozymes, or RNA interference.102-105 If haploinsufficiency occurs after suppression, 
introduction of a wildtype copy of the gene with GAT may be necessary, a strategy known as 
‘suppression and replacement’.87 Challenges in this approach include route of drug delivery, 
specificity for the gene that should be suppressed and reaching sufficient suppression. This 
approach also focuses on patients with relatively intact retinal tissue and function.
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Approximately 11% of the mutations involved in IRDs affect splicing processes.106,107 These 
mutations result in the inclusion of intronic sequences or the exclusion of exonic sequences 
in the messenger RNA (mRNA). Splicing correction for a small subset of splicing defects can 
be reached by the use of antisense oligonucleotides (AONs), which are synthetic molecules 
of generally around 20 nucleotides that mimic RNA structure. AONs can be directed towards 
specific mutated pre-mRNA sequences, where they bind and mask the pre-mRNA code 
containing the mutation to prevent recognition by the spliceosome, resulting in e.g. skipping 
of pseudo-exon that is inserted by an intronic mutation.107,108 Other strategies in splicing 
correction have been proposed, including the introduction of an adapted U1 component of 
the splice complex that is able to bind the mutated splice donor site.109-111
Optogenetics is a therapeutic approach in which light-gated ion channels are introduced 
in the remaining neurons of degenerated retinas that have lost photosensitivity because 
of a high degree of photoreceptor cell death. These ion channels, e.g. halorhodopsin, 
channelrhodopsin or archaerhodopsin, modulate membrane potentials (induce depolarization 
or hyperpolarization) when stimulated by photons, and thereby restore photosensitivity albeit 
in different cells than it originally was located in.112 The major challenges in this approach 
lie in choosing the right optogenetic tool and targeting the correct retinal cells.113-115 Other 
difficulties are the high levels of light needed to get light responses, and the high number 
of optogenetic protein expression, since these optogenetic tools do not benefit from 
amplification of the G-coupled cascade as normal opsins do.87,116 In contrast to the gene 
therapy approaches mentioned above, this approach focuses on patients with photoreceptor 
loss but intact bipolar and ganglion cells, which generally remain intact even in end-stage 
disease.
Oral (suppletion) therapy with a vitamin A derivate has been performed in patients 
suffering from Leber congenital amaurosis (LCA) due to RPE65 or LRAT mutations, two 
genes that are involved in the retinoid cycle (see chapter 1). These patients received 
oral administration of synthetic 9-cis-retinyl acetate for 7 days, which resulted in a rapid 
improvement of visual field and visual acuity.42 As observed in mice, 9-cis-retinyl acetate 
is thought to decrease the content of unbound chromophore, reducing the constitutive 
activation of the phototransduction cascade which is the cause of the retinal degeneration in 
RPE65 mutants, and thus slowing down photoreceptor degeneration.43,44,117 Although tested 
in a small cohort, the retinoid substrate was well tolerated and did not cause serious adverse 
events.42 Like gene therapy, this therapeutic approach focuses on patients with relatively 
intact retinal structure, although it is applicable in more advanced disease. Long-term side 
effects as well as duration of the beneficial effects have to be evaluated yet.
Stem cell therapy involves the administration of stem cell-derived retinal cells into the 
subretinal space, and have been optioned to repair retinal tissue defects in several retinal 
degenerative diseases, such as STGD1, RP and age-related macular degeneration.118,119 
The eye’s immunoprivileged nature makes it attractive for regenerative therapies involving 
stem cells. Different approaches are used, including transplantation of stem cell-derived 
RPE, photoreceptors or both.119 Currently, phase I/II trials are performed to assess safety, 
graft survival tolerance and activity of pluripotent stem cell progeny.118,120 In contrast to gene 
therapy, stem cell-based therapies focus on patients with damaged (outer) retinas, which 
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generally are observed in patients with advanced disease. Although clinical applications 
are still in their infancy, stem cell therapy approaches show a high potential, and could well 
become the therapy of choice in advanced retinal degeneration in the future.120,121
Implantation of retinal chips is another therapeutic approach that focuses on patients 
in even more advanced stage disease. Roughly, there are three kinds of retinal chips: the 
epiretinal, subretinal and suprachoroidal implants.122,123 Epiretinal implants stimulate the 
remaining retinal ganglion cells directly, whereas subretinal implants replace the lost outer 
retina and stimulate the interneurons and ganglion cells. Epiretinal implants are generally more 
easily implanted compared to subretinal chips.122 Two systems are currently commercially 
available: the Argus II epiretinal implant by Second Sight Medical Products Inc. (Sylmar, 
CA, USA), and the Alpha-IMS subretinal implant made by Retina Implant AG (Reutlingen, 
Germany).123 Currently, retinal implants are used in patients with end-stage disease that even 
cannot perceive hand movements (light perception level or worse) because the low spatial 
resolution that can be reached: the best recorded visual acuity in patients with the Argus II 
implant was 20/1260, and 20/546 in patients with the Alpha-IMS implant. Other challenges 
involve device survival, contrast sensitivity, color vision, temporal resolution, and binocular 
vision (so far implants have only been implanted unilaterally).123,124
Tongue stimulators have been developed in the past decade, and enable patients to 
provide information on the patient’s surroundings by electrostimulation of the tongue provided 
from a matrix of electrodes worn inside the mouth. The system (BrainPort Technology, 
WIBCAB Inc., Middleton, WI) catches the scenery with a camera, whose capture is translated 
into an impulse by a computer.125 This approach enables better orientation and navigation in 
(congenitally) blind individuals, and patients with this device even reached a ‘tactile’-acuity of 
20/430 measured with the Snellen’s tumbling E test after a 9 hour training.126-128 This relatively 
simple and noninvasive approach can also be used if the optic nerve has degenerated. Main 
downside is that the tongue stimulator hinders speech; yet the stimuli feel like a tickle or 
vibration and are not painful. A clinical trial with 75 patients has been performed, but awaits 
publication of the results (www.clinicaltrials.gov).
In general, therapies that aim at curing the cause of the disease are considered preferable, 
and hence much hope is directed towards the genetic therapy approaches. When available 
and effective, the these therapies probably will be superior compared to the other approaches, 
at least for patients in the early stage of their disease. On the other hand, one study on gene 
augmentation therapy in LCA2 (RPE65-associated LCA) revealed ongoing degeneration 
after treatment.129 This degeneration was assigned to photoreceptors that already were too 
damaged to prevent apoptosis in, as well as to photoreceptors that were not reached by the 
virus vectors and left untreated.130 This is difficult in patients in early disease phases, but even 
more problematic in patients in advanced disease, in whom stem cell transplantation may be 
a more appropriate approach. Determining the optimal treatment window for each approach 
will be tough and time-consuming, especially in the ‘transition phase’ where genetic therapies 
become gradually less beneficial and stem-cell transplantation is not amenable because 
loss of retinal tissue has not occurred yet. Combinational therapy, for example GAT to correct 
the genetic defect and simultaneously introduce neuroprotective factors, can be beneficial 
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in these patients. Moreover, it will still take many years, probably decades, before gene-
specific therapeutic approaches have been developed for most forms of IRD, and in the 
meantime many patients will progress into a disease phase where gene therapy alone is not 
sufficient anymore. The other approaches, which also show great potential, should not be 
considered rudimentary since their treatment may be necessary in addition to gene therapy.
The stem cell-based therapies are expected to progress enormously in the coming years. 
Its gene-independent nature and applicability in a broad spectrum of retinal diseases gives 
this approach great potential. However, the main downside – the degeneration processes 
continue in the non-treated areas of the retina– may make that this therapy may not be the 
solution on its own. Yet, it could extend the use of gene therapy if it would be possible 
to restore the retinal tissue with stem cell-derived photoreceptors and/or RPE cells, and 
treat the molecular defect with a gene therapy approach. When these therapies become 
available, further research has to show if this strategy is beneficial compared to one therapy 
alone, and determine which order is preferable. Induced pluripotent stem cells (iPSC) have 
shown potential in stem cell-based therapy, but since iPSCs are derived from the patient 
itself they harbor the genetic defect as well. Performing gene correction on the iPSCs prior to 
transplantation may solve this matter.
The retinal implant approach focuses on patients in end-stage disease. However, if 
genetic and stem cell therapies are applicable, this patient group tends to disappear. 
Yet, research on retinal implants is necessary, since the implants may also be beneficial 
in patients with any disease that leads to severe macular atrophy and an intact peripheral 
retina. The resolution of the image generated by the chip needs to be improved to the level 
of visual acuity that can be reached by the peripheral retina (generally about finger counting 
to 20/200). Then, these chips may become therapeutic options for STGD1 or age-related 
macular degeneration in a moderate disease stage. However, we do not know yet what the 
effect will be if patient get a chip implanted while the peripheral retina is still functional. Is 
the vision generated by the chip compatible with the vision from the peripheral retina? Will 
the photoreceptors neighboring the chip also be stimulated by pulses from the electrode 
array and lead to additional light sensations? How does the surviving retina respond to chip 
implantation in such cases? Will implantation of a chip damage the remaining functional 
areas of the retina and cause further degeneration? Anyway, the long-term results have to be 
determined yet. Not only on implant survival and function, but also on the endurance of the 
materials used, for example the waterproof, biocompatible encapsulation of the electronic 
circuits (is there a risk of siderosis bulbi or chalcosis bulbi?). For now, the retinal implants 
seem to be the last resort in the treatment of retinal dystrophies.
The development of new therapy strategies comes with ethical challenges. The development 
of a therapy from the proof-of-principle studies to the clinical trials necessary for government 
approval is very expensive. If the targeted disease is (extremely) rare, as is the case for 
many subtypes of IRD, the high costs of developing such treatment make it an unappealing 
prospect for pharmaceutical companies, since the limited number of patients are not 
sufficient to recover the big expenses from. Who will then develop these therapies if drug 
companies will not? Investigator-driven research may have problems of gaining sufficient 
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amounts of funding to perform these studies, since the expenses of investigator-driven 
research come from subsidies provided by the government or patient organizations, and 
yet, the therapy trials for more frequent forms of IRD will also gain more attention of these 
organizations since more patients benefit from such a therapy. International collaborations 
may collect sufficient funding to pay for trials on therapies for IRDs, but may counteract in 
raising costs and slowing down research proceedings. The concerns on research budget 
are less problematic for non-gene-specific therapies like stem cell transplantation and retinal 
implants, because they have a far broader patient population and therefore receive more 
interest of the pharmaceutical industry.
To make research on drugs for orphan diseases more attractive for investors, governmental 
agencies have been created in the European Union, United States and other countries. 
These orphan drug legislations offer tax benefits, fast drug approval by health authorities, 
and longer patents that guarantee extended exclusivity in the market.131 By these actions, 
several drugs for orphan diseases have been developed in the last decade. However, drug 
costs are generally high since the company’s intent to earn back the costs of research, 
development, regulatory and government drug coverage approval, and patients with serious 
medical conditions are willing to pay high prices to receive treatment. The limited number 
of patients and the lack of competition within the market further increase prices. Yet, the 
high prices of genetic therapy may only be manageable by the wealthy if the costs have 
to be covered by the patients themselves, which is morally unacceptable. All patients have 
an expectation of treatment whether their condition is common or rare. Fortunately, orphan 
drugs are usually covered in health insurances, but in this way the general population is 
burdened with the high expenses of few individuals. Ideally, the pharmaceutical industry 
is part of the solution allowing access to orphan drugs. Some companies do not pass the 
developmental costs in the drug’s price since they consider these costs as their research 
effort and contribution to a greater good.
The high expenses of these drugs increase the importance of detailed selection of 
patients amenable for treatment. A diverse population may qualify for a specific therapy, 
even in gene-specific therapies. Gene therapy, for example, can be beneficial in patients 
in early disease stages as well as patients in advanced disease stages with some spared 
visual function, like in some forms of RP that have profound constriction of the visual field but 
intact visual acuity in advanced disease. Individual assessment of the expected long-term 
clinical benefits will be necessary. An agency representing ophthalmologists, geneticists and 
ethicists may be necessary for the development of guidelines on the use of these expensive 
treatments for IRDs, although the (inter) national ophthalmic bodies, such as the European 
Society of Ophthalmology and the American Academy of Ophthalmology, will likely play a 
role in this as well.
Since genetic therapies (neuroprotective enhancement and optogenetics excluded) aim at 
treating the specific genetic defect, these approaches may – apart from therapeutic treatment 
– also be used as preventive measures when patients are treated before retinal degeneration 
occurs. Early detection of genetic mutations is in this case vital. Individuals from families with 
IRD patients can be genetically screened to detect patients that may develop retinal disease, 
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which than could be treated preventively. However, many IRD cases are isolated, like 46% 
of RP cases.132 To identify the isolated cases, genetic testing could be added to the neonatal 
heel prick screening (Guthrie test) or performed during prenatal screening (in case of LCA). 
Yet, genetic tests are not included in the Guthrie test up to now because of ethical concerns,133 
and require a huge sequencing capacity and are expensive. Moreover, if the genetic test 
identifies causative mutations for retinal disease, what treatment window should be used? 
Obviously, the onset of the disease is the main indication for the moment of treatment, and if 
disease starts at the age of 30, treatment may be postponed until early adulthood although 
the onset often is variable and difficult to predict. However, if disease initiates during infancy 
treatment should be administered within months after birth. Yet, safety and effectiveness of 
treatment at such age have to be determined, as well as the effects it may have on retinal/
vision development. And in patients that are born with severe dystrophic retinas, like some 
LCA patients, administration of gene therapy in the first months of life will even be too late, 
and intrauterine treatment would be necessary. Yet, both ethical and practical dilemmas on 
intrauterine gene therapy are numerous, and probably not easy to overcome. Altogether, 
preventive measures using gene therapy approaches may be possible in families with IRD 
patients, but probably will take long before prevention will be possible on population basis.
Conclusion
We experience an era of changing perspectives within the field of IRDs. In the coming years, 
the molecular diagnostics for IRDs will be expanded and we will be able to identify the genetic 
defect in the majority of IRD patients. However, much knowledge has to be gained on the other 
factors (genotype, epigenetics, nutritional status) involved in the retinal phenotype, which may 
lead to strong genotype-phenotype correlations. In the field of therapeutics developments 
generally go slower, although they proceed steadily. The first gene augmentation therapy 
for RPE65 defects is in the final phase of governmental approval and probably will become 
commercially available in the coming years. This stimulates research on gene therapies for 
IRDs due to defects in other genes. Some aspects of clinical research, such as ethical review 
board approval, may proceed faster, but it will still take long before more therapies will be 
available since each form of retinal dystrophy requires its own approach. Further research on 
the various therapeutic approaches is essential, since none of the therapies has shown to be 
capable of stopping disease or reclaim full visual function yet, and combinational therapies 
may be the ‘next-generation’ therapeutic approach for retinal dystrophies.
298  |  Chapter 12
References
1. Rohrschneider K, Bultmann S, Springer C. Use of fundus perimetry (microperimetry) to quantify 
macular sensitivity. Prog Retin Eye Res. 2008 Sep;27(5):536-48.
2. Delori FC, Dorey CK, Staurenghi G, Arend O, Goger DG, Weiter JJ. In vivo fluorescence of the 
ocular fundus exhibits retinal pigment epithelium lipofuscin characteristics. Invest Ophthalmol Vis 
Sci. 1995 Mar;36(3):718-29.
3. Kiernan DF, Mieler WF, Hariprasad SM. Spectral-domain optical coherence tomography: 
a comparison of modern high-resolution retinal imaging systems. Am J Ophthalmol. 2010 
Jan;149(1):18-31.
4. Triolo G, Pierro L, Parodi MB, et al. Spectral domain optical coherence tomography findings in 
patients with retinitis pigmentosa. Ophthalmic Res. 2013;50(3):160-4.
5. Drexler W, Fujimoto JG. State-of-the-art retinal optical coherence tomography. Prog Retin Eye 
Res. 2008 Jan;27(1):45-88.
6. Jacob J, Paques M, Krivosic V, et al. Meaning of visualizing retinal cone mosaic on adaptive 
optics images. Am J Ophthalmol. 2015 Jan;159(1):118-23 e1.
7. Drexler W. Cellular and functional optical coherence tomography of the human retina: the Cogan 
lecture. Invest Ophthalmol Vis Sci. 2007 Dec;48(12):5339-51.
8. Khanna H, Davis EE, Murga-Zamalloa CA, et al. A common allele in RPGRIP1L is a modifier of 
retinal degeneration in ciliopathies. Nat Genet. 2009 Jun;41(6):739-45.
9. Ebermann I, Phillips JB, Liebau MC, et al. PDZD7 is a modifier of retinal disease and a contributor 
to digenic Usher syndrome. J Clin Invest. 2010 Jun;120(6):1812-23.
10. Sanchez-Alcudia R, Corton M, Avila-Fernandez A, et al. Contribution of mutation load to the 
intrafamilial genetic heterogeneity in a large cohort of spanish retinal dystrophies families. Invest 
Ophthalmol Vis Sci. 2014;55(11):7562-71.
11. Venturini G, Rose AM, Shah AZ, Bhattacharya SS, Rivolta C. CNOT3 is a modifier of PRPF31 
mutations in retinitis pigmentosa with incomplete penetrance. PLoS Genet. 2012;8(11):e1003040.
12. Li M, Jia C, Kazmierkiewicz KL, et al. Comprehensive analysis of gene expression in human retina 
and supporting tissues. Hum Mol Genet. 2014 Aug 1;23(15):4001-14.
13. Nishiguchi KM, Rivolta C. Genes associated with retinitis pigmentosa and allied diseases are 
frequently mutated in the general population. PLoS One. 2012;7(7):e41902.
14. Aleman TS, Soumittra N, Cideciyan AV, et al. CERKL mutations cause an autosomal recessive 
cone-rod dystrophy with inner retinopathy. Invest Ophthalmol Vis Sci. 2009 Dec;50(12):5944-54.
15. Avila-Fernandez A, Riveiro-Alvarez R, Vallespin E, et al. CERKL mutations and associated 
phenotypes in seven Spanish families with autosomal recessive retinitis pigmentosa. Invest 
Ophthalmol Vis Sci. 2008 Jun;49(6):2709-13.
16. Tuson M, Marfany G, Gonzalez-Duarte R. Mutation of CERKL, a novel human ceramide kinase 
gene, causes autosomal recessive retinitis pigmentosa (RP26). Am J Hum Genet. 2004 
Jan;74(1):128-38.
17. Mackay DS, Henderson RH, Sergouniotis PI, et al. Novel mutations in MERTK associated with 
childhood onset rod-cone dystrophy. Mol Vis. 2010;16:369-77.
18. Shahzadi A, Riazuddin SA, Ali S, et al. Nonsense mutation in MERTK causes autosomal recessive 
retinitis pigmentosa in a consanguineous Pakistani family. Br J Ophthalmol. 2010 Aug;94(8):1094-
9.
19. Ostergaard E, Duno M, Batbayli M, Vilhelmsen K, Rosenberg T. A novel MERTK deletion is a 
common founder mutation in the Faroe Islands and is responsible for a high proportion of retinitis 
pigmentosa cases. Mol Vis. 2011;17:1485-92.
20. Ksantini M, Lafont E, Bocquet B, Meunier I, Hamel CP. Homozygous mutation in MERTK causes 
severe autosomal recessive retinitis pigmentosa. Eur J Ophthalmol. 2012 Jul-Aug;22(4):647-53.
21. Sohocki MM, Sullivan LS, Mintz-Hittner HA, et al. A range of clinical phenotypes associated 
with mutations in CRX, a photoreceptor transcription-factor gene. Am J Hum Genet. 1998 
Nov;63(5):1307-15.
22. Michaelides M, Gaillard MC, Escher P, et al. The PROM1 mutation p.R373C causes an autosomal 
dominant bull’s eye maculopathy associated with rod, rod-cone, and macular dystrophy. Invest 
Ophthalmol Vis Sci. 2010 Sep;51(9):4771-80.
23. Pras E, Abu A, Rotenstreich Y, et al. Cone-rod dystrophy and a frameshift mutation in the PROM1 
gene. Mol Vis. 2009;15:1709-16.
General discussion  |  299
12
24. Zhang Q, Zulfiqar F, Xiao X, et al. Severe retinitis pigmentosa mapped to 4p15 and associated 
with a novel mutation in the PROM1 gene. Hum Genet. 2007 Nov;122(3-4):293-9.
25. Hildebrandt F, Benzing T, Katsanis N. Ciliopathies. N Engl J Med. 2011 Apr 21;364(16):1533-43.
26. Mockel A, Perdomo Y, Stutzmann F, Letsch J, Marion V, Dollfus H. Retinal dystrophy in Bardet-
Biedl syndrome and related syndromic ciliopathies. Prog Retin Eye Res. 2011 Jul;30(4):258-74.
27. Estrada-Cuzcano A, Koenekoop RK, Senechal A, et al. BBS1 mutations in a wide spectrum of 
phenotypes ranging from nonsyndromic retinitis pigmentosa to Bardet-Biedl syndrome. Arch 
Ophthalmol. 2012 Nov;130(11):1425-32.
28. Bernal S, Ayuso C, Antinolo G, et al. Mutations in USH2A in Spanish patients with autosomal 
recessive retinitis pigmentosa: high prevalence and phenotypic variation. J Med Genet. 2003 
Jan;40(1):e8.
29. McGee TL, Seyedahmadi BJ, Sweeney MO, Dryja TP, Berson EL. Novel mutations in the long 
isoform of the USH2A gene in patients with Usher syndrome type II or non-syndromic retinitis 
pigmentosa. J Med Genet. 2010 Jul;47(7):499-506.
30. Rivolta C, Sweklo EA, Berson EL, Dryja TP. Missense mutation in the USH2A gene: association 
with recessive retinitis pigmentosa without hearing loss. Am J Hum Genet. 2000 Jun;66(6):1975-
8.
31. Seyedahmadi BJ, Rivolta C, Keene JA, Berson EL, Dryja TP. Comprehensive screening of the 
USH2A gene in Usher syndrome type II and non-syndromic recessive retinitis pigmentosa. Exp 
Eye Res. 2004 Aug;79(2):167-73.
32. Moore A, Escudier E, Roger G, et al. RPGR is mutated in patients with a complex X linked 
phenotype combining primary ciliary dyskinesia and retinitis pigmentosa. J Med Genet. 2006 
Apr;43(4):326-33.
33. Zito I, Downes SM, Patel RJ, et al. RPGR mutation associated with retinitis pigmentosa, impaired 
hearing, and sinorespiratory infections. J Med Genet. 2003 Aug;40(8):609-15.
34. Fishman GA, Stone EM, Grover S, Derlacki DJ, Haines HL, Hockey RR. Variation of clinical 
expression in patients with Stargardt dystrophy and sequence variations in the ABCR gene. Arch 
Ophthal. 1999 Apr;117(4):504-10.
35. Lois N, Holder GE, Bunce C, Fitzke FW, Bird AC. Phenotypic subtypes of Stargardt macular 
dystrophy-fundus flavimaculatus. Arch Ophthal. 2001 Mar;119(3):359-69.
36. Berson EL, Rosner B, Sandberg MA, et al. A randomized trial of vitamin A and vitamin E 
supplementation for retinitis pigmentosa. Arch Ophthal. 1993 Jun;111(6):761-72.
37. Berson EL. Treatment of retinitis pigmentosa with vitamin A. Digit J Ophthalmology. 1998;4(7):1-4.
38. Berson EL, Rosner B, Sandberg MA, et al. Vitamin A supplementation for retinitis pigmentosa. 
Arch Ophthal. 1993 Nov;111(11):1456-9.
39. Berson EL, Rosner B, Sandberg MA, Weigel-DiFranco C, Willett WC. omega-3 intake and 
visual  acuity in patients with retinitis pigmentosa receiving vitamin A. Arch Ophthal. 2012 
Jun;130(6):707-11.
40. Rotenstreich Y, Belkin M, Sadetzki S, et al. Treatment with 9-cis beta-carotene-rich powder in 
patients with retinitis pigmentosa: a randomized crossover trial. JAMA ophthalmology. 2013 
Aug;131(8):985-92.
41. Rayapudi S, Schwartz SG, Wang X, Chavis P. Vitamin A and fish oils for retinitis pigmentosa. 
Cochrane Database Syst Rev. 2013;12:CD008428.
42. Koenekoop RK, Sui R, Sallum J, et al. Oral 9-cis retinoid for childhood blindness due to Leber 
congenital amaurosis caused by RPE65 or LRAT mutations: an open-label phase 1b trial. Lancet. 
2014 Oct 25;384(9953):1513-20.
43. Van Hooser JP, Aleman TS, He YG, et al. Rapid restoration of visual pigment and function with 
oral retinoid in a mouse model of childhood blindness. Proc Natl Acad Sci U S A. 2000 Jul 
18;97(15):8623-8.
44. Van Hooser JP, Liang Y, Maeda T, et al. Recovery of visual functions in a mouse model of Leber 
congenital amaurosis. J Biol Chem. 2002 May 24;277(21):19173-82.
45. Yasuda S, Liang MH, Marinova Z, Yahyavi A, Chuang DM. The mood stabilizers lithium and 
valproate selectively activate the promoter IV of brain-derived neurotrophic factor in neurons. Mol 
Psychiatry. 2009 Jan;14(1):51-9.
46. Suuronen T, Nuutinen T, Ryhanen T, Kaarniranta K, Salminen A. Epigenetic regulation of clusterin/
apolipoprotein J expression in retinal pigment epithelial cells. Biochem Biophys Res Commun. 
2007 Jun 1;357(2):397-401.
300  |  Chapter 12
47. Kim HJ, Rowe M, Ren M, Hong JS, Chen PS, Chuang DM. Histone deacetylase inhibitors exhibit 
anti-inflammatory and neuroprotective effects in a rat permanent ischemic model of stroke: 
multiple mechanisms of action. J Pharmacol Exp Ther. 2007 Jun;321(3):892-901.
48. Chen PS, Wang CC, Bortner CD, et al. Valproic acid and other histone deacetylase inhibitors 
induce microglial apoptosis and attenuate lipopolysaccharide-induced dopaminergic 
neurotoxicity. Neuroscience. 2007 Oct 12;149(1):203-12.
49. Dragunow M, Greenwood JM, Cameron RE, et al. Valproic acid induces caspase 3-mediated 
apoptosis in microglial cells. Neuroscience. 2006 Jul 21;140(4):1149-56.
50. Gottlicher M, Minucci S, Zhu P, et al. Valproic acid defines a novel class of HDAC inhibitors 
inducing differentiation of transformed cells. EMBO J. 2001 Dec 17;20(24):6969-78.
51. Clemson CM, Tzekov R, Krebs M, Checchi JM, Bigelow C, Kaushal S. Therapeutic potential of 
valproic acid for retinitis pigmentosa. Br J Ophthalmol. 2011 Jan;95(1):89-93.
52. Sandberg MA, Rosner B, Weigel-DiFranco C, Berson EL. Lack of scientific rationale for use of 
valproic acid for retinitis pigmentosa. Br J Ophthalmol. 2011 May;95(5):744.
53. van Schooneveld MJ, van den Born LI, van Genderen M, Bollemeijer JG. The conclusions of 
Clemson et al concerning valproic acid are premature. Br J Ophthalmol. 2011 Jan;95(1):153; 
author reply -4.
54. Kumar A, Midha N, Gogia V, Gupta S, Sehra S, Chohan A. Efficacy of oral valproic acid in patients 
with retinitis pigmentosa. J Ocul Pharmacol Ther. 2014 Sep;30(7):580-6.
55. Shanmugam PM, Minija CK, Ramanjulu R, Tekwani P, Saxena M. Effect of short-term oral 
valproic Acid on vision and visual field in retinitis pigmentosa. Ophthalmology and therapy. 2012 
Dec;1(1):6.
56. Sisk RA. Valproic acid treatment may be harmful in non-dominant forms of retinitis pigmentosa. 
Br J Ophthalmol. 2012 Aug;96(8):1154-5.
57. Bhalla S, Joshi D, Bhullar S, Kasuga D, Park Y, Kay CN. Long-term follow-up for efficacy and safety 
of treatment of retinitis pigmentosa with valproic acid. Br J Ophthalmol. 2013 Jul;97(7):895-9.
58. Mitton KP, Guzman AE, Deshpande M, et al. Different effects of valproic acid on photoreceptor 
loss in Rd1 and Rd10 retinal degeneration mice. Mol Vis. 2014;20:1527-44.
59. Mancil RM, Mancil GL, King E, et al. Improving nighttime mobility in persons with night blindness 
caused by retinitis pigmentosa: A comparison of two low-vision mobility devices. J Rehabil Res 
Dev. 2005 Jul-Aug;42(4):471-86.
60. Hartong DT, Jorritsma FF, Neve JJ, Melis-Dankers BJ, Kooijman AC. Improved mobility and 
independence of night-blind people using night-vision goggles. Invest Ophthalmol Vis Sci. 2004 
Jun;45(6):1725-31.
61. Berson EL, Rabin AR, Mehaffey L, 3rd. Advances in night vision technology. A pocketscope for 
patients with retinitis pigmentosa. Arch Ophthal. 1973 Dec;90(6):427-31.
62. Pruett RC. Retinitis pigmentosa: clinical observations and correlations. Trans Am Ophthalmol 
Soc. 1983;81:693-735.
63. Fishman GA, Anderson RJ, Lourenco P. Prevalence of posterior subcapsular lens opacities in 
patients with retinitis pigmentosa. Br J Ophthalmol. 1985 Apr;69(4):263-6.
64. Heckenlively J. The frequency of posterior subcapsular cataract in the hereditary retinal 
degenerations. Am J Ophthalmol. 1982 Jun;93(6):733-8.
65. Berson EL, Rosner B, Simonoff E. Risk factors for genetic typing and detection in retinitis 
pigmentosa. Am J Ophthalmol. 1980 Jun;89(6):763-75.
66. Hagiwara A, Yamamoto S, Ogata K, et al. Macular abnormalities in patients with retinitis 
pigmentosa: prevalence on OCT examination and outcomes of vitreoretinal surgery. Acta 
Ophthalmol. 2011 Mar;89(2):e122-5.
67. Takezawa M, Tetsuka S, Kakehashi A. Tangential vitreous traction: a possible mechanism of 
development of cystoid macular edema in retinitis pigmentosa. Clin Ophthalmol. 2011;5:245-8.
68. Molday RS. Focus on molecules: retinoschisin (RS1). Exp Eye Res. 2007 Feb;84(2):227-8.
69. Luna G, Kjellstrom S, Verardo MR, et al. The effects of transient retinal detachment on cavity size 
and glial and neural remodeling in a mouse model of X-linked retinoschisis. Invest Ophthalmol Vis 
Sci. 2009 Aug;50(8):3977-84.
70. Larsen M, Engler CB, Haim M, Lund-Andersen H. Blood-retina barrier permeability is independent 
of trace substance lipid solubility in retinitis pigmentosa and in the healthy eye. Int Ophthalmol. 
1997;21(4):229-34.
General discussion  |  301
12
71. Gass JDM. Stereoscopic atlas of macular diseases : diagnosis and treatment. 4th ed. St. Louis ;: 
Mosby; 1997.
72. Fishman GA, Cunha-Vaz J, Salzano T. Vitreous fluorophotometry in patients with retinitis 
pigmentosa. Arch Ophthal. 1981 Jul;99(7):1202-7.
73. Mallick KS, Zeimer RC, Fishman GA, Blair NP, Anderson RJ. Transport of fluorescein in the ocular 
posterior segment in retinitis pigmentosa. Arch Ophthal. 1984 May;102(5):691-6.
74. Salvatore S, Fishman GA, Genead MA. Treatment of cystic macular lesions in hereditary retinal 
dystrophies. Surv Ophthalmol. 2013 Nov-Dec;58(6):560-84.
75. Apushkin MA, Fishman GA, Janowicz MJ. Monitoring cystoid macular edema by optical coherence 
tomography in patients with retinitis pigmentosa. Ophthalmology. 2004 Oct;111(10):1899-904.
76. Cox SN, Hay E, Bird AC. Treatment of chronic macular edema with acetazolamide. Arch Ophthal. 
1988 Sep;106(9):1190-5.
77. Ozdemir H, Karacorlu M, Karacorlu S. Intravitreal triamcinolone acetonide for treatment of 
cystoid macular oedema in patients with retinitis pigmentosa. Acta Ophthalmol Scand. 2005 
Apr;83(2):248-51.
78. Scorolli L, Morara M, Meduri A, et al. Treatment of cystoid macular edema in retinitis pigmentosa 
with intravitreal triamcinolone. Arch Ophthal. 2007 Jun;125(6):759-64.
79. Sallum JM, Farah ME, Saraiva VS. Treatment of cystoid macular edema related to retinitis 
pigmentosa with intravitreal triamcinolone acetonide: case report. Adv Exp Med Biol. 2003;533:79-
81.
80. Saraiva VS, Sallum JM, Farah ME. Treatment of cystoid macular edema related to retinitis 
pigmentosa with intravitreal triamcinolone acetonide. Ophthalmic Surg Lasers Imaging. 2003 
Sep-Oct;34(5):398-400.
81. Minnella AM, Falsini B, Bamonte G, et al. Optical coherence tomography and focal 
electroretinogram evaluation of cystoid macular edema secondary to retinitis pigmentosa treated 
with intravitreal triamcinolone: case report. Eur J Ophthalmol. 2006 Nov-Dec;16(6):883-6.
82. Yuzbasioglu E, Artunay O, Rasier R, Sengul A, Bahcecioglu H. Intravitreal bevacizumab (Avastin) 
injection in retinitis pigmentosa. Curr Eye Res. 2009 Mar;34(3):231-7.
83. Querques G, Prascina F, Iaculli C, Noci ND. Intravitreal pegaptanib sodium (Macugen) for 
refractory cystoid macular edema in pericentral retinitis pigmentosa. Int Ophthalmol. 2009 
Apr;29(2):103-7.
84. Artunay O, Yuzbasioglu E, Rasier R, Sengul A, Bahcecioglu H. Intravitreal ranibizumab in the 
treatment of cystoid macular edema associated with retinitis pigmentosa. J Ocul Pharmacol Ther. 
2009 Dec;25(6):545-50.
85. Melo GB, Farah ME, Aggio FB. Intravitreal injection of bevacizumab for cystoid macular edema in 
retinitis pigmentosa. Acta Ophthalmol Scand. 2007 Jun;85(4):461-3.
86. Salom D, Diaz-Llopis M, Garcia-Delpech S, et al. Intravitreal ranibizumab in the treatment of 
cystoid macular edema associated with retinitis pigmentosa. J Ocul Pharmacol Ther. 2010 
Oct;26(5):531-2.
87. Dalkara D, Sahel JA. Gene therapy for inherited retinal degenerations. Comptes rendus biologies. 
2014 Mar;337(3):185-92.
88. Maguire AM, High KA, Auricchio A, et al. Age-dependent effects of RPE65 gene therapy for Leber’s 
congenital amaurosis: a phase 1 dose-escalation trial. Lancet. 2009 Nov 7;374(9701):1597-605.
89. Maguire AM, Simonelli F, Pierce EA, et al. Safety and efficacy of gene transfer for Leber’s 
congenital amaurosis. N Engl J Med. 2008 May 22;358(21):2240-8.
90. Jacobson SG, Cideciyan AV, Ratnakaram R, et al. Gene therapy for leber congenital amaurosis 
caused by RPE65 mutations: safety and efficacy in 15 children and adults followed up to 3 years. 
Arch Ophthal. 2012 Jan;130(1):9-24.
91. Liang FQ, Aleman TS, Dejneka NS, et al. Long-term protection of retinal structure but not function 
using RAAV.CNTF in animal models of retinitis pigmentosa. Mol Ther. 2001 Nov;4(5):461-72.
92. Okoye G, Zimmer J, Sung J, et al. Increased expression of brain-derived neurotrophic factor 
preserves retinal function and slows cell death from rhodopsin mutation or oxidative damage. J 
Neurosci. 2003 May 15;23(10):4164-72.
93. Buch PK, MacLaren RE, Duran Y, et al. In contrast to AAV-mediated Cntf expression, AAV-
mediated Gdnf expression enhances gene replacement therapy in rodent models of retinal 
degeneration. Mol Ther. 2006 Nov;14(5):700-9.
302  |  Chapter 12
94. Dalkara D, Kolstad KD, Guerin KI, et al. AAV mediated GDNF secretion from retinal glia slows 
down retinal degeneration in a rat model of retinitis pigmentosa. Mol Ther. 2011 Sep;19(9):1602-8.
95. McGee Sanftner LH, Abel H, Hauswirth WW, Flannery JG. Glial cell line derived neurotrophic 
factor delays photoreceptor degeneration in a transgenic rat model of retinitis pigmentosa. Mol 
Ther. 2001 Dec;4(6):622-9.
96. Chen J, Flannery JG, LaVail MM, Steinberg RH, Xu J, Simon MI. bcl-2 overexpression reduces 
apoptotic photoreceptor cell death in three different retinal degenerations. Proc Natl Acad Sci U 
S A. 1996 Jul 9;93(14):7042-7.
97. Leonard KC, Petrin D, Coupland SG, et al. XIAP protection of photoreceptors in animal models of 
retinitis pigmentosa. PLoS One. 2007;2(3):e314.
98. Shan H, Ji D, Barnard AR, et al. AAV-mediated gene transfer of human X-linked inhibitor of 
apoptosis protects against oxidative cell death in human RPE cells. Invest Ophthalmol Vis Sci. 
2011;52(13):9591-7.
99. Zadro-Lamoureux LA, Zacks DN, Baker AN, Zheng QD, Hauswirth WW, Tsilfidis C. XIAP effects 
on retinal detachment-induced photoreceptor apoptosis [corrected]. Invest Ophthalmol Vis Sci. 
2009 Mar;50(3):1448-53.
100. Leveillard T, Sahel JA. Rod-derived cone viability factor for treating blinding diseases: from clinic 
to redox signaling. Sci Transl Med. 2010 Apr 7;2(26):26ps16.
101. Zhang K, Hopkins JJ, Heier JS, et al. Ciliary neurotrophic factor delivered by encapsulated cell 
intraocular implants for treatment of geographic atrophy in age-related macular degeneration. 
Proc Natl Acad Sci U S A. 2011 Apr 12;108(15):6241-5.
102. Wilson RC, Doudna JA. Molecular mechanisms of RNA interference. Annu Rev Biophys. 
2013;42:217-39.
103. Kurreck J. Antisense and RNA interference approaches to target validation in pain research. Curr 
Opin Drug Discov Devel. 2004 Mar;7(2):179-87.
104. Dias N, Stein CA. Antisense oligonucleotides: basic concepts and mechanisms. Mol Cancer 
Ther. 2002 Mar;1(5):347-55.
105. Doherty EA, Doudna JA. Ribozyme structures and mechanisms. Annu Rev Biophys Biomol 
Struct. 2001;30:457-75.
106. Stenson PD, Mort M, Ball EV, et al. The Human Gene Mutation Database: 2008 update. Genome 
Med. 2009;1(1):13.
107. Bacchi N, Casarosa S, Denti MA. Splicing-correcting therapeutic approaches for retinal 
dystrophies: where endogenous gene regulation and specificity matter. Invest Ophthalmol Vis 
Sci. 2014 May;55(5):3285-94.
108. Collin RW, den Hollander AI, van der Velde-Visser SD, Bennicelli J, Bennett J, Cremers FP. 
Antisense Oligonucleotide (AON)-based Therapy for Leber Congenital Amaurosis Caused by a 
Frequent Mutation in CEP290. Molecular therapy Nucleic acids. 2012;1:e14.
109. Schmid F, Hiller T, Korner G, Glaus E, Berger W, Neidhardt J. A gene therapeutic approach to 
correct splice defects with modified U1 and U6 snRNPs. Hum Gene Ther. 2013 Jan;24(1):97-104.
110. Schmid F, Glaus E, Barthelmes D, et al. U1 snRNA-mediated gene therapeutic correction of 
splice defects caused by an exceptionally mild BBS mutation. Hum Mutat. 2011 Jul;32(7):815-24.
111. Glaus E, Schmid F, Da Costa R, Berger W, Neidhardt J. Gene therapeutic approach using 
mutation-adapted U1 snRNA to correct a RPGR splice defect in patient-derived cells. Mol Ther. 
2011 May;19(5):936-41.
112. Busskamp V, Picaud S, Sahel JA, Roska B. Optogenetic therapy for retinitis pigmentosa. Gene 
Ther. 2012 Feb;19(2):169-75.
113. Bi A, Cui J, Ma YP, et al. Ectopic expression of a microbial-type rhodopsin restores visual 
responses in mice with photoreceptor degeneration. Neuron. 2006 Apr 6;50(1):23-33.
114. Lagali PS, Balya D, Awatramani GB, et al. Light-activated channels targeted to ON bipolar cells 
restore visual function in retinal degeneration. Nat Neurosci. 2008 Jun;11(6):667-75.
115. Busskamp V, Duebel J, Balya D, et al. Genetic reactivation of cone photoreceptors restores visual 
responses in retinitis pigmentosa. Science (80- ). 2010 Jul 23;329(5990):413-7.
116. Cepko CL. Emerging gene therapies for retinal degenerations. J Neurosci. 2012 May 
9;32(19):6415-20.
117. Woodruff ML, Wang Z, Chung HY, Redmond TM, Fain GL, Lem J. Spontaneous activity of opsin 
apoprotein is a cause of Leber congenital amaurosis. Nat Genet. 2003 Oct;35(2):158-64.
General discussion  |  303
12
118. Ramsden CM, Powner MB, Carr AJ, Smart MJ, da Cruz L, Coffey PJ. Stem cells in retinal 
regeneration: past, present and future. Development. 2013 Jun;140(12):2576-85.
119. Seiler MJ, Aramant RB. Cell replacement and visual restoration by retinal sheet transplants. Prog 
Retin Eye Res. 2012 Nov;31(6):661-87.
120. Schwartz SD, Regillo CD, Lam BL, et al. Human embryonic stem cell-derived retinal pigment 
epithelium in patients with age-related macular degeneration and Stargardt’s macular dystrophy: 
follow-up of two open-label phase 1/2 studies. Lancet. 2014 Oct 15.
121. Schwartz SD, Hubschman JP, Heilwell G, et al. Embryonic stem cell trials for macular degeneration: 
a preliminary report. Lancet. 2012 Feb 25;379(9817):713-20.
122. Arango-Gonzalez B, Leitritz MA, Fischer D, Gerberding M, Paquet-Durand F, Ueffing M. [Current 
therapeutic approaches in inherited retinal degeneration: from genes to chip]. Klin Monbl 
Augenheilkd. 2014 Mar;231(3):222-31.
123. Zrenner E. Fighting blindness with microelectronics. Sci Transl Med. 2013 Nov 6;5(210):210ps16.
124. Zrenner E, Bartz-Schmidt KU, Benav H, et al. Subretinal electronic chips allow blind patients to 
read letters and combine them to words. Proc Biol Sci. 2011 May 22;278(1711):1489-97.
125. Danilov Y, Tyler M. Brainport: an alternative input to the brain. J Integr Neurosci. 2005 Dec;4(4):537-
50.
126. Chebat DR, Schneider FC, Kupers R, Ptito M. Navigation with a sensory substitution device in 
congenitally blind individuals. Neuroreport. 2011 May 11;22(7):342-7.
127. Chebat DR, Rainville C, Kupers R, Ptito M. Tactile-’visual’ acuity of the tongue in early blind 
individuals. Neuroreport. 2007 Dec 3;18(18):1901-4.
128. Sampaio E, Maris S, Bach-y-Rita P. Brain plasticity: ‘visual’ acuity of blind persons via the tongue. 
Brain Res. 2001 Jul 27;908(2):204-7.
129. Hauswirth WW, Aleman TS, Kaushal S, et al. Treatment of leber congenital amaurosis due to 
RPE65 mutations by ocular subretinal injection of adeno-associated virus gene vector: short-term 
results of a phase I trial. Hum Gene Ther. 2008 Oct;19(10):979-90.
130. Lok C. Curing blindness: Vision quest. Nat New Biol. 2014 Sep 11;513(7517):160-2.
131. Llinares J. A regulatory overview about rare diseases. Adv Exp Med Biol. 2010;686:193-207.
132. Bunker CH, Berson EL, Bromley WC, Hayes RP, Roderick TH. Prevalence of retinitis pigmentosa 
in Maine. Am J Ophthalmol. 1984;97(3):357-65.
133. Thomas C. The use and control of heel prick blood samples. Med Law. 2005 Jun;24(2):259-77.

Summary
Samenvatting 
306  |  Summary
Summary
Inherited retinal dystrophies (IRDs) are a group of rare generally monogenetic diseases that 
are genetically and clinically highly heterogeneous. Specific phenotypes within the IRD group 
can be caused by mutations in many genes, sometimes even more than 60 genes as is the 
case for retinitis pigmentosa (RP). On the other hand, many genes involved in inherited retinal 
disease can give rise to multiple phenotypes. In the last decade, the pathological pathways 
underlying these diseases started to unravel as numerous genotype-phenotype correlations 
have been described. However, because of the heterogeneity of IRDs there remain many 
unsolved questions. The aim of this thesis is to provide detailed clinical descriptions of some 
forms of IRDs, as well as describe correlations between the molecular genetic background 
and the phenotype. This may enable better counseling of patients and their families, and is 
vital in the follow-up of the therapeutic effect in clinical trials on IRD treatments.
Chapter 1 serves as a general introduction on retinal anatomy, the processes that lead to 
vision, assessment of the retinal function, and the basic principles of molecular genetics. 
Additionally, the general clinical and genetic principles of retinal dystrophies are addressed.
In chapter 2, we provided the first detailed clinical description in patients with RP caused 
by recessive mutations in IMPG2. In this international collaborative study, we included 17 RP 
patients with IMPG2 mutations that were clinically examined in detail, using extensive medical 
history taking, slit-lamp biomicroscopy, ophthalmoscopy, perimetry, electroretinography 
(ERG), optical coherence tomography (OCT), fundus autofluorescence (FAF) imaging, 
fundus photography, and color vision tests. These patients revealed the classic RP features 
including night blindness and visual field loss, as well as optic disc pallor, attenuated retinal 
vessels, bone spicules and generalized atrophy of the retina and choriocapillaris. Additionally, 
we observed macular abnormalities in all patients, ranging from subtle mottling of the 
macular pigment epithelium to macular chorioretinal atrophy. This macular involvement was 
accompanied by severe decrease in central vision. This, in combination with the concentric 
loss of visual field, leads to relatively early, yet severe, visual impairment in patients with 
IMPG2-associated RP.
Chapter 3 describes the clinical observations in RP patients with mutations in the MAK gene. 
In this evaluation, we also focused on the presence of extra-ocular symptoms, since MAK 
encodes a ciliary protein and therefore may give rise to syndromic disease. In this study, we 
included 11 patients from 5 international ophthalmic centers. The patients were examined in 
detail, and in addition a questionnaire to evaluate the presence of clinical syndromic features 
was used. We performed the University of Pennsylvania Smell Identification Test (UPSIT) in 
several patients to rule out subclinical olfactory disability, since MAK is expressed in murine 
olfactory neurons, and smell disabilities often go unnoticed. The analyses resulted that 
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nonsense and missense mutations in MAK cause a fairly classic RP in which visual acuity 
may be normal up to high age, although profound concentric visual field loss. No extra-ocular 
symptoms were noted, and the UPSIT results were within the age-corrected normal limits. 
In addition, we provided an overview of the ciliary genes that cause nonsyndromic retinal 
disease, which elaborates on the retinal and extra-ocular symptoms observed in disease 
caused by these genes.
Chapter 4 provides the clinical aspects of retinal disease caused by mutations in C8orf37. 
Eight patients – 4 diagnosed with RP and 4 with cone-rod dystrophy (CRD) – were examined 
with routine ophthalmic examination, kinetic perimetry, ERG, as well as multimodal imaging 
(OCT, FAF and fundus photography) and evaluation of extra-ocular symptoms. The RP 
patients showed the classic RP symptoms of night blindness and concentric visual field 
loss, as well as severe loss of visual acuity up to levels of light perception in an early disease 
stage. The CRD patients revealed a classic CRD that initiated with a decrease in visual 
acuity. Two of the CRD patients had a history of postaxial polydactyly, which indicates that 
mutations in C8orf37 may give rise to syndromic disease. The occurrence of extra-ocular 
features may imply that C8orf37 has a ciliary function. However, the exact function of C8orf37 
is not known, which makes genotype-phenotype correlations impossible.
In chapter 5, we evaluated the genetic findings and phenotypic characteristics of patients 
from three families with ABHD12 gene mutations. The ABHD12 mutations were located with 
whole exome sequencing (WES). The patients were clinically evaluated by ophthalmologists, 
neurologists and otologist, since mutations in ABHD12 have been associated with the 
polyneuropathy-hearing loss-ataxia-RP-early-onset cataract (PHARC) syndrome. We 
identified five new mutations, including the first missense mutations described in this gene. 
The patients of two families had symptoms that fit the PHARC syndrome, whereas one family 
did not have any neurologic disabilities or hearing loss. In this study, we could widen the 
clinical spectrum associated to ABHD12 mutations, which ranges from nonsyndromic RP to 
complete PHARC syndrome. However, a clear genotype-phenotype correlation could not be 
established.
Chapter 6 describes the molecular findings in a Dutch family with autosomal recessively 
inherited hearing loss due to pathologic mutations in USH1G, a gene known to be involved 
in Usher syndrome type I and atypical Usher syndrome. The members of this Dutch family 
revealed early-onset progressive hearing loss with a downsloping audiogram configuration. 
Extensive ophthalmic and vestibular examinations demonstrated no abnormalities that 
are usually associated with Usher syndrome type I. With these findings we expanded the 
phenotypic spectrum of mutations in USH1G.
In chapter 7, we evaluated the efficiency of commercially available arrayed primer extension 
(APEX) microarray chip for autosomal recessive RP. We included 250 probands suspected 
of autosomal recessive RP who were genetically analyzed with the APEX microarray. The 
mode of inheritance had to be autosomal recessive (including isolated cases) according 
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to the pedigree. The efficiency of this microarray chip with additional Sanger sequencing 
approach was determined by the percentage of patients that received a molecular diagnosis. 
The APEX microarray chip for autosomal recessive RP identified the molecular diagnosis in 
8.5% of the patients in our cohort; 15.2% after additional Sanger sequencing in patients 
in whom the microarray analysis identified heterozygous mutation. Hence, next generation 
sequencing (NGS) techniques – reported to reach diagnostic yields up to 40% - outperform 
the APEX microarray approach by far.
Chapter 8 provides the genetic and clinical findings in patients with early-onset Stargardt 
disease. In this retrospective study, we included 51 Stargardt patients with an age at onset 
of 10 years or lower. We observed a decline in visual acuity to levels of counting fingers in a 
median of 23 years. Initial fundus examination revealed no abnormalities in 10 patients, foveal 
RPE alterations in 9 patients, and foveal atrophy whether or not accompanied by yellow-white 
fundus flecks in 22 patients. In 14 out of 50 patients, foveal atrophy occurred before the 
typical yellow-white fundus flecks appeared, which complicates early correct diagnosing. 
We identified ABCA4 mutations in all patients, but did not find clear mutational associations 
with the early onset and severe retinal degeneration observed in this cohort. Yet, early-onset 
Stargardt lies at the severe end of the spectrum of ABCA4-associated retinal phenotypes.
Chapter 9 describes the genetic and clinical characteristics of patients with Stargardt disease 
that reveal foveal sparing. We defined foveal sparing as retinal atrophy that surrounds the 
fovea by at least 180° and does not include the fovea. From our database, we identified 13 
unrelated patients that revealed foveal sparing in one or both eye (17 eyes in total). Foveal 
sparing eyes revealed a visual acuity of 20/40 or better, and 41% reached visual acuity levels 
of 20/25 or higher. However, eventually the fovea degenerates as the parafoveal atrophy 
expands, which results in a decline in visual acuity to 20/200 to counting fingers. Genetic 
analysis revealed at least one ABCA4 mutations in each patient, although no correlation with 
a specific mutation could be identified. The anatomy, metabolism, and biochemistry of the 
retina, as well as genetic variations in genes other than ABCA4, can influence the etiology of 
foveal sparing. Identifying these fovea-protecting factors will facilitate the future development 
of strategies designed to treat Stargardt disease. Foveal sparing occurs mainly in patients 
with late-onset Stargardt disease and represents the milder end of the clinical spectrum 
caused by ABCA4 mutations.
In chapter 10, we evaluated the clinical characteristics of autosomal dominant cystoids 
macular dystrophy (DCMD). We collected the long-term clinical data of 97 patients with 
DCMD, including multimodal imaging techniques (fluorescein angiography, FAF and OCT) 
and electrophysiologic examinations (ERG as well as electrooculography). We obtained 
blood samples from all patients for haplotype analysis. DCMD patients initially reveal 
macular cystoids fluid collections (CFCs) that eventually lead to chorioretinal atrophy and 
hyperpigmented deposits in the posterior pole. Most patients (92%) were (highly) hyperopic. We 
recognized 3 grades of DCMD, based on the fundoscopic, imaging and electrophysiological 
characteristics. In grade 1, patients were under the age of 20 and presented with CFCs with 
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fine folding of the internal limiting membrane and mild pigment changes. In grade 2, the CFCs 
tended to decrease in size, and moderate macular chorioretinal atrophy developed. In grade 
3, patients were generally over the age of 50 and showed profound chorioretinal atrophy, as 
well as coarse hyperpigmented deposits in the posterior pole. All DCMD patients shared the 
disease haplotype at the DCMD locus at 7p15.3, but the involved gene is currently unknown.
Chapter 11 describes the RD5000 database that we developed to register all ophthalmological 
and selected genetic data of patients with inherited retinal dystrophies in the Netherlands. In 
order to perform meaningful genotype-phenotype analyses for rare genetic conditions, it is 
necessary to collect data from sizable populations. Although standardized functional tests 
are widely used, ophthalmologic data are usually stored in local databases and not in multi-
center databases that are linked with other centers. Eleven Dutch ophthalmogenetic centers 
are connected to the RD5000 database. Authorization rights for the management, data entry 
and data sharing have been set-up, rendering this database into a user-friendly, secure and 
widely used repository that will facilitate future studies into molecular genetics and therapies 
for IRDs. RD5000db has the potential to grow into a European standard for the registration 
of data from IRDs.
Chapter 12 discusses the studies described in this thesis and their implications for 
researchers, physicians and patients. The general discussion attempts to shed a light on 
the clinical heterogeneity observed in inherited retinal dystrophies by discussing possible 
genetic modifying factors. This chapter additionally provides an overview of the therapeutic 
approaches that are currently evaluated, as well as the expected potential of these treatments 
and ethical complications.
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Erfelijke retinadystrofieën omvat een groep van zeldzame, veelal monogenetische 
ziektebeelden die een grote genetische en klinische heterogeniteit laten zien. Specifieke 
fenotypes, zoals bijvoorbeeld retinitis pigmentosa (RP), kunnen veroorzaakt worden door 
mutaties in meer dan 60 genen. Daarentegen kan het overgrote deel van de genen betrokken 
in retinadystrofieën verschillende klinische ziektebeelden veroorzaken. In de laatste decennia 
zijn verscheidene genotype-fenotype correlaties beschreven, die inzicht in de pathologische 
processen onderliggend aan deze ziekten geven. Echter de grote heterogeniteit laat veel 
vragen onbeantwoord. Dit proefschrift heeft als doel om een gedetailleerde klinische 
beschrijving van een aantal specifieke vormen van retinadystrofieën te geven, en daarbij 
de correlaties tussen de genetische achtergrond en de klinische kenmerken te beschrijven. 
Dit kan tot een betere (genetische) voorlichting aan patiënten en hun families leiden, en is 
essentieel voor het beoordelen van het effect van interventies in klinische studies.
Hoofdstuk 1 geeft een algemene introductie in de retinale anatomie, de processen die tot 
zicht leiden, beoordeling van de retinale functie, evenals de basisprincipes van de genetica. 
Tevens worden de klinische en genetische achtergrond van de retinadystrofieën beschreven 
in dit proefschrift besproken.
In hoofdstuk 2 geven wij een gedetailleerde klinische beschrijving van patiënten met 
RP op basis van mutaties in het IMPG2 gen. In deze internationale studie hebben wij 
17 patiënten met IMPG2-geassocieerde RP geïncludeerd die klinisch onderzocht zijn met 
uitgebreide anamnese, spleetlamp onderzoek, fundoscopie, perimetrie, elektroretinografie 
(ERG), optische coherentie tomografie (OCT), fundus autofluorescentie (FAF), fundus 
fotografie, en kleurenzien testen. De patiënten vertoonde de klassieke RP kenmerken van 
nachtblindheid, perifeer gezichtsveldverlies, een wasachtige bleke papil, vernauwde retinale 
bloedvaten, intraretinale beenbalkpigmentatie en gegeneraliseerde atrofie van de retina en 
choriocapillaris. Daarnaast vertoonde alle patiënten maculaire afwijkingen, welke varieerde 
van subtiele pigmentalteraties tot chorioretinale atrofie. Deze betrokkenheid van de achterpool 
ging gepaard met ernstig visusverlies, wat in combinatie met de perifere gezichtsvelduitval 
tot een ernstige, relatief vroeg optredende visuele beperking veroorzaakt in patiënten met 
RP door mutaties in IMPG2.
Hoofdstuk 3 beschrijft de klinische observaties in RP patiënten met mutaties in het MAK gen. 
Hierbij hebben wij ons tevens gericht op de aanwezigheid van extra-oculaire symptomen, 
aangezien MAK een ciliair proteïne codeert en daardoor tot een syndroom zou kunnen 
leiden. In deze studie konden wij 11 patiënten uit 5 internationale centra includeren. De 
patiënten werden klinisch gedetailleerd onderzocht, waarbij eveneens een vragenlijst werd 
afgenomen die de aanwezigheid van syndromale kenmerken evalueerde. Aanvullend hierop 
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werd in enkele patiënten een University of Pennsylvania Smell Identification Test (UPSIT) 
afgenomen ter uitsluiting van subklinische beperkingen van de reukzin, aangezien MAK 
tot uiting komt in de olfactoire neuronen in de muis, en beperkingen van de reukzin vaak 
niet opgemerkt worden. De analyses toonde dat nonsense en missense mutaties in MAK 
tot een relatief klassieke vorm van RP leiden met visusbehoud tot op hoge leeftijd, hoewel 
het gezichtsveld een forse concentrische beperking laat zien. Er waren geen syndromale 
symptomen aanwezig, en de UPSIT resultaten vielen binnen de leeftijdsgecorrigeerde 
normaalwaarden. Daarnaast geeft dit hoofdstuk een overzicht van de ciliaire genen die niet-
syndromale retinadystrofieën veroorzaken, waarbij de nadruk ligt op de retinale en extra-
oculaire symptomen in deze specifieke retinadystrofieën.
Hoofdstuk 4 biedt de klinische aspecten van C8orf37-geassocieerde retinadystrofie. 
Acht patiënten – vier met RP en vier met kegel-staaf dystrofie (CRD) – werden onderzocht 
met routine oogonderzoek, gezichtsveldonderzoek, ERG, OCT, FAF, fundus fotografie en 
evaluatie van extra-oculaire kenmerken. De RP patiënten lieten een klassiek RP beeld zien 
met nachtblindheid en concentrische gezichtsveldbeperking, met daarbij een ernstige 
visusdaling tot lichtperceptie niveau relatief vroeg in het ziekteproces. De CRD patiënten 
toonde een klassieke CRD die begon met een visusdaling en vervolgens progressie tot in 
een centraal scotoom vertoonde. Twee van de CRD patiënten hadden een voorgeschiedenis 
met postaxiale polydactylie. Dit zou kunnen wijzen op syndromale ziekte veroorzaakt door 
mutaties in het C8orf37 gen en dat C8orf37 een ciliaire functie heeft. De exacte functie 
van C8orf37 is daarentegen nog onbekend en dit maakt genotype-fenotype correlaties 
onmogelijk.
In hoofdstuk 5 evalueren we de genetische en klinische bevindingen van patiënten uit 
drie families met ABHD12 mutaties. De mutaties zijn met ‘ whole exome sequencing’ (WES) 
aangetoond. Mutaties in ABHD12 zijn geassocieerd met het polyneuropathie-gehoorverlies-
ataxie-RP-cataract (PHARC) syndroom en daarom werden de patiënten onderzocht door 
een oogarts, neuroloog en keel-neus-oorarts. Wij vonden vijf nieuwe mutaties waaronder 
de eerste missense mutatie beschreven in ABHD12. In twee families lieten de patiënten 
symptomen zien passend bij het PHARC syndroom, terwijl in de andere familie geen 
neurologische afwijkingen en gehoorverlies voorkwam. In deze studie konden we het 
klinische spectrum dat geassocieerd is met ABHD12 mutaties verbreden. Dit spectrum reikt 
van niet-syndromale RP tot aan een volledig PHARC syndroom. Desondanks kon er geen 
duidelijk genotype-fenotype correlatie gevonden worden.
Hoofdstuk 6 beschrijft de moleculaire bevindingen in een Nederlandse familie met 
autosomaal recessieve gehoorverlies door pathologische mutaties in het USH1G gen. Dit 
gen is eerder geassocieerd met type 1 Usher syndroom en een atypische vorm van het 
Usher syndroom. De patiënten uit deze familie lieten een progressief gehoorverlies zien 
met een zogenaamd aflopend verloop op het audiogram. Uitgebreid oogheelkundig en 
vestibulair onderzoeken lieten geen afwijkingen zien, welke bij het type 1 Usher syndroom 
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aanwezig zouden zijn. Met deze bevindingen is het klinische spectrum geassocieerd met 
mutaties in USH1G uitgebreid.
In hoofdstuk 7 onderzochten wij de efficiëntie van de ‘arrayed primer extension’ (APEX) 
microarray chip voor autosomaal recessieve RP. In deze studie werden 250 probanden 
geïncludeerd waarin op klinische gronden de diagnose autosomaal recessieve RP was gesteld 
en genetische analyse met behulp van de APEX microarray was verricht. Alleen probanden 
met een autosomaal recessief overervingspatroon in de stamboom (inclusief geïsoleerde 
casus) werden geïncludeerd. De efficiëntie van deze microarray chip met aanvullende 
Sanger sequencing werd bepaald door het percentage patiënten waarin een genetisch 
bevestiging van de klinische diagnose gevonden werd. De APEX microarray chip voor 
autosomaal recessieve RP kon een genetische bevestiging geven in 8.5% van de patiënten; 
dit percentage lag op 15.2% wanneer aanvullend Sanger sequencing werd gebruikt in de 
gevallen dat de microarray een heterozygote mutatie had gevonden. Geconcludeerd dient te 
worden dat de APEX microarray analyse voor autosomaal recessieve RP slechter presteren 
dan de huidige ‘next generation sequencing’ (NGS) technieken – waarvan efficiënties tot 
40% zijn gerapporteerd.
Hoofdstuk 8 beschrijft de klinische en genetische bevindingen in patiënten met de ziekte 
van Stargardt waarin de ziekte zich uiterlijk op een leeftijd van 10 jaar openbaart. In deze 
retrospectieve studie konden wij 51 Stargardt patiënten includeren. De visus in deze 
patiënten daalde in een tijdsbestek van 23 jaar tot het niveau van vingers tellen. Bij het eerste 
oogheelkundige onderzoek werden in 10 patiënten geen fundus afwijkingen gevonden. 
Negen patiënten toonde retinaal pigment epitheel (RPE) alteraties en 22 patiënten foveale 
atrofie al dan niet gecombineerd met de typische geel-witte fundus vlekjes. In 14 patiënten 
was de foveale atrofie eerder aanwezig dan de geel-witte fundus vlekjes, wat vroege 
diagnostisering bemoeilijkt. Alle patiënten droegen mutaties in het ABCA4 gen, maar er 
konden geen duidelijke associaties tussen specifieke mutaties en het klinische beeld 
gevonden worden. De ‘early-onset’ ziekte van Stargardt behoort tot de ernstigere ziekten 
veroorzaakt door ABCA4 mutaties.
In hoofdstuk 9 beschrijft de genetische en klinische kenmerken van Stargardt patiënten met 
‘foveal sparing’. Wij definiëren foveal sparing als retinale atrofie die minimaal 180° rondom 
de fovea ligt en niet de fovea betrekt. Vanuit onze database met Stargardt patiënten konden 
wij 13 ongerelateerde patiënten vinden die foveal sparing in één of beide ogen (17 ogen in 
totaal). De visus in deze ogen bedroeg 20/40 of beter, en minimaal 20/25 in 41% van de 
patiënten. Uiteindelijk degenereert de fovea als de parafoveale atrofie uitbreidt, wat resulteert 
in een visusdaling naar 20/200 tot vingers tellen. Genetische analyse liet minimaal één 
ABCA4 mutatie gevonden in elke patiënt, maar er werd geen correlatie gevonden tussen een 
specifieke mutatie en het klinische beeld. De retinale anatomie, metabolisme, biochemie en 
variaties in andere genen dan ABCA4 kunnen betrokken zijn bij het ontstaan van het foveal 
sparing fenomeen. Het ontrafelen van deze fovea-beschermende factoren kan openingen 
bieden voor therapeutische strategieën voor de ziekte van Stargardt. Foveal sparing komt 
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met name voor in de ‘late-onset’ vorm van de ziekte van Stargardt, en representeert daarmee 
de mildere kant van het klinische spectrum veroorzaakt door ABCA4 mutaties.
In hoofdstuk 10 evalueren wij de klinische kenmerken van autosomaal dominante cystoide 
macula dystrofie (DCMD). We hebben de klinische data – verzamelt over vele jaren – 
van 97 patiënten met DCMD verzameld, inclusief data uit verschillende beeldvormende 
technieken (fluorescentie angiografie, FAF en OCT) en elektrofysiologisch onderzoek (ERG 
en elektrooculografie). We verzamelde bloedmonsters van alle patiënten voor haplotype 
analyse. In de vroege ziektefase laten DCMD patiënten maculaire vocht collecties zien, die 
uiteindelijk tot chorioretinale atrofie en pigment deposities in de achterpool zullen leiden. 
De meeste patiënten (92%) zijn (hoog) hypermetroop. Wij herkenden 3 fasen van DCMD 
gebaseerd op de fundoscopische, beeldvormende en elektrofysiologische kenmerken. In de 
eerste fase zijn patiënten jonger dan 20 jaar en presenteren zich met retinale vochtcollecties, 
fijne vouwing van de membrana limitans interna en milde pigment alteraties. In de tweede 
fase verminderen de vochtcollecties qua omvang en geleidelijk ontstaat chorioretinale 
atrofie. De derde fase – de patiënten zijn doorgaans de 50 jaar gepasseerd – laat duidelijke 
chorioretinale atrofie en harde pigment deposities in de achterpool zien. Haplotype analyse 
toonde dat alle DCMD patiënten het DCMD locus op 7p15.3 hadden; het oorzakelijke gen is 
tot op heden niet bekend.
Hoofdstuk 11 omschrijft de RD5000 database, die wij hebben ontwikkeld om alle 
oogheelkundige en specifieke genetische data van Nederlandse patiënten met een 
retinadystrofie vast te leggen. Om genotype-fenotype analyse voor zeldzame genetische 
aandoeningen te kunnen verrichten is het belangrijk om data te verzamelen van grote 
populaties. Oogheelkundige data wordt doorgaans alleen genoteerd in lokale databases 
en niet in databases waar meerdere centra aan verbonden zijn. Er zijn momenteel elf 
Nederlandse oftalmogenetische centra aan de RD5000 database verbonden. Er werden 
protocollen opgezet omtrent de autorisatierechten van databeheer, -invoer en het delen van 
data, waardoor de RD5000 database een gebruiksvriendelijke, veilige en veel gebruikte 
database kan worden, die kan bijdragen aan toekomstige genetische, klinische en 
therapeutische studies naar retinadystrofieën. De RD5000 database heeft de potentie om uit 
te groeien naar een Europese database.
Hoofdstuk 12 bediscussieert de studies opgenomen in dit proefschrift en bespreekt de 
implicaties die deze studies hebben voor onderzoekers, (oog)artsen en patiënten. Het 
hoofdstuk probeert licht te schijnen op de klinische heterogeniteit van retinadystrofieën door 
de overige genetische factoren die mogelijk van invloed zijn op de fenotypes te bespreken. 
Daarnaast biedt dit hoofdstuk een overzicht van de therapeutische strategieën die momenteel 
worden onderzocht, en bespreekt de verwachtingen en potentie van deze behandelingen 
evenals de ethische bezwaren.
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Op de voorkant van dit proefschrift wat voor u ligt prijkt enkel de naam van ondergetekende, 
maar het had er nooit gelegen zonder de hulp, begeleiding, en het vertrouwen van anderen. 
In tegenstelling tot wat veel mensen denken, doe je onderzoek niet alleen. Natuurlijk zit je 
als promovendus regelmatig dagen achter de computer data het analyseren, theorieën op 
te stellen, verklaring te zoeken en dit in een artikel op te schrijven, maar promoveren is zo 
veel meer. Het is een reis waarbij je groeit – zowel als persoon als onderzoeker – maar ook 
leert waar je grenzen liggen. Je leert omgaan met teleurstellingen, tegenslagen te verwerken 
en deze in een kracht om te zetten. (“You live, you love, you cry, you lose, you bleed, you 
scream, you learn” Alanis Morissette – You learn) Gelukkig heeft deze ontdekkingstocht 
wegbewijzering, staat de autoradio aan en sta je niet alleen in de file: de dagen worden 
gekleurd door talloze overleggen en vergaderingen, congressen en cursussen, maar vooral 
ook de gezellige lunches en het directe contact met collega promovendi en arts-assistenten. 
Kortom: promoveren doe je niet alleen en daarom is een woord van waardering en dank op 
zijn plaats.
Geachte prof. dr. Hoyng, beste Carel, dank voor het vertrouwen, de vrijheid en dat ik heb 
mogen leren van jouw jarenlange ervaring met retinadystrofieën. Jij bent de man van het 
overzicht en de neuzen de juiste richting op. Jij weet altijd te bewaken wat de rode lijn moest 
zijn, waarbij het klinische belang nooit uit het oog verloren raakt: ‘wat wil ik nou weten als 
de patiënt tegenover me zit in de spreekkamer?’ Je schroomt niet om groot te denken en 
gedurfde keuzes te maken. (“That what he goes there for, is to unlock the door” Seal – Crazy)
Geachte dr. Klevering, beste Jeroen, dank voor de leerzame discussies, jouw brede en toch 
gedetailleerde kennis en jouw sturing. Jij was mijn directe begeleider de afgelopen jaren, 
en menigmaal als ik het spoor bijster was, had jij mij binnen een paar minuten weer op het 
juiste spoor. Als geen ander weet jij de vinger op het probleem te leggen, waarvoor je dan 
meestal een eenvoudige doch effectieve oplossing hebt, die niet bij uitzondering zo logisch 
en vanzelfsprekend blijkt dat je je afvraagt waarom je er zelf niet op gekomen bent.
(“Nobody said it was easy.” Coldplay – The Scientist)
Geachte dr. Collin, beste Rob, voor menig clinicus lijkt de moleculaire genetica ingewikkeld, 
onoverzichtelijk en een ver-van-mijn-bed verhaal, om nog maar te zwijgen hoe die genetica 
dan in expressie komt tot een fenotype. Jij wist mij daarentegen bij te sturen als ik mij op het 
gladde ijs van de genetica begaf en de bocht te kort dreigde te nemen. Dank hiervoor.
Geachte prof. dr. Cremers, beste Frans, vanaf het begin van mijn promotie viel mij de 
laagdrempeligheid op waarmee je te benaderen bent. Overleg met jouw is altijd hardop 
denken en hiermee samen het juiste pad bepalen. Jij was de grote drijfveer achter het 
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RD5000 project, wat een grote stempel op mijn promotieonderzoek heeft gedrukt. Een van 
de resultaten hiervan staat in hoofdstuk 11 beschreven.
Geachte dr. Van den Born, beste Ingeborgh, menigmaal hadden wij overleg om een 
samenwerking te creëren (hoe meer patiënten, hoe beter!) of om resultaten en interpretaties 
hiervan te bespreken. Dank je voor het delen van je grote klinische kennis van retinale 
dystrofieën.
Geachte prof. dr. Den Hollander, beste Anneke, slechts enkele keren werkten we samen 
aan een project, waarbij dan voorafgaand eerst goed werd bepaald hoe het doel efficiënt 
behaald kon worden. Dankzij je onberispelijke Engels waren jouw correcties meteen een 
‘semi-native’ speaker edit, iets wat zeer waardevol voor een artikel is. Dank je wel.
Geachte dr. Theelen, beste Thomas, voor hulp betreffende beeldvorming kon ik altijd bij u 
terecht. Je snelle en gedetailleerde beschrijvingen van de verschillende technieken brachten 
meer dan eens nieuwe inzichten aan het licht.
Geachte dr. Boon, beste Camiel, het was altijd fijn om met jou van gedachten te wisselen. 
Bij het geven van commentaren op een artikel weet jij feilloos de (soms bijna onzichtbare) 
zwakke punten eruit te pikken en hier eenvoudige doch stevige oplossingen voor te bieden. 
Dank voor je enthousiasme en kunde.
Geachte dr. Oomen, beste Clasien, wij hebben intensief samengewerkt aan verschillende 
onderdelen van het RD5000 project. Samen begaven wij ons in de wereld van data 
management, logistiek, regelgeving en gebruiksvriendelijkheid van de RD5000 database. 
Het volgende moment hadden we het over de website: waar moet welke tekst? Dank voor het 
overzicht en de prettige samenwerking binnen het RD5000 project.
Geachte prof. dr. Keunen, beste Jan, een deel van mijn promotietraject viel samen met mijn 
opleiding tot oogarts. U waarschuwde mij bij voorbaat voor de drukte die deze combinatie 
met zich mee zou gaan brengen. It was tough, but I made it! Dank voor de betrokkenheid en 
zorgzaamheid.
Geachte drs. Groenewoud, beste Hans, jij bent mijn statistische held. Speerpunt was altijd 
het vinden van de meest eerlijk en subtiele manier om deze specifieke statische vraag 
te beantwoorden. Ook als er overlegd moest worden over een output van een database 
stonden jij en je collegae klaar om hierover gedachten te wisselen, ondanks jouw drukke 
agenda gevuld met colleges en cursussen. Dank voor je motivatie en zorgvuldigheid.
Uiteraard ook veel dank aan mijn (oud) mede-promovendi van de afdeling oogheelkunde: 
Dženita, John, Mahesh, Yara, Shazia, Nicole, Freekje, Constantin, Myrte, Michel, Nathalie, 
Laura, Maartje, Roos en Stanley. Samen maakten we het doen van onderzoek leuk! Dank 
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voor het aanhoren van frustraties, alle zin en onzin die over en weer door de kamer ging, en 
de leuke uitjes. Een aantal van jullie is inmiddels ook in opleiding tot oogarts en ik hoop nog 
een aantal van jullie twee verdiepingen lager te mogen verwelkomen.
En dan kom je ‘beneden’, wederom een transitie van ‘oudste’ naar ‘jongste’ (will it ever 
stop?!?!). Pit, Jeroen, Milan, Irene, Samuel, Linda, Carla, Paulien, Ann-Laure, John, Dženita, 
Anita, Stefan, Jelina, Ellen, Frank, Yara, Nicole, Artin, Myrte en Anna; dank voor jullie warme 
onthaal en de fijne samenwerking. We zijn een leuke groep samen!
I would also like to thank my (ex-)colleagues at the department of Genetics: Susanne, Alejo, 
Imran, Anna, Alex, Galuh, Ellen, Marijke, Frederieke, Bjorn and Saskia. Thank you for your 
time and patience while answering my questions, explaining tests (results) or running certain 
tests.
Graag wil ik mijn collega bij de keel-, neus- en oorheelkunde, Anne Oonk, bedanken voor de 
fijne samenwerking. Het was verfrissend om eens verder dan het oog te kijken!
Ik ben ook zeker veel dank verschuldigd aan de dames en heren van de administratie, 
de verpleegpost, het trialcentrum en de optometrie. Dankzij jullie was het mogelijk om 
onderzoekspatiënten op de polikliniek te kunnen zien tussen het reguliere patiëntenverkeer 
door. Liesbeth, bedankt voor de bereidwilligheid om menig lunch op te geven om weer eens 
een ERG of een kleurenonderzoek voor mij te verrichten. Uiteindelijk heb je het mij zelfs 
geleerd om de bijzondere onderzoeken zelf uit te voeren.
Mijn vrienden Joep, Lianne, Lyvonne, Maaike, Monique, Nicky, Nienke, Wienke, Yara, Nicole, 
en Marleen wil ik bedanken voor het bieden van de broodnodige afleiding tussen alle 
avonden en weekenden werken: voor de leuke uitjes, de weekendjes weg, de hilarische 
impulsieve acties tussendoor, nutteloze discussies (gewoon omdat het kan), de avonden 
samen Wie is de Mol? kijken en de talloze spellendag (Ligretto stop!).
Mijn paranimfen wil ik graag nog apart bedanken voor de hulp bij de laatste loodjes. Maaike, 
bedankt voor de gezelligheid, de mooie concerten, de avonden film kijken, de nutteloze 
discussies gewoon omdat het kan (zijn wij toch wel experts in te noemen) en het luisterend 
oor als dat nodig was. Nicole, wij zaten op dezelfde golflengte vanaf seconde 1 dat ik je heb 
leren kennen. Jouw hilariteit, energie, en humor zijn goud waard, dank voor het delen ervan. 
*kinstagmus*
De personen die het belangrijkst voor je zijn worden vaak aan het eind bedankt en zo ook 
hier. Lieve Silf en Ivonka, lieve pap en mam, bedankt dat jullie er altijd voor me zijn geweest; 
altijd m’n ‘back gecoverd’ hebben. Ik kan niet anders dan apetrots op jullie zijn!
(“So sing your own song and never forget. N’oubliez jamais.” – Joe Cocker N’oubliez jamais)
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Lieve Frank, Ania en Adam, vanaf een afstandje – Warschau is nèt niet naast de deur – 
hebben jullie altijd interesse in mijn promotie getoond. Dank voor de technische hulp als de 
computer of telefoon B deed, terwijl ik A wilde. Dit jaar is Adam in de familie erbij gekomen, 
waarvoor ik – wederom vanaf afstand – voor suikeroom mag gaan spelen.J
Lieve Nina, jij bent altijd vrolijk en staat vooraan om een knuffel te geven. Wij hebben thuis 
dankzij jou veel geleerd, en niemand kan mij zo goed ‘aan elkaar slaan’ op de Wii als jij! Dank 
je wel en dikke knuffel terug!
(“Met een mooie glimlach of een lief gebaar, worden al jouw dromen waar.” – K3 – Toveren)
Lieve Niels, dank je dat je er altijd voor me bent. Ook als ik weer eens chagrijnig was omdat 
ik mezelf geen moment rust gunde en alleen maar tegen je kon klagen, wist jij zonder moeite 
de bui over te laten trekken. Dank je voor het begrip als ik weer eens ging zitten werken in 
plaats van samen op de bank een film kijken. Jij bent mijn thuis.
(“You are, home. Home, where I wanted to go.” Coldplay – Clocks)
